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Introduction 
 
 
 
 
Abstract:  
Naturally occurring glycosylated peptides and proteins play an important role in various 
biological processes, and are therefore interesting molecules for the preparation of new 
therapeutic drugs. However, synthesis of these natural glycopeptides is frequently 
hampered by the sensitivity of the glycosidic linkages to acidic and basic conditions. 
Another important pathway for glycopeptide degradation involves enzymatic cleavage of 
the carbohydrate moiety. A search for new, more stable mimics led to the development 
of C-linked isosteres, providing excellent chemical and enzymatic stability without 
negatively influencing the biological properties.  
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1.1 GENERAL INTRODUCTION 
As the result of years of worldwide interest in ‘genomics’ and ‘proteomics’, our 
current knowledge of basic structure and function of proteins has reached a level of 
high maturity. In contrast, our understanding of co- and posttranslational processes 
that are not under direct genetic control, e.g. phosphorylation, glycosylation, 
sulfation or lipidation, is rather poor. Posttranslational protein modification, 
however, often has a dramatic influence on protein complexity and exerts control 
over vital biological functions.1 For example, dynamic phosphorylation of proteins 
plays a decisive role in regulation of enzyme activity, which has inter alia led to 
enormous interest in kinase inhibitors for cancer treatment.2 Even less developed is 
our understanding of protein modification by glycosylation, despite the fact that as 
many as 50% of human proteins are O- or N-glycosylated.3  
 
Figure 1. Schematic representation of interactions of cell-surface glycoproteins. 
Protein glycosylation plays a crucial role in correct protein folding and thermal and 
proteolytic stability. As a consequence, errors in protein glycosylation cause various 
diseases,4 such as autoimmune diseases, storage diseases, diabetes and cancer. 
Furthermore, cell surface or membrane-bound glycoproteins (Figure 1) are essential 
mediators in cellular processes5 such as cell growth, cell differentiation, cell-cell 
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adhesion and intercellular communication. The essential connection in any 
glycoprotein is a covalent linkage between an anomeric center of a mono- or 
oligosaccharide and an amino acid side-chain of a protein. Typically, glycoproteins 
are categorized based upon the bond connecting the carbohydrate moiety to the 
amino acid functionality. Most commonly, N-glycoproteins contain an amide linkage 
to asparagine while the carbohydrates of the O-glycoproteins are bound to serine or 
threonine via an ether bridge.6 Less common are N-glycoproteins via the arginine 
side-chain and O-glycosidic linkages to hydroxylysine, 4-hydroxyproline and 
tyrosine. A few C-glycoproteins, S-glycoproteins and P-glycoproteins are also 
known, but not covered here.7 Despite the enormous diversity of glycoproteins 
known, only eight simple carbohydrates are involved in protein glycosylation, i.e. D-
glucose,D-galactose, D-mannose, L-fucose, D-N-acetylneuraminic acid (sialic acid), D-
N-acetylgalactosamine, D-N-acetylglucosamine, and D-xylose.7 Therefore, the unique 
structure of glycoproteins is not so much determined by the nature, but primarily by 
the arrangement of the sugar constituents. Since each carbohydrate has multiple 
hydroxy groups available for substitution, over 35,560 different tetrasaccharides can 
be generated from only four different sugars.8 
The N-linked glycoproteins are the most abundant in Nature3 and are commonly 
divided into three groups: high-mannose, complex, hybrid and poly-N-
acetyllactosamine glycans. All N-glycans share a common pentasaccharide core 
structure Man3GlcNAc29 as shown in Figure 2. The pentasaccharide core can be 
extended by up to five antennae, with high structural diversity in terms of 
substitution pattern, degree of branching and terminal sugars. 
The O-linked glycoproteins or O-glycans, second in order of biological importance, 
show a much higher degree of structural diversity, and eight core structures have 
been found10 (Figure 2). The majority of the O-linked chains on serum and membrane 
glycoproteins are of the sialylated tri- and tetrasaccharide type based on type 1 core, 
characterized by sialic acid α-2,3-linked to galactose and/or α-2,6-linked to GalNAc. 
Longer and more diverse oligosaccharides, e.g. incorporating L-fucose or KDO, have 
also been detected. Another type of O-glycosylation, not discussed here, takes place 
on nuclear and cytoplasmic proteins. In complex interplay with the well-studied 
protein O-phosphorylation/dephosphorylation, protein GlcNAc-ylation modulates 
signaling, and influences protein expression, degradation and trafficking.11 
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Figure 2. Core structures of natural N- and O-linked glycopeptides. Symbols adopted from the Consortium of 
Functional Glycomics.12 
The importance of protein glycosylation has provided a strong stimulus for research 
into glycoprotein glycobiology and applications for therapeutic approaches.13 
Unfortunately glycoproteins, both N- and O-linked, are typically expressed as 
mixtures of heterogeneous glycoforms that possess the same peptide backbone but 
differ in both the nature and site of glycosylation. As a consequence, the difficulty of 
obtaining homogeneous samples has significantly hampered our understanding of 
glycoprotein structure and function.14 In practice, glycosylation analysis, e.g. with 
HPLC or mass spectrometric techniques, is performed on a complex mixture of 
glycoforms, which complicates full structural and functional characterization. By the 
same token, heterogeneity in protein expression is also a significant hurdle in large-
scale biotechnological production of glycoproteins. 
1.2 SYNTHESIS OF GLYCOPEPTIDES AND PROTEINS 
The difficulty to obtain pure glycoproteins from natural sources has sparked wide 
interest in the production of glycoproteins by alternative means.14,15 Natural 
glycopeptides can serve as new therapeutic drugs,15,16 e.g. against carbohydrate-
based metabolic disorders,17 and in the battle against cancer18 and AIDS.19 In 
addition, non-natural glycosylation of peptide-based drugs may enhance their 
solubility, resistance against enzymatic degradation, and can positively influence 
biological and pharmacokinetic properties.20 
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However, at present only few glycopeptides or proteins are in use as treatment 
against diseases.6,21 Firstly, as delineated above, biotechnological production of 
glycoproteins inevitably leads to mixtures of glycoforms, as for example is the case 
for α-erythropoietin (EPO).22 Unfortunately, the large size of glycoproteins hampers 
a straightforward preparation by synthetic means, necessitating advanced molecular 
biology tools or a combination of protein expression systems, biochemical techniques 
and chemical modification.15 Smaller glycopeptides, however, typically of sizes up to 
50 amino acids, offer the possibility of synthetic preparation in homogeneous form 
by a range of techniques.23 For example, a large number of O-linked glycopeptides 
for cancer vaccination purposes have been prepared by incorporation of a 
presynthesized O-glycosylserine building block making use of standard solid-phase 
peptide synthesis24 (Scheme 1).  
1
peptide peptide
2
O
FmocHN
O
AcO
AcHN
AcO OAc
O
OH
(b) further elongation
(c) cleavage and deprotection
(a)
O
HO
AcHN
HO OH
O
enzymatic
glycosylation
 
Scheme 1. Solid-phase peptide synthesis towards O-linked glycopeptides. 
However, several problems may arise when applying glycoamino acid building 
blocks. Firstly, such an approach is suitable only for relatively small glyco-fragments, 
since steric hindrance leads to impractically low coupling yields for larger 
oligosaccharides. Similar arguments apply to N-linked glycoamino acids.  
Apart from that, reaction conditions required for final deprotection steps of O-linked 
glycopeptides must be carefully tuned in order to prevent undesired β-elimination25 
(Scheme 2), whereas acidic conditions may lead to cleavage of the rather unstable 
fucosyl fragments, if present. Hence, a large number of groups have focused on 
chemoenzymatic approaches for synthesis of complex glycoproteins, involving 
incorporation of a single sugar by chemical synthesis, followed by enzymatic 
elaboration after final deprotection of the glycopeptides. In this fashion, complicated 
glycopeptides have been assembled, but clearly such a strategy is limited by access to 
the requisite glycosyltransferases. 
Chapter 1 
 
6
B / H2O O
RO
HO OR
AcHN
N
H
O
O
OH
+
3
4 5
O
RO
AcHN
HO OR
O
N
H O
O
H
 
Scheme 2. β-Elimination process. 
Apart from (chemo)enzymatic procedures, purely enzymatic approaches have also 
been explored. The mild conditions of biocatalytic peptide bond formation avoid the 
potential pitfalls associated with chemical synthesis as discussed above. An 
additional advantage is the lack of racemization, while at the same time side-chain 
protecting groups can mostly be omitted. Unfortunately, a general method for 
chemoenzymatic synthesis of peptides has not been achieved yet, with major 
limitations being the hydrolytic activity of the protease and the enzyme specificity. 
Moreover, enzyme specificity limits the choice of suitable amino acids for synthesis 
of a peptide bond. Finally, glycopeptides have also been prepared by expression in 
eukaryotic systems,26 however it is not uncommon for them to exhibit glycoform 
microheterogeneity.27 
 
Figure 3. Example of the actions of naturally present endoglycosidases.30 
It is well-known that carbohydrate fragments on proteins substantially extend the 
protein lifetime under physiological conditions by offering protection against 
proteolytic degradation. However, the glycopeptide linkage itself may be a target of 
enzymatic cleavage of the carbohydrate moiety from the peptide backbone. For 
instance, GlcNAc-β-Ser/Thr can be cleaved by the action of β-N-
acetylglucoamidase,28 an enzyme expressed in every human tissue.7a Likewise, 
several (commercially available) endoglycosidases and glycosidases, originated from 
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bacteria and plants, have been employed to cleave the naturally occurring glycosidic 
N- and O-bonds (Figure 3).29 
1.3 ISOSTERES OF THE NATURAL N- OR O-LINKED GLYCOSIDIC 
AMINO ACIDS 
The drawbacks encountered in preparing natural glycopeptides, the sensitivity of the 
glycosidic bond and the disadvantages of non-chemical approaches, led to the search 
for metabolically stable derivatives of the naturally occurring O- and N-linked 
glycosides. Not only should these new unnatural glycosidic amino acids increase the 
chemical and metabolic stability, additionally they should not negatively alter the 
conformation of the glycoprotein, in other words they must truly behave as isosteres. 
In this regard, ether bonds (O-linked) have been mimicked by replacement of the 
oxygen with sulfur or carbon to form S-linked and C-linked isosteres 6 and 8, 
repectively (Figure 4).  
O
HO
HO
HO
CO2HH2N
HO
O
HO
HO
HO
O
CO2HH2N
HO
~
6 7
~
O
HO
HO
HO
S
CO2HH2N
HO
8  
Figure 4. Synthetic S- and C-linked glycopeptides. 
Synthetic examples of S-31 and C-linked glycopeptides7,32-37 (6 and 8, Figure 4), 
exhibited virtually the same conformation as the natural N- and O-linked 
glycopeptides38 besides being chemically as well as metabolically more stable. For 
instance, the group of Bertozzi39 showed that C-linked glycosides are robust and are 
known to sustain glycosidase degradation, glycosyltransferases, acid hydrolysis, as 
well as anomeric acetal- and β-elimination. In addition, solution conformations 
similar to the native conformation40 and biological activities similar to the native 
counterparts have been observed. Further investigation by the Bertozzi group,41 
including incorporation of a C-linked (S)-serine analogue into a peptide, led to the 
conclusion that these structures were perfectly suited for incorporation into drugs as 
stable O-linked serine isosteres. The latter assumption was corroborated by synthesis 
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of a C-linked galactosphingolipid analogue that blocked the interaction of 
recombinant HIV-1 gp120 with GalCer, and had an IC50 value comparable to the 
natural sphingolipid. 
Contrary to O-linked mimics, analogues of natural amide (N-linked) bonds are 
scarcer. The efforts of some groups to synthesize metabolically stable analogues of 
the N-linked glycosidic bonds are depicted in Figure 5. Besides the ethylene isostere 
11 prepared by several groups, Kessler et al.42 reported the synthesis of the retro 
amide 9 derived directly from the natural amide by reverting the orientation of the 
bond, resulting in a stable C-glycosidic analogue.  
~
10
~O
NHAc
HO
HO
HO
H
N
O NH
O
O
NHAc
HO
HO
HO
N
H NH
O
O
retro amide 9
O
NHAc
HO
HO
HO
NH
O
ethylene isostere 11  
Figure 5. Natural N-linked glycopeptide 10, the retro amide 9 and the C-glycosyl analogue 11. 
In addition to C-glycosidic amino acids closely resembling O- and N- glycopeptides, 
different C-linked building blocks have been prepared as well (e.g. C-glycosyl 
alanines, C-glycosyl tyrosines, C-glycosyl tryptophans and various miscellaneous 
compounds, Figure 6).  
O
NHAc
HO
HO
HO
N
H
O
O
HO
HO
HO
HO
NHBoc
CO2Me
NHBoc
CO2H
12
13
O
OAcAcO
AcO
O NHBoc
CO2H
14
AcHN
 
Figure 6. Selected examples of miscellaneous C-glycosidic amino acids. 
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Examples of the latter are the glycosylacetylenephenylalanine derivative 1243 and the 
conformationally constrained O-glycosyl serine 14,34 while Lee et al. described the 
synthesis of a C-linked glycopeptide 13 by inserting an additional carbon between 
the natural amide bond and the glycoside.44 A high-mannose derivative of such a 
compound was found to be resistant to N-glycanase-catalyzed hydrolysis while 
displaying inhibitory activity toward the enzyme. 
Due to their superior metabolic and chemical stability without negatively influencing 
the pharmaceutical properties, carbon analogues of N- and O-linked glycosides and 
glycoconjugates appear more and more in drug development today.45 
1.4 PREPARATION OF C-LINKED GLYCOSIDIC AMINO ACIDS 
Up until today nearly the whole repertoire of C-C ligation reactions have been 
applied. The first report concerning the synthesis of glucosyl and lactosyl glycines 
dates back from 1949, however, later attempts to repeat the procedure failed. The 
first well-documented synthesis, originating from 1975, was reported by Rosenthal 
and Brink,46 and describes the coupling of tetra-O-acetyl α-bromoglucose 15 with 
oxazoline 16 under strongly basic conditions (Scheme 3). The yield of the bis-
glycosylated oxazole 17 was rather low, but saponification led to the desired  
2-(β-D-glucopyranosyl)glycinate 18 as a mixture of diastereoisomers. 
O
AcO
AcO
AcO
AcO
15
Br
+
N
O PhO
16
BuLi O
AcO
AcO
AcO
AcO
O
N
O Ph
O
OAc
AcO
AcO
AcO
17
O
AcO
AcO
AcO
AcO
CO2Me
NHAc
18
1) HCl
MeOH
2) Ac2O
Py
 
Scheme 3. The first well-documented synthesis of a C-linked glycosidic amino acid. 
Remarkably, in the following decades only few reports on the synthesis of C-linked 
glycosidic amino acids were published, but then in the 90s due to the interest of 
glycosylation in pharmaceutical products suddenly many pathways were developed. 
Most of these methods have been extensively reviewed by the groups of 
Dondoni32and Wittmann,47of which the most relevant ones will be discussed below. 
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1.4.1 Preparation of ethylene isosteres of N-glycosyl asparagines 
C-Linked isosteres of naturally occurring N-glycosyl asparagines have been prepared 
via multiple strategies as depicted in Scheme 4. These pathways include various 
cross-metathesis approaches35,48 (described in Chapter 2), as well as a Wittig,49 and an 
alkyne coupling strategy,50 the latter being reported by the group of Dondoni. 
Moreover, Kessler et al.51 described the first synthesis of an asparagine analogue in 
1997 starting from the tributyltin derivative 25. A Suzuki coupling strategy was 
reported for compound 20 by Taylor et al.52 
O
OR
RO
NHR1
CO2R2 O
OROR
RO
OR O
O
OR
RO
OH
OR
RO
RO
OR
O
OR
RO
RO
OR
SnBu3
O
OROR
RO
RX
O
OROR
RO
RO
20
21
22 23
24
25
19n
ref. 35
ref. 48
ref. 49
ref. 50, 53
ref. 51ref. 52
 
Scheme 4. Synthesis of N-glycosyl asparagine analogues from a diversity of starting materials. 
Among these approaches the metathesis approaches from Nolen et al., discussed in 
Chapter 2, provided the highest overall yields. However, another noteworthy 
method was described in 2002 by Dondoni et al.53 and is considered a straightforward 
route for the synthesis of ethylene isosteres of N-glycosyl asparagines 19. Coupling of 
the lithium acetylide derived from 26 with Garner’s aldehyde led to alkyne 28 
(Scheme 5). Subsequently, diimine reduction of the alkyne, followed by  
Barton-McCombie deoxygenation of the hydroxyl group afforded C-glycoside 29.  
A final oxidative cleavage of the oxazolidine ring with Jones reagent yielded the 
ethylene-linked analogue of N-glycosyl asparagine (30). Besides the depicted 
acetylated glucose, a variety of other sugars could be ligated applying this  
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procedure, comprising the gluco, galacto, manno, and the corresponding 2-
acetamido residues synthesizing both α- and β-anomers. This approach meets both 
important criteria for an excellent synthesis, namely a) it represents an easy and 
broadly applicable approach to a large variety of products with different 
configurations in the glycosidic and amino acid moieties, and b) orthogonal 
protecting group strategies are possible. 
O
BnO
OBn
BnO
BnO
26
NH
O CHO
1) BuLi
2)
27
THF, -50 °C
O
BnO
OBn
BnO
BnO
OH
HN O
1) TsNHNH2
AcONa, 85 °C
2) Im2C=S, DMAP
70 °C
3) Bu3SnH, AIBN
85 °C28
29
O
BnO
OBn
BnO
BnO
HN
O
O
BnO
OBn
BnO
BnO
NHBoc
CO2H
30
Jones reagent
acetone, 0 °C
 
Scheme 5. Synthesis of ethylene isosteres of N-glycosyl asparagine by Dondoni et al. 
1.4.2 Preparation of O-glycosyl serine analogues 
Besides several routes applicable for the formation of N-asparagine isosteres (e.g. 
Wittig starting from the carbohydrate aldehyde,49 cross metathesis35,48) many 
pathways were developed for the preparation of serine isosteres (Scheme 6). These 
include a Wittig approach starting from the carbohydrate ylide,54 synthesis via a 
Ramberg-Bäcklund rearrangement,37,52 a Wittig-Horner olefination followed by 
catalytic asymmetric hydrogenation,55,56 an organozinc-glucal coupling,57 a Lewis-
acid-promoted coupling of galactopyranosyl trichloroacetimidate 38,58 reductive 
samariation,59 electrophilic amination of C-glycosyl oxazolidinone enolates60 
and an anionic [2,3]-Wittig sigmatropic rearrangement of ethanoyl  
D-vinylketoglucoside 32.61 
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Scheme 6. Retrosynthesis of O-glycosyl serine analogues. 
Whereas the cross metathesis approaches were high yielding for the asparagine 
analogues, serine derivatives could only be obtained in low yields. The shortest and 
highest yielding route to C-linked serine analogues applied the Wittig-Horner 
olefination followed by asymmetric hydrogenation as reported in 1997 by  
Toone et al.55 
The latter approach starts with the olefination of the Boc-protected phosphonate 
methyl ester 43 and carbohydrate 42 via a Horner-Emmons reaction resulting in the 
formation of enamide 44 in 79% yield (Scheme 7). Subsequent hydrogenation with 
(R,R)-Et-DuPHOS-Rh+ as catalyst precursor in toluene afforded the desired C-linked 
(S)-glycosidic amino acid 45 in good yield and with a diastereomeric excess (d.e.) of 
>95%. Besides glucosylated derivatives, the corresponding galacto- and manno-
derived glycosidic amino acids could be prepared as well, applying slightly modified 
conditions (solvents, catalyst). In addition, D- and L-amino acids were accessible by 
changing the DuPHOS ligand (e.g.(R,R)-Et ligands resulted in (R)-configured 
products while (S,S)-Me ligands provided the (S)-isomer). The versatility of the  
method was extended to β-configured anomers of the glucose, galactose and  
mannose serine isosteres, with the obtained yields and d.e.’s being equal to those of 
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the α-anomers. In addition, this strategy was applied in the preparation of β-carbon-
linked serine analogues of the Pk trisaccharide, a short peptide able to bind subunits 
of the Shiga-like toxin.56 
O
AcO
AcO
AcO
AcO
BocHN CO2Me
P(OMe)2
O
TMG, THF, -78 °C
O
AcO
AcO
AcO
AcO
BocHN CO2Me
O
AcO
AcO
AcO
AcO
BocHN CO2Me
[(COD)Rh-((R,R)-Et-
DuPHOS)]+OTF–
toluene, 90 psi, rt
44: 79% 45: 91% (de >95%)42
43
O
H
 
Scheme 7. Toone’s asymmetric hydrogenation strategy. 
Another noteworthy approach reported by Nolen et al.36 led to the desired product 
by ligation of a chiral glycine enolate derivative to a sugar iodoethyl derivative 
(Scheme 8). First, treatment of allylglycoside 46 with a catalytic amount of osmium 
tetroxide and sodium periodate provided the aldehyde, subsequent reduction with 
NaBH4 in methanol followed by iodination (triphenylphosphine, imidazole, and 
iodine) afforded the desired iodoethyl carbohydrate 47. The key step in the approach 
involved subjection of iodide 47 to LiHMDS, oxazinone 48, and HMPA to afford the 
C-C coupled product 49, followed by treatment with lithium in ammonia to  
remove the oxazinone chiral auxiliary and deprotect the benzyl ethers.  
O
OBn
BnO
BnO
BnO
O
OBn
BnO
BnO
BnO
47: 79% 49: 87%46 I
N
Boc
OLiO Ph
Ph
LiHMDS, THF, HMPA
O
OBn
BnO
BnO
BnO
N
Boc
OO Ph
Ph
1) OsO4, NaIO4
2) NaBH4, MeOH
3) PPh3, I2, im
O
OBn
BnO
BnO
BnO
CO2MeBocHN
1) Li, NH3
2) Ac2O, pyridine
3) CH2N2
48
50  
Scheme 8. Nolen’s chiral glycine enolate approach. 
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A workup involving acetic anhydride followed by diazomethane treatment yielded 
the C-glycosidic product 50. It was demonstrated that α- as well as β-anomers of 
gluco- and galacto-derived glycosidic amino acids could be prepared via the 
aforementioned strategy. 
1.5 PURPOSE AND OUTLINE OF THE RESEARCH 
The investigations described in this Thesis were part of a project to develop a set of 
integrated and complementary technologies for the synthesis of sugar-functionalized 
peptidomimetics, built from new, diverse and metabolically stable amino acid 
derivatives. A collaborative project between DSM (Geleen, The Netherlands), 
Chiralix (Nijmegen) and the Radboud University Nijmegen was funded by the 
agency of the Dutch Ministry of Economic Affairs (SenterNovem), supporting 
initiatives to stimulate sustainability and fundamental research. While DSM focused 
on developing new chemical and enzymatic strategies for the synthesis of linear 
peptides and research at Chiralix was directed at finding new strategies for the 
production of unnatural cyclic amino acids, it was our goal to explore new pathways 
for the development of stable analogues of the natural sugar amino acid linkages. 
In this chapter, a general introduction to natural glycopeptides as well as an 
overview of recent synthetic approaches for the preparation of new glycosidic amino 
acid isosteres has been given. 
Chapter 2 details our efforts to prepare stable glycosidic C-linked serine isosteres via 
a cross-metathesis reaction followed by a mercury-induced lactonization/reduction 
strategy.  
Chapter 3 discloses a novel expedient and high-yielding approach for the synthesis 
of glycosidic N-triazole-linked amino acids, isosteres of the natural N-linked 
glycosidic amino acids.62 
Chapter 4 describes our efforts towards a simple, stepwise coupling procedure for 
the preparation of glycopeptides applied in solution as well as on resin. In addition, 
the preparation and enzymatic resolution of the protected acetylenes are described.  
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In Chapter 5 a newly discovered reaction between a bromoacetylene and an organic 
azide coupled due to the combined action of CuI and Cu(OAc)2, forming a 5-bromo 
trisubstituted triazole is discussed.63 
Chapter 6 explores the possibility to apply an enzymatic coupling of N-triazole 
amino acids and amino acid amides. The results hereof are compared to coupling 
reactions of the natural amide-linked N-glycosidic amino acid.64 
Finally, in Chapter 7 the incorporation of a N-triazole amino acid in a cyclic RGD 
peptide is described. The αvβ3-binding affinity and tumor uptake of a cyclic 
glycosylated RGD peptide is compared to other cyclic RGDs in in vitro and in vivo 
studies.65 
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Stereoselective Synthesis of 
Glycosyl Serine Methylene 
Isosteres by Cross Metathesis 
 
 
 
Abstract:  
C-Glycosyl amino acids mimicking the natural O-linked glycoamino acids, as found in 
glycoproteins, have been prepared via an olefin cross metathesis/mercury(II)-induced 
cyclization strategy. The resulting C-linked glucosyl serine analogues, obtained in a few 
straightforward steps, are known to surpass the natural O-linked analogues in stability. 
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2.1 INTRODUCTION  
As delineated in the introductory chapter of this Thesis, there has been an extensive 
search throughout the years for derivatives of naturally occurring O- and N-linked 
glycosidic bonds with increased metabolic and chemical stability. The first known 
synthesis of a C-linked glycosyl (S)-serine isostere (4), reported in 1992 by Bednarski 
et al.1 (Scheme 1), starts with a condensation of a serine-derived Wittig reagent with 
2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl-derived aldehyde 1.  
O
OBn
OBn
BnO
BnO
CHO
O
HN
O
PPh3+
nBuLi, THF
O
OBn
OBn
BnO
BnO
N
H
O
O
1) TsNHNH2
AcONa
2) Boc2O
3) Cs2CO3
O
OBn
OBn
BnO
BnO
NHBoc
2 (34%) 3 (69%)
1) TFA, PhSH
2) Fmoc-OSu
3) Jones ox.
O
OBn
OBn
BnO
BnO
NHBoc
CO2H
4 (71%)
1
OH
 
Scheme 1. Synthesis of the first C-linked L-serine by Bednarski et al. 
From these two advanced intermediates, the final galactosylserine isostere 4 is 
prepared in a seven-step reaction sequence with an overall yield of 17%. The final 
product 4 has the acetal oxygen of the natural linkage replaced by a stable  
carbon-carbon bond, an isosteric substitution with minimal difference in steric 
properties.  
Until today several groups have explored new routes for the preparation of C-linked 
glycosyl amino acids, however most of the developed routes comprise many (low 
yielding) steps. One of the recent strategies that deserves attention utilizes the well-
known ruthenium-catalyzed olefin cross metathesis, followed by hydrogenation and 
Jones oxidation as recently reported by Dondoni et al.,2 thereby providing a variety of 
C-glycosyl amino acids (9-11, Scheme2) in moderate to good yields.  
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nCCl4, 100 °C, 3.5 h
2nd gen. Grubbs cat.
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Scheme 2. Cross metathesis route for preparation of C-glycosyl amino acids. 
Following almost the same strategy, the groups of McGarvey3 and Nolen4 directly 
coupled protected (S)-allylglycine (Scheme3) instead of a reduced derivative to the 
anomeric C-allyl glycosides 5 as mentioned above. Cross metathesis reactions of  
C-allyl glycosides 13 were high-yielding, but C-vinyl glycosides proved not to be 
good cross metathesis partners. Low yields of 12 were obtained ranging from  
11–32%, along with recovery of high percentages of starting materials. From these 
studies it became clear that a cross metathesis strategy between an allylic C-glycoside 
and an unsaturated amino acid cannot lead to C-analogues with spacers shorter than 
three methylene functions, since the poor behavior of C-vinyl glycosides in the cross 
metathesis seriously diminishes the final yield. 
nCCl4, 100 °C, 3.5 h
2nd gen. Grubbs cat.
O
OR
RO
RO
RO
O
OR
RO
RO
RO
R1HN CO2Me
n
n
O
OR
RO
RO
RO
R1HN CO2H
Pd/C or Pt/Alumina
12: n = 0 (11-32%)
13: n = 1 (64-82%)
14: n = 0 (N/A)
15: n = 1 (85-92%)
R1HN CO2Me
R1= Boc, Z, Fmoc
5a: R = Bn
5b: R = Ac  
Scheme 3. Nolen’s approach for the preparation of C-glycosyl amino acids. 
Ideally, the carbon isostere of the O-linked glycoamino acid has the same number of 
connecting atoms as the natural substrate. Therefore, an alternative approach to 
shorten the chain between the anomeric carbon and the amino acid group conducted 
by the group of Nolen4 is depicted in Scheme 4. An attempt was made to couple 
dehydroalanine derivative 17 to C-allyl glycoside 16, however, only self-metathesis 
of the saccharide moiety was observed. 
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2nd gen. Grubbs cat.
20 mol%
DCM
reflux, 12 h
O
OAc
AcO
AcO
AcO
O
OAc
AcO
AcO
AcO
16
BocHN CO2Me
+
CO2MeBocHN
17 18  
Scheme 4. Alternative approach to shorten the chain length. 
We hypothesized that the poor yields of cross metathesis with a vinyl- or 
dehydroamino acid could be circumvented by ligation of an open-chain unsaturated 
sugar (e.g. 22) via the cross metathesis strategy to an allylglycine derivative (e.g. 21), 
producing acyclic glycoamino acid alkenes (e.g. 20, Scheme 5). Subsequent 
cyclization was projected to lead to the desired product 19, a mimic of the natural  
O-linked glycoamino acids with the proper number of interconnecting atoms.  
OH
OR
RO
+
PGHN CO2R
RO
O
HO
HO
HO
CO2HH2N
HO
RO
19
21
22
OH
RO
RO
RO
CO2HH2N
RO
20
 
Scheme 5. Retrosynthesis of 19 via an open-chain hydroxyalkene prepared by cross metathesis. 
2.2 C-LINKED GLYCOSIDIC SERINE ANALOGUE 
To probe the feasibility of forming acyclic glycoamino acid alkenes via a cross 
metathesis approach, tetra-O-benzyl glucoheptenitol 23, readily prepared by Wittig 
olefination of tetra-O-benzylglucose, and Boc-protected allylglycine methyl ester 25 
were chosen as substrates for our initial experiments.  
Instead of the presumed cross metathesis, only self-metathesis of the amino acid 
derivative occurred, producing dimer 33 (Figure 1). Given the fact that neither the 
homo-coupled carbohydrate derivative 31 nor the desired product 27 were formed, it 
appeared likely that cross metathesis is hindered by sterical hindrance around the 
alkene moiety of the saccharide. 
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Table 1. Optimization of metathesis conditions. 
R2 CO2Me
OH
OR1
BnO
BnO
BnO
R2 CO2Me
OH
OR1
BnO
BnO
BnO
23: R1 = Bn
24: R1 = H
25: R2 = NHBoc
26: R2 = H
27: R1 = Bn, R2 = NHBoc
28: R1 = H, R2 = NHBoc
29: R1 = H, R2 = H
 
 
entry R1 R2 solvent T catalystc product yield 
1 Bn NHBoc DCM rt G2 (10 mol%) 27 0%
2   toluene rt G2 (10 mol%) 27 0%
3   toluene 80 °C G2 (10 mol%) 27 0%
4 H NHBoc DCM rt G2 (10 mol%) 28 37%
5   toluene rt G2 (10 mol%) 28 50%
6   toluene 80 °C G2 (10 mol%) 28 22%
7   toluene rt G1 (10 mol%) 28 33%
8   toluene rt H (10 mol%) 28 28%
9   DCM 135 °C G2 (10 mol%) 28 <15%a
10   toluene 40 °C G2 (7 mol%) 28 <10%b
11 H H toluene rt G2 (7 mol%) 29 59% 
aPerformed in microwave, 10 min at 300 Watt. bPerformed in microwave, 50 min at 100 Watt. cG2: 2nd gen. 
Grubbs catalyst (benzylidene[1,3- bis(2,4,6-trimethylphenyl)-2- imidazolidinylidene] 
dichloro(tricyclohexylphosphine)ruthenium), G1: 1st gen. Grubbs catalyst (benzylidene-bis 
(tricyclohexylphosphine)dichlororuthenium), H: Hoveyda-Grubbs catalyst (1,3-bis-(2,4,6-trimethylphenyl)-2-
imidazolidinylidene)dichloro(o-isopropoxyphenylmethylene)ruthenium).  
Consequently, the less sterically hindered tri-O-benzyl-glucoheptenitol 24 was 
prepared by stereoselective chain-extension of 2,3,5-tri-O-benzyl-D-arabinose.5 
Gratifyingly, subjection of heptenitol 24 and 25 to the aforementioned cross 
metathesis conditions in DCM at rt (entry 4, Table 1) now led to 37% of the desired 
product 28. By performing the reaction in toluene the yield was raised to 50%  
(entry 5). Unfortunately, further heating of the reaction mixture to 80 °C (entry 6) led 
to significant formation of the undesired by-product 30 (Figure 1) and a lower yield 
of the acyclic glycoamino acid alkene 28. Moreover, subjection to different catalysts 
(entries 7 and 8) or conducting the reaction in a microwave (entries 9 and 10) did not 
lead to improved yields. In addition, all attempts yielded besides the desired cross 
metathesis product 28, varying amounts of homo-coupled saccharide 32 and homo-
coupled amino acid 33, along with sugar derivative 30. The latter compound is the 
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result of double bond isomerization to the enol, followed by tautomerization to the 
ketone and ring-closure.  
OH
R1O
BnO
BnO
BnO
HO
OR1
OBn
OBn
OBn BocHN CO2Me
NHBocMeO2C
O
OBnBnO
BnO OH
30 31 : R = OBn
32 : R = H
33
 
Figure 1. By-products isolated from metathesis reactions. 
Since it appeared that the reaction could not be further optimized without lowering 
the overall atom efficiency, i.e. by using excess of one of the reaction partners, a 
maximum yield of 50% was an indication that reaction rates leading to the possible 
products are the same.6 Finally, to examine whether the outcome of the cross 
metathesis is also (partially) determined by the amino acid moiety, the less sterically 
hindered model alkene 26 was prepared, and together with heptenitol 24 subjected to 
the 2nd generation Grubbs catalyst (entry 11). The result, a yield of 59% of 29, 
indicates that steric hindrance on the amino acid also has some influence on the cross 
metathesis.  
Table 2. Epoxidation attempts of 29. 
OH
OH
BnO
BnO
BnO
CO2Me
OH
HO
BnO
BnO
BnO
CO2Me
O
29 34  
entry conditions 
1 Oxone, H2O/MeCN, NaHCO3    
2 Oxone, MeOH, NaHCO3 
3 m-CPBA, DCM, NaHCO3 
4 Ti(OiPr)4, DCM, tBuOOH 
5 Na2EDTA, acetone, Oxone, NaHCO3 
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Having the desired cross metathesis products in hand, an epoxidation/ring-closing 
strategy for the formation of the desired C-linked serine analogues was explored. To 
this end, alkene 29 lacking the α-NHBoc substituent was chosen as a model system 
and subjected to various epoxidation conditions (e.g. Oxone, m-CPBA, 
Ti(OiPr)4/tBuOOH) as depicted in Table 2. Unexpectedly, none of the epoxidation 
conditions conducted led to the desired epoxide 34, due to the fact that no 
transformation of 29 occurred. Several unlisted attempts to epoxidize compound 28 
were also undertaken but were equally unsuccessful. 
Table 3. Direct ring-closing strategy. 
O
BnO
BnO
BnO
R CO2Me
OH
OH
BnO
BnO
BnO
R CO2Me
HO
X
29: R = H
28: R = NHBoc
35: R = H, X = I
36: R = H, X = HgCl
37: R = NHBoc, X = I
38: R = NHBoc, X = HgCl
O
BnO
BnO
BnO
R CO2Me
HO
39: R = H
40: R = NHBoc
step 2
THF, -78°C
step 1
rt
 
entry R step 1 product yield step 2 product yield 
1 H IDCP, THF 35 0% - - -
2 H Hg(TFA)2, THF  36 b 85% LiBH4, Et3B, 10 min 39 58%
3 NHBoc IDCP, THF 37 0% - - -
4 NHBoc ICl, DCM 37 0% - - -
5 NHBoc Hg(OAc)2, THF 38 b 0% - - -
6 NHBoc Hg(OAc)2, THF, dark 38 b n.d.a - - -
7 NHBoc Hg(TFA)2, THF 38 b 87% 
LiBH4, Et3B, 10 min 40 68%
NaBH4, Et3B, 1 h 40 83%
aInseparable mixture of products. bAfter treatment with Hg(OAc)2 or Hg(TFA)2 the reactions were quenched 
with aqueous KCl. 
Since epoxidation strategies were ineffective, we wondered whether a direct ring-
closing approach, induced by electrophiles, would lead to the desired compounds 
(Table 3). Initial efforts to cyclize substrates 28 or 29 by subjection to a source of I+ 
(IDCP or ICl), however, were without success (entries 1, 3 and 4). In addition, 
subjection of compound 28 to mercury acetate (entries 5 and 6), conditions known to 
cyclize simple heptenitols,5,7 also failed to produce the desired ring-closed 
derivatives. A slight modification of the conditions, by applying the stronger 
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electrophile Hg(TFA)2, however, smoothly afforded the desired ring-closed 
tetrahydropyrans 36 and 38 in yields of 85% and 87%, respectively. Subsequent 
reduction of the carbon-mercury bonds yielded the desired glycosidic α-linked serine 
analogues 39 and 40, via treatment of 36 with LiBH4 and 38 with LiBH4 or NaBH4 at 
−78 °C.  
Stereochemistry of the ring-closed product 40 was determined by comparison of 
analytical data with literature reports,8 and is in agreement with Houk’s inside-
alkoxy model9 as mentioned by Nolen, were the alkyl groups favors the less 
hindered “anti” position, while the hydroxyl group favors the “inside” position 
(Scheme 6). Independently from us, the group of Nolen8 envisioned the same 
strategy and recently reported their successful synthesis of a C-serine analogue. 
 
HO
41: more sterically hindered
"inside alkoxy"
43: less sterically hindered
"outside alkoxy"
XHg
O
BocHN
MeO2C
OBn
OBnHO
OBn
O
OBn
HO
BnO
BnO
CO2MeBocHN
O
OBn
OH
BnO
BnO
NHBoc
CO2Me
red.
red.
H
HH
Hg
BocHN
MeO2C BnO
OBn
OBn
HO
HHO
H H
Hg
CO2Me
NHBocOBn
OBn
BnO
OH
HgX
O
CO2Me
NHBoc
BnO
BnO OH
BnO
H
H
42 40
44 45
 
Scheme 6. Stereochemistry rationalized using Houk’s inside alkoxy model. 
2.3 VARIATION OF CARBOHYDRATE MOIETY 
Having established a new route for the development of C-linked serine isosteres, we 
were intrigued if stereoisomeric sugars such as ribose, xylose and lyxose would 
provide the C-linked analogues as well. To this end, the ribo-, xylo- and lyxo–
configured heptenitols (46, 47, and 48, respectively) were prepared in a four-step 
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reaction sequence, starting from the unprotected furanoses. In contrast to the 
vinylation of arabinose to obtain the gluco-configured precursor 24, the three 
heptenitols now prepared were obtained as mixtures of stereoisomers at C-2: ribose 
afforded a 95:5 mixture of altrose:allose, xylose a 70:30 mixture of idose:gulose and 
lyxose did not show any stereoselectivity yielding a 50:50 mixture of talose:galactose.  
46: ribose heptenitol
(95:5 altro:allo)
OH
BnO
BnO
BnO
BocHN CO2Me
HO
OH
BnO
BnO OBn
BocHN CO2Me
HO
OH
BnO
BnO OBn
BocHN CO2Me
HO
predominantly β−altro
52 (65%)
mixture of isomers
53 (69%)
mixture of isomers
54 (52%)
O
BnO
BnO
BnO
HO
OH
BnO
BnO
OBn
HO
OH
BnO
BnO OBn
HO
OH
BnO
BnO OBn
HO
47: xylose heptenitol
(70:30 ido:gulo)
48: lyxose heptenitol
(50:50 talo:galacto)
49 (48 %) 50 (51%) 51 (44%)
CO2Me
NHBoc
O
BnO
BnO OBn
HO
CO2Me
NHBoc
O
BnO OBn
HO
CO2Me
NHBoc
BnO
 
Scheme 7. Synthesis of C-linked serine analogues from heptenitols 46-48. 
More importantly, however, all three heptenitols 46-48 reacted smoothly with  
(R)-Boc-(S)-allylglycine methyl ester when subjected to 10 mol% of 2nd generation 
Grubbs catalyst in toluene, affording the cross metathesis products 49-51 in moderate 
yields (44-51%). Subsequent mercury-induced lactonization of the alkenes, followed 
by reduction led to the C-linked glycosidic serine derivatives 52-54 as mixtures of 
diastereoisomers, albeit with varying stereochemistry (Scheme 7).  
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If the stereochemistry is in accordance with Nicotra’s reports and Houk’s theory, the 
ribose saccharide led almost solely to the β-altrose derivative, although the relative 
configurations could not be unequivocally determined. However, for the xylose 
derivative 50 as well as for the lyxose derivative 51, ring-closure followed by 
reduction resulted in a complex mixture of four isomers (two pairs of 
diastereoisomers). From these mixtures, the major isomer of the xylose product could 
be separated with flash-column chromatography, but also in this case the 
stereochemistry could not be exactly determined. 
Finally, attempts were undertaken to prepare a C-glycosyl isostere of serine 
glycosylated with an 2-NHAc-glycoside. Since Nature predominantly expresses 
N-acetylgalactose as saccharide moiety attached to serine, the synthesis of such 
C-linked analogues could be of much interest. To this end, 2,3,5-tri-O-benzyl-D-
arabinose was reacted with benzylamine to yield the anomeric N-benzyl derivative 
55 (Scheme 8). 
MgBr
ZnBr2
THF, rt
OH
X
HO
O X
BnO
BnO
55: (ara) X = NHBn
56: (ara) X = NH2
OH
BnHN
BnO
BnO
BnO
CO2MeBocHN
57: (ara) X = NHBn
58: (ara) X = NH2
59
[Ru]
 
Scheme 8. Attempts to prepare the glucosamine derivative 59.  
Subsequent selective N-debenzylation was investigated under several conditions 
(e.g. Pd(OH)210 or DIAD)11 but without success. Therefore, the N-benzyl arabinose 55 
was treated with divinylzinc, formed in situ from vinylmagnesium bromide and zinc 
bromide, to afford heptenitol 57 with complete stereoselectivity. Since steric 
hindrance around the amino function was expected to negatively influence the 
desired cross metathesis, conversion of the N-benzyl function to an azide appeared 
desirable. However, selective debenzylation of 57 again failed to produce the 
unprotected aminoheptenitol 58. A single attempt to use the benzylated substrate for 
cross metathesis reaction with 25 was conducted. However, as expected none of the 
desired alkene product 59 was obtained, but only homodimer 33 was observed. 
These findings are in accordance with earlier observations by others that cross 
metathesis of an N-acetyl-arabino heptenitol yielded minimal amounts of product.8 
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2.4 RCM 
OH
OH
BnO
BnO
BnO CO2H
DCC, DMAP
DCM
OH
O
BnO
BnO
BnO
O
O
O
BnO
BnO
BnO
O
O
O
OH
BnO
BnO
BnO
O
+ +
24
60
61 62 63  
Scheme 9. Synthesis of RCM precursor 63. 
Although a new route for the synthesis of C-linked glycosidic serine analogues was 
successfully developed, it was reasoned that the yields of the metathesis step could 
be significantly improved by performing a ring-closing metathesis (RCM) instead of 
a cross metathesis reaction. To this end, an attempt was made for a selective 
esterification of arabinose heptenitol 24 with commercially available 4-pentenoic acid 
(60). However, as summarized in Scheme 9, a mixture of mono- and diesters was 
obtained with little selectivity for the desired ester 61. 
Table 4. Attempts to apply the RCM approach for the synthesis of acyclic glycoamino acid alkenes. 
OH
O
BnO
BnO
BnO
O
OH
BnO
BnO
BnO
O
O
61 64  
entry solvent T catalystb product 
1 DCM rt G1 (10 mol%) 0% 
2 toluene rt G1 (10 mol%) 0% 
3 DCM rt G2 (10 mol%) mixture 
4 toluene rt G2 (10 mol%) mixture 
5 toluene 80 °C G2 (10 mol%) mixture 
6 toluene 135 °C G2 (10 mol%) mixturea 
aConducted in microwave; 10 min at 300 Watt. bG2: 2nd gen. Grubbs catalyst 
(benzylidene[1,3- bis(2,4,6-trimethylphenyl)-2- imidazolidinylidene] 
dichloro(tricyclohexylphosphine)ruthenium), G1: 1st gen. Grubbs catalyst 
(benzylidene-bis (tricyclohexylphosphine)dichlororuthenium). 
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More disturbingly, separation of the stereoisomers could not adequately be executed 
so that 61 could not be fully separated from regioisomer 62. Nevertheless, a slightly 
impure sample of 61 was used to estimate the value of a RCM strategy by subjection 
to different metathesis catalysts as shown in Table 4. Initially, the first generation 
Grubbs catalyst was applied but did not provide any product (entries 1 and 2). 
Subjecting 61 to the 2nd generation Grubbs catalyst in all cases led to complex 
mixtures of inseparable compounds, with no clear major product formed. 
2.5 CONCLUSION 
In conclusion, a new strategy was developed for the synthesis of C-linked glycosidic 
serine analogues. Key steps of the procedure consist of a cross metathesis reaction 
and a mercury induced etherification. Although the cross metathesis reaction could 
not be executed in a yield exceeding 51%, the strategy presented here is still favored 
over procedures from Dondoni2 and Nolen4 for the preparation of stable C-linked 
serine analogues in terms of yields.  
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2.7 EXPERIMENTAL 
General information.  
Solvents were distilled from appropriate drying agents prior to use and stored under 
nitrogen. When appropriate, reactions were carried out under inert atmosphere of dry 
nitrogen or argon. Standard syringe techniques were applied for the transfer of dry solvents 
and air- or moisture-sensitive reagents. Reactions were followed and Rf values were obtained 
using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 F254) with the 
indicated solvent mixture. Detection was performed with UV-light, and/or by charring at 
~150 °C after dipping into a solution of either 2% anisaldehyde in ethanol/H2SO4, 
(NH4)6Mo7O24.4H2O (25 g/L) or (NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% H2SO4. Melting points 
were analyzed with a Büchi melting point B-545 aparatus. IR spectra were recorded on an 
ATI Mattson Genesis Series FTIR spectrometer, or a Bruker Tensor 27 FTIR spectrometer. 
NMR spectra were recorded on a Bruker DMX 300 (300 MHz), and a Varian 400 (400 MHz) 
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spectrometer. Chemical shifts are given in ppm with respect to tetramethylsilane (TMS) as 
internal standard. Coupling constants are reported as J-values in Hz. Column or flash 
chromatography was carried out using ACROS silica gel (0.035–0.070 mm, and ca 6 nm pore 
diameter). Optical rotations were determined with a Perkin Elmer 241 polarimeter. High 
resolution mass spectra were recorded on a JEOL AccuTOF (ESI), or a MAT900 (EI, CI, and 
ESI). MALDI-TOF-MS spectra were measured on a Bruker Biflex III machine, with 
dihydroxybenzoic acid (DHB) as matrix. Microwave reactions were carried out in a CEM 
Discover microwave. 
 
3,4,5,7-Tetra-O-benzyl-D-glucohept-1-enitol (23)  
A suspension of 2,3,4,6-tetra-O-benzyl-D-glucopyranose (493 mg, 0.91 mmol) 
in dry THF (3 mL) was solubilized at 0 °C under dry nitrogen by the addition 
of n-butyllithium (0.60 mL, 1.6 M in hexanes, 0.96 mmol). A solution of 
methylenetriphenylphosphorane in dry THF (2 mL), prepared at −15 °C 
under dry argon from methyltriphenylphosphonium bromide (679 mg, 1.90 mmol) and n-
butyllithium (1.2 mL, 1.6 M in hexanes, 1.92 mmol) was added at room temperature. Next, 
the mixture was refluxed for 20 min and subsequently, the excess of Wittig reagent was 
destroyed by the addition of acetone (3 mL). The mixture was cooled to 0 °C, filtered, and 
concentrated in vacuo. The residue was purified via flash column chromatography to afford 
23 (328 mg, 0.61 mmol, 67%) as a colorless oil. Rf = 0.29 (EtOAc/heptanes, 1/5). 1H NMR (300 
MHz, CDCl3): δ = 7.36−7.20 (m, 20H), 5.84 (ddd, J = 17.1, 10.4, 7.6 Hz, 1H), 5.31−5.22 (m, 2H), 
4.76 (dd, J = 41.0, 11.3 Hz, 2H), 4.65−4.35 (m, 6H), 4.20 (dd, J = 7.5, 6.1 Hz, 1H), 4.09−3.95 (m, 
1H), 3.83−3.69 (m, 2H), 3.66−3.55 (m, 2H), 2.85 (d, J = 5.6 Hz, 1H). Spectral data are in 
accordance with literature.12 
 
(2S)-tert-Butoxycarbonylamino-4-pentynoic acid methyl ester (25) 
A suspension of (S)–allylglycine (1.13 g, 9.85 mmol) in MeOH (14 mL) was 
treated dropwise at 0 °C with SOCl2 (0.75 mL, 10.3 mmol) and heated to 
reflux for 4 h. The reaction mixture was concentrated in vacuo to give the 
crude amino ester as the HCl–salt. The crude residue was suspended in 
CH2Cl2 (20 mL), Et3N (3.0 mL, 21.6 mmol) and Boc2O (4.2 g, 19.2 mmol) were added and the 
reaction mixture stirred overnight at room temperature. The mixture was concentrated in 
vacuo and purified via flash column chromatography to afford 25 (2.08 g, 9.07 mmol, 92%). Rf 
= 0.29 (EtOAc/heptanes, 1/5). 1H NMR (400 MHz, CDCl3): δ = 5.69 (ddt, J = 17.0, 9.7, 7.2 Hz, 
1H), 5.15 (dd, J = 3.0, 1.3 Hz, 1H), 5.11 (dd, J = 3.0, 1.5 Hz, 1H), 5.03 (bd, J = 6.4 Hz, 1H), 
4.40−4.35 (m, 1H), 3.74 (s, 3H), 2.58−2.43 (m, 2H), 1.44 (s, 9H). Spectral data are in accordance 
with literature.13 
 
Methyl 4-pentenoate (26) 
A suspension of 4-pentenoic acid (7.0 g, 69.9 mmol) in MeOH (20 ml) was treated 
dropwise at 0 °C with SOCl2 (0.75 ml, 10.3 mmol) and heated to reflux for 4 h. The 
reaction mixture was concentrated in vacuo to afford 26 (7.95 g, quant.) as a 
colorless liquid. 1H NMR (400 MHz, CDCl3): δ = 5.85−5.79 (m, 1H), 5.06 (dd, J = 
17.2, 1.4 Hz, 1H), 5.00 (dd, J = 10.2, 0.8 Hz, 1H), 3.67 (s, 3H), 2.44−2.38 (m, 4H). Spectral data 
are in accordance with literature.14  
 
OH
OBn
OBn
BnO
BnO
CO2Me
BocHN CO2Me
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 General procedure A for the preparation of the heptenitols 24, 46-48. 
Step 1, preparation of methyl-D-furanose. To ice-cold methanol (6 mL) was 
added acetyl chloride (0.5 mL) and the mixture was stirred for 5 min. 
Subsequently the methanolic hydrogen chloride (6.5 mL) was added to a 
rapidly stirring solution of the unprotected D-furanose (1.0 g, 0.07 mmol) 
in methanol (20 mL). Stirring was continued for 3 hours at room 
temperature. Next, the reaction mixture was neutralized (saturated aqueous NaHCO3), 
filtered and evaporated in vacuo to afford the crude methyl-D-furanose as a yellow syrup. 
Step 2, preparation of 2,3,5-tri-O-benzyl-D-methyl-furanose. Sodium hydride (60% in oil, 0.8 
g) was added to a stirred solution of methyl-D-furanose (1.0 g, 6.1 mmol) in dry benzene (20 
mL) and dry DMF (11 mL) at 0-5 °C, after which the mixture was stirred for 10 min. Benzyl 
bromide (4.2 mL) was added, and the mixture was heated till 80 °C for 2 h. Next, methanol 
was added to carefully decompose the excess of sodium hydrate. Subsequently the product 
was extracted with ether, washed with water and dried (MgSO4). Purification of the product 
by flash column chromatography (EtOAc/Heptane 1/5) afforded 2,3,5-tri-O-benzyl-D-
methyl-furanose. Step 3, preparation of 2,3,5-tri-O-benzyl-D-furanose. To a solution of 2,3,5-
tri-O-benzyl-D-methylfuranose (320 mg) in acetic acid (40 mL) was added 1M H2SO4 (10 mL) 
and the mixture was heated at reflux for 2 hours. Next, the mixture was diluted with DCM 
(30 mL) and the organic layer was washed with water (3 × 50 mL), dried (Mg2SO4) and 
evaporated in vacuo to afford 2,3,5-tri-O-benzyl-D-furanose. Step 4, preparation of 1,3,4-
trisbenzyloxyhept-6-ene-2,5-diol. To a solution of vinylmagnesium bromide (14.4 mL) in dry 
THF (1 M) a solution of dried ZnBr2 (1.6 g) in THF (4 mL) was added. Subsequently, the 
reaction mixture was stirred for 30 min before adding a solution of 2,3,5-tri-O-benzyl-D-
furanose (1.5 g) in THF (20 mL). The reaction mixture was quenched (saturated aqueous 
NH4Cl), diluted with DCM and washed with 5% HCl, saturated NaHCO3 and water. The 
organic layer was dried (MgSO4) and evaporated in vacuo. Purification of the heptenitols was 
achieved via flash column chromatography using ethyl acetate-heptane mixtures.  
 
(2R,3R,4R,5S)-1,3,4-Tris(benzyloxy)-6-heptene-2,5-diol (arabinose heptenitol) (24) 
Preparation according to step 4 of the general procedure for the heptenitols 
starting from the 1,3,4-tris-benzyloxyhept-6-ene-2,5-diol derivative 
afforded 24 (1.5 g, 3.34 mmol, 93%) as a white solid. Rf = 0.62 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3425, 3084, 3062, 3023, 2863, 1079 
cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.37−7.22 (m , 15H), 5.91 (ddd, J = 17.2, 10.5, 5.6 Hz, 
1H), 5.26 (ddt, J = 56.1, 10.5, 1.6 Hz, 2H), 4.67 (dd, J = 28.7, 11.2 Hz, 2H), 4.53 (d, J = 2.4 Hz, 
2H), 4.57 (d, J = 14.9 Hz, 2H), 4.40 (dq, J = 3.5, 1.4 Hz, 1H), 4.06 (ddd, J = 6.8, 5.4, 3.8 Hz, 1H), 
3.80−3.54 (m, 4H), 2.88 (bs, 2H). 13C NMR (75 MHz, CDCl3): δ = 138.5, 138.1, 138.0, 138.0, 
128.6, 128.3, 128.1, 128.1, 128.0, 127.9, 116.2, 82.0, 78.9, 74.8, 73.9, 73.6, 72.2, 71.1, 70.9. HRMS 
(ESI) m/z calculated for C28H33O5 (M+H)+: 449.2328, found: 449.2310. HRMS (ESI) m/z 
calculated for C28H32O5Na (M+Na)+: 471.2147, found: 471.2138. 
 
(2R,3R,4S)-1,3,4-Tris(benzyloxy)hept-6-ene-2,5-diol (ribose heptenitol) (46) 
 Preparation according to the general procedure for the heptenitols 
afforded 46 (1.1 g, 2.59 mmol, 73%) as a white solid. Rf = 0.62 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3468, 3084, 3058, 3028, 2859, 1082 
cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.37−724 (m , 15H), 5.98 (ddd, J = 
OH
BnO
HO
OBn
OBn
OH
BnO
HO
OBn
OBn
OH
BnO
HO
OBn
OBn
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17.2, 10.6, 5.6 Hz, 1H), 5.32 (ddt, J = 62.6, 10.6, 1.7 Hz, 2H), 4.69−4.60 (m, 4H), 4.51 (d, J = 2.1 
Hz, 2H), 4.45−4.43 (m, 1H), 4.11 (dt, J = 5.0, 4.0 Hz, 1H), 3.78 (ap t,  J = 5.3 Hz, 1H), 3.72 (dd, J 
= 5.2, 3.7 Hz, 1H), 3.62 (bs, 1H), 3.61 (d, J = 2.2 Hz, 1H). 13C NMR (75 MHz, CDCl3): δ = 138.2, 
138.0, 137.9, 137.9, 128.6, 128.2, 128.1, 128.0, 128.0, 116.3, 81.0, 80.3, 74.0, 74.0, 73.6, 72.0, 71.1, 
71.0. HRMS (ESI) m/z calculated for C28H33O5 (M+H)+: 449.2328, found: 449.2354. HRMS (ESI) 
m/z calculated for C28H32O5Na (M+Na)+: 471.2147, found: 471.2129. 
  
(2R,3S,4S)-1,3,4-Tris(benzyloxy)hept-6-ene-2,5-diol (xylose heptenitol) (47) 
 Preparation according to the general procedure for the heptenitols 
afforded 47 (823 mg, 1.83 mmol, 61%) as a white solid. Mixture of isomers 
(7:3). Rf = 0.60 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3417, 3084, 3058, 
3028, 2859, 1091 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.37−7.20 (m, 15H), 
5.99 & 5.91 (ddd, J = 17.2, 10.5, 5.8 Hz & J = 17.2, 10.5, 5.8, 1H), 5.31 & 5.27 (ddt, J = 53.4, 10.5, 
1.6 Hz & J = 61.7, 10.6, 1.6 Hz, 2H), 4.78−4.40 (m, 7H), 4.11 & 4.06 (dt, J = 6.4, 1.6 Hz & J = 6.1, 
2.9 Hz, 1H), 3.76 & 3.72 (dd, J = 5.1, 2.9 Hz & J = 6.6, 1.7 Hz, 1H), 3.65−3.41 (m, 3H), 13C NMR 
(75 MHz, CDCl3): δ = 138.7, 138.1, 138.0, 138.0, 137.8, 137.5, 128.5, 128.4, 128.3, 128.2, 128.1, 
128.1, 127.9, 127.9, 116.5, 115.6, 80.6, 80.4, 87.6, 77.3, 74.5, 74.4, 73.5, 73.4, 72.8, 71.3, 71.2, 70.7, 
69.7, 68.4. HRMS (ESI) m/z calculated for C28H33O5 (M+H)+: 449.2328, found: 449.2336. HRMS 
(ESI) m/z calculated for C28H32O5Na (M+Na)+: 471.2147, found: 471.2153. 
 
(2R,3S,4S)-1,3,4-Tris(benzyloxy)hept-6-ene-2,5-diol (lyxose heptenitol) (48) 
Preparation according to the general procedure for the heptenitols 
afforded 48 (132 mg, 0.29 mmol, 37%) as a white solid. Mixture of isomers 
(7:3). Rf = 0.60 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3421, 3084, 3054, 
3032, 2876, 1087 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.41−7.22 (m, 15H), 
6.08−5.91 (m, 1H), 5.36 & 5.26 (ddt, J = 31.6, 17.2, 1.7 Hz & J = 16.9 ,10.6, 1.6 Hz, 2H), 
4.76−4.43 (m, 8H), 4.13−3.57 (m, 6H). 13C NMR (75 MHz, CDCl3): δ = 138.7, 138.0, 137.8, 133.6, 
129.9, 128.6, 128.4, 128.1, 128.0, 127.8, 116.1, 116.0, 82.7, 81.2, 79.7, 79.5, 79.4, 79.1, 74.6, 74.5, 
74.3, 74.0, 73.7, 73.1, 72.6, 72.4, 71.6, 71.4. HRMS (ESI) m/z calculated for C28H33O5 (M+H)+: 
449.2328, found: 449.2366. HRMS (ESI) m/z calculated for C28H32O5Na (M+Na)+: 471.2147, 
found: 471.2146. 
 
General procedure B for the cross metathesis reaction. 
To a solution of the saccharide (1 equiv, 0.1 M in toluene) was added a 
solution of the allyl substrate (1 equiv, 0.1 M in toluene) followed by the 
addition of the Grubbs catalyst (10 mol%). The resulting mixture was 
stirred at room temperature for 48 hours. Subsequently, the solvent was 
removed in vacuo and the product was isolated as a mixture of isomers via 
flash column chromatography using ethyl acetate/heptanes, 2/3. 
   
(2S,6S,7R,8R,9R)-Methyl 7,8,10-tris(benzyloxy)-2-(tert-butoxycarbonylamino)-6,9-
dihydroxydec-4-enoate (28) 
Preparation according to general procedure B for the cross metathesis 
afforded 28 (20 mg, 0.03 mmol, 50%) as a colorless oil. Rf = 0.16 
(EtOAc/heptanes, 2/3). FTIR (ATR): ν = 3339, 2975, 2880, 1043 cm−1. 1H 
NMR (300 MHz, CDCl3): δ = 7.30−7.23 (m, 15H), 5.67−5.54 (m, 2H), 5.08 
OH
BnO
HO
OBn
OBn
OH
BnO
HO
OBn
OBn
OH
BnO
HO
OBn
OBn
CO2MeR
OH
BnO
HO
OBn
OBn
CO2MeBocHN
Chapter 2 
 
34
(bd, J = 7.8 Hz, 1H), 4.71−4.53 (m, 6H), 4.34−4.31 (m, 2H), 4.01−3.98 (m, 1H), 3.69 (s, 3H), 
3.67−3.65 (m, 3H), 3.61 (t, J = 4.5 Hz, 1H), 3.06 (bd, J = 5.1 Hz, 1H), 3.01 (bd, J = 5.7 Hz, 1H), 
2.51−2.41 (m, 2H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.7, 155.3, 138.2, 138.1, 138.0, 
134.7, 128.6, 128.6, 128.3, 128.2, 128.1, 128.1, 128.0, 127.9, 126.0, 82.5, 80.2, 28.8, 74.7, 74.0, 73.6, 
71.6, 71.1, 70.1, 53.3, 52.5, 35.4, 28.5. HRMS (ESI) calculated for C37H48NO9 (M+H)+: 650.3329, 
found: 650.3357. HRMS (ESI) calculated for C37H47NO9Na (M+Na)+: 672.3149, found: 
672.3140. 
 
(6S,7R,8R,9R)-Methyl 7,8,10-tris(benzyloxy)-6,9-dihydroxydec-4-enoate (29) 
Preparation according to general procedure B for the cross metathesis 
afforded 29 (474 mg, 0.73 mmol, 59%) as a colorless oil. Rf = 0.47 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3447, 2915, 2863, 1731 cm−1. 1H 
NMR (400 MHz, CDCl3): δ = 7.38−7.23 (m, 15H), 5.73−5.65 (m, 1H), 5.53 
(ap dd, J = 15.4, 6.3 Hz, 1H), 4.74−4.50 (m, 4H), 4.34 (bs, 1H), 4.08−4.02 (m, 
1H), 3.70−3.62 (m, 6H), 3.64 (s, 3H), 2.88−2.85 (m, 2H), 2.38−2.33 (m, 4H). 
13C NMR (75 MHz, CDCl3): δ = 173.5, 138.1, 138.0, 137.9, 131.2, 128.5, 128.3, 128.2, 128.0, 128.0, 
127.9, 127.8, 82.2, 78.8, 74.7, 73.8, 73.5, 71.8, 71.1, 70.8, 51.6, 33.5, 27.6. HRMS (ESI) calculated 
for C32H38O7Na (M+Na)+: 557.2515, found: 557.2530. 
 
(2S,7S,8R,9R)-Methyl 7,8,10-tris(benzyloxy)-2-(tert-butoxycarbonylamino)-6,9-dihydroxy-
4-decenoate (49) 
Preparation according to general procedure B for the cross metathesis  
afforded 49 (399 mg, 0.60 mmol, 48%) as a colorless oil. Rf = 0.16 
(EtOAc/heptanes, 2/3). FTIR (ATR): ν = 3386, 2920, 2863, 1709 cm−1. 1H 
NMR (400 MHz, CDCl3): δ = 7.36−7.24 (m, 15H), 5.66−5.62 (m, 2H), 5.15 
(bd, J = 7.8 Hz, 1H), 4.79−4.47 (m, 6H), 4.40−4.34 (m, 2H), 4.08−4.04 (m, 
1H), 3.78−3.75 (m, 1H), 3.70 (s, 3H), 3.68−3.57 (m, 3H),  2.56−2.45 (m, 2H), 
1.41 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.1, 154.9, 137.6, 137.5, 134.2, 
128.2, 128.1, 128.1, 128.0, 128.0, 127.8, 127.9, 127.8, 127.8, 127.8, 127.6, 127.7, 127.6, 127.5, 127.5, 
127.4, 125.8, 81.0, 80.1, 73.8, 73.7, 73.3, 71.3, 71.1, 70.4, 53.1, 52.3, 35.3, 28.4. HRMS (ESI) 
calculated for C37H47NO9Na (M+Na)+: 672.3149, found: 672.3152. 
 
(2S,7S,8S,9R)-Methyl 7,8,10-tris(benzyloxy)-2-(tert-butoxycarbonylamino)-6,9-dihydroxy-4-
decenoate (50) 
Preparation according to general procedure B for the cross metathesis 
afforded 50 (73 mg, 0.11 mmol, 51%) as a colorless oil. Rf = 0.41 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3417, 2924, 2859, 1740, 1709 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.36−7.22 (m, 15H), 5.71−5.54 (m, 2H), 5.29 
& 5.19 & 5.08 (d, J = 8.1 & 8.0 & 8.0 Hz, 1H), 6.68−4.33 (m, 8H), 4.07 (bt, J = 
5.7 Hz, 1H), 3.72 & 3.72 & 3.70 (s, 3H), 3.59−3.41 (m, 3H), 3.21 & 3.11 (bs, 
1H), 2.54−2.45 (m, 2H), 1.42 & 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 
172.7, 155.4, 138.1, 138.0, 137.9, 134.9, 128.6, 128.5, 128.4, 128.1, 128.1, 127.9, 127.7, 125.8, 80.7, 
80.2, 78.3, 74.5, 74.3, 73.3, 71.1, 70.5, 68.4, 53.2, 52.4, 35.3, 28.4. HRMS (ESI) calculated for 
C37H47NO9Na (M+Na)+: 672.3149, found: 672.3152. 
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(2S,7R,8S,9R)-Methyl 7,8,10-tris(benzyloxy)-2-(tert-butoxycarbonylamino)-6,9-dihydroxy-
4-decenoate (51) 
Preparation according to general procedure B for the cross metathesis 
afforded 51 (342 mg, 0.53 mmol, 44%) as a colorless oil. Data of mixture of 
isomers: Rf = 0.41 (EtOAc/heptanes, 1/1). 1H NMR (400 MHz, CDCl3): δ = 
7.38−7.34 (m, 15H), 5.76−5.51 (m, 2H), 5.04 (d, J = 5.1 Hz, 1H), 4.76−4.51 (m, 
6H), 4.41−4.30 (m, 2H), 3.09−3.67 (m, 5H), 3.70 (s, 3H), 2.59−2.33 (m, 2H), 
1.42 (bs, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.6, 155.3, 138.1, 137.9, 
137.7, 134.8, 134.5, 130.0, 129.9, 128.6, 128.5, 128.3, 128.2, 128.1, 128.0, 127.7, 
127.6, 125.9, 82.5, 81.3, 80.1, 79.7, 79.5, 79.1, 74.4, 74.2, 74.1, 73.9, 73.7, 72.6, 71.9, 71.8, 71.1, 
61.4, 60.6, 53.2, 52.4, 35.4, 35.3, 28.4. HRMS (ESI) calculated for C37H48NO9 (M+H)+: 650.3329, 
found: 650.3300. HRMS (ESI) calculated for C37H47NO9Na (M+Na)+: 672.3149, found: 
672.3088. 
 
General procedure C for the mercury lactonization. 
The cross metathesis product (1 equiv) dissolved in DCM (0.05 M) was 
added dropwise to a solution of mercury(II)trifluoroacetate (1.2 equiv) in 
dry DCM (0.05 M) at −78°C. After the substrate disappeared (TLC), the 
reaction was quenched by addition of a saturated KCl solution and stirred 
for 1 hour. The product was extracted with DCM (3 ×) after which the 
organic layer was dried (MgSO4) and evaporated in vacuo to afford the 
crude mercury product as a grey solid.  
 
(1-((3R,4R,5R,6R)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-3-hydroxytetrahydro-2H-pyran-
2-yl)-4-methoxy-4-oxobutyl)mercury(II) chloride (36)  
Preparation according to the general procedure C for the mercury 
lactonization afforded 36 (125 mg, 0.162 mmol, 85%) as a grey solid. Rf = 
0.67 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3421, 2924, 1722, 1264 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.38−7.19 (m, 15H), 4.71−4.46 (m, 6H), 4.20 
(dd, J = 7.2, 1.7 Hz, 1H), 4.08 (ap dd, J = 9.3, 5.4 Hz, 1H), 3.83 (dd, J = 10.2, 
6.5 Hz, 1H), 3.76−3.60 (m, 5H), 3.71 (s, 3H), 2.55−2.37 (m, 3H), 2.14−1.87 (m, 
1H), 1.67 (s, 1H).  13C NMR (75 MHz, CDCl3): δ = 173.3, 138.1, 137.6, 137.1, 
128.9, 128.8, 128.5, 128.4, 128.3, 128.0, 127.9, 127.8, 76.5, 74.4, 73.4, 73.4, 73.2, 73.0, 72.8, 67.8, 
66.5, 51.9, 48.4, 35.7, 25.4. HRMS (ESI) calculated for C32H37ClHgO7Na (M+Na)+: 793.1872, 
found: 793.1872. 
 
((1R,3S)-1-((2S,3R,4R,5R,6R)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-3-hydroxytetrahydro-
2H-pyran-2-yl)-3-(tert-butoxycarbonylamino)-4-methoxy-4-oxobutyl)mercury(II) chloride 
(38) 
Preparation according to the general procedure C for the mercury 
lactonization afforded 38 (143 mg, 0.162 mmol, 87%) as a grey solid. Rf = 
0.63 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3381, 3036, 2920, 2872, 1722, 
1688 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.35−7.19 (m, 15H), 5.18 (bs, 
1H), 4.60−4.46 (m, 6H), 4.31 (bs, 1H), 4.17 (dd, J = 7.0, 1.6 Hz, 1H), 4.07−4.04 
(m, 1H), 3.81−3.55 (m, 6H), 3.77 (s, 3H), 2.41−1.82 (m, 2H), 1.90−1.83 (m, 
1H), 1.46 (s, 9H).  13C NMR (75 MHz, CDCl3): δ = 173.0, 155.8, 138.1, 137.6, 137.1, 128.8, 128.6, 
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128.3, 128.0, 127.9, 127.8, 80.8, 76.3, 74.2, 73.4, 73.4, 73.3, 73.0, 72.7, 67.7, 66.3, 54.4, 52.9, 43.2, 
33.0, 25.5. HRMS (ESI) calculated for C37H47ClHg200NO9Na (M+Na)+: 906.2442, found: 
906.2392. HRMS (ESI) calculated for C37H46ClHg202NO9Na (M+Na)+: 908.2465, found: 
906.2475. 
 
General procedure D for the reduction of the mercury substrates 
The mercury adduct (1 equiv) was dissolved in dry THF (0.2 M) and 
cooled to −78°C. Subsequently Et3B (1.2 equiv) and LiBH4 (1.05 equiv) were 
added and the mixture was stirred for 10 min at 78°C. Next, the reaction 
was quenched by carefully adding a solution of saturated NH4Cl. The 
product was extracted with Et2O (3 ×), and the combined organic layers 
were washed with water, dried (MgSO4), and evaporated in vacuo to afford 
the desired glycosylated product. 
 
Methyl 4-((3S,4R,5R,6R)-4,5-bis(benzyloxy)-6-(benzyloxymethyl)-3-hydroxytetrahydro-2H-
pyran-2-yl)butanoate (39) 
Preparation according to the general procedure D for the reduction of the 
mercury salt afforded 39 (24 mg, 0.04 mmol, 58%). Rf = 0.58 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3477, 3031, 2924, 2867, 1731 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.35−7.21 (m, 15H), 4.69−4.49 (m, 6H), 3.98 
(ap q, J = 5.1 Hz, 1H), 3.89−3.85 (m, 1H), 3.81 (dd, J = 10.2, 5.6 Hz, 1H), 
3.73−3.68 (m, 2H), 3.65 (s, 3H), 3.63 (ap t, J = 5.0 Hz, 2H), 2.83 (d, J = 7.9 Hz, 
1H), 2.35 (t, J = 7.1 Hz, 2H), 1.84−1.55 (m, 4H). 13C NMR (75 MHz, CDCl3): δ = 174.1, 138.3, 
138.1, 137.6, 128.7, 128.6, 128.5, 128.1, 127.9, 127.8, 127.7, 78.2, 75.3, 73.6, 73.5, 73.4, 73.1, 71.6, 
69.9, 68.3, 51.6, 34.0, 27.8, 21.3. HRMS (ESI) calculated for C32H39O7 (M+H)+: 535.2696, found: 
535.2686. HRMS (ESI) calculated for C32H38O7Na (M+Na)+: 557.2515, found: 557.2496. 
 
(S)-Methyl 4-((2R,3S,4R,5R,6R)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-3-
hydroxytetrahydro-2H-pyran-2-yl)-2-(tert-butoxycarbonylamino)butanoate (40) 
Preparation according to the general procedure D for the reduction of the 
mercury salt afforded 40 (30 mg, 0.05 mmol, 68%) as a colorless oil. Rf = 
0.55 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3417, 2933, 1740, 1709 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.36−7.19 (m, 15H), 5.15 (d, J = 8.2 Hz, 1H), 
4.68−4.72 (m, 6H), 4.36−4.25 (m, 1H), 3.96 (d, J = 5.1 Hz, 1H), 3.83 (dd, J = 
9.9 Hz, 1H), 3.81−3.76 (m, 1H), 3.74−3.57 (m, 4H), 3.70 (s, 3H), 2.88 (d, J = 
7.9 Hz, 1H), 2.03−1.90 (m, 1H), 1.76−1.57 (m, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 
173.0, 155.2, 138.0, 137.8, 137.3, 128.5, 128.4, 128.3, 127.8, 127.8, 127.7, 127.6, 127.5, 79.9, 78.1, 
75.1, 73.6, 73.4, 73.3, 73.1, 71.7, 69.8, 68.2, 53.7, 52.4, 29.1, 28.6, 24.5. HRMS (ESI) calculated for 
C37H48NO9 (M+H)+: 650.3329, found: 650.3316. HRMS (ESI) calculated for C37H47NO9Na 
(M+Na)+: 672.3149, found: 672.3106. 
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(S)-Methyl 4-((2S,3R,4S,5R,6R)-4,5-bis(benzyloxy)-6-(benzyloxymethyl)-3-
hydroxytetrahydro-2H-pyran-2-yl)-2-(tert-butoxycarbonylamino)butanoate (52) 
Preparation according to the general procedures C and D for the mercury 
lactonization followed by the reduction of the mercury salt provided 52 
(133 mg, 0.20 mmol, 55% overall) as a colorless oil. Data of major 
compound: Rf = 0.55 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3382, 2915, 
1744, 1714 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.38−7.18 (m, 15H), 5.24 
(d, J = 8.1 Hz, 1H), 4.71 (d, J = 12.1 Hz, 1H), 4.60−4.49 (m, 4H), 4.41 (d, J = 
11.5 Hz, 1H), 4.31−4.21 (m, 1H), 3.96−3.91 (m, 1H), 3.91−3.84 (m, 1H), 3.82 (d, J = 2.8 Hz, 1H), 
3.57 (d, J = 2.6 Hz, 1H), 3.81−3.66 (m, 6H), 3.70 (s, 3H), 2.68−2.43 (m, 1H), 1.91−1.53 (m, 4H), 
1.44 (s,  9H). 13C NMR (75 MHz, CDCl3): δ = 172.5, 154.9, 138.0, 137.7, 137.5, 127.8, 127.8, 
127.8, 127.2, 127.2, 127.2, 127.1, 127.1, 127.0, 79.4, 74.8, 74.4, 74.2, 73.1, 72.6, 72.5, 71.2, 69.7, 
53.2, 52.0, 28.8, 28.1, 26.3. HRMS (ESI) calculated for C37H48NO9 (M+H)+: 650.3329, found: 
650.3307. HRMS (ESI) calculated for C37H47NO9Na (M+Na)+: 672.3149, found: 672.3091. 
  
(S)-Methyl 4-((4S,5S,6R)-4,5-Bis(benzyloxy)-6-(benzyloxymethyl)-3-hydroxytetrahydro-2H-
pyran-2-yl)-2-(tert-butoxycarbonylamino)butanoate (53) 
Preparation according to the general procedures C and D for the mercury 
lactonization followed by the reduction of the mercury salt provided 53 (31 
mg, 0.05 mmol, 69%) as a colorless oil. A pure fraction of the major isomer, 
presumably the β-idose saccharide was isolated via column 
chromatography (11 mg, 0.02 mmol). Data of major isomer:  Rf = 0.55 
(EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3485, 2920, 2863, 1744, 1705 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.37−7.20 (m, 15H), 5.07 (d, J = 8.0, 1H), 4.58−4.52 (m, 4H), 
4.45 (d, J = 11.9 Hz, 2H) 4.40 (d, J = 11.4 Hz, 2H), 4.31−4.24 (m, 1H), 3.99 (t, J = 6.5 Hz, 1H), 
3.82 (t, J = 3.0 Hz, 1H), 3.70 (s, 3H), 3.61−3.45 (m, 4H), 3.30 (d, J = 11.7 Hz, 1H), 2.04−2.00 (m, 
1H), 1.91−1.76 (m, 3H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 173.5, 155.6, 138.3, 137.9, 
137.2, 128.7, 128.5, 128.4, 128.1, 127.9, 127.8, 79.9, 75.5, 74.5, 73.8, 73.6, 73.1, 72.5, 72.2, 69.3, 
69.0, 53.5, 52.3, 289, 28.5. HRMS (ESI) calculated for C37H48NO9 (M+H)+: 650.3329, found: 
650.3329. HRMS (ESI) calculated for C37H47NO9Na (M+Na)+: 672.3149, found: 672.3134. 
 
(S)-Methyl 4-((4R,5S,6R)-4,5-bis(benzyloxy)-6-(benzyloxymethyl)-3-hydroxytetrahydro-2H-
pyran-2-yl)-2-(tert-butoxycarbonylamino)butanoate (54) 
Preparation according to the general procedures C and D for the mercury 
lactonization followed by the reduction of the mercury salt provided 54 (21 
mg, 0.03 mmol, 52%) as a colorless oil. Data of inseparable mixture of 
isomers: Rf = 0.55 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3382, 2933, 2868, 
1740, 1709 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.37−7.20 (m, 15H), 
5.51−5.07 (m, 1H), 4.70−4.19 (m, 7H), 4.11−3.38 (m, 11H), 3.73 & 3.72 & 3.70 
& 3.69 (s, 3H), 2.05−1.75 (m, 2H), 1.43 & 1.43 & 1.42 (s, 9H). HRMS (ESI) calculated for 
C37H48NO9 (M+H)+: 650.3329, found: 650.3320. HRMS (ESI) calculated for C37H47NO9Na 
(M+Na)+: 672.3149, found: 672.3136. 
 
(3S,4R,5R)-3,4-Bis(benzyloxy)-5-(benzyloxymethyl)-2-ethyltetrahydrofuran-2-ol (30) 
Compound 30 is one of the main byproducts that are formed during the 
cross metathesis reaction when using (2R,3R,4R,5S)-1,3,4-tris(benzyloxy)-6-
O
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heptene-2,5-diol (24). Rf = 0.76 (EtOAc/heptanes, 1/1). 1H NMR (400 MHz, CDCl3): δ = 
7.31−7.28 (m, 15H), 4.65−4.40 (m, 6H), 4.15−3.44 (m, 5H), 1.85−1.76 (m, 2H), 1.58 (s, 1H), 0.97 
& 0.94 (2 x t, J = 5.4 Hz, 3H). Spectral data are in accordance with literature.8 
 
(3R,4R,5R,8R,9S,10S,E)-1,3,4,9,10,12-Hexakis(benzyloxy)dodec-6-ene-2,5,8,11-tetraol (32) 
Compound 32 is one of the byproducts that are formed during the 
cross metathesis reaction when applying (2R,3R,4R,5S)-1,3,4-
tris(benzyloxy)-6-heptene-2,5-diol (24). Rf = 0.30 (EtOAc/heptanes, 
1/1). FTIR (ATR): ν = 3430, 2920, 2863, 1455 cm−1. 1H NMR (400 
MHz, CDCl3): δ = 7.33−7.20 (m, 30H), 5.90−5.88 (m, 2H), 4.69−4.57 (m, 7H), 4.51−4.36 (m, 
7H), 4.11 (dt, J = 5.7, 3.5 Hz, 2H), 3.83 (ap t, J = 5.2 Hz, 2H), 3.75−3.45 (m, 6H). 13C NMR (75 
MHz, CDCl3): δ = 139.8, 139.7, 133.5, 129.4, 129.3, 129.2, 129.0, 128.9, 128.8, 128.6, 83.2, 81.9, 
75.2, 74.8, 74.3, 73.2, 72.8, 71.7. HRMS (ESI) calculated for C54H60NO10Na (M+Na)+: 891.4084, 
found: 891.4001. 
 
(2R,7S)-Dimethyl 2,7-bis(tert-butoxycarbonylamino)oct-4-enedioate (33) 
Compound 33 is one of the main byproducts that are formed during the 
cross metathesis reaction when using Boc-protected (R)-propargylglycine 
methyl ester (25). Rf = 0.62 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 3373, 
2980, 1744, 1718 cm−1. 1H NMR (400 MHz, CDCl3): δ = 5.42−5.38 (m, 2H), 
5.08 (d, J = 7.8 Hz, 2H), 4.31 (m, 2H), 3.73 (br s, 6H), 2.46−2.41 (m, 4H), 
1.42 (s, 18H). HRMS (ESI) calculated for C20H35N2O8 (M+H)+: 431.2393, 
found: 431.2374. HRMS (ESI) calculated for C20H35N2O8Na (M+Na)+: 453.2213, found: 
453.2197.   
 
2-Benzylamino-3,4,6-tri-O-benzylarabinose (55) 
To a stirred suspension of tri-O-benzylarabinose (306 mg, 0.73 mmol) in 
MeOH (0.3 mL) was added benzylamine (115 mg, 1.1 mmol) at room 
temperature. Next, the mixture was heated to 55° C and stirred for 48 
hours. Subsequently DCM (5 mL) was added and the resulting mixture was concentrated in 
vacuo to yield 55 as a yellow oil (369 mg, 0.72 mmol, 99%). 1H NMR (200 MHz, CDCl3): δ = 
7.34−7.20 (m, 20H), 4.86 & 4.82 (d, J = 2.2 & 3.7 Hz, 1H), 4.70−4.46 (m, 7H), 4.28−3.80 (m, 5H), 
3.66−3.50 (m, 2H).  Spectral data are in accordance with literature.15  
 
(2R,3R,4R,5S)-5-(Benzylamino)-1,3,4-tris(benzyloxy)-6-hepten-2-ol (57). 
To a 1M solution of vinylmagnesium bromide (5.9 mL, 5.9 mmol) in dry THF 
(6 mL) was added a solution of ZnBr2 (670 mg, 3.0 mmol) and the resulting 
mixture was stirred for 30 min to complete the divinylzinc formation. Next a 
solution of 2-benzylamino-3,4,6-tri-O-benzylarabinose (745 mg, 1.5 mmol) in THF (7 mL) was 
added and the reaction was stirred for 4 hours at room temperature. Subsequently the 
reaction was quenched by addition of a saturated NH4Cl solution. The organic layer was 
diluted with DCM, washed with 5% HCl, saturated aqueous NaHCO3 solution and water, 
dried (MgSO4) and evaporated in vacuo. Purification via flash column chromatography 
afforded 57 (517 mg, 0.96 mmol, 66%). 1H NMR (200 MHz, CDCl3): δ = 7.32−7.19 (m, 20H), 
5.78 (ddd, J = 17.1, 10.2, 8.7 Hz, 1H), 5.23 & 5.14 (dd, J = 10.3, 1.6 Hz & 17.2, 1.4 Hz, 2H), 
OH
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4.69−4.38 (m, 6H), 4.01−3.54 (m, 7H), 3.48 & 3.34 (d, J = 2.2 Hz, 1H). Spectral data are in 
accordance with literature.16 
 
(3R,4R,5R)-4,5,7-Tris(benzyloxy)-6-hydroxyhept-1-en-3-yl pent-4-enoate (61) 
To a solution of 4-pentenoic acid (23 mg, 0.23 mmol) in DCM (2 mL) was 
added DCC (51 mg, 0.25 mmol) and DMAP (3 mg, 0.024 mmol) and the 
mixture was stirred for 20 min, next (2R,3R,4R,5S)-1,3,4-tris(benzyloxy)-6-
heptene-2,5-diol (24) (100 mg, 0.22 mmol) was added and stirring continued 
for 2 hours. Evaporation of the solvent in vacuo and purification of the 
product by flash column chromatography afforded a slightly impure 61 (58 mg, 0.11 mmol, 
48%). 1H NMR (300 MHz, CDCl3): δ = 7.37−7.25 (m, 15H), 5.92−5.73 (m, 2H), 5.68−5.64 (m, 
1H), 5.34−5.16 (m, 2H), 5.09−4.95 (m, 2H), 4.71−4.50 (m, 6H), 4.03−3.98 (m, 1H), 3.85 (dd, J = 
6.6, 3.7 Hz, 1H), 3.67 (dd, J = 6.9, 3.6 Hz, 1H),  3.64−3.58 (m, 2H), 2.61 (d, J = 5.7 Hz, 1H), 
2.43−2.31 (m, 4H). 
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Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less.  
-Marie Curie 
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Synthesis of Triazole-linked 
Glycoamino Acids 
 
 
 
Abstract*:  
An expedient, high-yielding synthesis of triazole-linked glycopeptides is described via 
Cu(I)–catalyzed [3+2] cycloaddition of azido–functionalized glycosides and acetylenic 
amino acids. Both α- and β-configured triazolyl glycopeptides were efficiently prepared by 
a variety of suitably functionalized (oligo)saccharides and (oligo)peptides, resulting in a 
novel class of stable glycopeptide mimics.  
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*Part of this chapter has been published as: B. H. M. Kuijpers, S. Groothuys, A. R. Keereweer,  
P. J. L. M. Quaedflieg, R. H. Blaauw, F. L. van Delft, F. P. J. T. Rutjes, Expedient synthesis of 
triazole-linked glycosyl amino acids and peptides. Org. Lett. 2004, 6, 3123–3126. 
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3.1 INTRODUCTION 
1,3-Dipolar cycloaddition reactions have been applied for several years for the 
preparation of carbohydrate mimics.1 Among the applications is the [3+2] Huisgen 
cycloaddition in the synthesis of N–glycosyl triazoles2 as potential cytostatic agents. 
A drawback of the thermal Huisgen cycloaddition between an acetylene and an 
azide, however, is the inevitable mixture of  two product regioisomers, the 1,4- and 
1,5-disubstituted triazole compounds 4 and 3, respectively (Scheme 1).3 A valuable 
discovery was made in 2002, when Meldal4 and Sharpless5 independently described 
that a copper(I)-catalyzed procedure leads solely to the 1,4-disubstituted 
[1,2,3]-triazole 4. Seldomly a novel reaction attained popularity so rapidly as the 
Cu(I)-catalyzed cycloaddition between an azide and an acetylene,6,7 a reaction that is 
commonly referred to as 'click reaction' or more specifically CuAAC (copper-
catalyzed azido acetylene [3+2] cycloaddition). Several factors are responsible for the 
strong interest in the CuAAC, such as the simple procedures for introduction of 
azides or alkynes into organic molecules, the practical simplicity and mildness of the 
condensation reactions, and the compatibility with water and/or a multitude of 
functional groups as present in biomolecules. In particular the latter reason has led to 
extensive application of the CuAAC for bioconjugation, for example as a result of the 
fact that both acetylenes and azides can be readily introduced into proteins, e.g. by 
protein engineering.8  
N3
R1
R2
+
heat
[CuI], rt
"Huisgen"
"Sharpless / Meldal"
N
NN
R2
R1
+
N
NN R
1
R2
1
2
4, "anti"
1,4-regioisomer
3, "syn"
1,5-regioisomer
V : V
V:\  
Scheme 1. Thermal vs. Cu(I)-catalyzed cycloaddition.   
Although the 1,3-dipolar cycloaddition can be performed under the influence of 
various copper(I) sources (e.g. CuBr, CuI, CuCN, CuCl), best results are often 
achieved by in vivo generation of Cu(I) from a source of copper(II), e.g. CuSO4 or 
Cu(OAc)2, and a reducing agent (e.g. sodium ascorbate). The Cu(I)-catalyzed 
cycloaddition can be conducted in a variety of solvents (or mixtures thereof), 
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including water, alcohols, DMSO, DMF, MeCN and acetone. In most cases the 
reaction proceeds most quickly in an aqueous solvent mixture. However, due to the 
fact that Cu(I) is unstable in aqueous solvents, some of the more sluggish 
cycloadditions benefit from stabilizing ligands such as tris[(1-benzyl-1H-1,2,3-triazol-
4-yl)methyl]amine (TBTA).9  
A proposed mechanism for the copper(I)–catalyzed azido acetylene cycloaddition, 
based on calculations and kinetic studies6,10 is depicted in Scheme 2. 
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Scheme 2. Proposed mechanism for the copper(I)–catalyzed azido acetylene cycloaddition. 
The mechanism starts with the formation of a Cu-acetylide species 6 via coordination 
of Cu(I) (10) with acetylene 2 leading to the π-complex 5, followed by deprotonation 
and replacement of the acetylene proton. Next, an azide 1 replaces one of the ligands 
of the complex and binds to copper via the electron-rich nitrogen (7), thereby 
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inducing attack of the non-terminal acetylide carbon onto the remote nitrogen of 
azide, forming an unusual eight–membered metallocycle 8. Metallocycle 8 has the 
correct conformation for ring–contraction leading to the copper–triazole species 9. 
Proteolysis of 9 and thereby formation of the triazole product 4 completes the 
catalytic cycle and regenerates a Cu(I)-species 10 capable of starting a new cycle. 
N N
N
R1
R2
R1 N
H
R2
O ~
R1 to R2 : 3.9 Å
dipole : 3.92 Debye
R1 to R2 : 5.0 Å
dipole : 4.83 Debye
11 4
 
Figure 1. Physical properties of a triazole compared to an amide. 
During the course of our investigations we became intrigued by the idea of a triazole 
function acting as an amide isostere,6,11,12 in terms of electronic properties and 
placement of substituents, a hypothesis corroborated by studies of van  
Maarseveen et al.12 Despite the common characteristics, some notable differences 
remain, in particular a calculated increase of distance of 1.1 Å between R1 and R2 for 
a triazole as compared to that of an amide bond (Figure 1). In addition, a triazole 
possesses a stronger dipole moment compared to an amide bond,13 a feature that 
may actually enhance peptide bond mimicry by increasing the hydrogen bond donor 
and acceptor properties of a triazole. 
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Scheme 3. Nanotube (14) formation from triazole containing octapeptide 13. 
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A seminal example showing the potential of triazoles acting as amide mimics was 
provided by the group of Ghadiri,11 in a comparison of triazole-containing cyclic 
octapeptides 13 (Scheme 3) to natural peptides. It was found that triazole isosteres of 
peptides 13 behave highly similar to the natural non–triazole containing analogues 
12,14 both forming an extended network resulting in solvent–filled nanotubes 14 
(Scheme 3).  
We hypothesized that triazole mimics of the natural amide linkage in 
N-glycoproteins would entail a novel class of stable glycoprotein analogues with 
potentially relevant biological properties. Modification of proteins by glycosylation is 
an essential post-translational process, and diverse and numerous examples have 
illustrated its key role in the modulation of protein properties.15 For systematic study 
of the effects of protein glycosylation, efficient methods for the synthesis of pure, 
complex, differentially glycosylated proteins and mimics are therefore needed.16 
However, the synthesis of a typical glycoprotein is still far from trivial, while the 
final glycoproteins suffer from the inherent susceptibility to base-induced 
elimination (O-glycoprotein) or enzymatic hydrolysis (N-glycoprotein). Therefore, 
we became interested in an efficient, high-yielding synthesis of triazole-linked 
glycopeptides such as 19 and 20 (Scheme 4), as new and stable glycoamino acid 
isosteres, via the Cu–catalyzed procedure for the [3+2] cycloaddition between organic 
azides and acetylenes.  
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Scheme 4. Retrosynthesis of glycoamino acids. 
An additional stimulus to us was based on the fact that several of the building blocks 
required for the preparation of 19 and 20, i.e. condensation of azidoglycosides 21 
with acetylenic amino acids 22, or acetylenic glycosides 23 with azide–containing 
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amino acids 24, respectively, had already been prepared by us by (chemo)enzymatic 
means. Obviously, besides the aim to solely construct stable glycopeptide mimics, 
the resulting substituted triazoles may be applied for the investigation of 
glycoprotein function but may also serve as a novel compound class for 
pharmaceutical application, for example as vaccines17 or for the treatment of AIDS.18 
3.2 OPTIMIZATION OF REACTION CONDITIONS 
As a model system to probe the viability of coupling azidosugars with organic 
aceylenes, azidoglucoside 26 and (R)-N-Boc-propargylglycine methyl ester (25) were 
chosen (Table 1). The cycloaddition was investigated by application of a variety of 
Cu(I) species (e.g., CuI, CuCl, and CuCN) and bases (e.g. Et3N and DIPEA). Entries 1 
and 2 display the attempts to perform the cycloaddition without a base using a 
mixture of tert-butyl alcohol and water (entry 2) or the non-protic solvent THF  
(entry 1). As shown, only small amounts of the desired product could be isolated  
(2 to 10% yield). 
Table 1. Optimization of the reaction conditions. 
HN CO2Me
O
AcO
AcO
AcO
N3
OAc
+
[Cu]
25 26 27
Boc CO2MeHN
Boc
OAcO
AcO
OAc
AcO
NN
N
 
entry Cu-source mol% base / reductor solvent time yield (%) 
1 CuXa 20 – THF 2 d 3-10
2 CuXa 20 – tBuOH:H2O (1:1) 2 d 2-10
3 CuCN 20 20 equiv DIPEA tBuOH:H2O (1:1) 3 d 50 
4 CuI 20 0.4 equiv DIPEA THF 1 d 64 
5 CuI 20 20 equiv DIPEA THF 5 h 63 
6 Cu-wire N.A. 20 equiv DIPEA THF 2 d ~15 
7 Cu-wire N.A. 20 equiv DIPEA THF 12 d 71 
8 Cu(OAc)2 20 Na ascorbate tBuOH:H2O (1:1) 8 h 98 
9 Cu(OAc)2 1 Na ascorbate tBuOH:H2O (1:1) 2 d 74 
aX = Cl or I or CN 
Clearly, addition of DIPEA as a base dramatically improved the outcome of the 
reaction (entry 3), giving the desired adduct 27 in a yield of 50% after stirring for 3 
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days. Similar results were obtained with CuI or copper wire in THF (entries 4-7). 
Additional equivalents of the base improved the reaction rate, but had negligible 
influence on the yield of the reaction. Optimal results were obtained by addition of 
0.2 equiv of Cu(OAc)2 and 0.4 equiv of sodium ascorbate in a 1:1 (v/v) mixture of 
water and tert-butyl alchohol (entry 8), providing the targeted glycoamino acid 27 in 
98% yield. Reduction of catalyst loading (entry 9) resulted in prolonged reaction time 
and reduced yield.  
3.3 SYNTHESIS OF TRIAZOLE-LINKED GLYCOPEPTIDES 
3.3.1 CuAAC of various sugar azides 
Having optimized the [3+2] cycloaddition for azidoglucoside 26 and (R)-N-Boc-
propargylglycine methyl ester (25), the scope of the CuAAC reaction for the 
preparation of a variety of glycoamino acids was explored. To this end, several 
different protected azidosugars (Table 2) were prepared via literature procedures and 
subjected to [3+2] cycloaddition with (R)-N-Boc-propargylglycine methyl ester (25) 
under the optimal conditions (0.2 equiv of Cu(OAc)2 and 0.4 equiv of sodium 
ascorbate in a 1:1 (v/v) mixture of water and tert-butyl alchohol). First of all, 
condensation of galacto-configured azide 28 (entry 2) proceeded similarly smooth as 
the model gluco-configured model glycoside 26 (entry 1) to provide the targeted 
glycoamino acid 29 in 89% yield. Under the same conditions, the more sterically 
hindered and more electron-rich benzylated glycosylazide 30a also led to the 
corresponding adduct 31a in excellent yield. As shown, the same azide as a mixture 
of anomers 30a/b (α:β = 1:4) gave the triazolyl product 31a/b in the same anomeric 
ratio and yield as the starting azides (entry 4), providing a strong indication that α 
and β-anomers react similarly. Since the first carbohydrates on N- and  
O-glycoproteins in Nature are mostly formed by N-acetyl-β-D-glucosamine or  
N-acetyl-α-D-galactosamine, we were intrigued whether 1-azido-N-
acetylglucosamine (32) and 1-azido-N-acetylgalactosamine (34) would also be 
compatible with the conditions of the [3+2] cycloaddition.  
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Therefore, the preparation of 32 and 34 was first undertaken by subjecting 
N-acetylglucosamine and N-acetylgalactosamine to Shiozaki conditions19 (with the 
slight modification of substituting pure tin(IV)chloride by a 1 M solution in DCM), 
but complex mixtures of inseparable compounds were obtained. The desired 
1-azidosugars 32 and 34 could be prepared, however, by SN2 displacement of the 
corresponding anomeric chlorides, in turn readily obtained by treatment of the  
N-acetylated aminosugar with neat acetyl chloride. Gratifyingly, these azides reacted 
efficiently with the acetylenic amino acid 25 to give the corresponding products 33 
and 35 in good yields (entries 5 and 6). Reaction of the benzoyl-protected 
glucosamine 36 proceeded smoothly as well, leading to rapid conversion of starting 
material, although partial decomposition during work-up and column 
chromatography resulted in a somewhat lower yield of glycoamino acid 37  (entry 7). 
The glucose derivative 38 containing a 2-azido function shows the possibility of 
introducing the triazole to other positions of the carbohydrate (as reported by 
Meldal),4 giving the desired coupling product 39 in 71% yield (entry 8). Finally, 
condensation of 5-ring azidofuranose 40 leading to the triazolyl glycoamino acid 41 
(entry 9) proceeded uneventfully. Clearly, there were no noticeable differences in 
reactivity between the several monosaccharides or between the α- and β-isomers. 
3.3.2 CuAAC of various amino acids 
Besides variation of the saccharide moiety, the compatibility of a diversity of amino 
acid protective groups with the established conditions was also investigated. Several 
of the non-proteinogenic amino acids were available to us, while others were readily 
prepared by known methods.20 A variety of N-protective groups was investigated, 
including Fmoc (48 and 50), tosyl (52), nosyl (54), and Cbz (42). Additionally, various 
carboxyl protecting groups were applied including a benzyl (48) and a tert-butyl (54) 
ester. Substrates of various chain-length were included (44 and 46), as well as α-
methyl propargylglycine (56) and an acetylenic aminonitrile (58). The results of 
condensing the array of various acetylenic amino acids under the optimal conditions 
(0.2 equiv of Cu(OAc)2 and 0.4 equiv of sodium ascorbate in a 1:1 (v/v) mixture of 
water and tert-butyl alcohol) with azidoglucoside 26 are displayed in Table 3. Entries 
1-2 and 5-7 show that besides the Boc also Cbz, Fmoc, Ts and Ns are well-suited, 
providing the desired products in moderate to good yields (50–91%).  
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The somewhat lower yield of the Cbz protected product 43 as compared to the  
Boc-protected analogue was probably due to solubility problems of the starting 
material. In addition to the methyl ester, a variety of different carboxyl protecting 
groups appeared perfectly stable under the reaction conditions, such as benzyl (49) 
and tert-butyl esters (55). Increasing the length of the side chain, as for (R)-N-Boc-
homopropargylglycine methyl ester 44 or (R)-N-Boc-bishomopropargylglycine 
methyl ester 46 (entries 2 and 3) showed no significant change in reactivity, 
providing products 45 and 47 in good yields. Similarly, α-methyl–substituted 
propargylglycine 56 (entry 8) afforded the glycoamino acid 57 in 85% yield, but 
application of the acetylenic aminonitrile 58 afforded the desired adduct 59 in 
somewhat lower yield (60%). Summarizing, a wide range of carboxyl and  
N-protective groups is suitable for CuAAC with azidosugars, but amino acids 
lacking an amino protective group 60 could not be successfully coupled.  
3.3.3 Other combinations of azidosugars and acetylenic amino acids 
Besides the triazolyl glycoamino acids described above, a few additional 
combinations of azidosugars and acetylenic amino acids were subjected to copper(I)-
catalyzed cycloaddition (Table 4). Not surprisingly, cycloaddition of previously 
applied substrates (entries 1 and 2) proceeded uneventfully. To validate the use of 
unprotected carbohydrates azidoglucosamine 32 was hydrolyzed using a solution of 
K2CO3 in MeOH affording the O-unprotected azidosugar 64. Remarkably, Cu(I)-
catalyzed cycloaddition with unprotected sugar 64 and (R)-N-Boc-propargylglycine 
methyl ester 25 (entry 3) also proceeded smoothly, leading to quantitative formation 
of the desired compound 65 as indicated by TLC analysis. However, due to the high 
water solubility of compound 65, it could not be isolated in sufficiently purified 
form. Finally, the unprotected sugar 64 was also reacted with propargylglycine 62 
containing a free carboxylic acid, again giving full conversion to the desired product 
66 as shown by TLC. 
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Table 4. Other triazolyl glycoamino acids via CuAAC. 
saccharide
Cu(OAc)2, Na-ascorbate
H2O / tBuOH
amino acidN3
NN
N
saccharide
amino acid
 
entry azido saccharide amino acid acetylene glycopeptidea yieldb 
1
3
CO2MeHN
Ts
CO2HHN
Boc
CO2HHN
Boc
2
N3
O
BnO
BnO
BnO
BnO
N3
O
AcO
AcO
AcO
AcHN
N3
O
HO
HO
HO
NHAc
52
62
62
30a
32
64
3
CO2MeHN
Boc
N3
O
HO
HO
HO
NHAc
2564
(82%)
(86%)
(n.i.)
(53%)
61
63
66
65
NN
N
CO2MeHN
O
BnO
BnO
BnO
BnO
Ts
CO2HHN
O
AcO
AcO
AcO
NHAc
Boc
NN
N
O
HO
HO
HO
NHAc
CO2MeHN
Boc
NN
N
O
HO
HO
HO
NHAc
CO2HHN
Boc
NN
N
 
aReagents and conditions: 1 equiv azidoglycoside 30a, 32 or 64, 1 equiv amino acid 25, 52 or 62, 0.2 
equiv Cu(OAc)2, 0.4 equiv Na-ascorbate, H2O/tBuOH, 1:1 (v/v), rt, 16 h. bYield of isolated product. 
Purification was now effected with ion-exchange chromatography, albeit that only a 
moderate yield (53%) of 66 was obtained. An easier and higher yielding route 
towards unprotected triazolyl glycoamino acids is based on cycloaddition of the 
acetyl-protected analogues, followed by deprotection with K2CO3 in MeOH.  
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3.3.4 CuAAC of dipeptides and disaccharides 
Table 5. Cycloaddition reactions of dipeptides. 
dipeptide
Cu(OAc)2, Na-ascorbate
H2O /
tBuOH
26
O
AcO
AcO
AcO
N3
OAc N
NNO
AcO
AcO
AcO
OAc
dipeptide
 
entry acetylenic dipeptide glycopeptidea yieldb 
N
NN
(86%)
MeO2C N
H
O
Me
NH
1
67
N
NN
(92%)
MeO2C NH
O
N2
69
Boc
Boc
Boc-Ala-N CO2Me
H
Boc-Pro-N CO2Me
H
O
AcO
AcO
AcO
OAc
O
AcO
AcO
AcO
OAc
N
H
CO2Me
O
TsHN
71
3
O
AcO
AcO
AcO
N
OAc
NN
TsHN
H
N
O
CO2Me
N
N
N
O
AcO
AcO
AcO
OAc
(55%)c
68
70
72
 
aReagents and conditions: 1 equiv azidoglycoside 26, 1 equiv dipeptide, 0.2 equiv Cu(OAc)2, 0.4 
equiv sodium ascorbate, H2O/tBuOH 1:1 (v/v), rt, 16 h. bYield of isolated product. c2 equiv 
azidoglycoside 26 was used. 
As a first study towards the assembly of complex triazolyl glycopeptides, it is 
essential that CuAAC is not limited to single amino acids or saccharides, but can be 
efficiently extended to oligopeptides and olgiosaccharides, respectively. Thus, 
dipeptides 67, 69 and 71 were prepared via standard coupling procedures, and 
served as simple model peptides to explore the suitability of CuAAC for the 
preparation of glycoproteins (Table 5). For example, the two protected dipeptides 67 
and 69 were successfully coupled to glycosyl azide 26, affording the glycopeptides 68 
and 70 in 86 and 92% yield, respectively.  
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Table 6. Cycloaddition reactions involving a disaccharide. 
amino acid
Cu(OAc)2, Na-ascorbate
H2O / tBuOH
O
AcO
AcO OAc
AcO
O
AcO
O
AcO
N3
OAc73
N
NNO
AcO
AcO OAc
AcO
O
AcO
O
AcO
OAc
amino acid
 
entry amino acid acetylene glycopeptidea yieldb 
1
2
N
NN
(81%)
MeO2C NH
O
NH
N
NN (83%)
CO2MeHN25
67
Me
Boc
Boc
CO2MeHN
Boc
CO2MeBoc-Ala-N
H
O
AcO
AcO OAc
AcO
O
AcO
O
AcO
OAc
O
AcO
AcO OAc
AcO
O
AcO
O
AcO
OAc
74
75
 
aReagents and conditions: 1 equiv azidoglycoside 73, 1 equiv amino acid, 0.2 equiv Cu(OAc)2, 
0.4 equiv Na-ascorbate, H2O/tBuOH 1:1 (v/v), rt, 16 h. bYield of isolated product. 
 
The dipeptide 71 bearing two adjacent acetylene functionalities could also be readily 
reacted with azidosugar 26. The diglycosylated dipeptide 72 was successfully 
obtained, although the reaction proceeded considerably slower and therefore led to 
the desired product in somewhat lower yield (55%), possibly due to increased steric 
interactions. Inversely, the disaccharide azide 73 was coupled to amino acid 25 or 
dipeptide 67 to give the corresponding triazoles 74 and 75 with satisfactory yields 
(Table 6). 
3.3.5 CuAAC involving β-cyclodextrin and an oligopeptide 
Considering the fact that disaccharides and dipeptides coupled smoothly under the 
action of Cu(I)-catalysis, the stage was set to investigate the synthesis of triazole 
compounds involving larger and more complex structures like oligosaccharides and 
oligopeptides. To this end, mono-6-O-azido-β-cyclodextrin was chosen as a readily 
accessible model oligosaccharide. Treatment of dried β-cyclodextrin 76 with tosyl 
choride (0.9 equiv) in pyridine provided mono-6-O-tosylated β-cyclodextrin 77 as the 
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main product (Scheme 5), in combination with amounts of di- and trisubstituted 
products. Because separation of the differentially substituted products failed to 
proceed satisfactorily, the crude mixture containing 77 was treated with NaN3 in 
DMF to provide the mono- , di- and trisubstituted azides. The desired monoazido-β-
cyclodextrin 78 could now be separated from the other azides by repetitive flash 
column chromatography, providing compound 78 in 15% over the two steps.  
OH
7
TsCl, pyridine
0 °C rt
RHO 6
O
HO OH
HO
O
7
76
77: R = OTs
78: R = N3
(15%, 2 steps)
NaN3
90 °C
DMF
1) Cu(OAc)2,
Na-Ascorbate
tBuOH/H2O
2) LiOH (aq)
dioxane
NHO 6 N
N
CO2HBocHN
79 (81%)
CO2MeBocHN
25
→
 
Scheme 5. Cu(I) catalyzed cycloaddition of mono azido-β-cyclodextrin. 
Compound 78 is a completely unprotected heptasaccharide and therefore suitable to 
serve as a typical oligosaccharide prototype. In order to establish whether CuAAC of 
78 would occur with an azidofunctionalized amino acid, Boc-protected 
propargylglycine methyl ester (25) was stirred with monoazido-β-cyclodextrin 78 
under the standard conditions with Cu(OAc)2 and sodium ascorbate in a mixture of 
tert-butanol and water (1:1), leading to a novel compound as judged by TLC analysis. 
Subsequent hydrolysis of the methyl ester and purification by ion exchange column 
chromatography provided a white fluffy substance, NMR analysis of which showed 
the typical triazole singlet at 7.64 ppm (1H NMR). Moreover, high resolution mass 
spectrometry revealed that a compound had been formed with the accurate mass of 
the expected product 79, isolated in a yield of 81%. It is therefore safe to conclude 
that copper(I)-catalyzed azide acetylene cycloaddition can be perfectly applied to 
oligosaccharide systems.  
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Figure 2. Glycosylated peptide analogue of HIV fragment C34 (80). 
The final question to be answered is whether CuAAC is also suitable for synthesis of 
longer chain oligopeptides. Thus, a 34-mer fragment of the HIV gp41 glycoprotein21 
was synthesized on solid phase. Cycloaddition to azidoglucosamine 32 under the 
typical conditions proceeded successfully leading to the desired 34-mer glycosylated 
peptide 8022 (Figure 2). 
3.3.6 C–linked triazolyl glycoamino acids  
Table 7. Synthesis of triazole-linked glycosidic amino acids from acetylene containing saccharides.23 
HN CO2R
N3
Cu(OAc)2, Na-ascorbate
H2O / tBuOH
N
NN
CO2RHN
( )n
( )nBoc
Boc
83-84saccharide
saccharide
 
entry acetylenic saccharide  amino acid  n R glycopeptidea yieldb 
1 
O
HO
HO
HO
OH81  
83a 1 H 85a 70% 
2 83b 2 H 85b 73% 
3 83c 3 H 85c 71% 
4 84 1 Me 86 84% 
   
 
O
HO
HO
HO
HO
82  
 
5 83a 1 H 87a 60% 
6 83b 2 H 87b 60% 
aReagents and conditions: 1 equiv acetylenic glycoside, 1 equiv amino acid, 0.2 
equiv Cu(OAc)2, 0.4 equiv Na ascorbate, H2O/tBuOH 1:1 (v/v), rt, 16 h. bYield of 
isolated product. 
Since all examples so far comprise the combination of azidoglycosides with 
acetylenic amino acids, we were intrigued whether ligation of constituents with 
inverted functionality, with the triazole N1 position bound to the amino acid, would 
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also be feasible. Therefore, a set of acetylenic glycosides and azide–containing amino 
acids were prepared and it was shown that N-linked triazolyl glycopeptides can also 
be readily obtained via the Cu-catalyzed [3+2] cycloaddition. Both α- and  
β-glycopeptide products (85–87) were formed uneventfully in yields ranging from 60 
to 84% (Table 7). In general, the slighly lower yields for the amino acid derivatives 
containing a free carboxylic acid can be rationalized by the somewhat more 
cumbersome purification as compared to the corresponding methyl ester 
counterparts. Furthermore, virtually no change in reactivity was observed upon 
elongation of the amino acid side chain as can be inferred from Table 7, entries 1-3. 
3.4 CONCLUSION 
In conclusion, we have developed a straightforward, versatile and high yielding 
method for the synthesis of a novel class of glycopeptides, involving the copper(I)-
catalyzed azide-alkyne cycloaddition. The resulting triazole-linked products, 
mimicking the N-linked glycosides found in Nature, have potential biological 
properties. By application of this method a small library of glycosidic amino acids 
was prepared by combination of a variety of azido-functionalized glycosides with a 
range of acetylenic amino acids. We have shown that a wide range of saccharide as 
well as amino acids protecting groups are compatible with the conditions used. 
Furthermore we demonstrated that neither the chain-length of the amino acids nor 
the anomeric configuration of the saccharide moiety significantly influences reaction 
rates. Besides single amino acids and saccharides, more complex (oligo)peptides and 
(oligo)saccharides can be successfully ligated in this manner. 
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3.6 EXPERIMENTAL 
General information. For general experimental details, see Section 2.6 
 
Nomenclature of the triazole-linked glycosidic amino acids. For the sake of clarity the 
names of the triazole-linked glycosidic amino acids/peptides in the experimental part of this 
Thesis were abbreviated, applying the standard three letter codes for natural amino acids. 
For the non-proteinogenic amino acids we derived a code as depicted in Figure 6. 
Propargylglycine was abbreviated as Pgl, T4M stands for a triazol-4-yl-methylglycine-
containing amino acid (Figure 3) and triazol-1-yl-butylglycine was for example abbreviated 
as T1B. Any substituents are presented in brackets. 
 
 
N
H
NN
NX
O
n = 1: T1M(4-x)
[2-(4-X-Tr iazol-1-yl)Methyl]glycine
n = 2: T1E(4-x)
[2-(2-[4-X-Triazol-1-yl]Ethyl)]glycine
n = 3: T1P(4-x)
[2-(3-[4-X-Triazol-1-yl]Propyl)]glycine
N
H
N
NN
X
O
n = 1: T4M(1-x)
[2-(1-X-Tr iazol-4-yl)Methyl]glycine
n = 2: T4E(1-x)
[2-(2-[1-X-Triazol-4-yl]Ethyl)]glycine
n = 3: T4P(1-x)
[2-(3-[1-X-Triazol-4-yl]Propyl)]glycine
( )n ( )n
 
Figure 3. Nomenclature of the triazole-linked glycosidic amino acids. 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl azide (26) 
Trimethylsilyl azide (238 μL, 1.79 mmol) and tin tetrachloride (930 μL, 1 M in 
DCM) were added at room temperature to a solution of 1,2,3,4,6-penta-O-
acetyl-D-glucopyranose (500 mg, 1.28 mmol) in DCM (4 mL). Additional 
DCM was added after stirring the reaction mixture for 45 min and the 
solution was washed with H2O, aqueous 1 M HCl and saturated aqueous NaHCO3. The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo to afford 26 (472 mg, 
1.26 mmol, 99%) as a white solid. Rf = 0.52 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 2111, 1748, 
1364, 1238, 1208 cm−1. 1H NMR (400 MHz, CDCl3): δ = 5.21 (app t, J = 9.5 Hz, 1H), 5.01 (app t, 
J = 9.7 Hz, 1H), 4.95 (dd, J = 9.5, 8.9 Hz, 1H), 4.64 (d, J = 8.9 Hz, 1H), 4.27 (dd, J = 12.5, 4.8 Hz, 
2H), 4.17 (dd, J = 12.5, 2.3 Hz, 1H), 3.79 (ddd, J = 10.0, 4.8, 2.3 Hz, 1H), 2.10 (s, 3H), 2.07 (s, 
3H), 2.01 (s, 3H), 1.99 (s, 3H). Spectral data are in accordance with literature.24  
 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl azide (28) 
Trimethylsilyl azide (0.8 mL, 6.08 mmol) and tin tetrachloride (3.8 mL, 1M in 
DCM) were added at room temperature to a solution of 1,2,3,4,6-penta-O-
acetyl-D-galactopyranose (2.02 g, 5.17 mmol) in DCM (20 mL). Additional 
DCM was added after stirring the reaction mixture for 45 min and the 
solution was washed with H2O, aqueous 1 M HCl and saturated aqueous NaHCO3. The 
organic layer was dried (Na2SO4), filtered and concentrated in vacuo to afford 28 (1.92 g, 5.15 
OAcO
AcO
OAc
AcO N3
O
AcO OAc
OAc
AcO N3
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mmol, 99%) as a white solid. Rf = 0.42 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 2120, 1735, 
1372, 1216 cm−1. 1H NMR (400 MHz, CDCl3): δ = 5.43 (dd, J = 3.2, 1.2 Hz, 1H), 5.17 (dd, J = 
10.4, 8.8 Hz, 1H), 5.04 (dd, J = 10.4, 3.6 Hz, 1H), 4.60 (d, J = 8.4 Hz, 1H), 4.17 (dd, J = 7.2, 3.2 
Hz, 2H), 4.02 (dt, J = 6.6, 1.2 Hz, 1H), 2.17 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 1.99 (s, 3H). 
Spectral data are in accordance with literature.25 
 
2,3,4,6-Tetra-O-benzyl-β-D-glucopyranosyl azide (30a) 
A solution of 2,3,4,6-tetra-O-benzyl-D-glucose (222.6 mg, 0.41 mmol) in DCM 
(10 mL) and DMF (0.40 ml, 5.15 mmol), was treated with oxalyl chloride (0.5 
mL, 5.26 mmol) and stirred for 4 h. Concentration of the reaction mixture in 
vacuo afforded the crude sugar halide. Next, the sugar halide was treated 
with NaN3 (30 mg, 0.46 mmol) in DMF (5 mL) and stirred for 4 h at room temperature before 
concentrating the organic layer to a small volume in vacuo. EtOAc was added and the 
mixture was washed with H2O, aqueous 1 M HCl, and saturated aqueous NaHCO3, dried 
(Na2SO4) and concentrated in vacuo to afford 30a (207 mg, 0.37 mmol, 90%) as a white solid. 
Rf = 0.82 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 3347, 2907, 2111 cm−1. 1H NMR (400 MHz, 
CDCl3): δ = 7.35−7.22 (m, 18H), 7.15−7.08 (m, 2H), 4.90−4.71 (m, 5H), 4.63−4.50 (m, 4H), 
3.72−3.59 (m, 2H), 3.49−4.39 (m, 1H), 3.38−3.33 (m, 1H). Spectral data are in accordance with 
literature.26 
 
2,3,4,6-tetra-O-benzyl-α,β-D-glucopyranosyl azide (30a/b) 
To a solution of 2,3,4,6-tetra-O-benzyl-D-glucose (179 mg, 0.33 mmol) in 
DMF (5 mL) was added DBU (82 μL, 0.60 mmol) and DPPA (168 mg, 0.61 
mmol) and the mixture was stirred for 12 h. Subsequently, EtOAc was added 
and the mixture was washed with H2O, aqueous 1 M HCl, and saturated 
aqueous NaHCO3, dried (Na2SO4) and concentrated in vacuo. The crude 
product was purified by flash column chromatography (EtOAc/heptane, 1/3)to afford 30a/b 
(150 mg, 80%) as a mixture of isomers (α:β 1:4). For spectral data of the major isomer see 30a. 
 
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl azide (32) 
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (500 mg, 1.28 mmol) was dissolved 
in acetyl chloride (4 mL) and stirred until it became a thick pink mass. Next, 
again 4 mL of acetyl chloride was added and the mixture was stirred 
overnight and subsequently diluted with ice–cold DCM, and poured into an 
NaHCO3 ice–bath. The crude α–chloride was extracted with EtOAc, washed with ice–cold 
brine, dried (Na2SO4) and concentrated in vacuo. Then it was redissolved in DMF (5 mL), 
NaN3 (125 mg, 1.93 mmol) was added and the mixture was stirred overnight at room 
temperature The mixture was concentrated in vacuo and taken up in EtOAc and H2O. The 
aqueous layer was extracted with EtOAc and the combined organic layers were washed with 
saturated aqueous NaHCO3 and brine, dried (Na2SO4) and concentrated in vacuo. The crude 
product was purified by flash column chromatography (EtOAc/heptane, 2/1) to obtain 32 
(73.1 mg, 0.19 mmol, 15%) as a white solid. Rf = 0.10 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 
2115, 2098, 1744, 1221 cm−1. 1H NMR (400 MHz, CDCl3): δ = 5.66 (d, J = 8.9 Hz, 1H), 5.24 (dd, 
J = 10.6, 9.3 Hz, 1H), 5.10 (dd, J = 10.0, 9.4 Hz, 1H), 4.76 (d, J = 9.3 Hz, 1H), 4.28 (dd, J = 12.5, 
4.8 Hz, 1H), 4.17 (dd, J = 12.4, 2.4 Hz, 1H), 3.94−3.87 (m, 1H), 3.79(ddd, J = 10.4, 4.8, 2.4 Hz, 
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1H), 2.10 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.98 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 171.0, 
170.7, 170.5, 169.3, 88.4, 74.0, 72.2, 68.1, 61.9, 54.2, 23.2, 20.7, 20.6, 20.5. Spectral data are in 
accordance with literature.24 
 
2-Acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-galactopyranosyl azide (34) 
Galactosamine (249 mg, 1.12 mmol) was dissolved in acetyl chloride (4 mL) 
and stirred until the mixture became a thick pink mass. Next another 4 mL of 
acetyl chloride was added, the mixture was stirred overnight and 
subsequently diluted with ice–cold DCM, and poured into an NaHCO3 ice–
bath. The crude α–chloride was extracted with EtOAc, washed with ice–cold brine, dried 
(Na2SO4) and concentrated in vacuo, and redissolved in DMF (5 mL). NaN3 (125 mg, 1.93 
mmol) was added and the mixture was stirred overnight at room temperature The mixture 
was concentrated in vacuo and taken up in EtOAc and H2O. The aqueous layer was extracted 
with EtOAc and the combined organic layers were washed with saturated aqueous NaHCO3, 
brine, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by flash 
column chromatography (EtOAc/heptane, 2/1) to obtain 34 (20 mg, 0.05 mmol, 5%) as a 
white solid. Rf = 0.13 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 2111, 1739, 1364, 1225 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 5.58 (d, J = 8.8 Hz, 1H), 5.38 (dd, J = 3.3, 0.8 Hz, 1H), 5.24 (dd, 
J = 11.2, 3.3 Hz, 1H), 4.79 (d, J = 9.2 Hz, 1H), 4.17−4.15 (m, 2H), 4.03−3.99 (m, 2H), 2.16 (s, 3H), 
2.06 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H). Spectral data are in accordance with literature.27 
 
2,3,5-Tri-O-benzyl-β-D- ribofuranosyl azide (40) 
Acetic anhydride (2 mL) was added to a solution of 2,3,5-tri-O-benzyl ribose (102 mg, 0.24 
mmol) in pyridine (1 mL), the mixture was stirred overnight at room 
temperature. Saturated aqueous NaHCO3 was carefully added and 1–O–
acetyl–2,3,5–tri–O–benzyl ribose was extracted with DCM (3 ×). After 
purification with flash column chromatography (94 mg, 0.20 mmol, 84%), the 
compound was dissolved in dry DCM (1 mL) and , trimethylsilyl azide (35 μL, 0.26 mmol) 
and tin tetrachloride (20 μL, 1M in DCM) were added at room temperature. Next, the 
reaction mixture was stirred for 45 min, DCM was added and the solution was washed with 
H2O, aqueous 1M HCl and saturated aqueous NaHCO3. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography to afford 40 (85 mg, 0.19 mmol, 79% 2 steps) as a white solid. Rf = 0.26 
(EtOAc/heptane, 1/3). 1H NMR (400 MHz, CDCl3): δ = 7.38−7.28 (m, 15H), 5.35 (d, J = 2.1 
Hz, 1H), 4.36 (ddd, J = 6.8, 4.6, 3.3 Hz, 1H), 4.67−4.47 (m, 6H), 4.08 (dd, J = 6.7, 4.7 Hz, 1H), 
3.77 (dd, J = 4.6, 2.1 Hz, 1H), 3.67 (dd, J = 10.8, 3.3 Hz, 1H), 3.56 (dd, J = 10.8, 4.6 Hz ,1H). 
Spectral data are in accordance with literature.28 
 
2-Acetamido-2-deoxy-β-D-glucopyranosyl azide (64) 
To a solution of 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D glucopyranosyl 
azide (32, 100 mg, 0.27 mmol) in MeOH was added K2CO3 (5 mg, 0.03 mmol) 
and the mixture was stirred overnight. Next acidic ion–exchange (amberlite 
IR–120) was added until the solution became neutral. After filtration the 
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solvent was evaporated in vacuo to afford 64 (74 mg, 0.26 mmol, 96%) as a white solid. 
1H NMR (400 MHz, D2O): δ = 4.72 (d, J = 9.1 Hz, 1H), 4.09−4.06  (m, 1H), 4.23−3.72 (m, 2H), 
3.42−3.19 (m, 3H), 2.01 (s, 3H). Spectral data are in accordance with literature.29 
 
2,3,5,2',3',4',6'-Hepta-O-acetyl-β-D-lactopyranosyl azide (73) 
To a suspension of D-lactose (1.00 g, 2.92 mmol) in acetic 
anhydride (15 mL) was added NaOAc (240 mg, 2.93 mmol) and 
the resulting mixture was heated until reflux for 5 h. After cooling, 
EtOAc was added and the organic layer was washed with heptane, 
H2O, saturated aqueous NaHCO3 and brine, dried (MgSO4) and evaporated in vacuo to afford 
the crude 1,2,3,5,2',3',4',6'–octa–O–acetylα,β–D–lactopyranose as slightly yellow solid. Next, 
trimethylsilyl azide (100 μL, 0.75 mmol) and tin tetrachloride (510 μL, 1M in DCM) were 
added at room temperature to a solution of the crude octaacetylated lactose (435 mg, 0.64 
mmol)  in dry DCM (4 mL). After 45 min, DCM was added and the solution was washed 
with H2O, aqueous 1 M HCl and saturated aqueous NaHCO3. The organic layer was dried 
(Na2SO4), filtered and concentrated in vacuo. The crude product was purified by flash column 
chromatography (EtOAc/heptane, 1/1) to afford 73 (294 mg, 0.44 mmol, 69%) as a white 
solid. FTIR (ATR): ν = 2116, 1740, 1368, 1208 cm−1. Rf = 0.48 (EtOAc/heptane, 1/1). 1H NMR 
(400 MHz, CDCl3): δ = 5.35 (dd, J = 3.4, 1.0 Hz, 1H), 5.20 (app t, J = 9.1 Hz, 1H), 5.10 (dd, J = 
10.4, 7.9 Hz, 1H), 4.95 (dd, J = 10.4, 3.5 Hz, 1H), 4.86 (dd, J = 9.5, 8.8 Hz, 1H), 4.62 (d, J = 8.8 
Hz ,1H), 4.52−4.47 (m, 2H), 4.15−4.05 (m, 3H), 3.88−3.79 (m, 2H), 3.70 (ddd, J = 9.9, 5.1, 2.1, 
1H), 2.15 (s, 3H), 2.13 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 1.96 (s, 3H). 
Spectral data are in accordance with literature.30 
 
Methyl (2R)-2-[(tert-butoxycarbonyl)amino]-4-pentynoate (25)  
A suspension of (R)–propargylglycine (300 mg, 2.65 mmol) in MeOH (10 mL) 
was treated dropwise at 0 °C with SOCl2 (0.5 mL, 6.85 mmol) and heated to 
reflux for 3 h. The reaction mixture was concentrated in vacuo to give the crude 
amino ester as the HCl-salt. The crude residue was suspended in DCM (20 mL), 
Et3N (590 μL, 5.83 mmol) and Boc2O (884.4 mg, 4.05 mmol) were added and the reaction 
mixture stirred for 3 h at room temperature. The mixture was concentrated in vacuo and 
purified by flash column chromatography (EtOAc/heptane, 3/1) to afford 25 (513 mg, 2.26 
mmol, 85%). Rf = 0.81 (EtOAc/heptane, 2/1). 1H NMR (400 MHz, CDCl3): δ = 5.35 (d, J = 6.8 
Hz, 1H), 4.51−4.46 (m, 1H), 3.78 (s, 3H), 2.77−2.71 (m, 2H), 2.05 (t, J = 2.5 Hz, 1H), 1.46 (s, 9H). 
13C NMR (75 MHz, CDCl3): δ = 170.9, 154.8, 80.2, 78.4, 71.6, 52.8, 52.1, 28.5, 23.1. Spectral data 
are in accordance with literature.20 
 
Methyl (2S)-[(benzyloxycarbonyl)amino]-4-pentynoate (42) 
 (S)-Propargylglycine (750 mg, 6.64 mmol) was dissolved in water (10 mL) at 
pH 11 (NaOH). Benzyl chloroformate (1.01 mL, 7.09 mmol) was added 
dropwise at 0 °C. A white precipitate of benzyl chloroformate was formed after 
30 min. The reaction mixture was stirred overnight at ambient temperature. 
Next the pH was lowered to 1 using conc. aqueous H2SO4 and the product was extracted 
with EtOAc (3 ×). The combined organic layers were washed with brine, dried (Na2SO4) and 
evaporated in vacuo yielding 1.3 g (= 77%) of the crude Z–l–propargylglycine. (Rf = 0.72 (n–
OO
AcO
OAc
AcO N3
OAcO
AcO
OAc
AcO
HN CO2Me
Boc
HN CO2Me
Cbz
Chapter 3 
 
62
BuOH/HOAc/EtOAc/H2O, 1/1/1/1); 1H NMR (300 MHz, CDCl3): δ = 7.67 (d, J = 8.4 Hz, 
1H), 7.37−7.30 (m, 5H), 5.05 (d, 8.2 Hz, 2H), 4.16−4.12 (m, 1H), 2.87 (m, 1H), 2.60 (m, 2H)). 
Subsequently the crude Z–l–propargylglycine was dissolved in MeOH (10 mL) and SOCl2 
(0.4 mL, 5.51 mmol) was added at 0 °C. Next the solution was refluxed for 4 h, after which the 
solvent was evaporated in vacuo. The crude product was purified by flash column 
chromatography (EtOAc/heptanes, 1/1) to afford 42 (1.3 g, 4.98 mmol, 75% 2 steps). Rf = 
0.86 (EtOAc). 1H NMR (400 MHz, CDCl3): δ = 7.87 (d, J = 8.1 Hz, 1H), 7.40−7.29 (m, 5H), 5.05 
(d, 8.2 Hz, 2H), 4.27−4.19 (m, 1H), 3.64 (s, 3H), 2.91−2.89 (m, 1H), 2.55−2.35 (m, 2H).  
 
Methyl (2S)-2-[(tert–butoxycarbonyl)amino]-5-hexynoate (44) 
Applying the same procedure as for 25, (S)-homopropargylglycine (65 mg, 0.51 
mmol) was protected and purified by flash column chromatography to afford 
44 (75 mg, 0.31 mmol, 61%) as a white solid. 1H NMR (400 MHz, CDCl3): δ = 
5.22 (bd, J = 7.7 Hz, 1H), 4.41−4.37 (m,  1H), 3.75 (s, 3H), 2.28 (dt, J = 7.6, 2.6 Hz, 
2H), 2.02−2.08 (m, 1H), 2.00 (t, J = 2.5 Hz, 1H), 1.92−1.87 (m, 1H), 1.45 (s, 9H). 
Spectral data are in accordance with literature.20 
 
Methyl (2S)-2-[(tert-butoxycarbonyl)amino]-6-heptynoate (46) 
Applying the same procedure as for 25, (S)-bishomopropargylglycine (148 mg, 
1.05 mmol) was protected and purified by flash column chromatography to 
afford 46 (171 mg, 0.67 mmol, 64%) as a colorless oil. 1H NMR (400 MHz, 
CDCl3): δ = 5.05 (bd, J = 7.8 Hz, 1H), 4.33−4.30 (m, 1H), 3.75 (s, 3H), 2.23 (dt, J = 
6.8, 2.6 Hz, 2H), 1.99 (t, J = 2.7 Hz, 1H), 1.88−1.51 (m, 4H), 1.45 (s, 9H). Spectral 
data are in accordance with literature.20 
 
(2S)-2-[(9H-Fluoren-9-ylmethoxycarbonyl)amino]-4-pentynoic acid (50) 
A mixture of (S)-propargylglycine (102 mg, 0.91 mmol) and Na2CO3 (107 mg, 
1.01 mmol) in H2O (1.5 mL) was added dropwise to a stirred solution of Fmoc–
succinimide in dioxane, cooled in ice to 8 °C. The solution was allowed to warm 
to room temperature overnight and was poured into water after 24 h. The 
solution was extracted with DCM (2 ×) and the organic fractions were 
combined, washed, dried (MgSO4) and concentrated in vacuo. Recrystallization 
from Et2O/hexane afforded 50 (159 mg, 0.48 mmol, 57%). Rf = 0.17 (EtOAc/heptane, 1/1). 
1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.6 Hz, 2H), 7.61 (d, J = 7.2 Hz, 2H), 7.40 (t, J = 7.4 
Hz, 2H), 7.31 (t, J = 7.5 Hz, 2H), 5.69 (d, J = 7.8 Hz, 1H), 4.62−4.50 (m, 1H), 4.41 (d, J = 7.0 Hz, 
2H), 4.25 (t, J = 7.0 Hz, 1H), 2.84 (br s, 2H), 2.12 (br s, 1H).  
 
Methyl (2S)-(4-methylphenylsulfonamido)pent-4-ynoate (52) 
A suspension of (S)-propargylglycine (202 mg, 1.78 mmol) in MeOH (10 mL) 
was treated dropwise at 0 °C with SOCl2 (0.15 mL, 2.05 mmol) and refluxed for 
3 h. The reaction mixture was concentrated in vacuo to give the crude amino 
ester HCl-salt. The crude residue was suspended in DCM (10 mL), Et3N (0.75 
ml, 5.34 mmol) and p-TsCl (411 mg, 2.16 mmol) were added and the reaction mixture was 
stirred for 4 h. The mixture was concentrated in vacuo and taken up in EtOAc and H2O. The 
aqueous layer was extracted with EtOAc (3 ×) and the combined organic layers were washed 
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with brine, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by 
flash column chromatography (EtOAc/heptane, 1/1) to afford 52 (107 mg, 0.38 mmol, 21%) 
Rf = 0.83 (EtOAc/heptane, 2/1). 1H NMR (400 MHz, CDCl3): δ = 7.75 (d, J = 8.3 Hz, 2H), 7.30 
(d, J = 8.3 Hz, 2H), 5.50 (d, J = 8.6 Hz, 1H), 4.14−4.10 (m, 1H), 3.61 (s, 3H), 2.74−2.61 (m, 2H), 
2.42 (s, 3H), 2.03 (t, J = 2.6 Hz, 1H). Spectral data are in accordance with literature.20 
 
Methyl 2-(tert-butoxycarbonylamino)-2-methyl-4-pentynoate (56) 
Applying the same procedure as for 25, α-methylhomopropargylglycine (300 
mg, 2.36 mmol) was protected and purified by flash column chromatography to 
afford 56 (310 mg, 1.28 mmol, 54%) as a white solid. 1H NMR (400 MHz, 
CDCl3): δ = 5.23 (bs, 1H), 3.76 (s, 3H), 2.96−2.86 (m, 2H), 2.02 (t, J = 2.7 Hz, 1H), 
1.55 (s, 3H), 1.43 (s, 9H).  
 
(2S)-2-[(tert-Butoxycarbonyl)amino]-4-pentynoic acid (62)  
To a suspension of (S)-propargylglycine (145 mg, 1.29 mmol) in dioxane/water 
(20 mL, 1/1) was added Boc2O (375 mg, 1.72 mmol) followed by a 2M aqueous 
NaOH solution (1.3 mL). The mixture was stirred until completion (TLC) after 
which DCM (3 mL) and KHSO4 (3 mL, 5% solution in water) were added. The 
product was extracted with DCM (3 ×) and the combined organic layers were washed with 
brine, dried (MgSO4) and evaporated in vacuo to afford 62 as a white solid (248 mg, 90%). 
1H NMR (400 MHz, CDCl3): δ = 5.34 (br d, J = 7.5 Hz, 1H), 4.53−4.49 (m, 1H), 2.85−2.73 (m, 
2H), 2.08 (t, 1H), 1.47 (s, 9H).  
 
2-(2-tert-Butoxycarbonylaminopropionylamino)-pent-4-ynoic acid methyl ester (67).  
A suspension of (S)-propargylglycine (308.9 mg, 2.73 mmol) in MeOH 
(10 mL) was treated dropwise at 0 °C with SOCl2 (2.5 mL, 3.45 mmol) 
and refluxed for 3 h. The reaction mixture was concentrated in vacuo 
affording the crude amino ester as the HCl–salt. A part of the crude 
residue (174 mg, 1.37 mmol) was dissolved in DCM (5 mL), Et3N (0.23 mL, 1.63 mmol), Boc-
L-alanine (266 mg, 1.41 mmol) and PyBOP (849.2 mg, 1.63 mmol) were added, the reaction 
mixture was kept basic by adding Et3N (0.35 mL, 2.49 mmol), and stirred for 4 h. Water was 
added and the aqueous solution was extracted with DCM (3 ×). The combined organic layers 
were dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(EtOAc/heptane, 1/2) afforded 67 (144 mg, 0.48 mmol, 35%) as a white solid. Rf = 0.36 
(EtOAc/heptane, 1/1). 1H NMR (400 MHz, CDCl3): δ = 6.86 (d, J = 6.1 Hz, 1H), 4.97 (br s, 
1H), 4.72 (dt, J = 7.8, 4.7 Hz, 1H), 4.28−4.16 (m, 1H), 3.79 (s, 3H), 2.80−2.75 (m, 2H), 2.02 (t, J = 
2.7 Hz, 1H), 1.46 (s, 9H), 1.39 (d, J = 7.0 Hz, 3H).  
 
2-(1-Methoxycarbonylbut-3-ynylcarbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
(69).  
A suspension of (S)-propargylglycine (309 mg, 2.73 mmol) in MeOH (10 
mL) was treated dropwise at 0 °C with SOCl2 (2.5 mL, 3.45 mmol) and 
refluxed for 3 h. The reaction mixture was concentrated in vacuo affording 
the crude amino ester as the HCl–salt. A part of the crude residue (173.5 
mg, 1.37 mmol) was dissolved in DCM (5 mL), Et3N (0.23 mL, 1.63 mmol), 
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Boc-L-proline (292 mg, 1.36 mmol) and PyBOP (869 mg, 1.67 mmol) were added, the reaction 
mixture was kept basic by adding Et3N (0.35 mL, 2.49 mmol), and stirred for 4 h. Water was 
added and the aqueous solution was extracted with DCM (3 ×). The combined organic layers 
were dried (MgSO4) and concentrated in vacuo. Purification by flash column chromatography 
(EtOAc/heptane, 1/1) afforded 69 (309 mg, 0.95 mmol, 70%) as a white solid. Rf = 0.45 
(EtOAc/heptane, 2/1). 1H NMR (400 MHz, CDCl3): δ = 4.72 (br. s, 1H), 4.40−4.22 (m, 1H), 
3.78 (s, 3H), 3.57−3.27 (m, 2H), 2.83−2.69 (m, 2H), 2.38−2.10 (m, 2H), 2.00 (br. s, 1H), 1.96−1.84 
(m, 2H), 1.48 (s, 9H).  
 
(S)-Methyl 2-((S)-2-(4-methylphenylsulfonamido)pent-4-ynamido)pent-4-ynoate (71).  
This product was formed as byproduct when synthesizing methyl (2S)-
2-{[(4-methylphenyl)sulfonyl]amino}-4-pentynoate (52). Rf = 0.61 
(EtOAc/heptane, 2/1). 1H NMR (400 MHz, CDCl3): δ = 7.77 (app d, J = 
8.3 Hz, 2H), 7.34−7.31 (m, 2H), 7.24 (bd, J = 8.5 Hz, 1H), 5.46 (d, J = 8.1 
Hz, 1H),  4.63 (t, J = 4.7 Hz, 1H), 4.61 (t, J = 4.7, 1H), 3.91 (ddd, J = 8.1, 
7.1, 4.6 Hz, 1H), 3.79 (s, 3H), 2.80 (ddd, J = 17.0, 4.6, 2.7 Hz, 1H), 2.72 (ddd, J = 17.0, 4.4, 2.7 
Hz, 1H), 2.60 (ddd, J = 17.0, 5.0, 2.7 Hz, 1H), 2,43 (s, 3H), 2.37 (ddd, J = 17.0, 7.0, 2.7 Hz, 1H), 
2.07 (t, J = 2.6, 1H), 2.02 (t, J = 2.6, 1H). 
 
General procedure A for the cycloaddition:  
To a solution of the glycoside (1 equiv) and the amino acid derivative (1 equiv) in tert–
butanol (0.5 M) was added a mixture of Cu(OAc)2 (20 mol%) and sodium ascorbate (40 
mol%) in H2O (0.04 M and 0.08 M, respectively). The reaction was stirred overnight, water 
was added and the product was extracted with DCM (2 ×). The combined organic layers 
were washed with saturated aqueous NaHCO3 (except for the free acids), brine, dried 
(NaSO4) and evaporated in vacuo. The product was purified by flash column 
chromatography using EtOAc/heptane mixtures. 
 
Boc-(R)-T4M(1-[β-D-Glc(Ac)4])-OMe (27) 
Preparation according to general procedure A for the 
cycloaddition afforded 27 (232 mg, 0.39 mmol, 98%) as a white 
solid. Rf = 0.37 (EtOAc/heptane, 2/1). [α]20D = −32.8 (c = 0.69, 
DCM). FTIR (ATR): ν = 3391, 2980, 2362, 2340, 1738, 1709, 1498 
cm−1. 1H NMR (400 MHz, CDCl3) δ = 7.60 (s, 1H), 5.83−5.80 (m, 
1H), 5.47−5.38 (m, 3H), 5.26−5.21 (m, 1H), 4.64−4.62 (m,1H), 4.31 (dd, J = 12.6, 5.0 Hz, 1H), 
4.15 (dd, J = 12.6, 2.0 Hz, 1H), 3.99 (ddd J = 10.1, 5.0, 2.1, 1H), 3.73 (s, 3H), 3.28 (dd, J = 15.0, 
5.3, 1H) 3.20 (dd, J = 15.0, 4.6 Hz 1H), 2.09 (s, 3H), 2.07 (s, 3H), 2.03 (s, 3H), 1.89 (s, 3H), 1.45 
(s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.4, 170.2, 169.6, 169.1, 168.8, 155.2, 143.4, 120.6, 
85.8, 80.0, 75.3, 72.6, 70.4, 67.9, 61.7, 53.1, 52.6, 28.8, 28.6, 21.0, 20.9, 20.8, 20.4. 1455. HRMS 
(ESI) m/z calculated for C25H37O13N4 (M+H)+: 601.2357, found: 601.2383.  
 
Boc-(R)-T4M(1-[β-D-Gal(Ac)4])-OMe (29) 
Preparation according to general procedure A for the 
cycloaddition afforded 29 (44 mg, 0.07 mmol, 89%) as a white 
solid. Rf = 0.32 (EtOAc/heptane, 2/1). [α]20D  = −14.1 (c = 1.41, 
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DCM). FTIR (ATR): ν = 3373, 2976, 2358, 2332, 1753, 1709 cm−1. 1H NMR (400 MHz, CDCl3): δ 
= 7.93 (s, 1H), 5.78 (d, J = 9.3 Hz, 1H), 5.59−5.42 (m, 3H), 5.24 (dd, J = 10.4, 3.3 Hz, 1H), 
4.67−4.59 (m, 1H), 4.24−4.10 (m, 3H), 3.73 (s, 3H), 3.29 (dd, J = 15.1, 5.2 Hz, 1H), 3.21 (dd, J = 
15.1, 4.6 Hz, 1H), 2.23 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.90 (s, 3H), 1.45 (s, 9H). 13C NMR (75 
MHz, CDCl3): δ = 171.5, 170.1, 169.7, 169.6, 169.0, 155.2, 143.4, 120.8, 86.4, 80.0, 74.3, 70.8, 68.0, 
67.1, 61.3, 53.2, 52.7, 30.0, 28.6, 21.0, 20.8, 20.5. HRMS (ESI) m/z calculated for C25H37O13N4 
(M+H)+: 601.2357, found: 601.2347.  
 
Boc-(R)-T4M(1-[D-Glc(Bn)4])-OMe (30a/b) 
Preparation according to general procedure A for the 
cycloaddition afforded 30a (64 mg, 0.08 mmol, 87%) and 30a/b 
(58 mg, 0.07 mmol, 87%) as a white solid. Rf = 0.47 (EtOAc). 
Spectral data of major isomer (30a): FTIR (ATR): ν = 3391, 3028, 
2915, 2362, 2323, 1744, 1714, 1498 cm−1. 1H NMR (400 MHz, 
CDCl3): δ = 7.46 (s, 1H), 7.36−7.27 (m, 13H), 7.24−7.20 (m, 3H), 7.19−7.13 (m, 3H), 6.99−6.94 
(m, 2H), 4.93 (d, J = 11.1 Hz, 1H), 4.89 (d, J = 10.9 Hz, 1H), 4.85 (d, J = 10.7 Hz, 1H), 4.60 (d, J = 
10.8 Hz, 1H), 4.54 (d, J = 12.1, 1H), 4.48 (d, J = 12.1 Hz, 1H), 4.47 (d, J = 10.6 Hz, 1H), 4.07−3.96 
(m, 1H), 4.02 (d, J = 10.5 Hz, 1H), 3.90−3.76 (m, 2H), 3.74−3.65 (m, 3H), 3.64 (s, 3H), 3.24 (d, J 
= 4.5 Hz, 2H), 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.6, 155.2, 143.0, 138,0, 137.7, 
136.9, 128.4, 128.4, 128.3, 128.2, 127.9, 127.9, 127.8, 127.7, 127.7, 121.4, 87.6, 85.5, 81.0, 80.2, 
78.2, 77.4, 75.9, 75.4, 75.1, 73.7, 68.6, 53.2, 52.7, 28.6. HRMS (ESI) m/z calculated for 
C45H53O19N4 (M+H)+: 793.3812, found: 793.3837 
 
Boc-(R)-T4M(1-[β-D-GlcNAc(Ac)3])-OMe (33) 
Preparation according to general procedure A for the 
cycloaddition afforded 33 (70 mg, 0.12 mmol, 91%) as a white 
solid. Rf = 0.44 (EtOAc). [α]20D  = −44.5 (c = 0.91, DCM). FTIR 
(ATR): ν = 3304, 2976, 2250, 1753 cm−1. 1H NMR (400 MHz, 
CDCl3): δ =7.69 (s, 1H), 6.2 (br d, J = 9.0 Hz, 1H), 5.93 (d, J = 10.0 
Hz, 1H), 5.65 (d, J = 8.6 Hz, 1H), 5.45 (dd, J = 10.0, 9.8 Hz, 1H), 5.21 (dd, J = 9.8, 9.6 Hz, 1H), 
4.65−4.52 (m, 2H), 4.27 (dd, J = 12.6, 4.7 Hz, 1H), 4.13 (dd, J = 12.6, 2.1 Hz, 1H), 4.03 (ddd, J = 
10.1, 4.7, 2.1 Hz, 1H), 3.71 (s, 3H), 3.28 (dd, J = 14.8, 5.7, 1H), 3.16 (dd, J = 14.8, 4.9, 1H), 2.07 
(s, 3H), 2.06 (s, 6H), 1.77 (s, 3H), 1.43 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.6, 170.7, 
170.4, 170.3, 169.1, 155.4, 142.9, 121.7, 86.2, 80.0, 75.1, 72.3, 68.2, 61.9, 53.7, 53.3, 52.6, 28.8, 28.6, 
23.0, 21.0, 21.0, 20.9. HRMS (ESI) m/z calculated for C25H37O12N5 (M+H)+: 622.2336, found: 
622.2367. 
 
Boc-(R)-T4M(1-[β-D-GalNAc(Ac)3])-OMe (35) 
Preparation according to general procedure A for the 
cycloaddition afforded 35 (17.1 mg, 0.03 mmol, 72%) as a white 
solid. Rf = 0.41 (EtOAc). [α]20D  = −22.0 (c = 0.58, DCM). FTIR 
(ATR): ν = 3321, 2980, 2353, 2340, 1748 cm−1. 1H NMR (400 MHz, 
CDCl3): δ = 7.72 (s, 1H), 5.90−5.87 (m, 2H), 5.68 (br d, J = 8.6 Hz, 
1H), 5.50 (d, J = 2.7 Hz, 1H), 5.45−5.34 (m, 1H), 4.75−4.59 (m, 2H), 4.27−4.04 (m, 3H), 3.73 (s, 
3H), 3.30 (dd, J = 14.5, 4.9 Hz, 2H), 3.17 (dd, J = 14.5, 4.4 Hz, 1H), 2.22 (s, 3H), 2.03 (s, 3H), 
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2.03 (s, 3H), 1.79 (s, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.6, 170.6, 170.2, 169.9, 
155.5, 142.8, 121.9, 86.7, 79.9, 74.1, 72.0, 66.8, 61.6, 53.3, 52.6, 50.4, 28.7, 23.2, 21.0. HRMS (ESI) 
m/z calculated for C25H37O12N5 (M+H)+: 622.2336, found: 622.2383. 
 
Boc-(R)-T4M(1-[β-D-GlcNAc(Bz)3])-OMe (37) 
Preparation according to general procedure A for the 
cycloaddition afforded 37 (23 mg, 0.03 mmol, 30%) as a white 
solid. Rf = 0.33 (EtOAc/heptane, 1/1). [α]20D  = +5.0 (c = 1.38, 
DCM). FTIR (ATR): ν = 3321, 2980, 2353, 2340, 1748 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 8.01 (d, J = 6.8 Hz, 2H), 7.94−7.78 
(m,4H), 7.73 (s, 1H), 7.53−7.32 (m, 9H), 6.05 (d, J = 9.6 Hz, 1H), 5.89−5.80 (m, 3H), 5.70−5.69 
(m, 1H), 4.84−4.79 (m, 1H), 4.67−4.62 (m, 1H), 4.64 (dd, J = 12.4, 2.8 Hz, 1H), 4.47 (dd, J = 12.4, 
4.8 Hz, 1H), 4.36 (ddd, J = 9.2 ,4.8, 2.4, 1H), 3.70 (s, 3H), 3.32 (dd, J = 14.4, 5.4, 1 H), 1.72 (s, 
3H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 170.9, 167.0, 166.3, 165.2, 143.4, 134.2, 134.0, 
133.7, 130.3, 130.2, 130.1, 129.7, 129.0, 128.9, 128.8, 128.6, 122.2, 87.2, 77.8, 76.0, 73.3, 69.3, 63.3, 
54.8, 53.7, 53.0, 29.1, 23.5. HRMS (ESI) m/z calculated for C40H44N5O12 (M+H)+: 786.2987, 
found: 786.3059.  
 
Boc-(R)-T4M(1-[2-deoxy-1,3,4,6-tetra-O-acetyl-α,β-D-glucopyranos-2-yl])-OMe (39) 
Preparation according to general procedure A for the cycloaddition 
afforded 39 (43 mg, 0.07 mmol, 71%) as a white solid. Rf = 0.30 
(EtOAc/heptane, 2/1). Major isomer: FTIR (ATR): ν = 3382, 2980, 
2358, 2336, 2250, 1744 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.39 (s, 
3H), 6.13 (d, J = 8.6 Hz, 1H), 5.75−5.70 (m, 1H), 5.46 (br d, J = 7.6 Hz, 
1H) 5.26−5.09 (m, 1H), 4.63 (dd, J = 10.6, 8.9 Hz, 1H), 4.59−4.51 (m, 1H), 4.34 (dd, J = 12.4, 4.4 
Hz, 1H), 4.13 (dd, J = 12.4, 1.6 Hz, 1H), 4.05−4.01 (m, 1H), 3.66 (s, 3H), 3.18 (br d, J = 4.1 Hz, 
2H), 2.06 (s, 3H), 2.00 (s, 3H), 1.96 (s, 3H), 1.84 (s, 3H), 1.39 (s, 9H). 13C NMR (75 MHz, 
CDCl3): δ = 171.4, 170.3, 169.3, 169.0, 168.0, 155.1, 142.9, 122.1, 91.6, 80.1, 73.2, 72.0, 68.1, 62.8, 
61.5, 53.1, 52.6, 28.6, 21.0, 20.8, 20.7, 20.5. HRMS (ESI) calculated for C25H36N4O13Na (M+Na)+: 
623.2177, found: 623.2180. 
 
Boc-(R)-T4M(1-[β-D-Ara(Bn)3])-OMe (41) 
Preparation according to general procedure A for the 
cycloaddition afforded 41 (60mg, 0.09 mmol, 88%) as a white solid. 
Rf = 0.49 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 3369, 1735, 1709, 
1217 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.58 (s, 1H), 7.37−7.21 
(m, 15 H), 6.16 (d, J = 2.8 Hz, 1H), 5.51 (d, J = 8.2 Hz, 1H), 4.69−4.44 
(m, 6H), 4.42 (dd, J = 6.4, 3.2 Hz, 1H),4.39 (dd, J = 6.4, 3.2 Hz, 1H), 4.18 (dd, J = 6.4, 4.8 Hz, 
1H), 3.78 (dd, J = 10.9, 2.9 Hz, 1H), 3.68 (s, 3H), 3.58 (dd, J = 10.9, 3.3 Hz, 1H), 3.07−2.96 (m, 
2H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.5, 155.0, 142.2, 137.1, 136.9, 136.5, 128.0, 
127.7, 127.6, 127.5, 127.3, 120.6, 90.8, 81.7, 80.0, 79.4, 75.6, 73.0, 72.1, 68.4, 52.5, 51.9, 27.8. 
HRMS (ESI) m/z calculated for C37H45O8N4 (M+H)+: 673.3237, found: 673.3260 and HRMS 
(ESI) m/z calculated for C37H44O8N4 (M+Na)+: 695.3057, found: 695.3066. 
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Cbz-(S)-T4M(1-[β-D-Glc(Ac)4])-OMe (43) 
Preparation according to general procedure A for the 
cycloaddition afforded 43 (50%) as a white solid. FTIR (ATR): ν = 
3373, 2950, 1740, 1212 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.55 
(s, 1H), 7.38−7.28 (m, 5H), 5.82 (d, J = 9.1 Hz, 2H), 5.44−5.30 (m, 
2H), 5.21 (dd, J = 10.1, 9.2 Hz, 1H), 5.09 (s, 2H), 4.75−4.65 (m, 1H), 
4.28 (dd, J = 12.6, 5.0 Hz, 1H), 4.12 (dd, J = 12.6, 2.1 Hz, 1H), 3.98 (ddd, J = 10.1, 5.0, 2.1 Hz, 
1H), 3.73 (s, 3H), 3.27 (d, J = 4.9 Hz, 2H), 2.05 (s, 3H), 2.05 (s, 3H), 2.00 (s, 3H), 1.81 (s, 3H). 13C 
NMR (75 MHz, CDCl3): δ = 171.5, 170.5, 169.9, 169.4, 169.2, 156.0, 143.5, 136.4, 128.6, 128.2, 
120.5, 85.8, 75.2, 72.6, 70.3, 67.8, 67.1, 61.6, 53.3, 52.7, 28.1, 20.8, 20.6, 20.6, 20.1. HRMS (ESI) 
m/z calculated for C28H34N4O13Na (M+Na)+: 657.2020, found: 657.2025.  
 
Boc-(S)-T4E(1-[β-D-Glc(Ac)4])-OMe (45) 
Preparation according to general procedure A for the 
cycloaddition afforded 45 (50 mg, 0.08 mmol, 80%) as a white 
solid. Rf = 0.29 (EtOAc/heptane, 2/1). [α]20D  = −28.4 (c = 0.89, 
DCM). FTIR (ATR): ν 3382, 2980, 1753, 1710 cm−1. 1H NMR 
(400 MHz, CDCl3): δ = 7.57 (s, 1H), 5.86−5.80 (m, 1H), 5.44−5.36 (m, 2H), 5.26−5.19 (m, 1H), 
5.17, (br d, J = 8.6 Hz, 1H), 4.31 (d, J = 5.1 Hz ,1H), 4.28 (dd, J = 12.7, 4.9 Hz, 1H), 4.13 (dd, J = 
12.7, 2.0 Hz, 1H), 3.98 (ddd, J = 10.1, 4.9, 2.0 Hz, 1H), 3.71 (s, 3H), 2.78 (t, J = 8.0 Hz, 2H), 
2.24−2.16 (m, 1H), 2.06 (s, 3H), 2.05 (s, 3H), 2.03−1.95 (m, 1H), 2.00 (s, 3H), 1.85, (s, 3H), 1.42 
(s, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.6, 170.2, 169.7, 169.1, 168.7, 155.2, 147.2, 119.4, 
85.7, 80.1, 75.2, 72.8, 70.3, 67.9, 61.7, 53.1, 52.6, 32.5, 28.6, 22.1, 21.0, 20.9, 20.8, 20.5. HRMS 
(ESI) m/z calculated for C26H38N4O13Na (M+Na)+: 637.2333, found: 637.2374.  
 
Boc-(S)-T4P(1-[β-D-Glc(Ac)4])-OMe (47) 
Preparation according to general procedure A for the 
cycloaddition afforded 47 (45 mg, 0.07 mmol, 76%) as a white 
solid. Rf = 0.29 (EtOAc/heptane, 2/1). Major isomer: [α]20D  = 
−11.1 (c = 0.76, DCM). FTIR (ATR): ν = 3378, 2958, 1744, 1714 
cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.54 (s, 1H), 5.85 (d, J = 
8.8 Hz, 1H), 5.45−5.36 (m, 2H), 5.24 (dd, J = 9.8, 9.4 Hz, 1H), 5.15 (br d, J = 8.2 Hz, 1H), 
4.35−4.26 (m, 1H), 4.32 (dd, J = 12.7, 5.0 Hz, 1H) 4.15 (dd, J = 12.7, 2.0 Hz, 1H), 4.01 (ddd, J = 
10.2, 4.9, 2.0 Hz, 1H), 3.74 (s, 3H), 2.84−2.65 (m, 2H), 2.09 (s, 3H), 2.07 (s, 3H), 2.04 (s, 3H), 1.80 
(s, 3H), 1.88−1.57 (m, 4H), 1.43 (m, 9H). 13C NMR (75 MHz, CDCl3): δ = 173.1, 170.4, 169.8, 
169.3, 169.0, 155.5, 148.2, 119.3, 86.0, 80.1, 75.4, 72.8, 70.8, 68.1, 61.9, 53.6, 52.7, 32.3, 28.8, 25.7, 
25.5, 21.2, 21.0, 21.0, 20.6. HRMS (ESI) m/z calculated for C27H40N4O13Na (M+Na)+: 651.2490, 
found: 651.2521.  
 
Fmoc-(S)-T4M(1-[β-D-Glc(Ac)4])-OBn (49) 
Preparation according to general procedure A for the 
cycloaddition afforded 49 (83.4 mg, 0.11 mmol, 70%) as a white 
solid. Rf = 0.16 (EtOAc/heptane, 1/1). [α]20D  = −5.7 (c = 0.29, 
DCM). FTIR (ATR): ν = 3378, 2950, 2353, 2340, 1753 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 8.03−7.89 (m, 5H), 8.09 (d, J = 7.4 
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Hz, 2H), 7.73 (s, 1H), 7.58−7.48 (m, 4H), 7.44−7.32 (m, 7H), 6.05 (d, J = 9.7 Hz, 1H), 5.88−5.77 
(m, 3H), 5.70−5.67 (m, 1H), 4.84−4.78 (m, 1H), 4.64 (dd, J = 12.4, 2.6 Hz, 2H), 4.47 (dd, J = 12.4, 
4.8 Hz, 2H), 4.39−4.34 (m, 1H), 3.70 (s, 3H), 3.23 (dd, J = 14.8, 5.1 Hz, 1H), 3.16 (dd, J = 14.8, 
4.4 Hz, 1H), 1.73 (s, 3H), 1.42 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 170.6, 170.2, 169.6, 169.2, 
169.0, 155.8, 143.8, 143.7, 141.1, 135.3, 128.6, 128.5, 127.6, 127.0, 125.2, 120.5, 120.0, 85.9, 73.4, 
72.5, 70.6, 67.9, 67.6, 67.4, 61.7, 53.6, 47.4, 28.4, 21.0, 20.9, 20.9, 20.4. HRMS (ESI) m/z calculated 
for C41H42N4O13Na (M+Na)+: 821.2646, found: 821.2674.  
 
Fmoc-(S)-T4M(1-[β-D-Glc(Ac)4])-OH (51) 
Preparation according to general procedure A for the 
cycloaddition afforded 51 (3.24g, 4.59 mmol, 91%) as a white solid. 
Rf = 0.10 (EtOAc/heptane 1/1). 1H NMR (400 MHz, CDCl3): δ = 
7.75 (d, J = 7.6 Hz, 1H), 7.70 (s, 1H), 7.61−7.58 (m, 2H), 7.41−7.37 
(m, 2H), 7.32−7.28 (m, 2H), 6.00 (d, J = 7.8 Hz, 1H), 5.86−5.83 (m, 
1H), 5.48−5.35 (m, 2H), 5.31−5.19 (m, 1H), 4.80−4.67 (m, 1H), 4.38 (d, J = 7.2 Hz, 2H), 4.30 
(ABdd, J = 12.6, 5.1 Hz, 1H), 4.23 (t, J = 7.2 Hz, 1H), 4.15−4.09 (m, 1H), 3.99 (ddd, J = 10.2, 4.9, 
2.0 Hz, 1H), 3.45−3.30 (m, 2H), 2.10 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 1.84 (s, 3H). 13C NMR (75 
M Hz, CDCL3): δ = 173.2, 170.7, 170.0, 169.8, 169.6, 156.2, 143.9, 143.6, 141.4, 127.9, 127.2, 
125.3, 121.4, 120.1, 85.9, 75.4, 72.6, 70.6, 67.9, 67.4, 61.7, 53.4, 47.3, 27.9, 20.8, 20.7, 20.6, 20.2. 
HRMS (ESI) m/z calculated for C34H37N4O13 (M+H)+: 709.2344 found: 709.2357 
 
Ts-(S)-T4M(1-[β-D-Glc(Ac)4])-OMe (53) 
Preparation according to general procedure A for the 
cycloaddition afforded 53 (60 mg, 0.09 mmol, 64%) as a white 
solid. Rf = 0.28 (EtOAc/heptane, 2/1). [α]20D = −8.6 (c = 0.40, 
DCM). FTIR (ATR): ν = 3481, 3278, 3140, 2950, 2362, 2254, 1744, 
1601v. 1H NMR (400 MHz, CDCl3): δ = 7.73 (d, J = 8.2 Hz, 2H), 
7.60 (s, 1H), 7.29 (d, J = 8.0 Hz, 2H), 5.83 (d, J = 9.0 Hz, 1H), 5.57 (d, J = 8.8 Hz, 1H), 5.42 (t, J = 
9.3 Hz, 1H), 5.38 (t, J = 9.2 Hz, 1H), 5.24 (dd, J = 10.0, 9.2 Hz, 1H), 4.32 (dd, J = 12.7, 4.9 Hz, 
1H), 4.284.26 (m, 1H), 4.16 (dd, J = 12.7, 2.0 Hz, 1H), 4.00 (ddd, J = 10.0, 6.8, 2.0 Hz, 1H), 3.57 
(s, 3H), 3.19 (d, J = 5.2 Hz, 2H), 2.42 (s, 3H), 2.10 (s, 3H), 2.07 (s, 3H), 2.07 (s, 3H), 1.89 (s, 3H), 
1.58 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 170.5, 170.3, 169.7, 169.1, 169.1, 143.5, 142.5, 136.8, 
129.6, 127.2, 120.9, 85.9, 75.3, 72.7, 70.5, 67.9, 61.7, 54.9, 53.0, 29.7, 21.9, 21.1, 20.9, 20.9, 20.5. 
HRMS (ESI) m/z calculated for C27H34O13N4NaS (M+Na)+: 677.1741, found: 677.1767.  
 
Ns-T4M(1-[β-D-Glc(Ac)4])-OtBu (55) 
Preparation according to general procedure A for the 
cycloaddition afforded 55 (66 mg, 0.09 mmol, 87%) as a mixture 
of isomers (1:1). Rf = 0.26 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 
3369, 1735, 1709, 1221 cm−1. 1H NMR (400 MHz, CDCl3): δ = 8.31 
& 8.29 (ap d, J = 9.1 Hz, 2H), 8.02 & 8.00 (ap d, J = 9.1 Hz, 2H), 
9.79 & 7.61 (s, 1H), 6.01 & 5.91 (d, J = 9.7 & 9.0 Hz, 1H), 5.83 & 5,78 (d, J = 9.1 & 8.9 Hz, 1H), 
5.47−5.33 (m, 2H), 5.24 (dd, J = 19.4, 9.3 Hz, 1H), 4.31 & 4.28 (dd, J = 12.7, 4.9 Hz, 1H), 4.24−4.20 
(m, 1H), 4.19−4.14 (m, 1H), 4.02 & 4.01 (ddd, J = 7.5, 5.0, 1.9 & 6.5, 5.2, 1.9, 1H), 3.35 & 3.25 
(ABdd, J = 14.6, 4.1 & 15.3, 5.3, 1H), 3.20 & 3.14 (ABdd, J = 14.6, 4.7 & 15.3, 4.8, 1H), 2.09 (s, 3H), 
2.06 (s, 3H), 2.06 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H) 2.02 (s, 3H), 1.98 (s, 3H), 1.86 (s, 
N
NN
CO2HHN
Fmoc
OAcO
AcO
OAc
AcO
N
NN
CO2MeHN
Ts
OAcO
AcO
OAc
AcO
N
NN
CO2tBuHN
Ns
OAcO
AcO
OAc
AcO
Synthesis of Triazole-linked Glycoamino Acids  
 
69
3H), 1.27 (s, 9H), 1.26 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 170.3, 170.2, 170.0, 169.6, 169.6, 
169.3, 169.0, 169. 168.9, 167.9, 149.9, 149.8, 145.9, 145.9, 142.5, 142.0, 128.4, 124.1, 124.0, 121.7, 
120.7, 85.9, 85.8, 83.5, 83.4, 75.4, 75.3, 72.5, 72.1, 70.9, 70.7, 68.0, 67.8, 61.7, 61.6, 60.6, 55.6, 55.6, 
30.1, 29.9, 28.0, 28.0, 21.0, 21.0, 20.9, 21.8, 20.5, 20.4, 14.5, 14.5. HRMS (ESI) m/z calculated for  
(C29H37O15N5)2Na (2M+Na)+: 1477.3911, found: 1477.3820.  
 
Boc-α-methyl-T4M(1-[β-D-Glc(Ac)4])-OMe (57) 
Preparation according to general procedure A for the 
cycloaddition afforded 57 (55 mg, 0.09 mmol, 85%) as a white 
solid. Rf = 0.15 (EtOAc/heptane, 2/1). Mixture of 
diastereoisomers: FTIR (ATR): ν = 3382, 2958, 2362, 1748, 1709 
cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.52 (s, 1H), 7.51 (s, 1H), 
5.82 (d, J = 9.2 Hz, 1H), 5.81 (d, J = 9.4 Hz, 1H), 5.43−5.27 (m, 6H), 5.21 (t, J = 10.3 Hz, 2H), 
4.28 (dd, J = 12.5, 5.0 Hz, 2H), 4.12 (dd, J = 12.5, 2.0 Hz, 2H), 4.01−3.97 (m, 4H), 2.05 (s, 3H), 
2.05 (s, 3H), 2.04 (s, 3H), 1.99 (s, 3H), 1.84 (s, 3H), 1.84 (s, 3H), 1.42 (s, 9H). 13C NMR (75 MHz, 
CDCl3): δ = 173.8, 173.8, 170.2, 170.2, 169.6, 169.6, 169.1, 169.1, 168.7, 168.6, 154.2, 154.2, 143.6, 
143.6, 121.0, 121.0, 85.8, 85.8, 79.9, 75.3, 75.2, 72.6, 72.5, 70.7, 70.5, 67.9, 67.9, 61.7, 61.7, 59.3, 
59.2, 52.9, 52.8, 28.6, 28.6, 23.8, 23.7, 21.0, 20.8, 20.8, 20.4, 20.3. HRMS (ESI) m/z calculated for 
C26H38N4O13Na (M+Na)+: 637.2333, found: 637.2352. 
 
(S)–2–[(tert–Butoxycarbonyl)amino]–3–{1–(2,3,4,6–tetra–O–acetyl–β–D–
glucopyranosyl)[1,2,3]triazol–4–yl}propanenitrile(59). 
Preparation according to general procedure A for the cycloaddition 
afforded 59 (34 mg, 0.06 mmol, 60%) as a white solid. Rf = 0.14 
(EtOAc/heptane, 1/1). [α]20D  = −8.8 (c = 1.01, DCM). FTIR (ATR): ν = 
3356, 2980, 2254, 1753, 1714 cm−1. 1H NMR (400 MHz, CDCl3): δ = 
7.79 (s, 1H), 5.87 (d, J = 8.8 Hz, 1H), 5.75 (bd, J = 5.7 Hz, 1H), 5.45 (t, J 
= 9.3 Hz, 1H), 5.40 (t, J = 9.3 Hz, 1H) 5.25 (dd, J = 10.0, 9.4 Hz, 1H), 4.96 (bs, 1H), 4.26 (dd, J = 
12.7, 5.1, 1H), 4.19 (dd, J = 12.7, 2.2 Hz, 1H), 4.05−4.01 (ddd, J= 10.2, 5.1, 2.1 Hz, 1H), 3.28 (dd, 
J = 15.0, 5.3 Hz, 1H), 3.20 (dd, J = 15.0, 5.5 Hz, 1H), 2.09 (s, 3H), 2.08 (s, 3H), 2.04 (s, 3H), 1.9 (s, 
3H). 13C NMR (75 MHz, CDCl3): δ = 170.5, 169.8, 169.3, 169.2, 154.3, 142.1, 121.6, 118.0, 86.2, 
81.2 75.6, 72.7, 70.8, 68.1, 61.9, 42.5, 29.7, 28.7, 21.2, 21.1, 21.0, 20.7. HRMS (ESI) m/z calculated 
for C24H33N5O11Na (M+Na)+: 590.2075, found: 590.2080.  
 
Ts-(S)-T4M(1-[β-D-Glc(Bn)4])-OMe (61) 
Preparation according to general procedure A for the 
cycloaddition afforded 61 (57.0 mg, 0.067 mmol, 82%) as a white 
solid. Rf = 0.34 (EtOAc/heptane, 1/1). 1H NMR (400 MHz, 
CDCl3): δ = 7.68 (d, J = 8.2 Hz, 2H), 7.52 (s, 1H), 7.34−7.20 (m, 
18H), 7.19−7.15 (m,2H), 6.99−6.96 (m, 2H), 5.56−5.52 (m, 2H), 
4.90−4.89 (m, 2H), 4.86 (ABd, J = 10.7 Hz, 1H), 4.61 (ABd, J = 10.9 Hz, 1H), 4.56 (ABd, J = 11.9 
Hz, 1H), 4.50 (ABd, J = 12.1 Hz, 1H), 4.45 (ABd, J = 10.7 Hz, 1H), 4.22 (dt, J = 8.4, 5.3 Hz, 1H), 
4.03 (ABd, J = 10.6 Hz, 1H), 4.00−3.96 (m, 1H), 3.85−3.65 (m, 5H), 3.46 (s, 3H), 3.21 (ABdd, J = 
15.0, 5.1 Hz, 1H), 3.14 (ABdd, J = 15.0, 5.1 Hz, 1H), 2.39 (s, 3H). 
 
N
NN
CO2MeHN
Me
Boc
OAcO
AcO
OAc
AcO
N
NN
CNHN
Boc
O
AcO
AcO
AcO
OAc
N
NN
CO2MeHN
Ts
O
BnO
BnO
BnO
OBn
Chapter 3 
 
70
Boc-(S)-T4M(1-[β-D-GlcNAc(Ac)3])-OH (63) 
Preparation according to general procedure A for the 
cycloaddition afforded 63 (1.25 g, 2.14 mmol, 86%) as a white 
solid. FTIR (ATR): ν = 1744, 1364, 1213 cm−1. 1H NMR (400 MHz, 
CDCl3): δ = 7.75 (s, 1H), 6.48 (br d, J = 9.6 Hz, 1H), 5.95 (d, J = 10.0 
Hz, 1H), 5.62 (d, J = 8.0 Hz, 1H), 5.39 (dd, J = 10.8, 10.0 Hz, 1H), 
5.24 (t, J = 9.6 Hz, 1H), 4.71−4.55 (m, 2H), 4.30 (dd, J = 12.8, 4.8 Hz, 1H), 4.18−4.10(m, 1H), 
4.07−4.01 (m, 1H), 3.34 (dd, J = 15.2, 5.2, 1H), 3.23 (dd, J = 15.2, 4.8, 1H), 2.08 (s, 3H), 2.07 (s, 
3H), 2.06 (s, 3H), 1.80 (s, 3H), 1.45 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.6, 170.7, 170.4, 
170.3, 169.1, 155.4, 142.9, 121.7, 86.2, 80.0, 75.1, 72.3, 68.2, 61.9, 53.7, 53.3, 52.6, 28.8, 28.6, 23.0, 
21.0, 21.0, 20.9. HRMS (ESI): m/z calculated for C24H35O12N5Na (M+Na)+ 608.21799, found 
608.21924.  
 
Boc-(S)-T4M(1-[β-D-GlcNAc])-OH (66) 
Preparation according to general procedure A for the cycloaddition 
afforded 66 (22 mg, 0.05 mmol, 53%) as a white solid. FTIR (ATR): ν 
= 3347, 2971, 2933, 2358, 2340, 2111 cm−1. 1H NMR (400 MHz, 
CDCl3): δ = 7.92 (s, 1H), 5.77 (d, J = 9.8 Hz, 1H), 4.44−4.37 (m, 1H), 
4.17 (t, J = 9.9 Hz, 1H), 3.89 (dd, J = 12.3 Hz, 1H), 3.78−3.67 (m, 3H), 
3.61−3.43 (m, 2H), 3.22 (dd, J = 14.9 Hz, 1H), 3.12 (dd, J = 14.9 Hz, 1H), 1.79 (s, 3H), 1.42 (s, 
9H). 13C NMR (75 MHz, CDCl3): δ = 175.3, 173.5, 157.7, 144.8, 123.0, 88.0, 81.3, 80.6, 75.6, 71.5, 
62.4, 56.9, 54.9, 29.1, 28.7, 22.6. LRMS m/z calculated for C18H29N5O9 (M−H)−: 458.2, found: 
458.3 
 
Boc-Ala-(S)-T4M(1-[β-D-Glc(Ac)4])-OMe (68) 
Preparation according to general procedure A for the 
cycloaddition afforded 68 (70 mg, 0.11 mmol, 86%) as a white 
solid. Rf = 0.18 (EtOAc/heptane, 2/1). [α]20D  = −1.3 (c = 0.80, 
DCM). FTIR (ATR): ν = 3365, 2971, 2358, 2250, 1748, 1511 
cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.63 (s, 1H), 6.88 (d, J = 
7.8 Hz, 1H), 5.82 (d, J = 9.2 Hz, 1H), 5.42 (t, J = 9.5 Hz, 1H), 5.34 (t, J = 9.4 Hz, 1H), 5.27−5.17 
(m, 1H), 5.23 (dd, J = 10.2, 9.2 Hz, 1H), 4.90 (dt, J = 8.0, 5.1 Hz, 1H), 4.33 (dd, J = 12.7, 5.3 Hz, 
1H), 4.25−4.12 (m, 1H), 4.15 (dd, J = 12.7, 2.2 Hz, 1H), 4.00 (ddd, J = 10.2, 5.1, 2.1 Hz, 1H), 3.76 
(s, 3H), 3.34 (dd, J = 15.0, 5.1 Hz, 1H), 3.26 (dd, J = 15.0, 5.1 Hz, 1H), 2.09 (s, 3H), 2.07 (s, 3H), 
2.03 (s, 3H), 1.90 (s, 3H), 1.45 (s, 9H), 1.35 (d, J = 7.0 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 
172.4, 170.9, 170.3, 169.6, 169.1, 169.0, 155.1, 143.3, 120.5, 85.9, 80.0, 75.4, 72.6, 70.6, 67.9, 61.7, 
52.9, 51.6, 50.3, 28.6, 28.0, 21.0, 20.9, 20.8, 20.4, 18.9. HRMS (ESI) m/z calculated for 
C28H41O14N5Na (M+Na)+: 694.2548, found: 694.2544.  
 
Boc-Pro-(S)-T4M(1-[β-D-Glc(Ac)4])-OMe (70) 
Preparation according to general procedure A for the 
cycloaddition afforded 70 (48 mg, 0.07 mmol, 92%) as a white 
solid. Rf = 0.14 (EtOAc/heptane, 2/1). [α]20D  = −33.7 (c = 1.03, 
DCM). FTIR (ATR): ν = 3360, 3140, 2980, 2358, 2336, 2254, 
1752, 1679, 1524 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.62 (br 
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s, 1H), 7.15−6.91 (m, 1H), 5.89−5.74 (m, 1H), 5.44−5.32 (m, 2H), 5.26−5.12 (m, 1H), 4.95−4.76 
(m, 1H), 4.34−4.09 (m, 3H), 3.99 (ddd, J = 10.0, 4.9, 2.2 Hz, 1H), 3.71 (s, 3H), 3.52−3.34 (m, 2H), 
3.30−3.20 (m, 2H), 2.20−1.96 (m, 2H), 2.05 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.92−1.75 (m, 2H), 
1.85 (s, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.3, 170.9, 170.2, 169.7, 169.2, 168.8, 
145.7, 143.5, 120.7, 86.0, 80.5, 75.5, 73.1, 70.7, 68.3, 62.0, 61.2, 52.8, 51.9, 47.3, 28.9, 28.8,24.4, 
21.0, 20.9, 20.8, 20.4. HRMS (ESI) m/z calculated for C30H43O14N5Na (M+Na)+: 720.2704, found: 
720.2732.  
 
Ts-(S)-T4M(1-[β-D-Glc(Ac)4])-(S)-T4M(1-[β-D-Glc(Ac)4])-OMe (72) 
Preparation according to general procedure A for the 
cycloaddition afforded 72 (57 mg, 0.05 mmol, 55%) as a 
white solid. Rf 0.17 (EtOAc/heptane, 5/1). 1H NMR (400 
MHz, CDCl3): δ = 8.57 (s, 1H), 7.69−7.68 (m, 3H), 7.58 (d, J = 
5.8 Hz, 1H), 7.32 (d, J = 8.0 Hz, 2H, 6.24−6.19 (m, 1H), 
5.86−5.82 (m, 2H), 5.67−5.63 (m, 2H), 5.50−5.45 (m, 1H), 
5.44−5.36 (m, 2H), 5.30−5.26 (m, 1H), 4.79−4.75 (m, 1H), 
4.34−4.29 (m, 2H), 4.27−4.22 (m, 1H), 4.20−4.14 (m, 2H), 4.11−4.05 (m, 1H), 4.02 (ddd, J = 10.2, 
4.5, 1.8 Hz, 1H), 3.85 (s, 3H), 3.61 (ABdd, J = 14.7, 4.4 Hz, 1H), 3.53 (ABdd, J = 15.6, 2.0 Hz, 
1H), 3.30 (ABdd, J = 14.7, 4.4 Hz, 1H), 2.78 (ABdd, J = 15.4, 6.8 Hz, 1H), 2.44 (s, 3H), 2.12 (s, 
3H), 2.09 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 1.91 (s, 3H), 1.83 (s, 3H), 1.77 (s, 3H). 
13C NMR (75 MHz, CDCl3): δ = 172.1, 170.7 170.0 169.5, 169.0, 168.6, 145.5, 143.3, 120.5, 85.8, 
80.3, 75.3, 72.9, 70.5, 68.1, 61.8, 52.6, 51.7, 47.1, 28.6, 28.3, 24.2, 20.8, 20.7, 20.6, 20.3. 
 
Boc-(R)-T4M(1-[β-D-Lac(Ac)7])-OMe (74) 
Preparation according to general procedure A for the 
cycloaddition afforded 74 (74 mg, 0.08 mmol, 83%) as a 
white solid. Rf = 0.17 (EtOAc/heptane, 2/1). [α]20D  = 
−17.8 (c = 1.08, DCM). FTIR (ATR): ν = 3378, 2980, 2366, 
2250, 1744 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.50 (s, 
1H), 5.75 (d, J = 9.0 Hz, 1H), 5.44−5.29 (m, 4H), 5.08 (dd, 
J = 10.4, 7.9 Hz, 1H), 4.94 (dd, J = 10.4, 3.3 Hz, 1H), 4.60−4.53 (m, 1H), 4.50 (d, J = 7.8 Hz), 4.43 
(d, J = 11.9 Hz), 4.13−4.03 (m, 4H), 3.94−3.86 (m, 3H), 3.67 (s, 3H), 3.21 (dd, J = 14.7, 5.4 Hz, 
1H), 3.14 (dd, J = 14.7, 4.6 Hz, 1H), 2.11 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 
3H), 1.92 (s, 3H), 1.83 (s, 3H), 1.39 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.6, 170.3, 170.1, 
170.0, 170.0, 169.3, 169.2, 169.0, 155.3, 143.4, 120.7, 101.3, 85.8, 80.2, 76.3, 76.0, 72.7, 71.2, 71.2, 
70.8, 69.4, 67.0, 62.0, 61.2, 53.3, 52.8, 28.9, 28.8, 21.3, 21.2, 21.2, 21.1, 21.1, 21.0, 20.6. HRMS 
(ESI) m/z calculated for C37H53N4O21 (M+H)+: 889.3202, found: 889.3248.  
 
Boc-Ala-(S)-T4M(1-[β-D-Lac(Ac)7])-OMe (75) 
Preparation according to general procedure A for 
the cycloaddition afforded 75 (117 mg, 0.12 mmol, 
81%) as a white solid. Rf = 0.13 (EtOAc/heptane, 
2/1). [α]20D  = −0.5 (c = 1.13, DCM). FTIR (ATR): ν = 
3382, 3144, 2980, 2362, 2254, 1752, 1502 cm−1. 
1H NMR (400 MHz, CDCl3): δ = 7.58 (s, 1H), 6.94 (d, 
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J = 7.8 Hz, 1H), 5.78 (d, J = 9.3 Hz, 1H), 5.41−5.25 (m, 4H), 5.14 (dd, J = 10.5, 7.8 Hz, 1H), 4.99 
(dd, J = 10.2, 3.4 Hz, 1H) 4.89 ( dt, J = 8.0, 5.2 Hz, 1H), 4.55−4.48 (m, 2H), 4.21−4.10 (m, 4H), 
3.95−3.40 (m, 3H), 3.75 (s, 3H), 3.32 (dd, J = 15.1, 4.9 Hz, 1H), 3.25 (dd, J = 15.1, 5.4 Hz, 1H), 
2.17 (s, 3H), 2.12 (s, 3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 1.98 (s, 3H), 1.89 (s, 3H), 1.44 (s, 
9H), 1.33 (d, J = 7.1 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ = 172.4, 170.9, 170.1, 170.0, 169.8, 
169.8, 169.2, 169.2, 168.8, 155.1, 143.1, 120.4, 101.1, 85.7, 80.0, 76.2, 75.8, 72.4, 71.0, 71.0, 70.8, 
69.2, 66.7, 61.8, 61.0, 52.8, 51.5, 50.3, 28.6, 28.1, 21.1, 21.0, 21.0, 20.9, 20.9, 20.8, 20.5, 18.8. HRMS 
(ESI): m/z calculated for C40H57O22N5Na (M+Na)+: 982.3393, found: 982.3440.  
 
Mono–6–tosyl–6–deoxy–β–cyclodextrin (77) 
β–Cyclodextrin was dried at 110 ºC under high vacuum for 24 h. 
Subsequently the β–cyclodextrin (1.71 g, 1.51 mmol) was dissolved in 
pyridine (20 mL) and cooled in an ice bath. A solution of tosyl 
chloride (256 mg, 1.34 mmol) in pyridine (2 mL) was added 
dropwise to the mixture and stirred for 20 h. The mixture was 
concentrated in vacuo, taken up in slightly acidic water (pH 5) and 
washed with DCM (2 ×). Next, The water layer was concentrated to yield a white solid. 
Recrystallization from water yielded the crude mono–6–tosyl–6–deoxy–β–cyclodextrin 77 
(811 mg, 0.63 mmol). HRMS (ESI) m/z calculated for C49H76O37SNa (M+Na)+: 1311.3684, 
found: 1311.3688. 
 
Mono–6–azido–6–deoxy–β–cyclodextrin (78) 
The crude mono–6–tosyl–6–deoxy–β–cyclodextrin 78 was dissolved 
in DMF , NaN3 (39.2 mg, 0.63 mmol) was added and the reaction 
mixture was stirred for 5 h at 90 ºC. Subsequently the mixture was 
concentrated in vacuo and the crude product was purified by several 
flash column chromatography steps using water/acetronitrile 
mixtures to afford the mono azide (196 mg, 0.17 mmol, 15% 
calculated from 76). HRMS (ESI) m/z calculated for C42H69O34N3Na (M+Na)+: 1182.3660, 
found: 1182.3683.  
 
Boc-Ala-D-T4M(1-[β-6–deoxy–β–cyclodextrin-6-yl])-OMe (79) 
A mixture of Cu(OAc)2 (6.8 mg, 0.034 mmol) and sodium ascorbate 
(14.0 mg, 0.071 mmol) in water (1 mL) was added to a solution of 78 
(50.2 mg, 0.04 mmol) and 25 (20.3 mg, 0.09 mmol) in tert-butanol (1 
mL). The resulting mixture was stirred for 8 h, subsequently the 
methyl ester was saponified by treatment with NaOH, after which 
the product was purified by ion exchange chromatography, 
affording the cyclodextrin–amino acid triazole–linked product 80 (48 
mg, 0.03 mmol 81%) as a white solid. 1H NMR (400 MHz, CDCl3) δ = 
7.64 (s, 1H) (relevant peaks). HRMS (ESI) m/z calculated for 
C52H84O38N4Na (M+Na)+: 1395.4661, found: 1395.4720.  
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Stepwise Orthogonal Coupling 
Procedure for the Synthesis of 
Glycopeptide Mimics 
 
 
 
Abstract:   
A range of protective groups was examined for application in an orthogonal coupling 
procedure en route to triazole analogues of natural glycopeptides with multiple 
glycosylated side-chains. Both TMS- and TBDPS-protected propargylglycine derivatives 
were prepared via an alkylation strategy, while subsequent enzymatic resolution afforded 
the enantiopure TMS-derivative. Subsequently, a variety of pentapeptides, bearing a free 
as well as a protected (TMS or TBDPS) acetylene side-chain, were prepared via solid-
phase chemistry. A stepwise [3+2] cycloaddition, deprotection and again [3+2] 
cycloaddition, either on a resin but also in solution afforded the desired diglycosylated 
glycopeptides. 
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4.1 INTRODUCTION 
It is believed that in Nature more than 50% of the known glycoproteins are heavily 
glycosylated with multiple carbohydrate moieties bound to the peptide side-chains,1 
as exemplified by the imaginative glycopeptide 1 (Figure 1). Glycosylation occurs 
predominantly at the asparagine side-chain, resulting in so-called N-glycoproteins, 
although glycosylation at other sites occurs also frequently, specifically on serine and 
threonine, giving rise to O-glycoproteins.2 Unfortunately, the synthesis of both N- 
and O-glycopeptides is still a tremendous task, partially due to the inherent 
instability of the glycosidic linkages of the products. We were intrigued, therefore, 
whether we could extend our research on triazole isosteres of glycoamino acids3 to 
triazole-linked analogues (2) of N-glycoproteins, in particular glycoproteins bearing 
multiple glycosyl side-chains. 
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Figure 1. Amide- (1) and triazole- (2) linked multi-glycosylated peptide. 
Various strategies can be envisaged to obtain peptides bearing multiple 
carbohydrates, as illustrated in Figure 2. Thus, the desired peptide with “sugar 1” 
and “sugar 2” in the side-chain can be prepared in three distinct fashions  
(Figure 2): (a) by peptide coupling of two separately synthesized triazole-linked 
glycoamino acids building blocks (route a), (b) by incorporation of an acetylenic 
amino acid in a peptide already containing one glycoamino acid in the chain (route 
b), followed by [3+2] cycloaddition, or (c) by synthesis of a peptide containing both a 
terminal and a protected acetylene, thereby allowing sequential [3+2] cycloaddition, 
acetylene deprotection, and again [3+2] cycloaddition (route c). Routes a and b are 
obviously preferable for the preparation of a small number of short, glycosylated 
Stepwise Orthogonal Coupling Procedure for the Synthesis of Glycopeptide Mimics 
 
77
peptides. Although more advanced glycoamino acid building blocks are required, 
relatively few steps are needed for the peptide synthesis itself. On the other hand, for 
the assembly of a larger variety of differentially glycosylated glycopeptides, both 
routes a and b are more laborious due to the requisite investment in glycoamino acid 
building blocks. The third approach (c) stands out in terms of simplicity to obtain the 
peptide backbone in large quantity, thereby providing a versatile scaffold for the 
preparation of a large variety of different triazole-linked glycopeptides via sequential 
incorporation of glycosides. Obviously, the latter approach is especially attractive for 
the combinatorial preparation of libraries needed for screening purposes.  
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Figure 2. Different strategies for the preparation of peptides bearing multi-carbohydrate moieties. 
4.2 PROTECTED ACETYLENES 
With the objective to prepare a peptide containing a combination of free and 
protected acetylenes, suitable protected acetylenic amino acids were needed first. An 
interesting protective group that was initially considered, due to the fact that it can 
be readily introduced on alkynes in one step, is the dicobalt hexacarbonyl complex 3 
(Figure 3). Additionally, we envisioned that straightforward replacement of the 
acetylene proton by a bromide (4) could also serve as protection for the [3+2] 
cycloaddition, because it is generally accepted that only terminal acetylenes 
participate in the copper-catalyzed Huisgen cycloaddition. Apart from that, common 
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acetylene protective groups based on silicon as in compound 5 (e.g. SiMe3 (TMS), 
SiPh2tBu (TBDPS), etc.) were also considered highly versatile. 
H2N CO2H
(OC)3Co
Co(CO)3
H2N CO2H
SiRn
H2N CO2H
Br
3 4 5  
Figure 3. Different side-chain protected propargylglycine derivatives. 
4.2.1 Cobalt hexacarbonyl complex 
The first acetylene protective group that was investigated involved the cobalt 
hexacarbonyl complex, a remarkably stable bridged structure involving two carbons 
and two cobalt atoms. In order to determine the applicability of the cobalt 
hexacarbonyl complex for our purposes, Boc-protected (R)-propargylglycine 6 was 
reacted under typical conditions with dicobalt octacarbonyl in ether, providing the 
dicobalt hexacarbonyl complex 7 in a high yield (Scheme 1). 
HN CO2Me
Boc
6
Co2(CO)8
3 h, rt, Et2O
HN CO2Me
Boc
(OC)3Co
(CO)3
Co
7 (92%)
HN
Boc
(OC)3Co
(CO)3
Co
CO2R
O
H
N
8
1) NaOH
2) PyBOP, DiPEA
 
Scheme 1. Formation of the dicobalt hexacarbonyl complex. 
Subsequently, the compatibility of cobalt complex 7 with the typical copper-
catalyzed [3+2] cycloaddition conditions was determined. Therefore, cobalt complex 
7, azidosaccharide, Cu(OAc)2 and Na-ascorbate were dissolved in a mixture of  
tert-butyl alcohol and water and stirred for 24 hours at room temperature. As 
anticipated, no reaction occurred and the cobalt complex could be recovered in high 
yield, thus paving the way to an orthogonal pathway towards double functionalized 
peptides.  
With the aim of conducting a preliminary test to prepare peptides with multiple 
functionalities in the side-chains, a dipeptide was required bearing both a free and a 
“cobalt” protected acetylene. Consequently, methyl ester 7 was saponified and 
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coupled to D-propargylglycine methyl ester under the action of PyBOP. Much to our 
surprise, a complex mixture of compounds was formed, either containing or lacking 
cobalt functionality as could be clearly judged by TLC. Although no detailed analysis 
of the reaction products was executed, possible side-reactions known to occur in the 
presence of multiple acetylenes include alkyne-alkyne coupling reactions4 and cobalt 
carbonyl-mediated alkyne trimerization.5 Unfortunately, no major product could be 
isolated from the complex mixture, although some products were identified that 
appeared to result from inter- and intramolecular cobalt hexacarbonyl migration 
from one acetylene to another (not depicted). As a result, the many side-reactions 
that occurred made the cobalt complex useless for the preparation of 
multiglycosylated peptides. 
4.2.2 Acetylenic bromide 
Normally, introduction of bromide on a terminal acetylene will not be considered as 
a protecting group. However, replacement of the acetylene hydrogen with any other 
atom was assumed to render it unreactive under the mild conditions for copper-
catalyzed [3+2] cycloaddition. To test such an assumption, D-propargylglycine 
derivative 6 was treated with N-bromosuccinimide and a catalytic amount of silver 
nitrate in acetone6 to afford bromopropargylglycine 9 (Scheme 2). Unfortunately, a 
subsequent experiment to determine the compatibility of 9 with the typical 
conditions for copper-catalyzed cycloaddition proved that the bromide is not suited 
as a protective group. When bromoacetylene 9 and azidoglucose 10 were subjected to 
the above mentioned conditions, the 1,4-disubstituted triazole 11 normally formed 
via cycloaddition with the unprotected acetylene was predominantly formed, 
presumably due to in situ debromination followed by the typical [3+2] cycloaddition. 
Apart from compound 11, a minor product was formed that appeared to be the 
remarkable double addition product 12. The latter findings clearly excluded bromide 
protection of acetylenes as a coupling strategy, but were the prelude to a range of 
subsequent experiments for the formation of 1,4,5-trisubstituted triazoles, as 
described in Chapter 5.  
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Scheme 2. Incompatibility of bromoacetylenes with typical conditions for [3+2] cycloaddition. 
4.2.3 Silyl protective groups 
Silicon-based moieties are well-established as protective groups for acetylenes,7,8 
providing excellent stability against a variety of different chemical procedures. 
Among the silicon substituents, the trimethylsilyl (TMS) is by far the most frequently 
applied for protection of acetylenes due to the mild basic conditions for silicon 
removal. Moreover, the fact that some silicon-based protective groups can be 
orthogonally deprotected was considered convenient for the multiple and selective 
introduction of a variety of carbohydrates onto peptides. For example, removal of a 
TMS group normally requires mild base or fluoride ion at ambient temperature, 
while a tert-butyldiphenylsilyl (TBDPS) group often requires a fluoride ion at 
elevated temperatures to achieve desilylation. Therefore, incorporation of a terminal 
acetylene, in combination with a TMS and a TBDPS-protected acetylene in a peptide, 
should allow the stepwise introduction of three (different) carbohydrates via 
intermediate selective deprotection of silyl functions. 
4.2.3.1 Acetylene silylation of propargylglycine 
Typical conditions for silylation of acetylenes known in literature involve 
deprotonation of an acetylene with a strong base, followed by addition of an 
electrophilic silylating reagent such as a silyl chloride. Our first attempts to adapt 
such a deprotonation-silylation approach to D-propargylglycine 6 (Table 1) involved 
treatment of 6 with a variety of strong bases, e.g. EtMgBr (entry 1), NaHMDS  
(entry 2) or nBuLi (entry 3) followed by the addition of chlorotrimethylsilane. 
Unfortunately, no silylation occurred, but instead partial saponification of the methyl 
ester was detected in all cases (5-15%). Other methods, involving a Lewis acid to 
promote silylation9 (entry 4) or a mild base10 (entry 5) also failed to provide the 
desired product 13. 
Stepwise Orthogonal Coupling Procedure for the Synthesis of Glycopeptide Mimics 
 
81
Table 1. Direct silylation of Boc-protected propargylglycine. 
HN CO2Me
Boc
TMS
HN CO2Me
Boc
6 13  
entry TMS-source base/catalyst solvent result 
1 TMSCl EtMgBr THF partial hydrolysis of the ester
2 TMSCl NaHMDS THF partial hydrolysis of the ester 
3 TMSCl nBuLi THF partial hydrolysis of the ester 
4 TMSCl Zn(OTf)2 / Et3N DCM no reaction 
5 TMSCl CsOH·H2O THF:DMSO hydrolysis of the ester 
4.2.3.2 α-Alkylation of glycine 
Having found that direct alkylation of enantiopure propargylglycine was not 
successful, attempts were made to prepare the desired silyl-protected compounds 14 
and 15 via α-alkylation of glycine derivative 17 with protected propargyl bromides 
1811 and 1912 (Scheme 3). Obviously, such a route provides the intermediate product 
16 as a racemic compound. Although asymmetric alkylations13 are known for similar 
compounds, a racemic synthesis of 16 followed by enzymatic resolution was 
considered as easier, economically more feasible for larger quantities,14 and a better 
guarantee for a high enantiomeric excess.  
OMe
O
R
N
H
Br
+
HN
OH
O
R
PG
alkylation
14: R = TMS
15: R = TBDPS
18: R = TMS
19: R = TBDPS
HN
OMe
O
Renzymatic
resolution
16
17
PGPG
 
Scheme 3. Retrosynthesis of enantiomerically pure protected propargylglycine derivatives.  
Preparation of TMS-protected propargylglycine was achieved by deprotonation of 
the diphenylketimine protected esters 20 and 21 with a strong base (KOH) at −40 °C 
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(Scheme 4 / Table 2). Subsequent addition of TMS-propargyl bromide11 afforded the 
alkylated methyl ester 22 and tert-butyl ester 24 in excellent yields (Table 2, entry 1 
and 2).  
N
OR1
O
Ph
Ph
N
OR1
O
Ph
Ph
R2
20: R1 = Me
21: R1 = tBu
22: R1 = Me, R2 = TMS (>99%)
23: R1 = Me, R2 = TBDPS (76%)
24: R1 = tBu, R2 = TMS (>99%)
25: R1 = tBu, R2 = TBDPS (0%)
1) 1M HCl
Et2O, 72 h
2) Boc2O, Et3N
DMC, o.n., rt
BocHN
OMe
O
R2
26: R2 = TMS (99%)
27: R2 = TBDPS (77%)
for conditions
seeTable 2
 
Scheme 4. Preparation of silyl-protected racemic propargylglycines 26 and 27. 
Alkylation of the tBu-ester 21 under identical conditions with TBDPS-protected 
propargyl bromide12 as electrophile (entry 4), however, completely failed to afford 
the desired product 25. Fortunately, the synthesis of the TBDPS-protected 
propargylglycine derivate could be achieved upon subjection of methyl ester 20 to 
LDA,15 followed by alkylation to afford the desired product 23 in 76% yield (entry 5).  
Table 2. Alkylation of 20 and 21 with protected propargyl bromide derivatives. 
Method A:
TBAB 10 mol%, KOH 50% aq.
25 or 26 5 equiv
toluene: THF 7:3, 8h, -40 °C
Method B:
1) LDA 1.2 equiv
2) alkylation agent 2 equiv
HMPA 1.2 equiv, THF, 4h, r.t.  
entry R1 R2 method product yield 
1 Me TMS A 22 >99% 
2 tBu TMS A 24 >99% 
3 Me TMS B 22 28% 
4 tBu TBDPS A 25 no reaction 
5 Me TBDPS B 23 76% 
 
Subsequent treatment of the methyl esters 22 and 23 with a 1 M HCl solution effected 
the hydrolysis of the N-diphenylketimine which was followed by Boc–protection of 
the resulting free amine to afford the Boc-protected TMS- and TBDPS- protected 
propargylglycine methyl esters 26 and 27 in 99% and 77% yield, respectively. 
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4.2.3.3 Proof-of-concept of stepwise [3+2] cycloaddition 
Having the racemic silyl-protected propargylglycines 26 and 27 at hand, the stage 
was set to verify the concept of stepwise cycloaddition onto peptides containing 
differentially protected side-chains. Therefore the diacetylenic dipeptide 28 was 
prepared by condensing the (racemic) TMS-protected propargylglycine methyl ester 
26 with commercially available Boc-(S)-propargylglycine via standard peptide 
coupling chemistry.  
BocHN
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OBn
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O
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N3
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Scheme 5. Preparation of a differentially glycosylated triazole-linked glycopeptide. 
The potential of a stepwise introduction of carbohydrates via [3+2] cycloaddition was 
now investigated by first cycloaddition of the dipeptide 28 with tetra-O-benzyl 
azidoglucoside under the typical Cu(OAc)2/Na-ascorbate conditions. As anticipated, 
a smooth and clear introduction of a single carbohydrate moiety was observed, 
leaving the trimethylsilyl function fully unaffected. Subsequent desilylation with 
K2CO3 in methanol proceeded uneventfully, followed by another [3+2] cycloaddition, 
this time involving tetra-O-acetylazidoglucose, to afford the triazole-linked 
diglycosylated peptide 29 in an excellent total yield of 77% for the three steps 
(Scheme 5). 
4.2.3.4 Enzymatic resolution of silyl-protected propargylglycine 
With the proof-of-concept for stepwise introduction of azides by [3+2] cycloaddition 
firmly established, enzymatic resolution of the TMS- and TBDPS-protected substrates 
26 and 27 became requisite for the preparation of diastereomerically pure peptides. 
The industrially available alcalase, an enzyme mixture produced by Bacillus 
licheniformis containing subtilisin Carlsberg as the major enzyme component, seemed 
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perfectly suitable16 for such a purpose, since alcalase is known for its high activity and 
stability in alcoholic solvents.17 
The first enzymatic resolution of TMS-protected propargylglycine 26 was attempted 
by suspension of 26 in a mixture of tert-amyl alcohol and aqueous KHCO3 (Table 3). 
Next, a stoichiometric equivalent of alcalase solution (a mass equal to the amount of 
substrate) was added and the resulting mixture was vigorously stirred at 37 °C. After 
25 hours, HPLC analysis indicated a yield of 37% of the amino acid (entry 1), which 
luckily could be increased to 50%, the maximum yield for a classical resolution, upon 
addition of eight mass-equivalents of alcalase (entry 2). Subsequent isolation afforded 
the (S)-amino acid 28 in a yield of 48% with an excellent enantiomeric excess of 98%. 
Table 3. Enzymatic resolution of silyl-protected propargylglycines 26 and 27.  
BocHN
OMe
O
R
BocHN
OH
O
R
BocHN
OMe
O
R
+
26: R= TMS
27: R= TBDPS
28: R= TMS
29: R= TBDPS
alcalase
1M KHCO3
solvent
30: R= TMS
31: R= TBDPS  
aIsolated yield.  
Moreover, the reaction profile (Figure 4) revealed the high specificity of the alcalase, 
since prolonged stirring (24-48 h) did not drive the conversion above the theoretical 
yield of 50% for enantioselective hydrolysis. Contrary to the TMS-protected 
substrate, subjection of TBDPS-protected propargylglycine 27 to identical conditions 
failed to show any conversion to the desired amino acid 29 (entry 3), probably due to 
the poor solubility of 27 in tert-amyl alcohol.  
entry R solvent alcalase 
(mass equiv) 
time conversion to 
acid 
e.e. of 
acid 
1 TMS tamylOH 1 25 h 37% − 
2 TMS tamylOH 8 24 h 50% (48%)a 98% 
3 TBDPS tamylOH 1 − 8 22 h 0% − 
4 TBDPS tamylOH/DMF (3:1) 8 24 h 23% − 
5 TBDPS tBuOH/ DMF (3:1) 8 45 h 43% - 50% 3% - 40% 
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Figure 4. Enzymatic resolution of 26 and 27. 
In order to enhance the solubility of TBDPS-protected propargylglycine 27, 
resolution was attempted in a mixture of DMF, tert-amyl alcohol and aqueous 
KHCO3. After 24 hours, HPLC analysis indicated that indeed conversion was taking 
place, but only to an extent of 23%. Gratifyingly, substitution of tamylOH by tBuOH 
led to significantly increased conversion of 43-50% of the desired free acid. 
Nevertheless, it was disappointing to find that the reaction seemed to proceed with a 
large fluctuation in enantioselectivity, with ee varying from 3 to 40% for reasons 
unclear to us. Therefore, it was decided to temporarily continue with the racemic 
TBDPS-protected propargylglycine for incorporation in peptides and to postpone 
further optimization of the enzymatic resolution to a later time.  
4.3 ORTHOGONAL COUPLING ONTO PEPTIDES 
4.3.1 Peptide synthesis 
The most straightforward and reliable approach for the preparation of a given 
peptide is by Fmoc-based solid phase peptide chemistry. For this purpose, a trityl 
resin was selected to ensure that the final protected peptides could be smoothly 
cleaved from the resin, without removal of the silyl protective groups. As the solid 
phase approach demands Fmoc groups, the Boc-groups of TMS- (28) and TBDPS- 
(obtained by base saponification of 27) containing amino acids were removed (TFA, 
DCM), followed by Fmoc-protection with FmocOSu, to afford the amino acids 32 and 
33, respectively (Scheme 6).  
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FmocHN
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O
TBDPS
32 (95%)
FmocHN
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O
TMS
33 (63%)
: R1 = (S)-TMS-propargyl, R2 = Ac
: R1 = TBDPS-propargyl, R2 = Ac
: R1 = (S)-TMS-propargyl, R2 = Fmoc
: R1 = (S)-(CH2)4N3, R2 = Fmoc
R1
ValR2 Gly Gly GlySer(tBu)
Gly GlySer(tBu)Fmoc
34
35a
35b
35c
36  
Scheme 6. Preparation of the peptides. 
Subsequently, peptides 34 and 35a-c were prepared by standard Fmoc-based peptide 
chemistry, involving HOBt/DIPCDI-mediated coupling on a C-terminal glycine 
followed by piperidine-induced Fmoc deprotection. The resin-bound tripeptide 34 
was prepared to determine the optimal conditions for on-resin [3+2] cycloaddition. 
Furthermore, an azido-containing peptide 36 including a lysine derivative18 was 
synthesized applying the same technique (Scheme 6).  
4.3.2 Optimization of on resin [3+2] cycloaddition 
Resin-bound tripeptide 34 and tetraacetylated 1-azidoglucose 10 were subjected to 
various copper-catalyzed [3+2] cycloaddition conditions (Table 4). In order to 
monitor progression of the reaction, small portions of the peptide were washed, 
dried, cleaved from the resin and examined with LCQ-MS. Reactions conducted in 
acetonitrile with Et3N or 2,6-lutidine/DiPEA as base resulted in the formation of the 
product although significant amounts of starting material remained after 24 hours 
(entries 1 and 2). The conversion improved upon utilizing DMF as solvent and a  
2,6-lutidine/DiPEA base combination, but again small amounts of starting material 
were still present after 24 hours (entry 3). Much to our satisfaction, treatment of the 
peptide with CuI in DMF in the presence of Et3N or DiPEA led to full conversion to 
the desired triazole product (entry 4). For comparison, conditions described by 
Kirshenbaum et al.19 were also attempted (entry 5), but a more sluggish reaction was 
observed, producing several side-products.  
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Table 4. Optimization studies of on-resin [3+2] cycloaddition. 
OAcO
AcO
OAc
AcO N3
catalyst, TBTA,
base
solvent, 24h, rt
N
N
N
O
AcO
AcO
AcO
AcO
Gly GlySer(tBu)FmocGly GlySer(tBu)Fmoc
10
34 37  
 
entry solvent catalyst base resulta 
1 MeCN CuI Et3N +/− 
2 MeCN CuI 2,6-lutidine/ DiPEA +/− 
3 DMF CuI 2,6-lutidine/ DiPEA +/− 
4 DMF CuI Et3N or DiPEA + 
5 DMF: pyridine 7:3 CuI DiPEA +b 
a+ = Only mass of product found, +/− = Mass of product and s.m. found, − = Only mass of s.m. 
found bFormation of byproduct was evidenced. 
4.3.3 Orthogonal couplings on resin 
With suitable conditions for [3+2] cycloaddition clearly established, a synthetic route 
towards multiple glycosylated peptides was investigated. To this end, resin bound 
pentapeptide 35c was subjected to the conditions derived in the optimization studies 
(Table 5, entry 1). Surprisingly, a negligible amount of the desired mono-glycosylated 
product 38 was formed, but instead a second [3+2] cycloaddition had occurred on  
the presumed protected TMS-propargylglycine, leading to the diglycosylated 
product 39a.  
Apparently, in situ desilylation had taken place under the conditions employed. At 
first, complexation of copper(I) to TBTA was believed responsible for the production 
of an iodide source that is sufficiently nucleophilic to desilylate the acetylene. 
However, omission of TBTA (entry 2) led to complete absence of product formation. 
Similar observations were made with Fmoc-protected pentapeptide 35c, leading to a 
mixture of 38c and 39c. Application of a different copper source (entry 5) or a single 
equivalent of azidoglucose (entry 4) did not improve matters. 
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Table 5. First resin bound [3+2]-cycloaddition. 
N
N
N
O
AcO
AcO
AcO
AcO
ValR1 Gly Gly GlySer(tBu)ValR1 Gly Gly GlySer(tBu)
10 , 2 equiv
CuI, TBTA
DiPEA
DMF, 24h, rt
: R1= Ac
: R1= Fmoc
N
N
N
O
AcO
AcO
AcO
AcO
O
AcO
AcO
AcO
AcO
N
N
N
ValR1 Gly Gly GlySer(tBu)
TMSTMS
35a
35c
38a/c
39a/c  
entry R1 solvent ligand product resulta 
1 Ac DMF TBTA 39a + 
2 Ac DMF − − −b 
3 Fmoc DMF TBTA 38c + 39c + 
4 Fmoc DMF TBTA 38c + 39c +d 
5 Fmoc DMF TBTA − −c 
6 Fmoc MeCN TBTA − − 
7 Fmoc THF TBTA 38c + 
8 Ac THF TBTA 38a + 
a+ = Only mass of product(s) found, – = Only mass of s.m. found. bNo TBTA added to reaction mixture. 
cCu(MeCN)4PF6 used as catalyst. d1 Equiv of. azide added to reaction mixture  
In contrast, when the reaction was performed in THF instead of DMF, a dramatic 
improvement in selectivity took place, leading to the exclusive formation of the 
desired monoglycosylated products 38c and 38a, entries 7 and 8, respectively. A 
possible explanation for the desilylation encountered in DMF may be found in the 
increased nucleophilicity of the iodide in DMF, possibly in combination with  
π-interaction between the triazole-bound copper ion and TMS-acetylene in a 
diacetylene copper complex20 formed during the [3+2] cycloaddition. This was 
substantiated by the fact that control experiments with only TMS-propargylglycine, 
CuI, Et3N and DMF did not lead to desilylation. 
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Scheme 7. Acetylene deprotection, [3+2] cycloaddition and subsequent cleavage from the resin to 42. 
Having successfully introduced a single glycoside onto the monoprotected 
dipropargylpeptide, deprotection of the TMS-acetylene of the resin-bound 
monoglycosylated pentapeptide 38a was investigated under a variety of conditions. 
However, none of the known solution phase conditions for desilylation,7 e.g. 
K2CO3/MeOH, NaOMe, NaH and NaOH led to deprotection of the acetylene. 
Nevertheless, finally it was found that treatment of 38a with TBAF (1 M in THF) led 
to smooth desilylation along with saponification of acetyl functions, giving rise to 
resin–bound peptide 40 (Scheme 7). Unfortunately, TMS deprotection with TBAF to 
some extent also induced cleavage from the resin. Nevertheless, preparation of the 
final diglycosylated resin bound peptide 42 was achieved by [3+2] cycloaddition of 
the TMS-deprotected intermediate 40 with tetra-O-acetyl-1-azidoglucosamine 41 in 
DMF. Subsequent cleavage from the resin afforded the diglycosylated peptide 42 in a 
promising overall yield of 35% (Scheme 7).  
Finally, the same sequence was followed for the TBDPS-protected peptide 35b. We 
were pleased to find that the more robust TBDPS-group was fully unaffected by 
conditions of DMF, CuI and Et3N, and the pentapeptide 35b smoothly afforded the 
monoglycosylated derivative (not depicted). Subsequently, deprotection of the 
TBDPS-group with concomitant deacetylation to 40 could be achieved upon 
subjection to TBAF at 40 °C for 6 hours, although also in this case partial peptide 
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cleavage from the resin was observed. Other methods for the deprotection of the 
TBDPS group, e.g. KF or HF-pyridine gave no desilylation or led to cleavage from the 
resin, respectively. Naturally, subsequent cycloaddition and cleavage from the resin 
led to the racemic derivative of 42.  
4.3.3.1 [3+2] Cycloadditions onto a pentapeptide bearing an  azidobutylglycine 
and propargylglycine moiety 
Besides the TMS- and TBDPS-protected pentapeptides, an azido-containing amino 
acid derived from lysine was also incorporated in pentapeptide 36. The latter peptide 
was designed for the orthogonal introduction of different carbohydrate moieties via 
[3+2] cycloaddition. Although the peptide bears both an azide and an acetylene 
function, intramolecular cycloaddition is not likely based on earlier findings in our 
laboratory.21  
OAcO
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DMF, o.n., rt
1)
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10 min, rt
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Scheme 8. Resin bound strategy for the synthesis of a diglycosylated peptide. 
We were gratified to find that introduction of an acetylene-containing glucose 
derivative to the azidolysine moiety under the optimized conditions proceeded 
smoothly and selectively, providing resin-bound peptide 43 after 24 hours  
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(Scheme 8). The resin was washed and without the need for an intermediate 
deprotection a second [3+2] cycloaddition was performed with azidoglucose 
derivative 11 under the same conditions providing the diglycosylated peptide 44 in a 
32% overall yield after cleavage from the resin (1% TFA in DCM). 
4.3.3.2 Orthogonal couplings in solutions 
Although solid phase procedures are generally preferred over solution-based 
protocols for the preparation of peptides (e.g. with regard to purification), the 
difficulties encountered during cycloaddition and desilylation on the solid support 
stimulated us to investigate whether solution synthesis of the same peptides might 
be beneficial. Thus, pentapeptides 35a and 35b were cleaved from the resin and 
dissolved in THF before addition of azidoglucose 11, CuI and DiPEA. The desired 
triazole adducts 38a and 45 were formed without incidence and isolated in 34 and 
42%, respectively (Scheme 9).   
CuI 0.1 equiv
DiPEA 1.0 equiv
THF, rt
OAcO
AcO
OAc
AcO N3
2.0 equiv
38a: K2CO3, MeOH
o.n., rt Cu(OAc)2, Na-ascorbate
H2O/tBuOH
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AcO
NHAc
AcO N3
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N
N
N
O
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HO
HO
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ValAc Gly Gly Gly OH
40 (96%)
Ser(tBu) 42 (98%)
N
N
N
O
AcO
AcO
AcO
AcO
ValAc Gly Gly Gly OHSer(tBu)ValAc Gly Gly Gly OHSer(tBu)
R R
35a: R = TMS
35b: R = TBDPS
(racemic propargyl glycine)
38a: R = TMS (34%)
45: R = TBDMS (42%)
(racemic propargyl glycine)
45: TBAF, THF
10
41
 
Scheme 9. Solution phase procedure for the preparation of a diglycosylated peptide. 
Next, removal of the TMS-group from 38a and simultaneous saponification of acetyls 
was achieved under the action of K2CO3 in MeOH, providing substrate 40 in 96%. 
For compound 45, complete desilylation of the TBDPS group was evidenced by TLC 
and LCQ-MS upon subjection to 1 M TBAF in THF. Finally, pentapeptide 40 was 
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dissolved in a mixture of tert-butyl alcohol and water, due to insolubility in THF, in 
order to induce the second copper-catalyzed [3+2] cycloaddition with Cu(OAc)2 and 
Na-ascorbate as described in Chapter 3. It was highly rewarding to find that  
the latter cycloaddition resulted in a near quantitative yield of the diglycosylated 
peptide 42. 
4.4 CONCLUSIONS 
Stepwise introduction of carbohydrates onto an orthogonally protected peptide was 
successfully achieved. While cobalt hexacarbonyl and bromide protection proved 
unsuitable as protection of acetylene function, TMS and TBDPS-protected 
propargylglycine served the desired goal well. To this end, both silylated 
propargylglycines were prepared via alkylation of a glycine derivative, followed by 
enzymatic resolution under the action of alcalase. Enantiomerically pure L-TMS-
protected propargylglycine was obtained in excellent yield, but the TBDPS-
counterpart led to variable yields and stereoselectivities appeared hard to reproduce. 
Both the racemic TBDPS-protected as well as the enantiopure TMS-protected 
propargylglycine derivative were incorporated in a pentapeptide for stepwise [3+2] 
cycloaddition, deprotection and again [3+2] cycloaddition, both on resin and in 
solution. A minor disadvantage of the on resin approach involved partial cleavage of 
the peptide from the resin during desilylation, while the solution approach was 
slightly hindered by difficulties encountered during purification, leading to a 
decrease in total yield. Nevertheless, both the solid phase strategy as well as 
reactions in solution led to clean double introduction of carbohydrates onto the 
pentapeptide with a high overall yield of approximately 35%.  
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4.6 EXPERIMENTAL 
General information. For general experimental details, see Section 2.7 
 
Nomenclature of the peptides. For information on the nomenclature, see Section 3.6 
 
Methyl (2R)–2–[(tert–butoxycarbonyl)amino]–4–pentynoate dicobalthexacarbonyl 
complex (7). 
To a solution of (R)-Boc-propargylglycine methyl ester (80 mg, 0.35 mmol) in 
ether (2 mL) was added dicobalt octacarbonyl (128 mg, 0.37 mmol). The 
resulting mixture was stirred for 4 hours, evaporation of the solvent in vacuo 
and purification by flash column chromatography afforded 7 (167 mg, 0.33 
mmol, 92%) as a thick red oil. Rf = 0.34 (EtOAc/heptane, 1/3). 1H NMR (400 
MHz, CDCl3): δ = 5.29 (d, J = 7.4 Hz, 1H), 4.48−4.35 (m, 1H), 3.71 (s, 3H), 2.76−2.56 (m, 2H), 
1.98 (t, J = 2.6 Hz, 1H), 1.38 (s, 9H). 
 
(2R)-5-Bromo-2-tert-butoxycarbonylamino-4-pentynoic acid methyl ester (9) 
To a solution of (R)-Boc-propargylglycine methyl ester (98 mg, 0.43 mmol) in 
acetone (10 mL) was added N-bromosuccinimide (84 mg, 0.47 mmol) and a 
catalytic amount of AgNO3 (5.0 mg, 0.03 mmol). The mixture was stirred for 1 
h, water was added and the product was extracted with pentane, purification 
by flash column chromatography afforded 9 (91 mg, 0.30 mmol, 69%). Rf = 0.64 
(EtOAc/heptane, 1/1). 1H NMR (400 MHz, CDCl3): δ = 5.31 (br d, J = 7.2 Hz, 1H), 4.49−4.44 
(m, 1H), 3.79 (s, 3H), 2.84−2.69 (m, 2H), 1.46 (s, 9H). Spectral data are in accordance with 
literature.22  
 
N-(Diphenylmethylene)glycine methyl ester (21) 
A solution of benzophenone imine (1.0 g, 5.52 mmol), glycine methyl ester 
hydrochloride (0.697 g, 5.52 mol) in DCM (20 mL) was stirred for 24 h at 
room temperature, filtrated and the organic solvent was evaporated in 
vacuo. The crude product was redissolved in Et2O (10 mL), filtrated, washed 
with H2O, and dried (MgSO4). Subsequent evaporation of the solvent in vacuo followed by 
recrystallization in ether/hexane afforded 21 (1.12 g, 4.43 mmol, 80%). Rf = 0.35 
(EtOAc/heptane, 1/3). 1H NMR (400 MHz, CDCl3): δ = 7.77−7.65 (m,2H), 7.49−7.32 (m, 6H), 
7.19−7.17 (m, 2H), 4.22 (s, 2H), 3.75 (s, 3H). Spectral data are in accordance with literature.23 
 
N-(Diphenylmethylene)trimethylsilanepropargylglycine methyl ester (22) 
To a mixture of N-(diphenylmethylene)glycine methyl ester (20) (254 mg, 
1.0 mmol), tetrabutyl ammonium bromide (1 equiv) and TMS-propargyl 
bromide (18, 950 mg, 5.0 mmol) in toluene/THF (5 mL, 7:3) was added 
KOH (1.5 mL, 50% aqueous) at −40 ˚C. The resulting mixture was stirred 
for 8 hours at −40˚C, water was added and the product was extracted 
with Et2O (2 ×). The combined organic layers were washed with saturated aqueous NaCl, 
dried (Na2SO4) and evaporated in vacuo. The product was purified by flash column 
chromatography affording 22 (362 mg, 1.0 mmol, >99%) as a white solid. Rf = 0.6 
BocHN CO2Me
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(EtOAc/heptane, 1/2). 1H NMR (400 MHz, CDCl3): δ = 7.65−7.63 (m, 2H), 7.46−7.28 (m, 6H), 
7.19−7.16 (m, 2H), 4.31 (dd, J = 7.6, 6.2 Hz, 1H), 3.72 (s, 3H), 2.97−2.78 (m, 2H), 0.11 (d, J = 
15.1 Hz, 9H). 13C NMR (75 MHz, CDCl3): δ = 172.0, 171.3, 139.8, 136.2, 132.5, 130.5, 130.2, 
129.2, 128.9, 128.5, 128.4, 128.1, 103.6, 86.8, 64.8, 52.5, 25.0, 0.1. HRMS (ESI) m/z calculated for 
C22H26NO2Si (M+H)+: 364.1733, found: 364.1731. 
 
N-(Diphenylmethylene)-(3-tert-butyldiphenylsilylpropargyl)glycine methyl ester (23) 
To a solution of i-Pr2NH (1.86 mL, 13.2 mmol), in THF (5 ml) was added 
1.6 M n-BuLi in hexane (8.23 mL, 13.2 mmol) at −78˚C. The resulting 
mixture was stirred for 20 min at −78˚C, N-(diphenylmethylene)glycine 
methyl ester (20, 2.77 g, 10.9 mmol) was added and stirring was 
continued for 20 min. Next, HMPA (2.29 mL, 13.2 mmol) and TBDPS-
propargyl bromide (19, 7.80 g, 21.9 mmol) were added and the reaction was stirred for 3 
hours. It was poured into saturated NH4Cl and the product was extracted with Et2O (3 ×). 
The combined organic layers were washed with saturated aqueous NaCl, dried (Na2SO4) and 
evaporated in vacuo. The product was purified by flash column chromatography affording 23 
(4.38 g, 8.28 mmol, 76%). Rf = 0.6 (EtOAc/heptanes, 1/2). 1H NMR (400 MHz, CDCl3) δ = 
7.73−7.67 (m, 6H), 7.44−7.27 (m, 7H), 7.24−7.08 (m, 7H), 4.39 (dd, J = 8.8, 4.6 Hz, 1H), 3.72 (s, 
3H), 3.14−3.01 (m, 2H), 1.02 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 139.5, 136.0, 135.7, 135.7, 
133.6, 133.6, 130.6, 129.4, 129.4, 129.3, 128.7, 128.5, 128.3, 128.2, 127.7, 127.7, 107.7, 81.9, 64.2, 
52.5, 27.2, 25.4, 18.6. HRMS (ESI) m/z calculated for C35H36NO2Si (M+H)+: 530.2515, found: 
530.2507. 
 
N-(Diphenylmethylene)-(3-trimethylsilylpropargyl)glycine tert-butyl ester (24) 
To a mixture of N-(diphenylmethylene)glycine tert-butyl ester (21, 297 
mg, 1 mmol), tetrabutylammonium bromide (35 mg, 0.1 mmol) and TMS-
propargyl bromide (18, 956 mg, 5 mmol) in toluene/THF (4 ml, 7:3) was 
added KOH (1.5 mL, 50% aqueous) at −40˚C. The resulting mixture was 
stirred for 8 hours at −40˚C, water was added and the product was 
extracted with Et2O (2 ×). The combined organic layers were washed with saturated aqueous 
NaCl, dried (Na2SO4) and evaporated in vacuo. The product was purified by flash column 
chromatography affording 24 (405 mg, 1.00 mmol, >99%). Rf = 0.72 (EtOAc/heptanes, 1/5). 
1H NMR (400 MHz, CDCl3): δ = 7.65−7.63 (m, 2H), 7.44−7.27 (m, 6H), 7.19−7.18 (m, 2H), 4.17 
(dd, J = 8.2 Hz, 1H), 2.91−2.77 (m, 2H), 1.44 (s, 9H), 0.10 (s, 9H). Spectral data are in 
accordance with literature.24 
 
2-(tert-Butoxycarbonylamino)-5-(trimethylsilyl)pent-4-ynoic methyl ester (26) 
To a solution of N-(diphenylmethylene)trimethylsilanepropargylglycine 
methyl ester (22, 2.02 g, 5.58 mmol) in Et2O (30 mL) was added 1 M 
aqueous HCl (5 mL). Next, the reaction mixture was stirred for 72 h at 
room temperature, H2O (10 mL) was added and the reaction mixture was 
washed with DCM (3 ×). Subsequently, saturated aqueous NaHCO3 was 
added and the product was extracted with DCM (3 ×), dried (Na2SO4), filtrated and 
concentrated in vacuo to afford the HCl-salt. To a solution of the HCl salt (1.31 g, 5.57 mmol) 
in DCM (15 mL) was added Boc2O (2.43 g, 11.14 mmol) and Et3N (1.54 mL, 11.1 mmol). The 
reaction mixture was stirred overnight at room temperature and subsequently acidified to 
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pH 4 (5% KHSO4) and the product was extracted with DCM (3 ×). The combined organic 
layers were washed with saturated aqueous NaCl, dried (Na2SO4) and evaporated in vacuo. 
The product was purified by flash column chromatography affording 26 (1.41 g, 4.72 mmol, 
85%). Rf = 0.53 (EtOAc/heptanes, 1/2). 1H NMR (400 MHz, CDCl3): δ = 4.48−4.40 (m, 1H), 
3.76 (s, 3H), 2.78 (dd, J = 17.0, 4.8 Hz, 1H), 2.70 (dd, J = 17.0, 4.8 Hz, 1H), 1.46 (s, 9H), 0.14 (s, 
9H). Spectral data are in accordance with literature.25  
 
Methyl 2-(tert-butoxycarbonylamino)-5-(tert-butyldiphenylsilyl)pent-4-ynoate (27) 
A solution of N-(diphenylmethylene)-(3-tert-
butyldiphenylsilylpropargyl)glycine methyl ester 23 (2.00 g, 3.78 mmol) 
in Et2O (20 mL) was treated with 1 M aqueous HCl (35 mL). Next, the 
reaction mixture was stirred for 72 h at room temperature, H2O (10 mL) 
was added and the reaction mixture was washed with DCM (3 ×). Next, 
saturated NaHCO3 was added and the product was extracted with DCM (3 ×), dried 
(Na2SO4), filtrated and concentrated in vacuo to afford the HCl-salt. To a solution of the HCl-
salt (1.33 g, 3.64 mmol) in DCM (15 mL) was added Boc2O (1.59 g, 7.28 mmol) and Et3N (1.01 
mL, 7.28 mmol). The reaction mixture was stirred overnight at room temperature and 
subsequently acidified to pH 4 (5% KHSO4) and the product was extracted with DCM (3 ×). 
The combined organic layers were washed with saturated aqueous NaCl, dried (Na2SO4) and 
evaporated in vacuo. The product was purified by flash column chromatography affording 27 
(1.28 g, 2.75 mmol, 73%). Rf = 0.59 (EtOAc/heptanes, 1/2). 1H NMR (400 MHz, CDCl3): δ = 
7.79−7.73 (m, 4H), 7.42−7.32 (m, 6H), 5.41 (d, J = 7.3 Hz, 1H), 4.65−4.46 (m, 1H), 3.76 (s, 3H), 
2.96 (d, J = 4.4 Hz, 2H), 1.45 (s, 9H), 1.07 (s, 9H). HRMS (ESI) m/z calculated for C27H35NO4Si 
(M+H)+: 488.2233, found: 488.2211. 
 
(S)-2-(tert-Butoxycarbonylamino)-5-(trimethylsilyl)pent-4-ynoic acid (28) 
To a suspension of N-Boc protected amino acid methyl ester 26 (688 mg, 
2.30 mmol) in t-amylalcohol (6.9 mL) was added 1 M KHCO3 (6.9 mL) and 
aqueous alcalase solution (5.5 mL). The reaction mixture was stirred 
vigorously at 35 ˚C for 18 hours. Next, alcalase (1.4 mL ) was added and the 
reaction mixture was stirred for another 6 hours, water was added and the 
mixture was washed with DCM (2 ×), subsequently acidified to pH 4 (5% KHSO4 ) and the 
product was extracted with EtOAc (3 ×). The combined organic layers were dried (Na2SO4) 
and evaporated in vacuo affording 28 (0.31 g, 1.08 mmol, 47%). Rf = 0.20 (1% acetic acid in 
EtOAc/heptanes, 1/2). FTIR (film): ν 3442, 2958, 2180, 1692, 1160 cm−1. 1H NMR (400 MHz, 
D2O): δ = 4.48−4.45 (m, 1H), 2.85-2.73 (m, 2H), 1.47 (s, 9H), 0.15 (s, 9H). 13C NMR (75 MHz, 
CD3OD): δ = 174.3, 157.4, 103.2, 87.7, 80.6, 53.8, 28.7, 24.2, 0.3. HRMS (ESI) calculated for 
C13H23NO4Si (M-H)-: 284.0968, found: 284.0946. 
 
(S)-2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-(trimethylsilyl)pent-4-ynoic acid (32) 
To a solution of 27 (240 mg, 0.84 mmol) in DCM (5 mL) was added TFA 
(5 mL) and the reaction mixture was stirred for 30 min at room 
temperature. Toluene was added and solvents were removed in vacuo 
affording the crude TFA salt.  
Next, the (S)-2-amino-5-(trimethylsilyl)pent-4-ynoic acid TFA salt (226 
mg, 0.80 mmol) was resuspended in H2O/MeCN (20 mL, 1:1) and the pH was adjusted to 8.5 
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(Et3N). Then, a solution of Fmoc-succinimide (257 mg, 0.762 mmol) in MeCN (20 mL) was 
added and the mixture was stirred for 4 h at pH 8.5. Subsequently, the mixture was acidified 
to pH 2.7 (1 M aqueous HCl), the organic layer was evaporated in vacuo, and the product was 
extracted with EtOAc (3 ×). The combined organic layers were washed with water (pH 4), 
dried (Na2SO4) and evaporated in vacuo affording 32 (325 mg, 0.80 mmol, 95 %). Rf = 0.3 
(EtOAc/heptanes, 1/2). 1H NMR (400 MHz, CDCl3): δ = 7.79−7.76 (m, 2H), 7.64−7.59 (m, 
2H), 7.43−7.39 (m, 2H), 7.35−7.30 (m, 2H), 4.58−4.54 (m, 1H), 4.42 (t, J = 6.6 Hz, 2H), 4.26 (t, J 
= 7.2 Hz, 1H), 2.86−2.83 (m, 2H), 0.17 (s, 9H).  
 
2-(((9H-Fluoren-9-yl)methoxy)carbonylamino)-5-(tert-butyldiphenylsilyl)pent-4-ynoic acid 
(33) 
To a solution of 28 in THF (5.7 mL) was added 0.15 M LiOH in H2O (5.7 
mL, 0.86 mmol) and the mixture was stirred for 4 h at room 
temperature. The organic solvent was removed in vacuo, 5% KHSO4 
was added and the free acid was extracted with EtOAc (3 ×). The 
combined organic layers were dried (Na2SO4), and concentrated in 
vacuo. Subsequently the free acid was redissolved in DCM (2 mL), TFA (2 mL) was added 
and the reaction mixture was stirred for 30 min at room temperature. Toluene was added 
and solvents were removed in vacuo affording the crude TFA salt (395 mg, 0.86 mmol, 100%). 
Next, part of the (R/S)-2-amino-5-(tert-butyldiphenylsilyl)pent-4-ynoic acid TFA salt (226 mg, 
0.80 mmol) was resuspended in H2O/MeCN (10 mL, 1/1) and the pH was adjusted to 8.5 
(Et3N). Then, a solution of Fmoc-succinimide (274 mg, 0.817 mmol) in MeCN (8.3 mL) was 
added and the mixture was stirred for 3 h at pH 8.5. Subsequently the mixture was acidified 
to pH 2.3 (1 M aqueous HCl), the organic layer was evaporated in vacuo, and the product was 
extracted with EtOAc (3 ×). The combined organic layers were washed with water (pH 4), 
dried over Na2SO4 and concentrated in vacuo. Purification via flash column chromatography 
afforded 33 (311 mg, 0.52 mmol, 63%). Rf = 0.2 (1% acetic acid in EtOAc/heptane, 1/2). 1H 
NMR (400 MHz, CD3OD): δ = 7.79−7.76 (m, 6H), 7.63−7.60 (m, 2H), 7.41−7.31 (m, 8H), 
7.24−7.20 (m, 2H), 4.52−4.48 (m, 1H), 4.32−4.29 (m, 2H), 4.19−4.15 (m, 1H), 3.08−2.89 (m, 2H), 
1.03 (s, 9H). 13C NMR (75 MHz, CD3OD): δ = 173.8, 158.3, 145.2, 142.5, 136.7, 134.6, 130.6, 
128.8, 128.2, 126.3, 120.9, 107.8, 83.5, 68.3, 54.5, 27.6, 24.4, 19.3. HRMS (ESI) m/z calculated for 
C36H35NO4Si (M+H)+: 596.2233, found 596.2253. 
 
General procedure A for the synthesis of the peptides.  
Loading of the trityl resin, synthesis of the pentapeptides, and capping, were carried out 
following standard Fmoc peptide chemistry protocols, involving HOBt/DIPCDI-mediated 
couplings and piperidine-induced Fmoc deprotections. Side-chain protection was tert-butyl 
(tBu) for serine.  
 
General procedure B for the cleavage from the resin.  
The resin was treated with TFA:DCM (1:100) and shaken for 10 min. Subsequently, the resin 
was filtrated and the filtrate was neutralized with a 1:1 pyridine/methanol mixture. This 
procedure was repeated until TLC analysis indicated the absence of free amine in the filtrate. 
The combined organic layers were evaporated in vacuo affording the peptide. 
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General procedure C for the cycloaddition in solution.  
To a solution of the peptide (1 equiv) and glycoside (1 equiv) in THF (0.25 M) was added CuI 
(1 equiv) and TBTA (1 equiv). Next, the mixture was stirred for 24 h at room temperature, 
KHSO4 (5% aqueous) was added and the product was extracted with EtOAc (3 ×). The 
combined organic layers were washed with saturated aqueous NaHCO3, brine, dried 
(Na2SO4) and evaporated in vacuo. The product was purified by flash column 
chromatography using EtOAc/heptane mixtures or by preparative TLC using 
butanol/H2O/acetic acid (4/1/1). 
 
General procedure D for the cycloaddition in solution:  
To a solution of the peptide (1 equiv) and the glycoside (1 equiv) in tert–butanol (0.03 M) was 
added a mixture of Cu(OAc)2 (20 mol%), sodium ascorbate (40 mol%) and TBTA (20 mol%) 
in H2O (0.006 M and 0.013 M, respectively). The reaction was stirred for 24 h at room 
temperature, KHSO4 (5% aqueous) was added and the product was extracted with EtOAc  
(3 ×). The combined organic layers were washed with saturated aqueous NaHCO3, brine, 
dried (Na2SO4) and evaporated in vacuo. The product was purified by preparative TLC using 
butanol/H2O/acetic acid (4/1/1). 
 
General procedure E for the resin bound cycloaddition.  
To the immobilized peptide (1 equiv) was added the glycoside (2 equiv), CuI (1 equiv), TBTA 
(1 equiv) followed by the addition of THF and DiPEA (1 equiv). Next, the mixture was 
shaken or rolled for 24 h at room temperature, subsequently the resin was washed with THF 
(3 ×), MeOH (1 ×) and dried.  
 
Boc-T4M(1-[β-D-Glc(Bn)4]-T4M(1-[β-D-Glc(Ac)4]-OMe (29) 
To a solution of Boc-Pgl-Pgl(TMS)-OMe (28, 103 mg, 0.26 
mmol) and tetra-O-benzyl azidoglucose (149 mg, 0.26 
mmol) in tert–butanol (4 mL) was added a mixture of 
Cu(OAc)2 (16 mg, 21 mol%), sodium ascorbate (21 mg, 41 
mol%) in H2O (4 mL). The reaction was stirred for 24 h at 
room temperature, KHSO4 (5% aqueous) was added and 
the product was extracted with EtOAc (3 ×). The combined 
organic layers were washed with saturated aqueous 
NaHCO3, brine, dried (Na2SO4) and evaporated in vacuo. Next, the monoglycosylated peptide 
was dissolved in MeOH (4 mL) and a catalytic amount of K2CO3 was added. The mixture 
was stirred for 4 h, amberlite IR 120 plus was added until the solution was neutral, and the 
ion exchange was filtered off. Evaporation of the solvent in vacuo afforded the deprotected 
peptide. A subsequent cycloaddition and workup using tetra-O-acetylazidoglucose, followed 
by purification via flash column chromatography afforded 29 (264 mg, 0.20 mmol, 77%). FTIR 
(ATR): ν = 3360, 1744, 1218 cm−1. 1H NMR (400 MHz, CDCl3): δ = 7.66 (s, 1H), 7.54 (s, 1H), 
7.31−7.11 (m, 18H), 6.93−6.91 (m, 2H), 5.78−5.75 (m, 1H), 5.68 (d, J = 7.2 Hz, 1H), 5.58 (d, J = 
9.0 Hz, 1H), 5.36 (dd, J = 6.6 Hz, 2H), 5.25−5.21 (m, 1H), 4.88−4.79 (m, 3H), 4.71 (d, J = 6.1 Hz, 
1H), 4.57−4.39 (m, 6H), 4.27 (dd, J = 12.5 Hz, 1H), 4.09−4.06 (m, 1H), 4.02−3.92 (m, 2H), 3.89 
(ddd, J = 9.9, 4.3, 1.5 Hz, 1H), 3.80−3.74 (m, 2H), 3.73−3.62 (m, 3H), 3.66 (s, 3H), 3.28−3.08 (m, 
4H), 2.01 (s, 3H), 1.97 (s, 3H), 1.96 (s, 3H), 1.80 (s, 3H), 1.36 (s, 9H). 13C NMR (75 MHz, 
CDCl3): δ = 171.1, 171.1, 170.6, 170.0, 169.4, 169.3, 155.7, 143.6, 143.3, 138.3, 137.9, 137.9, 137.2, 
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128.6, 128.5, 128.5, 128.3, 128.1, 128.0, 127.9, 127.9, 127.8, 122.0, 121.1, 87.6, 85.8, 85.6, 81.0, 
80.3, 78.0, 77.4, 75.9, 75.3, 75.2, 74.9, 73.6, 72.7, 70.7, 68.6, 67.8, 61.6, 53.7, 52.7, 51.9, 28.4, 27.9, 
27.8, 20.7, 20.7, 20.6, 20.2. HRMS (ESI) m/z calculated for C64H77N8O19 (M+H)+: 1261.5305, 
found: 1261.5354. 
 
Ac-Val-(S)-Pgl(TMS)-Ser(OtBu)-(S)-Pgl-Gly-OH (35a) 
Preparation according to general procedures A and B 
for the synthesis of the peptides and cleavage from 
the resin afforded 35a (19 mg, 0.03 mmol, 64%). 1H 
NMR (400 MHz, CD3OD): δ = 8.42 (d, J = 7.4, 1H), 
4.61−4.56 (m, 1H), 4.53−4.50 (m, 1H), 4.43−4.38 (m, 
1H), 4.24−4.18 (m, 1H), 4.00−3.88 (m, 2H), 3.72−3.58 (m, 2H), 2.80−2.77 (m, 1H), 2.75−2.73 (m, 
1H), 2.70− 2.67 (m, 1H), 2.36−2.33 (m, 1H), 2.14−2.07 (m, 1H), 2.01 (s, 3H), 1.20 (s, 9H), 0.99 
(dd, J =  6.7, 4.5 Hz, 6H), 0.11 (s, 9H). HRMS (ESI) m/z calculated for C33H47N5O9Si (M+H)+: 
644.3092, found: 644.3046. 
 
Ac-Val-Pgl(TBDPS)-Ser(OtBu)-(S)-Pgl-Gly-OH (35b) 
Preparation according to general procedures A and B 
for the synthesis of the peptides and cleavage from 
the resin afforded 35b (25 mg, 0.03 mmol, 59%). 13C 
NMR (75 MHz, CD3OD): δ = 174.2, 174.0, 173.2, 172.3, 
172.0, 171.9, 136.6, 136.6, 134.4, 134.4, 130.5, 130.5, 
128.7, 128.7, 107.8, 107.5, 83.3, 83.2, 80.6, 80.3, 75.1, 74.9, 72.2, 72.0, 62.4, 62.2, 60.6, 60.2, 56.1, 
55.6, 54.1, 54.0, 53.6, 53.4, 32.2, 31.6, 27.7, 27.7, 27.6, 22.6, 22.6, 22.5, 22.3, 19.9, 19.9, 18.8, 18.7. 
HRMS (ESI) m/z calculated for C42H57N5O8Si (M+H)+: 832.3693 found: 832.3686. 
 
Ac-Val-(S)-T4M(1-[β-D-Glc(Ac)4])-Ser(tBu)- (S)-T4M(1-[β-D-Glc(Ac)4])-Gly-OH (39a) 
Preparation from resin bound PG-Val-Pgl(TMS)-
Ser(OtBu)-Pgl-Gly-OH (35a) similar to the general 
procedure E for the resin bound cycloaddition 
using azido saccharide as glycoside, with the 
exception of using DMF instead of THF as 
solvent. Subsequent cleavage from the resin 
afforded 39a (53 mg, 0.041 mmol, 40%). 1H NMR 
(400 MHz, CD3OD): δ = 8.29 (d, J = 7.8 Hz, 1H), 8.24 (d, J = 7.8 Hz, 1H), 8.18 (d, J = 28.0 Hz, 
2H), 8.09 (d, J = 6.8 Hz, 1H), 7.96 (t, J = 5.9 Hz, 1H), 6.10 (dd, J = 9.1, 2.8 Hz, 2H),  5.67 (t, J = 
9.4 Hz, 1 H), 5.61 (t, J = 9.3 Hz, 1H), 5.56−5.49 (m, 2H), 5.30 (dt, J = 9.5, 2.8 Hz, 2H), 4.41 (dd, J 
= 12.4,  5.7 Hz, 1H), 4.33−4.16 (m, 8H), 3.95 (d, J = 5.7 Hz, 2H), 3.66 (d, J = 0.4 Hz, 4H), 2.06 (s, 
3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 
1.17 (s, 9H), 0.93 (dd, J = 6.7,  2.1 Hz, 6H). 13C NMR (75 MHz, CD3OD): δ = 171.9, 171,7, 171.0, 
170.9, 170.4, 169.6, 169.5, 169.4, 168.7, 143.3, 143.2, 134.8, 134.7, 127.2, 126.9, 121.9, 121.7, 84.6, 
73.9, 73.2, 72.3, 72.2, 70.2, 70.1, 67.4, 67.3, 66.3, 61.2, 60.6, 58.7, 57.4, 57.1, 54.1, 52.2, 51.9, 40.1, 
39.5, 36.0, 29.8, 28.9, 28.8, 26.8, 26.6, 20.7, 18.8, 18.7, 18.4, 17.9, 17.4, 16.9, 16.5. HRMS (ESI) m/z 
calculated for C54H77N11O26 (M+H)+: 1340.4758, found: 1340.4720. 
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Ac-Val-(S)-Pgl(TMS)-Ser(tBu)- (S)-T4M(1-[β-D-Glc(Ac)4])-Gly-OH (38a) 
Preparation from PG-Val-Pgl(TMS)-Ser(OtBu)-Pgl-
Gly-OH (35a) according to general procedure C for 
the cycloaddition in solution afforded 38a (19 mg, 
0.019 mmol, 34%). 1H NMR (400 MHz, CD3OD): δ = 
8.15 (s, 1H), 6.10 (d, J = 9.1 Hz, 1H), 5.60 (t, J = 9.3 Hz, 
1H), 5.52 (t, J = 9.4 Hz, 1H), 5.28 (t, J = 9.6 Hz, 1H), 
4.67 (dd, J = 8.8, 4.4 Hz, 1H), 4.51 (dd, J = 9.9, 4.4 Hz, 
1H), 4.41 (t, J = 5.8 Hz, 1 H), 4.30 (dd, J = 12.0, 4.6 Hz, 1 H), 4.25−4.15 (m, 4H), 3.78−3.73 (m, 
2H), 3.71−3.66 (m, 2H), 3.61−3.57 (m, 1H), 3.22−3.14 (m, 1H), 2.92−2.74 (m, 2H), 2.06 (s, 3H), 
2.04 (s, 3H), 2.04 (s, 3H), 2.00 (s, 3H), 1.83 (s, 3H), 1.17 (s, 9H), 1.00 (dd, J = 6.8, 3.6 Hz, 6H), 
0.11 (s, 9H). 13C NMR (75 MHz, CD3OD): δ = 174.3, 174.0, 172.5, 172.4, 172.3, 172.0, 171.5, 
171.3, 170.5, 123.6, 104.1, 87.6, 86.6, 75.9, 75.3, 74.2, 72.1, 69.3, 63.1, 62.6, 61.1, 55.8, 54.6, 54.2, 
31.8, 30.8, 28.5, 27.8, 22.9, 22.7, 20.7, 20.7, 20.6, 20.2, 20.0, 19.1, 0.2. HRMS (ESI) m/z calculated 
for C43H66N8O17Si (M+H)+: 995.4393, found: 995.4407. 
 
Ac-Val-Pgl(TBDPS)-Ser(tBu)- (S)-T4M(1-[β-D-Glc(Ac)4])-Gly-OH (45) 
Preparation from PG-Val-Pgl(TBDPS)-Ser(OtBu)-Pgl-
Gly-OH (35b) according to general procedure C for 
the cycloaddition in solution afforded afforded 45 
(12.9 mg, 0.01 mmol, 42%).  
1H-NMR (400 MHz, CD3OD) δ = 7.79-7.70 (m, 5H), 
7.38-7.30 (m, 6H), 4.66 & 4.63 (2 ×  dd, J = 7.9, 3.7 & 6.4, 
3.7 Hz, 1H), 4.53 & 4.52 (2 × t, J = 7.9 & 8.1, 1H), 4.37 & 
4.36 (2 × t, J = 4.1 & 4.5 Hz, 1H), 4.19 & 4.07 (2 × d, J = 6.8 & 7.1, 1H), 3.90-3.78 (m, 2H), 3.60 
(ddd, J = 14.1, 9.3, 4.7 Hz, 1H), 3.48-3.38 (m, 1H), 3.06-2.98 (m, 1H), 2.90-2.76 (m, 1H), 2.73-
2.55 (m, 2H), 2.24 & 2.23 (2 × t, J = 2.6 & 2.6 Hz, 1H), 2.04-1.94 (m, 1H), 1.93 (s, 2H), 1.86 (s, 
2H),1.10 & 1.06 (2 × s, 9H), 0.99 (d, J = 5.6, 9H), 0.87 & 0.81 (2 × dd, J = 8.1, 7.0 & 8.7, 6.9 Hz, 
6H. HRMS (ESI) m/z calculated for C56H77N8O17Si (M+H)+: 1161.5176, found: 1161.5217. 
 
Ac-Val-(S)-Pgl-Ser(tBu)- (S)-T4M(1-[β-D-Glc])-Gly-OH (40) 
A) A solution of Ac-Val-Pgl(TBDPS)-Ser(tBu)-4TA(1’-
[β-D-Glc(Ac)4])-Gly-OH (45, 12.9 mg, 0.01 mmol) in 
THF (2 mL) was treated with 1 M TBAF in THF (0.3 
mL, 0.3 mmol) and stirred for 24 h at 40 °C. 
Completion of the reaction was evidenced by LRMS 
after 2 days.  
 
B) To a solution of Ac-Val-Pgl(TMS)-Ser(tBu)-4TA(1’-[β-D-Glc(Ac)4])-Gly-OH (38a, 19 mg, 
0.019 mmol) in MeOH (2mL) was added solid K2CO3 (excess) and the mixture was stirred 
overnight at room temperature. Amberlite IR 120 plus was added until the solution was 
neutral, and the ion exchange was filtered off. Evaporation of the solvent in vacuo afforded 40 
(13.7 mg, 0.018 mmol, 96%). 1H NMR (400 MHz, CD3OD): δ = 8.31 (s, 1H), 5.90 (d, J = 9.2 Hz, 
1H), 4.78 (t, J = 6.8 Hz, 1H), 4.65 (t, J = 5.6 Hz, 1H), 4.33 (d, J = 7.1 Hz, 1H), 4.17 (t, J = 9.1 Hz, 
1H), 4.13−4.09 (m, 1H), 4.01−3.81 (m, 10H), 3.54 (dd, J = 15.3, 5.5 Hz, 1H), 3.48−3.41 (m, 1H), 
2.92−2.90 (m, 2H), 2.63 (t, J = 2.5 Hz, 1H),  2.24 (s, 3H), 1.35 (s, 9H), 1.15 (d, J = 6.8 Hz, 6H). 13C 
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NMR (75 MHz, CD3OD): δ = 173.9, 173.3, 172.9, 171.2, 170.9, 170.7, 142.7, 122.9, 87.0, 78.9, 
78.3, 75.4, 75.2, 74.7, 71.8, 68.4, 60.5, 59.9, 59.0, 53.7, 52.6, 51.6, 29.8, 26.7, 25.9, 21.2, 20.5, 17.9, 
17.0. HRMS (ESI) m/z calculated for C32H50N8O13 (M+H)+: 777.3395, found: 777.3396. 
 
Ac-Val-(S)-T4M(1-[β-D-GlcNAc(Ac)3])-Ser(tBu)- (S)-T4M(1-[β-D-Glc])-Gly-OH (42) 
A) Preparation from Ac-Val-Pgl-Ser(tBu)-4TA(1’-
[β-D-Glc])-Gly-OH (40) according to general 
procedure B for the cycloaddition in solution 
afforded 42 (18 mg, 0.016 mmol, 98%).  
B) Preparation from resin bound PG-Val-
Pgl(TMS)-Ser(OtBu)-Pgl-Gly-OH (38a) by first 
performing a cycloaddition on the resin 
(according to general procedure E) using azidoglucose as glycoside, followed by 
deprotection of the TMS-acetylene by treatment with 1 M TBAF in THF at room temperature 
for 7.5 h. Subsequently, a second cycloaddition applying azidoglucoseamine as glycoside 
(according to general procedure E) was performed and finally the peptide was cleaved from 
the resing according to general procedure B to afford 42 (13.8 mg, 0.011 mmol, 35%). HRMS 
(ESI) m/z calculated for C46H70N12O21 (M+H)+: 1149.4676, found: 1149.4691.  
 
Fmoc-Val-(S)-T1B(1-[β-D-Glc(Ac)4])-Ser(tBu)- (S)-T4M(1-[β-D-Glc(Ac)4])-Gly-OH (44) 
Preparation from resin bound 36 by applying 
the general procedure E for the resin bound 
cycloaddition twice (first using an 
azidosaccharide and subsequently an acetylenic 
saccharide as glycoside), followed by cleavage 
from the resing according to general procedure 
B afforded 44 (48 mg, 0.032 mmol, 32%). 1H 
NMR (400 MHz, CD3OD/DMSO-D6): δ = 7.90 
(s, 1H), 7.88 (s, 1H), 7.78−7.72 (m, 2H), 7.51−7.35 
(m, 6H), 6.22 (d, J = 8.7 Hz, 1H), 5.67−5.56 (m, 2H), 5.44 (t, J = 9.4 Hz, 1H), 5.35−5.28 (m, 2H), 
5.16 (t, J = 9.7 Hz, 1H), 4.88 (d, J = 9.9 Hz, 1H), 4.83−4.71 (m, 3H), 4.46−3.99 (m, 11H), 
3.95−3.90 (m, 2H), 3.66−3.51 (m, 2H), 3.28−3.09 (m, 2H), 2.64 ( dq, J = 1.9, 1.6 Hz, 1H), 2.10 (s, 
3H), 2.08 (s, 3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 1.86 (s, 3H), 1.86 (s, 3H), 
1.42−1.30 (m, 4H), 1.17 (s, 9H), 0.96 (bs, 6H). HRMS (ESI) m/z calculated for C70H91N11O27Na 
(M+Na)+: 1540.5984, found: 1540.6019. 
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Copper(I)-Mediated  
Synthesis of Trisubstituted 
[1,2,3]-Triazoles 
 
 
 
Abstract*:  
A novel copper-catalyzed cycloaddition of bromoalkynes and organic azides is described. 
Copper-mediated coupling resulted in the formation of bromo-containing trisubstituted 
[1,2,3]-triazole derivatives in high yield and a regioselective manner, and was applied in 
the cycloaddition of a variety of bromoacetylenes and azides. The bromide substituent in 
the resulting triazoles provided a versatile synthetic handle for further functionalization to 
trisubstituted [1,2,3]-triazoles. 
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Method A:
5 mol% CuI, 5 mol% Cu(OAc)2
THF, 50 °C
Method B:
20 mol% CuBr, 20 mol% Cu(OAc)2
THF, 50 °C
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*Part of this chapter has been published as: B. H. M. Kuijpers, G. C. T. Dijkmans, S. Groothuys, P. 
J. L. M. Quaedflieg, R. H. Blaauw, F. L. van Delft, F. P. J. T. Rutjes, Copper(I)-mediated synthesis 
of trisubstituted 1,2,3-triazoles. Synlett 2005, 3059-3062. 
Chapter 5 
 
104
5.1 INTRODUCTION 
For a long time, the [1,2,3]-triazole compound class received rather little appreciation 
among the nitrogen-containing aromatic heterocycles. Nevertheless, [1,2,3]-triazoles 
are versatile compounds, as reflected in the broad variety of applications including 
anticorrosive agents, dyes, agrochemicals and photographic materials.1 Although no 
occurrences in Nature have been reported, [1,2,3]-triazoles feature in diverse 
pharmaceutical substances including anti-HIV2 and anti-microbial3 drugs as well as 
selective α3-adrenergic receptor agonists.4 Although the synthesis of [1,2,3]-triazoles 
had been studied for many years,5 the recent discovery by the groups of Meldal and 
Sharpless that Cu(I)-salts catalyze the [3+2] cycloaddition between organic  
azides and acetylenes contributed significantly to the efficient preparation of  
1,4-disubstituted-[1,2,3]-triazoles with exclusive regioselectively and in generally 
high yields.6 As with most of the earlier synthetic procedures, however, the Meldal 
and Sharpless procedures are only appropriate for the preparation of disubstituted 
triazoles. Methods for the synthesis of trisubstituted triazoles are scarce, and are 
frequently hampered by a lack of regioselectivity or by a restriction in choice of 
functional groups.7,8  
Two synthetic procedures for the regioselective synthesis of disubstituted triazoles 
deserve mentioning. Firstly, a strategy developed recently by Sharpless et al.8 
involves the synthesis of 1,5-disubstituted [1,2,3]-triazoles via the addition of 
bromomagnesium acetylides 2 to azides 1 (Scheme 1), and is applicable to a wide 
array of azides and alkynes. A useful feature of the strategy is the option to trap the 
magnesium intermediate 3 with a suitable electrophile, affording regioselectively the 
1,4,5-trisubstituted [1,2,3]-triazoles 4. 
R1
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R3R2MgBrR2
+
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MgBrR2
1
2 3 4
R1 N3
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Scheme 1. Trisubstituted [1,2,3]-triazoles via reaction of magnesium acetylides with azides. 
While in the above procedure the organic moieties of the acetylene and the azide end 
up in a 1,5-disposition in the resulting triazole, another strategy recently reported by 
Chen et al.9 describes the preparation of 5-iodo-1,4-disubstituted [1,2,3]-triazoles 
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(Scheme 2). It was shown that subjecting an acetylene (5) and an azide (1) to a 
combination of stoichiometric amounts of CuI and ICl led to the corresponding 
desired triazoles in a one-pot reaction with yields averaging around 70% for a variety 
of substrates. The resulting 5-iodo-1,4-disubstituted triazoles could be further 
functionalized by several palladium-catalyzed cross-coupling reactions (e.g. Suzuki, 
Heck and Sonogashira reactions). 
R1
N
N
N
R2R3
R1
N
N
N
R2I
Heck, Suzuki
or
Sonigashira
6 4
Et3N (5 equiv)
THF, rt
CuI (1 equiv)
ICl (1 equiv)
R2
+
1
5
R1 N3
 
Scheme 2. Trisubstituted [1,2,3]-triazoles via Cu(I)-mediated reaction of acetylenes and azides. 
Considering the fact that equimolar quantities of both copper-salts and iodine 
monochloride are required, we were prompted to further explore our finding that an 
organic azide and a bromoacetylene upon treatment with 20 mol% of Cu(OAc)2 and 
sodium ascorbate in a mixture of tert-butyl alcohol and water, not only yielded a  
1,4-disubstituted triazole lacking the bromide (i.e. the product normally formed  
from a terminal acetylene), but also a 1,4,5-trisubstituted triazole, as reported in 
Section 4.2.2. 
To investigate the generality of such trisubstituted triazole formation from an azide 
and a (substituted) bromoacetylene, a model system consisting of benzyl azide 7 and 
phenylbromoacetylene 8 was subjected to “optimized” [3+2]-CuAAC conditions 
(Scheme 3) as described earlier (Chapter 3), leading to a mixture of the standard 
cycloadduct 9, and a trisubstituted triazole product 10. The formation of such a 
trisubstituted compound is attractive, thus attempts to improve the yield were 
examined. We envisioned that performing the reaction in an aprotic medium  
(e.g. THF), would disfavour the formation of 9 and could consequently lead to  
an improved yield of the trisubstituted triazole product 10. As a first study, a  
1:1 mixture of 7 and 8 in THF was subjected to 10 mol% of CuI, however,  
it was disappointing to find that nearly no reaction took place. Likewise,  
treatment of the substrates with 10 mol% of Cu(OAc)2 failed to yield any 
trisubstituted product. 
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N
N
N
R
N
N
N
Br
9: R = H (34%)
10: R =
11 (89%)
Cu(OAc)2
Na-Ascorbate
tBuOH : H2O
12 h , rt
+
7 8
N3
CuI / Cu(OAc)2
THF
42 h , rt
C C Ph
Br
(22%)  
Scheme 3. Initial experiments with a model system. 
To our surprise, treatment of phenylbromoacetylene (8) and benzyl azide (7) with a 
mixture of CuI and Cu(OAc)2 (5 mol% each, THF), resulted in the new 5-bromo-1,4–
disubstituted triazole compound 11. The specific regiochemistry of the new triazole 
was determined via reduction to the 5-hydrogen-[1,2,3]-triazole by subjection to 
iPrMgCl, followed by quenching with methanol, and spectral comparison of the 
formed product to the known 1,4-disubstituted triazole. Further study proved that 
besides the 5-bromotriazole, a small amount of 5-iodotriazole was formed as well. 
In our opinion, the 5-bromosubstituted triazole 11 was even more interesting than 
the trisubstituted triazole 10, taking into account that a bromide can act as a versatile 
handle for further functionalization reactions, such as Pd-catalyzed cross-coupling 
reactions, as recently described by Chen10 for the iodotriazoles.  
5.2 OPTIMIZATION OF REACTION CONDITIONS 
Encouraged by the results achieved with phenylbromoacetylene and benzyl azide (7 
and 8) we selected the less volatile p-nitrobenzyl azide (12) and methyl 
bromopropiolate (13) as model substrates for optimization studies, as summarized in 
Table 1. Entries 1 and 2 show that Cu-catalysis plays an essential role in the 
mechanism, while subjecting 12 and 13 to 10 mol% of CuI (entry 3) led to a 4:1 
mixture of the bromo- and iodosubstituted 1,4-disubstituted triazoles 14 and 15. The 
low yield (32%) of the reaction was effectively raised to 78% upon heating to 55 °C 
(entry 4). Heating the reaction mixture to temperatures higher than 50 °C, however, 
led to the formation of (small) amounts of the undesired 1,5-regioisomer, probably 
formed via thermal [3+2] cycloaddition.  
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Table 1. Optimization of the [3+2] cycloaddition conditions. 
+
N
N
N
CO2Me
catalyst, solvent
temperature X
12 13 14: X = Br
15: X = I
O2N
N3
O2N
Br CO2Me
 
entry catalyst loading (mol%) solvent T     t (h) conva (yield)c 14:15 
1 - - THF rt 22   trace 100:0
2 - - THF 55 °C 22   12% 100b:0
3 CuI 10 THF rt 22   32% 80:20
4 CuI 10 THF 55 °C 22   78% 84b:16
5 Cu(OAc)2 10 THF rt 40   trace n.d.
6 CuI/Cu(OAc)2 5/5 THF rt 16   66% 95:5
7 CuI/Cu(OAc)2 5/5 MeCN rt 16 <7% n.d.
8 CuI/Cu(OAc)2 5/5 Et2O rt 16   3% n.d.
9 CuI/Cu(OAc)2 5/5 DMF rt 16   10% n.d.
10 CuI/Cu(OAc)2 5/5 toluene rt 16   2% n.d.
11 CuI/Cu(OAc)2 5/5 DCM rt 16   3% n.d.
12 CuI/Cu(OAc)2 5/5 THF 50 °C 16 >99% (99%) 94:6
13 CuI/Cu(OAc)2 5/5 THF reflux 16 >99% (95%) 93b:7
14 CuI/Cu(OAc)2 5/5 THF rt 40   97% (93%) 95:5
15 CuBr/Cu(OAc)2 5/5 THF rt 40   29% 100:0
16 CuBr/Cu(OAc)2 20/20 THF rt 40   56%c 100:0
17 CuBr/Cu(OAc)2 20/20 THF 50 °C 16 >99% (97%) 100:0
18 CuI/Cu(OAc)2 9/1 THF rt 48   36% n.d.
19 CuI/Cu(OAc)2 1/9 THF rt 48 <5% n.d.
20 CuI + DIPEA 10 THF rt 16   trace n.d.
21 CuI/PdCl2 5/5 THF rt 48   trace n.d.
22 CuI/CuSO4 5/5 THF rt 48 <5% n.d.
23 CuBr/Cu(OAc)2 5/5 THF rt 48   29% 100:0
24 CuI/CuCl2 5/5 THF rt 48   12% n.d.
25 CuCN/Cu(OAc)2 5/5 THF rt 48 <5% n.d.
26 CuBr 10 THF rt 48 <5% 100:0
aConversion determined by 1H-NMR. b(Small) amounts of the regioisomer were also detected. cIsolated yields.  
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Much to our satisfaction, upon the combined action of CuI and Cu(OAc)2, the 
conversion of substrates 12 and 13 greatly improved to 66% at room temperature 
(entry 6) and was driven to completion after prolonged reaction time or upon heating 
to 50 °C (entries 14 and 12). Next, we investigated the influence of other Cu-salts (e.g. 
CuCN, Cu(OAc)2, CuCl2, and CuBr), a mixture of CuI/PdCl2 (entry 21), different 
relative catalyst loadings (entries 19 and 20) and solvents (e.g. DCM, DMF, MeCN, 
Et2O and toluene, entries 7-11). In most cases, however, only small amounts of the 
desired product 14 could be isolated.  
In cases that CuI was used, a small amount of the corresponding 5-iodotriazole 15 
was also formed. To circumvent the formation of iodide 15, a CuBr/Cu(OAc)2 couple 
was used. As projected the 5-bromo-1,4-disubstituted triazole 14 was solely formed, 
albeit the reaction proceeded significantly slower (entry 15). In general, elevating the 
temperature (entries 6 vs 12 and 16 vs 17) and increasing the amount of catalyst 
(entry 15 vs 16) independently accelerated the reaction rate. 
R1
N
N
N
R2Br
Method A:
5 mol% CuI, 5 mol% Cu(OAc)2
THF, 50 °C
Method B:
20 mol% CuBr, 20 mol% Cu(OAc)2
THF, 50 °C
17
Br R2
+
1
16
R1 N3
 
Scheme 4. Optimized cycloaddition conditions. 
The optimal conditions that we eventually selected are shown in Scheme 4. With 
method A, reactions generally proceed faster, but the bromotriazole product is 
inevitably accompanied by small amounts of the 5-iodotriazole. Obviously, the 
formation of such by-products is hardly disadvantageous in case the halide 
substituent is further reacted to introduce other substituents such as in palladium-
catalyzed cross-coupling reactions as reported by Chen et al.10 Alternatively, in cases 
where a mixture of halide substituents is not desired, method B can be applied 
leading to the bromosubstituted triazole only. 
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5.3 SYNTHESIS OF 5-BROMO-[1,2,3]-TRIAZOLES 
Table 2. Variation of the bromoacetylene. 
Method A:
5 mol% CuI, 5 mol% Cu(OAc)2
THF, 50 °C
Method B:
20 mol% CuBr, 20 mol% Cu(OAc)2
THF, 50 °C
N
N
N
Br acetylene
+
acetylene O2N
N3
O2N
12
Br
 
entry acetylene product yield 
1
2
3
4
5
6
21a: 94%a,b (18 h)
21b: 85% (76 h)
19a: 85%b (16 h)
19b: 92% (75 h)
N
N
N
Br
OMe
23a: 85%c,d (50 h)
23b: 84% (124 h)
26a: 63% (16 h)b
26b: 98% (69 h)
N
N
N
Br O
OBnBnO
BnO OBn
Br
CO2MeBocHN
Br
OH
Br
OMe
O
BnO
BnO
OBn
OBn
Br
N
N
N
BrO2N
N
N
N
O2N
O2N
O2N
OH
CO2MeBocHN
Br
N N
N
Br
OH
O2N
OH
Br 28b: 48% (50 h)
N
N
N
Br
24a: 93%c,d (19 h)
24b: 39% (19 h)O2NBr
18
20
22
8
25
27
aReactions performed at rt. bIsolated as a 95:5 Br:I mixture. cIsolated as a 84:16 Br:I mixture. dReactions 
were carried out with 20 mol% of each catalyst. 
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Having found two novel procedures for the [3+2] cycloaddition of bromoacetylenes, 
an array of triazoles was prepared by reaction of p-nitrobenzyl azide (12) with 
different bromoacetylenes, as summarized in Table 2. Bromoacetylenes are stable 
compounds, readily prepared in quantitative yields from acetylenes upon the action 
of NBS and catalytic AgNO3. From Table 2, it becomes clear that the cycloaddition 
proceeds equally well for a range of different acetylenes including electron-donating 
or electron-withdrawing substituents. Yields are generally high, although a clear 
difference in reaction rate can be distinguished between the two methods. To our 
satisfaction, both methods were also applicable to sterically demanding acetylenic 
saccharides and amino acids as in the case of products 21a/b and 26a/b (entries 2  
and 5).  
Whereas earlier the azide starting material was kept constant, the coupling of methyl 
bromopropiolate (13) with a range of organic azides was also investigated, as 
displayed in Table 3. Clearly, a variety of different azides is well-tolerated, including 
sterically demanding azides (entries 5 and 6), resulting in the monosaccharide-
substituted triazoles 36a/b and 38a/b. Furthermore, several substituted benzylic 
azides were also successfully applied, leading to triazoles 14, 30, 32 and 34. Again, it 
is clear that method B proceeds considerably slower than method A. However, by 
extension of reaction times, the CuBr-mediated reactions can generally be driven to 
completion as well. 
At present, the mechanism of the [3+2] cycloaddition of bromoacetylenes and azides 
is unclear to us. One possibility is that only Cu(I)-species are involved, suggesting 
that the mechanism would proceed via Cu/Br-exchange, followed by cycloaddition 
and subsequent reaction of the Cu(I)-triazole complex with ‘Br+’. An alternative 
possibility involves an oxidative addition/reductive elimination cycle, in which 
initial oxidative addition of the bromoalkyne to Cu(I) leads to a Cu(III)-species,11 
followed by cycloaddition to a Cu(III)-triazole complex, and subsequent reductive 
elimination to the corresponding halotriazole. 
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Table 3. Variation of the azide. 
N
N
N
CO2MeBr
azide
Method A:
5 mol% CuI, 5 mol% Cu(OAc)2
THF, 50 °C
Method B:
20 mol% CuBr, 20 mol% Cu(OAc)2
THF, 50 °C
CH2O2Me
+
13
N3
azide
Br
 
entry azide product yield 
14a: 99%a (16 h)
14b : 97% (16 h)
36a: 83%a (16 h)
36b: 99% (140 h)
30a: 81%a,b (16 h)
30b: 99% (164 h)
32a: 80%a,b (40 h)
34a: 81%a,b (40 h)
N
N
N
CO2MeBr
N3
O
OAc
OAc
AcO
AcO
1
2
3
4
5
6
N
N
N
CO2MeBr
O
OAc
OAc
AcO
AcO
12
29
31
33
35
O2N
N
N
N
CO2MeBr
MeO2C
N
N
N
CO2MeBrBr
N
N
N
CO2MeBr
N3
O2N
N3
MeO2C
N3
Br
N3
38a: 67%a (16 h)
38b: 91% (147 h)N3
O
OAc
OAc
AcO
AcO N
N
N
CO2MeBr
O
OAc
OAc
AcO
AcO
37  
aIsolated as a 95:5 Br:I mixture. bReactions were performed at rt.  
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5.4 TRISUBSTITUTED [1,2,3]-TRIAZOLYL GLYCOPEPTIDES 
Prior to our discovery that bromoacetylenes and organic azides can be ligated via a 
[3+2] cycloaddition, the synthesis of 5-bromotrisubstituted triazoles was already 
explored in the development of trisubstituted triazole-linked glycopeptides. In an 
early stage we envisioned that applying high pressure to substituted 
propargylglycines and azidosaccharides would lead to a mixture of 1,4- and 1,5-
regioisomers. 
Table 4. High pressure-mediated cycloadditions. 
 
O
AcO
AcO
AcO
N3
OAc
15 kbar, 50 °C, 2d
CDCl3
O
AcO
AcO
AcO
OAc
CO2MeHN
Boc
HN CO2Me
Boc
+37
HN CO2Me
Boc
R
41a: R = Br
41b: R = Me
42a: R = Br
42b: R = Me
39: R = Br
40: R = Me
N
N
N
R
O
AcO
AcO
AcO
OAc
N
N
N
R
 
entry R yield of mixture product ratio (41:42) product 
1 Br 80% 41a 2:1 42a 
2 Me 72% 41b 2:1 42b 
In order to validate such an assumption, bromopropargylglycine 39 and 
methylpropargylglycine 40 were separately mixed with azidoglycoside 37 in 
deuterated chloroform and placed under 15 kbar at 50 °C for several days (Table 4). 
As anticipated, for both substrates a cycloaddition reaction occurred although very 
sluggishly, the reaction rate profile for formation of bromo-substituted triazole  
derivative (41a/42a) is depicted in Figure 1. It becomes clear that in the first 50 hours 
a relative fast reaction to 60% conversion took place, however, after that time  
the reaction rate dropped leading to 80% conversion after 175 hours. In addition,  
the methylpropargylglycine derivative 40 led to 72% conversion in a similar 
timeframe.   
Copper(I)-Mediated Synthesis of Trisubstituted [1,2,3]-Triazoles  
 
113
 
 
 
 
 
 
 
 
As expected, both 1,4- (41) and 1,5-regioisomers (42) were formed, in a 2:1 ratio 
respectively, with preference for the less sterically hindered 1,4-regioisomer. 
Unfortunately, separation of the regioisomers was futile. Therefore, also taking into 
consideration the very low reaction rate, the high pressure strategy for the formation 
of trisubstituted triazoles was abandoned. 
A more positive argument to explore other routes to trisubstituted triazoles came 
from our observation that halide-containing derivatives of triazoles can be 
synthesized in a stereoselective manner resulting in only the 1,4 regioisomer under 
copper(I)-catalysis. Thus, by application of the aforementioned methods A or B, 
bromo-substituted propargylglycine derivative 20 was coupled to azidogalactoside 
35 (Scheme 5), resulting in acceptable yields of the glycosidic amino acid derivative 
43. 
Method A:
20 mol% CuI
20 mol% Cu(OAc)2
THF, 50 °C
Method B:
20 mol% CuBr
20 mol% Cu(OAc)2
THF, 50 °C
N
N
N
Br
O
OAc
OAc
AcO
AcO
CO2MeBocHN
N3
O
OAc
OAc
AcO
AcO
+
BocHN CO2Me
Br
43a: 16 h (85%, Br:I 84:16)
43b: 50 h (65%)
20
35  
Scheme 5. Synthesis of a 5-bromotriazole-linked glycoamino acid. 
 
Figure 1. Conversion over time for 41a/42a. 
Chapter 5 
 
114
5.5 CYCLOADDITION OF IODOACETYLENES 
Since application of method A to bromoacetylenes inevitably led to the concomitant 
formation of small amounts of iodo-substituted triazoles, the possibility of preparing 
pure 5-iodotriazoles from the corresponding iodoacetylenes was also investigated. 
To this end, p-bromobenzyl azide (31) and methyl iodopropiolate (44) were subjected 
to a mixture containing 5 mol% CuI and Cu(OAc)2 in THF at 50 °C. After 16 hours, 
full conversion of starting materials was observed, yielding the desired 5-iodo-1,4-
disubstituted triazole 45 in excellent yield (Scheme 6). 
Br
N3
+
CO2Me
I
Br
N
N
N
CO2Me
CuI / Cu(OAc)2
THF, 50 °C, 16 h
I
31 44 45 (>99%)  
Scheme 6. Preparation of a 5-iodo-triazole. 
Unfortunately, the iodoacetylenes 46 and 47 (Figure 2) appeared too unstable to 
survive the reaction conditions, and condensing them with several azides failed to 
produce the desired iodotriazoles. 
 
I
OH
I
46 47  
Figure 2. Iodoacetylenes unable to undergo the cycloaddition. 
5.6 COUPLING REACTIONS 
Various coupling reactions such as Suzuki couplings, Heck, and Sonogashira 
reactions were described by Chen et al.10 for 5-iodotriazole-containing substrates. 
Applying several of these exact conditions to 5-bromotriazoles, however, was only 
partially successful. For example, Sonogashira reactions of 5-bromo-substituted 
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triazole 11 with acetylene 48 or 49 resulted in the formation of the desired products 
10 and 50 in moderate yields of 46% and 43%, respectively (Scheme 7).  
N
N
N
Br
PdCl2(PPh3)2 (10 mol%)
Et3N (1.2 equiv), CuI (20 mol%)
100 °C, DMF
+
N
N
N
R
R
11 48: R = Ph
49: R = C2H4OH
10: R = Ph (46%)
50: R = C2H4OH (43%)  
Scheme 7. Sonogashira reaction with bromotriazole 11. 
Even less rewarding were several attempts to functionalize the 5-bromo substrates by 
Heck reaction (e.g. Pd(PPh3)2Cl2, K2CO3, THF, 80 °C) since the desired products were 
not observed at all. More successful was the, not by Chen et al. described, metal-
halogen exchange of either halides (Br or I) under the action of BuLi at low 
temperature, followed by quenching with an appropriate electrophile such as 
benzaldehyde. Starting from 11, the corresponding alcohol 51 was formed in high 
yield (Scheme 8). Nevertheless, given the fact that Chen et al. already investigated the 
further transformation of halotriazoles under a range of conditions, this line of 
research was not further explored. 
N
N
N
X
1) BuLi, –95 °C
2) benzaldehyde
–95 °C
N
N
N
51 (90%)
OH
11: X = Br:I 95:5  
Scheme 8. Example of halogen-metal exchange. 
5.7 CONCLUSIONS 
In conclusion, we have shown for the first time that the Cu-catalyzed cycloaddition 
between bromoalkynes and organic azides proceeds readily to form the 
corresponding 5-bromo-[1,2,3]-triazole derivatives in high yield and in a 
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regioselective manner. The procedure offers access to a variety of halide-containing 
trisubstituted triazoles, in particular with bromide, since various iodoacetylenes 
proved to be incompatible with the required reaction conditions. In cases where a 
mixture of halide substituents is undesirable, method B (CuBr/Cu(OAc)2) can be 
applied leading solely to the bromo-substituted triazoles. The copper-catalyzed 
cycloaddition of bromoacetylenes and azides can be smoothly applied in the 
preparation of sterically demanding, trisubstituted [1,2,3]-triazolyl glycoamino acids. 
Finally, the halogen substituent of the resulting trisubstituted substrates offers a 
range of synthetic applications via metal-mediated derivatization. 
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5.9 EXPERIMENTAL 
General procedure A for the azide formation. 
To the bromine containing substrate (1 equiv) in MeCN (0.5 M) was added NaN3 (1.7 equiv) 
and the mixture was stirred overnight at room temperature. Next, the mixture was 
concentrated in vacuo and subsequently taken up in DCM. The organic layer was washed 
with water, saturated aqueous NaHCO3, brine, dried (MgSO4) and evaporated in vacuo. 
Purification of the products was achieved via flash column chromatography.  
 
p-Nitrobenzyl azide (12) 
 Preparation according to the general procedure A for azide formation 
afforded 12 (1.06 g, 5.91 mmol, 99%) as a colorless liquid. 1H NMR (400 
MHz, CDCl3): δ = 8.25 (d, J = 8.7 Hz, 2H), 7.52−7.49 (m, 2H), 4.51 (s, 2H). 
Spectral data are in accordance with literature.12 
 
3-Azidomethyl benzoic acid methyl ester (29) 
 Preparation according to the general procedure A for azide formation 
afforded 29 (1.27 g, 6.64 mmol, >99%) as a colorless liquid. 1H NMR (400 
MHz, CDCl3): δ = 8.03−7.99 (m, 2H), 7.54−7.45 (m, 2H), 4.41 (s, 2H), 3.93 
(s, 3H). Spectral data are in accordance with literature.13 
 
p-Bromobenzyl azide (31) 
 Preparation according to the general procedure A for azide formation 
afforded 34 (1.27 g, 5.89 mmol, 96%) as a colorless liquid. 1H NMR (400 MHz, 
CDCl3): δ = 7.52 (d, J = 8.4 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 4.31 (s, 2H). 
Spectral data are in accordance with literature.14 
N3
O2N
N3
MeO2C
N3
Br
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p-Methylbenzyl azide (33) 
 Preparation according to the general procedure A for azide formation 
afforded 36 (1.01 g, 5.70 mmol, 94%) as a colorless liquid. 1H NMR (400 MHz, 
CDCl3): δ = 7.20 (ap d, J = 1.3 Hz, 2H), 4.29 (s, 2H), 2.36 (s, 3H). Spectral data 
are in accordance with literature.15 
 
General procedure B for the preparation of the acetylenic bromides. 
To a solution of the acetylene (1 equiv) in acetone (0.5 M) were added AgNO3 (5 mol%) and 
N-bromosuccinimide (1.2 equiv) and the mixture was stirred for 4 h and diluted with water. 
Next the product was extracted with DCM (2 ×), and the combined organic layers were 
washed with water, saturated aqueous NaHCO3, brine, dried (MgSO4) and evaporated in 
vacuo to afford the desired product.  
 
Bromophenylacetylene (8) 
 Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 8 (177 mg, 0.87 mmol, 87%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3): δ = 7.46−7.43 (m, 2H), 7.36−7.27 (m, 3H). Spectral 
data are in accordance with literature.16 
 
Methyl 3-bromopropiolate (13) 
 Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 13 (873 mg, 4.66 mmol, 78%) as a yellow oil. 1H 
NMR (400 MHz, CDCl3): δ = 3.79 (s, 3H). Spectral data are in accordance with 
literature.17  
 
4-Bromo-3-butynol (18) 
 Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 28 (788 mg, 3.26 mmol, 54%) as a liquid. 1H NMR 
(400 MHz, CDCl3): δ = 3.73 (t, J = 6.3 Hz, 2H), 2.49 (t, J = 6.3 Hz, 2H), 1.97 (br s, 
1H). Spectral data are in accordance with literature.18 
 
(S)-N-Boc-Bromopropargylglycine methyl ester (20) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 20 (155 mg, 0.51 mmol, 77%) as a yellowish 
solid. 1H NMR (400 MHz, CDCl3): δ = 5.30 (br d, J = 6.8 Hz, 1H), 4.49−4.44 
(m, 1H), 3.79 (s, 3H), 2.84−2.69 (m, 2H), 1.46 (s, 9H). Spectral data are in 
accordance with literature.19  
 
4-Methoxyphenylbromoacetylene (22) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 22 (212 mg, 0.97 mmol, 94%) as a yellowish 
solid. 1H NMR (400 MHz, CDCl3): δ = 7.38 (d, J = 9.0 Hz, 2H), 6.83 (d, J = 
9.0 Hz, 2H), 3.81 (s, 3H). Spectral data are in accordance with literature.20  
 
N3
Br
CO2Me
Br
Br
OH
Br
CO2MeBocHN
Br
OMe
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3-Bromo-1,1-dimethyl-2-propynol (27) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 28 (148 mg, 0.76 mmol, 76%) as a liquid. 1H NMR 
(400 MHz, CDCl3): δ = 1.95 (br s, 1H), 1.52 (s, 6H). Spectral data are in 
accordance with literature.21 
 
Tetra-O-benzyl-1-bromoacetylenic glucose (35) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 35 (115 mg, 0.17 mmol, 95%) as a yellow 
oil. 1H NMR (400 MHz, CDCl3): δ = 7.36−7.24 (m, 18H), 7.13−7.10 (m, 
2H), 4.92 (dd, J = 10.4, 3.2 Hz, 2H), 4.82 (dd, J = 11.0, 7.4 Hz, 2H), 4.79 (d, 
J = 10.6, 1H), 4.57 (dd, J = 33.0, 12.2 Hz, 2H), 4.51 (d, J = 10.8), 4.06−4.04 (m, 1H), 3.74−3.65 (m, 
2H), 3.62−3.58 (m, 3H), 3.43-3.39 (m, 1H). Spectral data are in accordance with literature.22  
 
(R)-N-Boc-Bromopropargylglycine methyl ester (39) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides afforded 39 (91.4 mg, 0.30 mmol, 69%) as a white solid. 
Rf = 0.64 (EtOAc/heptanes, 1/1). 1H NMR (400 MHz, CDCl3): δ = 5.31 (br d, J 
= 6.8 Hz, 1H), 4.49−4.44 (m, 1H), 3.79 (s, 3H), 2.84−2.69 (m, 2H), 1.46 (s, 9H). 
 
Methyl 3-bromopropiolate (44) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides, using N-iodosuccinimide instead of N-bromosuccinimide, 
afforded 44 (873 mg, 4.66 mmol, 78%) as a yellow oil. 1H NMR (400 MHz, 
CDCl3): δ = 3.71 (s, 3H).  
 
Iodophenylacetylene (46) 
Preparation according to the general procedure B for the preparation of 
acetylenic bromides, using N-iodosuccinimide instead of N-bromosuccinimide, 
afforded 46 (1.31 g, 5.8 mmol, 96%) as a yellow oil. 1H NMR (400 MHz, CDCl3): 
δ = 7.45−7.41 (m, 2H), 7.33−7.28 (m, 3H). Spectral data are in accordance with 
literature.23  
 
3-Iodo-1,1-dimethyl-2-propynol (47) 
Preparation similar to the general procedure B for the preparation of acetylenic 
bromides, using N-iodosuccinimide instead of N-bromosuccinimide, afforded 
47 (232 mg, 0.88 mmol, 88%) as a liquid. 1H NMR (400 MHz, CDCl3): δ = 1.96 (br 
s, 1H), 1.53 (s, 6H). Spectral data are in accordance with literature.24 
 
General method C for the preparation of 5-bromo-1,4-disubstituted triazoles.  
To a solution of the bromoacetylene (1 equiv) and the azide derivative (1 equiv) in dry THF 
(0.5 M) was added CuI (5 mol%) and Cu(OAc)2 (5 mol%) The reaction was stirred at 50 °C. 
The solution was concentrated in vacuo, water was added and the product was extracted 
with DCM (2 ×). The combined organic layers were washed with saturated aqueous 
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NaHCO3, brine, dried (MgSO4) and evaporated in vacuo. The product was purified by flash 
chromatography using EtOAc/heptane mixtures. 
 
General method D for the preparation of 5-bromo-1,4-disubstituted triazoles.  
To a solution of the bromoacetylene (1 equiv) and the azide derivative (1 equiv) in dry THF 
(0.5 M) was added CuBr (20 mol%) and Cu(OAc)2 (20 mol%) The reaction was stirred at 50 
°C. The solution was concentrated, water was added and the product was extracted with 
DCM (2 ×). The combined organic layers were washed with saturated aqueous NaHCO3, 
brine, dried (MgSO4) and evaporated in vacuo. The product was purified by flash 
chromatography using EtOAc/heptane mixtures. 
 
1-Benzyl-4-phenyl-[1,2,3]-triazole (9) 
Benzyl azide 7 (30 mg, 0.23 mmol) and phenylbromoacetylene 8 (44 mg, 
0.24 mmol) were subjected to the Cu(OAc)2/Na-ascorbate catalyzed [3+2] 
cycloaddition conditions as described in Chapter 3. Purification by 
column chromatography afforded 11 (18 mg, 0.08 mmol, 34%). 1H NMR 
(400 MHz, CDCl3): δ = 7.79 (d, J = 7.2 Hz, 2H), 7.66 (s, 1H), 7.44−7.25 (m, 8H), 5.58 (s, 2H). 
Spectral data are in accordance with literature.25 
 
1-Benzyl-5-bromo-4-phenyl-[1,2,3]-triazole (11) 
Preparation according to general method C afforded 11 (98 mg, 0.31 
mmol, 89%). FTIR (ATR): ν = 3062, 2924, 2850 cm–1.  1H NMR (400 MHz, 
CDCl3): δ  = 7.97 (d, J = 8.8 Hz, 2H), 7.46−7.34 (m, 8H), 5.63 (s, 2H). 13C 
NMR (75 MHz, CDCl3): δ = 144.8, 133.9, 129.5, 128.9, 128.5, 128.5, 127.7, 
126.7, 108.0, 53.2. HRMS (EI) m/z calculated for C15H12Br79N3 (M): 313.0215, 
found:  313.0213.  
 
5-Bromo-4-methylcarboxy-1-(4-nitrobenzyl)-[1,2,3]-triazole (14) 
Preparation according to general method C afforded 14 (135 mg, 
0.40 mmol, 99%) as a white solid. Preparation according to general 
procedure D afforded 14 (274 mg, 0.60 mmol, 97%) as a white solid. 
Rf = 0.38 (EtOAc/heptanes, 1/1). FTIR (ATR): ν = 2954, 1722, 1519, 
1342 cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.24 (d, J = 8.8 Hz, 2H), 7.45 (d, J = 8.8 Hz, 2H), 
5.73 (s, 2H), 3.99 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 160.1, 148.4, 140.0, 138.2, 128.9, 124.5, 
116.6, 52.7, 52.3. HRMS (CI) m/z calculated for C11H9BrN4O4 (M): 340.9885, found:  340.9887. 
 
5-Bromo-4-(hydroxyethyl)-1-(4-nitrobenzyl)-[1,2,3]-triazole (19) 
Preparation according to general method C afforded 14 (112 mg, 
0.34 mmol, 85%) as a white solid. Preparation according to general 
method D afforded 19 (111 mg, 0.34 mmol, 92%) as a white solid. Rf 
= 0.22 (EtOAc/heptane, 2/1). FTIR (ATR): ν = 3357, 2848, 1611, 
1538, 1517 cm–1. 1H NMR (400 MHz, CDCl3): δ = 8.23 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 
2H), 5.65 (s, 2H), 4.01 (q, J = 6.0 Hz, 2H), 2.90 (t, J = 6.0 Hz, 2H), 2.48 (t, J = 6.0 Hz, 1H). 13C 
NMR (75 MHz, CDCl3): δ = 148.2, 145.4, 140.9, 128.8, 124.4, 110.2, 61.0, 52.1, 28.3. HRMS (CI) 
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m/z calculated for C11H11Br81N4O3 (M): 327.9994, found:  327.9993. HRMS (CI): m/z calculated 
for C11H11Br79N4O3 (M): 326.0014, found 326.0001. 
 
Methyl (R)-2-[(tert-Butoxycarbonyl)amino]-3-{1-(4-nitrobenzyl)-5-bromo-[1,2,3]-triazol-4-
yl}propionate (21) 
Preparation according to general method C afforded 21 (91 mg, 
0.19 mmol, 94%) as a pink oil. Preparation according to general 
method D afforded 21 (165 mg, 0.34 mmol, 85%) as a pink oil. Rf = 
0.45 (EtOAc/heptane, 1/1. FTIR (ATR): ν = 1705, 1528, 1342 cm–1. 
1H NMR (400 MHz, CDCl3): δ = 8.23 (d, J = 8.6 Hz, 2H), 7.38 (d, J 
= 8.4 Hz, 2H), 5.63 (s, 2H), 5.55−5.45 (m, 1H), 4.72−4.60 (m, 1H), 3.73 (s, 3H), 3.19 (bd, J = 3.6 
Hz, 2H), 1.41 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.5, 155.2, 148.0, 142.9, 140.9, 128.4, 
124.2, 111.0, 80.0, 52.6, 52.5, 52.0, 28.3, 28.0. HRMS (ESI) m/z calculated for C18H2379BrN5O6 
(M+H)+: 484.0832, found: 484.0810. HRMS (ESI) m/z calculated for C18H2279BrN5O6Na 
(M+Na)+: 506.0651, found: 506.0638.  
 
5-Bromo-4-(4-methoxyphenyl)-1-(4-nitrobenzyl)-[1,2,3]-triazole  (23) 
Preparation according to general method C afforded 23 (133 mg, 
0.34 mmol, 85%) as an off-white solid. Preparation according to 
general method D afforded 23 (130 mg, 0.33 mmol, 84%) as an off-
white solid. Rf = 0.59 (EtOAc/heptane, 1/1. 1H NMR (400 MHz, 
CDCl3): δ = 8.23 (d, J = 8.8 Hz, 2 H), 7.90 (d, J = 8.8 Hz, 2 H), 7.46 
(d, J = 8.8 Hz, 2 H), 6.99 (d, J = 8.8 Hz, 2 H), 5.71 (s, 2 H), 3.85 (s, 3 H). 13C NMR (75 MHz, 
CDCl3): δ = 160.1, 148.1, 145.3, 141.1, 128.6, 128.2, 124.3, 121.8, 114.2, 107.3, 55.4, 52.1. HRMS 
(CI) m/z calculated for C16H13Br79N4O3 (M): 388.0171, found: 388.0175. HRMS (CI) m/z 
calculated for C16H13Br81N4O3 (M): 390.0152, found: 390.0164. 
 
5-Bromo-1-(4-nitrobenzyl)-4-(phenyl)-[1,2,3]-triazole (24) 
Preparation according to general method C afforded 24 (134 mg, 0.37 
mmol, 93%) as a yellow solid. Preparation according to general 
method D afforded 24 (57 mg, 0.16 mmol, 39%) as a yellow solid. Rf = 
0.50 (EtOAc/heptane, 1/1). 1H NMR (400 MHz, CDCl3): δ  =  8.24 (d, 
J = 8.8 Hz, 2H), 7.99−7.97 (m, 2H), 7.50−7.39 (m, 5H), 5.73 (s, 2H). 13C NMR (75 MHz, CDCl3): 
δ = 150.3, 134.4, 130.3, 129.0, 128.7, 128.6, 127.9, 127.5, 54.5. HRMS (EI) m/z calculated for 
C15H11Br79N4O2 (M): 358.0065, found: 358.0048. 
 
5-Bromo-1-(4-nitrobenzyl)-4-(2,3,4,6-tetra-O-acetyl-D-galactopyranosyl)-[1,2,3]-triazole (26) 
Preparation according to general method C afforded 26 (54 mg, 0.07 
mmol, 63%) as an oil. Preparation according to general method D 
afforded 26 (87 mg, 0.11 mmol, 98%) as an oil. Rf = 0.70 
(EtOAc/heptane, 1/1). FTIR (ATR): ν = 3200, 2103, 1671, 1066 cm-1. 
1H NMR (400 MHz, CDCl3): δ = 8.07 (d, J = 8.6 Hz, 2H), 7.35−7.13 (m, 
20H), 6.94 (d, J = 6.9 Hz, 2H), 5.57 (q, J = 15.7 Hz, 2H), 4.91 (s, 2H), 
4.86 (d, J = 10.8 Hz, 1H), 4.69 (d, J = 11.2 Hz, 1H), 4.63−4.42 (m, 4H), 4.25 (d, J = 11.2 Hz, 1H), 
4.11 (t, J = 9.4 Hz, 1H), 3.82 (t, J = 8.9 Hz, 1H), 3.77−3.60 (m, 4H). 13C NMR (75 MHz, CDCl3): 
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δ = 148,0, 144,3, 140,7, 138,5, 138,1, 138,0, 138,0, 128,5, 128,4, 128,2, 128,0, 127,8, 127,6, 127,6, 
127,4, 124,2, 112,0, 86,9, 80,8, 79,8, 78,1, 75,7, 75,2, 74,7, 73,4, 73,2, 69,1, 51,8. HRMS (EI) m/z 
calculated for C43H41Br79N4O7 (M): 804.2158, found: 804.2147. HRMS (EI) m/z calculated for 
C43H41Br81N4O7 (M): 806.2138, found:  806.2146. 
 
5-Bromo-4-(2-hydroxy-2-propanyl)-1-(4-nitrobenzyl)-[1,2,3]-triazole (28) 
Preparation according to general method D afforded 28 (66 mg, 0.19 
mmol, 48%). Rf = 0.55 (EtOAc/heptane, 1/1). 1H NMR (400 MHz, 
CDCl3): δ  = 8.21 (d, J = 8.8 Hz, 2 H), 7.44 (d, J = 8.8 Hz, 2 H), 5.66 (s, 
2H), 2,97 (bs, 1H), 1,67 (s, 6H). HRMS (CI) m/z calculated for 
C12H13Br79N4O3 (M): 340.0171, found: 340.0157. HRMS (CI) m/z calculated for C16H13Br81N4O3 
(M): 390.0152, found: 390.0164.  
 
5-Bromo-1-(3-(methoxycarbonyl)benzyl)-4-methylcarboxy-[1,2,3]-triazole (30)   
Preparation according to general method C afforded 30 (117 mg, 
0.33 mmol, 81%) as a white solid. Preparation according to 
general method BD afforded 30 (127 mg, 0.36 mmol, 99%) as a 
white solid. Rf = 0.45 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 2590, 1725, 1531, 1286, 1225 cm–
1. 1H NMR (400 MHz, CDCl3): δ = 8.06−7.97 (m, 2H), 7.50−7.40 (m, 2H), 5.66 (s, 2H), 3.97 (s, 
3H), 3.92 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 166.0, 160.0, 137.7, 133.5, 132.1, 131.0, 130.1, 
129.3, 129.0, 116.3, 53.0, 52.6, 52.6 HRMS (EI) m/z calculated for C13H13BrN3O4 (M+H)+: 
354.0089, found: 354.0081. 
 
5-Bromo-1-(4-bromobenzyl)-4-methylcarboxy-[1,2,3]-triazole (32) 
Preparation according to general method C afforded 32 (121 mg, 0.32 
mmol, 80%) as a white solid. Rf = 0.51 (EtOAc/heptane, 1/1. FTIR 
(ATR): ν = 1727, 1524, 1230 cm–1. 1H NMR (400 MHz, CDCl3): δ = 7.49 
(d, J = 8.4 Hz, 3H), 7.17 (d, J = 8.4 Hz, 3H), 5.54 (s, 2H), 3.94 (s, 3H). 13C NMR (75 MHz, 
CDCl3): δ = 129.9, 137.7, 132.2, 132.0, 129.5, 13.1, 116.2, 52.7, 52.6. HRMS (EI) m/z calculated 
for C11H9Br279N3O2 (M): 372.9062, found:  372.9058.  
 
1-(4-Methylbenzyl)-4-methylcarboxy-5-bromo-[1,2,3]-triazole (34)   
Preparation according to general method C afforded 34 (100 mg, 0.32 
mmol, 81%). Rf = 0.61 (EtOAc/heptane, 1/1. FTIR (ATR): ν = 2946, 
1722, 1524, 1450, 1225 cm–1. 1H NMR (400 MHz, CDCl3): δ = 7.20−7.14 
(m, 4H), 5.57 (s, 2H), 3.97 (s, 3H), 2.33 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 160.1, 138.7, 
137.5, 130.1, 129.6, 127.8, 116.1, 53.2, 52.5, 21.5. HRMS (EI) m/z calculated for C12H12BrN3O2 
(M): 309.0113, found:  309.0117. 
 
5-Bromo-4-methylcarboxy-1-(2,3,4,6-tetra-O-acetyl-D-galactopyranosyl)-[1,2,3]-triazole (36) 
Preparation according to general method C afforded 36 (179 mg, 0.33 
mmol, 83%). Preparation according to general method D afforded 36 
(192 mg, 0.36 mmol, 99%). Rf = 0.30 (EtOAc/heptane, 1/1). FTIR 
(ATR): ν = 2358, 1744, 1528, 1437, 1368, 1212 cm–1. 1H NMR (400 MHz, 
CDCl3): δ = 6.11 (t, J = 9.6 Hz, 1H), 5.84 (d, J = 9.4 Hz, 1H), 5.55 (d, J = 
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3.3 Hz, 1H), 5.25 (dd, J = 10.2, 3.3 Hz, 1H), 3.98 (s, 3H), 4.25−4.15 (m, 3H), 2.22 (s, 3H), 2.05 (s, 
3H), 2.02 (s, 3H), 1.88 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 170.0, 169.9, 169.6, 168.3, 159.7, 
137.9, 116.8, 85.5, 73.7, 70.9, 66.7, 66.4, 61.1, 52.2, 20.4, 20.4, 20.3, 20.0. HRMS (CI) m/z 
calculated for C18H23Br79N3O11 (M+H)+: 536.0516, found:  536.0528. 
 
5-Bromo-4-methylcarboxy-1-(2,3,4,6-tetra-O-acetyl-D-glucopyranosyl)-[1,2,3]-triazole (38) 
Preparation according to general method C afforded 38 (144 mg, 0.27 
mmol, 67%) as a white solid. Preparation according to general 
method D afforded 38 (172 mg, 0.32 mmol, 91%) as a white solid. Rf 
= 0.30 (EtOAc/heptane, 1/1). FTIR (ATR): ν = 1748, 1537, 1433, 1368, 
1225 cm–1. 1H NMR (400 MHz, CDCl3): δ = 5.99 (t, J = 9.3 Hz, 1H), 
5.86 (d, J = 9.5 Hz, 1H), 5.42 (t, J = 9.4 Hz, 1H), 5.29 (t, J = 9.8 Hz, 1H), 4.26 (dd, J = 12.6, 4.8 
Hz, 1H), 4.20 (dd, J = 12.6, 2.2 Hz, 1H), 4.03−3.99 (m, 1H), 3.98 (s, 3H), 2.08 (s, 6H), 2.04 (s, 
3H), 1.87 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 170.3, 170.0, 169.1, 168.3, 159.7, 138.0, 117.1, 
84.7, 74.9, 72.8, 69.0, 67.4, 61.3, 52.4, 20.5, 20.4, 20.1. HRMS (CI) m/z calculated for 
C18H23Br81N3O11 (M+H)+: 538.0496, found:  538.0520. 
 
Methyl (R)-2-[(tert-Butoxycarbonyl)amino]-3-{1-(2,3,4,6-tetra-O-acetyl-D-
galactopyranosyl)-5-bromo-[1,2,3]-triazol-4-yl}propionate (43) 
Preparation according to general method C afforded 43 (115 mg, 
0.17 mmol, 85%). Preparation according to general method D 
afforded 43 (89 mg, 0.13 mmol, 65%). Rf = 0.54 (EtOAc/heptane, 
2/1). FTIR (ATR): ν = 2971, 1748, 1368 cm–1.  1H NMR (400 MHz, 
CDCl3): δ = 6.01 (t, J = 10.0 Hz, 1 H), 5.78 (d, J = 9.2 Hz, 1H), 5.58 (d, 
J = 8.0 Hz, 1H), 5.56 (d, J = 3.2 Hz, 1H), 5.25 (dd, J = 3.2, 10.0 Hz, 
1H), 4.69−4.64 (m, 1H), 4.26−4.14 (m, 3H), 3.75 (s, 3H), 2.22 (s, 3H), 2.06 (s, 3H), 2.03 (s, 3H), 
1.98 (s, 3H), 1.44 (s, 9H). 13C NMR (75 MHz, CDCl3): δ = 171.4,170.4, 170.1, 170.0, 168.8, 155.3, 
143.2, 111.2, 86.0, 79.8, 73.9, 71.1, 66.9, 66.7, 61.3, 52.6, 52.5, 28.4, 27.4, 20.7, 20.6, 20.2. HRMS 
(FAB) m/z calculated for C25H36BrN4O13 (M+H)+: 679.1462, found:  679.1469. 
 
1-(4-Bromobenzyl)-5-iodo-4-methylcarboxy-[1,2,3]-triazole (45) 
Preparation similar to general method C, applying an iodoalkyne afforded 
45 (82 mg, 0.19 mmol, 99%). Rf = 0.51 (EtOAc/heptane, 1/1). FTIR (ATR): ν 
=1731. 1H NMR (400 MHz, CDCl3): δ = 7.49 (d, J = 8.6 Hz, 2H), 7.16 (d, J = 8.7 
Hz, 2H), 5.62 (s, 2H), 3.97 (s, 3H). 13C NMR (75 MHz. CDCl3): δ =  160.4, 
142.1, 132.4, 132.1, 129.5, 123.0, 54.1, 53.3. HRMS (EI) m/z calculated for 
C11H9Br79IN3O2 (M): 420.8923, found: 420.8924. HRMS (EI) m/z calculated for 
C11H9Br81IN3O2 (M): 422.8903, found: 42.8902. 
 
(2S)-2-tert-Butoxycarbonylamino-4-hexynoic acid methyl ester (40) 
(2S)-2-Amino-4-hexynoic acid was suspended in DCM (10 ml), Et3N (0.22 ml, 
1.57 mmol) and Boc2O (243 mg, 1.12 mmol) were added and the reaction 
mixture was stirred for 3 h. The mixture was concentrated in vacuo and purified 
by chromatography (EtOAc/heptane, 3/1) to afford 31 (121 mg, 0.50 mmol, 
68%). Rf = 0.77 (EtOAc/heptane, 1/1). 1H NMR (400 MHz, CDCl3): δ = 5.30 (d, J 
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= 7.8 Hz, 1H), 4.43−4.39 (m, 1H), 3.77 (s, 3H), 2.75−2.59 (m, 2H), 1.78 (t, J = 2.5 Hz, 3H), 1.46 
(s, 9H). Spectral data are in accordance with literature.19 
 
3-[5-Bromo-1-(3,4,5-triacetoxy-6-acetoxymethyltetrahydropyran-2-yl)-1H-[1,2,3]-triazol-4-
yl]-2-tert-butoxycarbonylaminopropionic acid methyl ester (41a/42a) 
A solution of 30 (20 mg, 0.07 mmol) and 14 (27 mg, 0.07 mmol) in 
CDCl3 was placed under a pressure of 15 kbar for 2 days at 50°C, 
resulting in an inseparable mixture of 1,4- and 1,5-regioisomers. 
Data of mixture of regioisomers: Rf  = 0.26 (EtOAc/heptane, 1/1). 
1H NMR (400 MHz, CDCl3): δ = 5.80 & 5.71 (t, J = 9.4 & 9.4 Hz, 
2H), 5.84 & 5.44 (d, J = 8.2 & 7.6 Hz, 1H), 5.34 & 5.20 (t, J = 9.1 & 9.8 Hz, 2H), 4.62−4.48 (m, 
1H), 4.32 & 4.29 (d, J = 4.0 & 4.0 Hz, 1H), 4.20 (dd, J = 12.6, 4.8 Hz, 1H), 4.14 (dd, J = 12.6, 2.2 
Hz, 1H), 4.04−3.89 (m, 1H), 3.68 & 3.67 (s, 3H), 3.29−3.07 (m, 2H), 2.05 & 2.01 (s , 3H), 2.00 (br 
s, 3H), 1.98 & 1.97 (s, 3H), 1.81 & 1.79 (s, 3H), 1.37 (br s, 3H). HRMS (ESI) calculated for 
C25H3679BrN4O13 (M+H)+: 679.1462, found: 679.1452. HRMS (ESI) calculated for 
C25H3579BrN4O13Na (M+Na)+: 701.1282, found: 701.1260. 
 
2-tert-Butoxycarbonylamino-3-[5-methyl-1-(3,4,5-triacetoxy-6-acetoxymethyltetrahydro-
pyran-2-yl)-1H-[1,2,3]-triazol-4-yl]propionic acid methyl ester (41b/42b) 
A solution of 31 (17.5 mg, 0.07 mmol) and 14 (26.7 mg, 0.07 mmol) 
in CDCl3 was placed under a pressure of 15 kbar for 2 days at 50 
°C, resulting in an inseparable mixture of 1,4- and 1,5-
regioisomers. Data of mixture of regioisomers: Rf = 0.36 
(EtOAc/heptanes, 1/1). 1H NMR (400 MHz, CDCl3): δ = 5.93 & 
5.78 (d, J = 10.0 & 9.4 Hz, 1H), 5.68 & 5.50 (t, J = 9.3 & 9.5 Hz, 1H), 5.41 (app t, J = 9.5 Hz, 1H), 
5.35 & 5.23 (t, J = 9.6 & 9.7 Hz, 1H), 4.65−4.43 (m, 1H), 4.38 & 4.35 (d, J = 3.6 & 3.6 Hz, 1H), 
4.28 (dd, J = 12.6, 4.9 Hz, 1H), 4.20−4.15 (m, 1H), 4.06−4.02 & 3.98−3.94 (m, 1H), 3.74 & 3.72 (s, 
3H), 3.24−3.04 (m, 2H), 2.36 & 2.28 (s, 3H), 2.14 (s, 1H), 2.07 (br s, 4H), 2.06 (s, 1H), 2.04 & 2.02 
(s, 3H), 1.86& 1.83 (s, 3H), 1.45 & 1.39 (s, 9H). 
 
1-Benzyl-4-phenyl-5-phenylethynyl-1H-1,2,3-triazole (10) 
To a solution of 5-bromotriazole 11 (32 mg, 0.10 mmol) in THF (3 mL) were 
added phenylacetylene 49 (22 µL, 0.42 mmol), PdCl2(PPh3)2 (7 mg, 0.01 
mmol, 10%), CuI (4 mg, 0.02 mmol) and Et3N (17 µL, 0.12 mmol) under 
Schlenck conditions. Next, the mixture was stirred at 70 °C for 5 h and the 
solvent was removed in vacuo. Purification of the crude product by flash 
column chromatography afforded 11 (27 mg, 0.05 mmol, 46%).  1H NMR 
(400 MHz, CDCl3): δ = 8.22−8.15 (m, 2H), 7.54−7.31 (m, 13H), 5.68 (s, 2H). 
HRMS (ESI) calculated for C23H18N3 (M+H+) 336.1501, found: 336.1480. 
Spectral data are in accordance with literature.10 
 
4-(1-Benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)but-3-yn-1-ol (50) 
To a solution of 5-bromotriazole 11 (63 mg, 0.20 mmol) in THF (3 mL) 
were added 3-butynol 49 (28 µL, 0.37 mmol), PdCl2(PPh3)2 (15 mg, 0.02 
mmol), CuI (8 mg, 0.04 mmol) and Et3N (24 µL, 0.24 mmol) under 
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Schlenk conditions. Next, the mixture was stirred at 70 °C for 5 h and the solvent was 
removed in vacuo. Purification of the crude product by flash column chromatography 
afforded 50 (26 mg, 0.09 mmol, 43%). 1H NMR (400 MHz, CDCl3): δ = 8.12−80.9 (m, 2H), 
7.47−7.39 (m, 2H), 7.37−7.29 (m, 6H), 5.58 (s, 2H), 3.81 (t, J = 6.2 Hz, 2H), 2.78 (t, J = 6.2 Hz, 
2H).  
 
(1-Benzyl-4-phenyl-1H-1,2,3-triazol-5-yl)(phenyl)methanol (51) 
To a solution of 5-bromotriazole 11 (31 mg, 0.10 mmol) in THF (3 mL) at 
−78°C was added Buli (1 equiv) after which stirring was continued for 15 
min. Next, a solution of benzaldehyde (13 µL, 0.13 mmol) was added and 
the mixture was slowly warmed-up to rt. Evaporation of the solvent in 
vacuo, followed by purification of the crude product by flash column 
chromatography afforded 51 (30 mg, 0.09 mmol, 90%). 1H NMR (400 MHz, 
CDCl3): δ = 7.63−7.60 (m, 2H), 7.42−7.37 (m, 3H), 7.29−7.27 (m, 3H), 
7.24−7.18 (m, 5H), 7.07−7.05 (m, 2H), 6.33 (d, J = 5.1 Hz, 1H), 5.49 (d, J = 15.1 Hz, 1H), 5.27 (d, 
J = 15.1 Hz, 1H).  
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Enzymatic Hydrolysis and 
Coupling of Triazolyl Amino 
Acids 
 
 
 
Abstract*:  
Chemoenzymatic peptide coupling of glycosylated triazolyl- and amide-linked amino acid 
methyl esters was effected by alcalase, a proteolytic enzyme mixture produced by 
Bacillus licheniformis. Both the common amide-linked as well as the unnatural triazole-
linked substrates were ligated to amino acid amides in moderate to good yields, 
producing dipeptides. Moreover, a first study towards the enzymatic glycosylation of 
triazole-linked glycopeptides is presented.   
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*Parts of this chapter have been published as: B. H. M. Kuijpers, S. Groothuys, C. Hawner, J. ten 
Dam, P. J. L. M. Quaedflieg, H. E. Schoemaker, F. L. van Delft, and F. P. J. T. Rutjes, Cu-Catalyzed 
formation of triazole-linked glycoamino acids and application in chemoenzymatic peptide synthesis. 
Org. Process Res. Dev. 2008, 503. and S. Groothuys, B. H. M. Kuijpers, P. J. L. M. Quaedflieg, H. 
C. P. F. Roelen, R. W. Wiertz, R. H. Blaauw, F. L. van Delft, F. P. J. T. Rutjes, Chemoenzymatic 
synthesis of triazole-linked glycopeptides. Synthesis 2006, 3146. 
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6.1 INTRODUCTION 
Peptides are generally defined as oligomers or polymers of amino acids with less 
than 100 monomers. As such, peptides are essential molecules in the fields of 
healthcare and nutrition, for example as food additives1 and therapeutics.2 
Consequently, over the years a variety of different technologies have been developed 
for the efficient production of pure peptides, including extraction from natural 
sources,3 production via recombinant DNA technology,4 expression in cell-free 
systems,5 production in genetically modified animals6 or plants, solution based 
chemical synthesis,7 resin based chemical synthesis8 and enzymatic ligation 
technology.9 Natural peptides can be readily obtained by most of these techniques, 
but for designed or non-natural peptides only chemical and chemoenzymatic 
syntheses can be applied. From these two strategies, the chemical procedure clearly 
stands out as the most mature technology. Nevertheless, lack of specificity and 
environmental burden of chemical synthesis, has led to an increasing interest in 
chemoenzymatic biocatalysis over the last decade.10 Chemoenzymatic synthesis is 
characterized by a number of specific advantages over chemical peptide synthesis: 
(a) chemoenzymatic peptide coupling reactions are free from racemization, (b) side-
chain protection can mostly be omitted, (c) the coupling reagent (enzyme) can often 
be recycled, (d) reactions proceed under mild conditions, (e) conditions are 
environmentally friendly and (f) couplings proceed with high specificity.  
Two distinguishable strategies can be identified for chemoenzymatic ligation, a 
thermodynamically (or equilibrium) controlled approach and a kinetically controlled 
variant. In the thermodynamic approach, involving the reversal of proteolysis, an 
N-protected amino acid (bearing a free carboxyl group) is condensed with a 
C-protected amino acid. Since the reaction is driven by equilibrium, substrate 
solubility must be high, while solubility of the product must be low to shift the 
balance to the product side (Le Chatelier's principle). Typically, equilibrium-
controlled synthesis is pH-sensitive, and the acidity of the reaction must be chosen 
carefully, since only the non-ionic forms of both acid and amine are involved in the 
reaction.11 In contrast, a kinetically controlled approach depends on the use of 
activated carboxyl compounds. The advantage is that much less enzyme is required, 
the reaction time to obtain maximum product yield is significantly shorter, and the 
reaction can be carried out between pH 7 and 9. Another important advantage is the 
fact that the yield is predominantly determined by the properties of the enzyme, 
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however, a drawback of kinetic control is the fact that in an aqueous medium 100% 
product formation is nearly never attained, due to increasing hydrolysis of the  
newly formed peptide bond in the product formed. Suitable enzymes for kinetic 
peptide synthesis include commercially available serine, metallo-, and aspartate 
proteases.12  
Moreover, it was demonstrated by Chen et al. that alcalase, a cheap and commercially 
available proteolytic enzyme mixture produced by Bacillus licheniformis, containing 
subtilisin Carlsberg as the major enzyme component, can be conveniently applied for 
enzymatic peptide bond formation as well.12,13 In addition, alcalase was found to be 
stable in a variety of organic solvents, retaining more than 65% of the original activity 
in tert-amyl alcohol after 10 days, and more than 60% in tert-butyl alcohol after 6 
days. Based on these results, we set out to investigate the chemoenzymatic synthesis 
of dipeptides via C-terminal elongation of propargylglycine, azidopropylglycine, and 
glycosylated triazolyl-containing amino acid methyl esters ('activated donor') with a 
proteinogenic amino acid amide ('inactive acceptor').14 In order to make a fair 
comparison, both conventional solution-phase chemical peptide synthesis as well as 
an enzymatic procedure under the action of the protease alcalase were applied, results 
of which are summarized in Table 1. 
To this end, three Cbz-protected amino acid methyl esters (ornitine-derived 
(3-azidopropyl)glycine 1a, propargylglycine 1b, and glycosyl triazolylmethylglycine 
1c) were coupled to an amino acid amide (phenylalanine amide or glycine amide) by 
two routes: (a) under the action of alcalase or (b) by basic ester hydrolysis followed by 
carbodiimide-mediated coupling. Chemoenzymatic coupling was executed by 
coevaporation of the methyl ester with DMF, followed by dissolution of both methyl 
ester and amino acid amide in tert-amyl alcohol. Subsequently, alcalase was 
repeatedly added, until HPLC analysis indicated complete conversion of starting 
material. Much to our delight, alcalase-mediated coupling proceeded smoothly for 
both protected (S)-azidoornithine (entries 1 and 4) and (S)-propargylglycine (entries 
2 and 5) with either phenylalanine or glycine amide, providing the desired 
dipeptides in excellent yield (entries 1-2 and 4-5). 
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Table 1. Initial enzymatic synthesis of dipeptide derivatives. 
CbzHN OMe
O
H
N NH2
O
CbzHN
O
R1 R
1
R2
2a-c (R2 = CH2Ph)
3a-c (R2 = H)
alcalase
Gly-NH2, or Phe-NH2
tBuOH, DMF, 35 °C
CH2C CH
1a: R1 = (CH2)3N3
1b: R1 =
1c: R1 =
chemical
1) NaOH, THF
2) Phe-NH2 or Gly-NH2,
EDCI, HOAt, DIPEA, DMF
enzymatic
(H2C)3
O OBn
OBn
OBn
BnON
N N  
entry substrates nucleophile chemical 
yield (%) 
enzymatic 
yield (%) 
dipeptide 
1 1a Phe-NH2 69 77 2a 
2 1b  55 79 2b 
3 1c  86 40a 2c 
4 1a Gly-NH2 80 93 3a 
5 1b  60 80 3b 
6 1c  82 10 3c 
aConversion of the acyl donor as determined by HPLC  
Interestingly, the chemoenzymatic coupling reaction proceeded with considerably 
higher yields as compared to the chemical peptide ligation, although it has to be 
noted that one equivalent of amide was added in the chemical synthesis, in contrast 
to 4 equivalents in the enzymatic ligation. On the other hand, for the triazole-linked 
glycosylated amino acid 1c the chemical coupling procedure was preferable since 
chemoenzymatic coupling failed to afford the desired products 2c and 3c in good 
yields (entries 3 and 6). In fact, HPLC analysis showed only 40% conversion after 8 
days, resulting in an isolated yield of approximately 10%.  
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Figure 1. Substrates for enzymatic ligation. 
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Nevertheless, the findings that glycosylated triazole-linked substrates appeared to be 
suitable for enzymatic ligation was taken as an encouragement, since it was 
anticipated that the yield could be raised using less sterically hindered and better 
soluble substrates as depicted in Figure 1. Moreover, we studied possible differences 
in chemoenzymatic ligation between triazole-linked glycosidic amino acids 4 and 5 
and the naturally occurring amide-linked glycoamino acid 6. 
6.2 HYDROLYSIS STUDIES 
In order to validate the hypothesis that acetylated sugars are better substrates for 
alcalase than the bulky benzylated compound 1c, some hydrolysis experiments were 
conducted with substrate 4 before coupling reactions were attempted (Table 2). 
Therefore, compound 4 was dissolved in a 1:1 mixture of tert-butyl or tert-amyl 
alcohol and aqueous potassium bicarbonate, and treated with alcalase. The reaction in 
either tert-butyl or tert-amyl alcohol proceeded equally fast, and we were delighted 
to find that despite the fact that compound 4 did not dissolve completely, after 24 
hours more than 80% of the substrate was hydrolyzed by the action of alcalase 
(entries 1 and 2).  
Table 2. Results of hydrolysis experiments of compound 4 under the action of alcalase. 
O
AcO
AcO
AcO
OAc
CbzHN CO2Me
alcalase
org. solvent / KHCO3
O
AcO
AcO
AcO
OAc
CbzHN
OH
O
4 7
NN
N
NN
N
 
aYield as determined by HPLC bdetection limit. 
  Acid (7) (%)a at t (h) 
entry  t = 0.5  t = 4 t = 6 t = 24 
1 tBuOH / 1 M aq. KHCO3 (v/v = 1/1) 5 - 32 81 
2 tamylOH / 1 M aq. KHCO3 (v/v = 1/1) 3 22 - 82 
3 1M  aq. KHCO3  (w/o alcalase) <1.4b <1.4b - <1.4b 
4 tBuOH / 1M aq. KHCO3 / DMF (v/v = 10/9/1) 4 17 - 59 
5 tBuOH / 1M KHCO3 / acetonitrile (v/v = 10/9/1) 4 21 - 66 
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To enhance solubility, addition of DMF or acetonitrile in combination with water was 
applied in other systems,15 although alcalase has been reported to be insoluble in 
acetonitrile. Unfortunately, in our hands upon addition of DMF (entry 4) or 
acetonitrile (entry 5), the rate of hydrolysis rapidly declined. In addition, a control 
experiment was performed without the addition of alcalase (entry 3) to exclude that 
ester hydrolysis was due to the slightly alkaline conditions. Nevertheless, 80% 
hydrolysis after 24 hours was taken as a promising result compared to the extremely 
slow reaction with the benzylated substrate 1c reported earlier.  
6.3 ENZYMATIC LIGATION OF TRIAZOLE-LINKED GLYCOSIDIC 
AMINO ACIDS 
Both tert-butyl and tert-amyl alcohol showed similar results in the hydrolysis studies. 
However, tert-amyl alcohol was preferred as solvent for the coupling experiments, 
since alcalase is reported to be more stable in tert-amyl alcohol.12 Unless stated 
otherwise, dried alcalase was added three times a week during the course of the 
reaction in all subsequent experiments. 
Table 3. Application of triazole-linked glycosidic substrates in enzymatic coupling experiments.  
O
AcO
AcO
AcO
X
CbzHN CO2Me
alcalase
tamylOH, DMF, 35 °C
O
AcO
AcO
AcO
X
CbzHN
H
N
O
H2N COR2
R1
COR2
R1
4: X = OAc
5: X = NHAc
8-12
NN
N
NN
N
 
 
entry substrate R1 R2 t (days) product HPLC yieldc isolated yield 
1 4 H NH2 6 8 100%a,b 98%
2 4 Bn NH2 8 9 57%a (34%)b 30%
3 4 Bn Val-NH2 15 10 53%a n.d.
4 5 H NH2 11 11 31%a,d n.d.
5 5 Bn NH2 21 12 73%a,d n.d.
aOptimal HPLC yield. bHPLC yield before quenching and isolation. cThe given HPLC values contain an error of 
approximately 8% caused by weighing the reactants, pipetting the enzyme, pipetting the thick reaction 
mixtures for taking HPLC samples and the HPLC instrument itself. dAlcalase was added two times a week. 
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First, chemoenzymatic ligation was tested between N-triazole-linked glycosidic 
amino acid (NTGA) 4 and glycine amide (Table 3, entry 1). We were delighted to find 
that the desired dipeptide 8 was formed smoothly and could be isolated in nearly 
quantitative yield after 6 days (entry 1). A less satisfactory result was obtained when 
the same methyl ester 4 was condensed with phenylalanine amide as a nucleophile, 
resulting in the isolation of dipeptide 9 in a rather poor 30% yield along with several 
byproducts. Unfortunately, the identity of the impurities could not be established, 
although it was clear that enzymatic hydrolysis of the starting material was not an 
issue. Since glycine amide was added in excess to the reaction mixture, formation of 
a tripeptide (NTGA-Gly-Gly-NH2) might be one of the possibilities.  
 
Figure 2. Reaction profile of triazole-linked glycosidic amino acid 4 with glycine amide. 
A closer inspection of the reaction profile with HPLC, however, showed that at first 
the reaction advanced slowly leading to a maximal yield of 57% after 7 days, along 
with 30% of unidentified side-products (Figure 2). Only after this time, the formation 
of side-products increased rapidly with concomitant decrease in yield of dipeptide 9 
to 34% as judged by HPLC, resulting in the 30% isolated yield (entry 2). Next, a 
slightly more challenging ligation was carried out, involving addition of the 
dipeptide nucleophile H-Phe-Val-NH2 to methyl ester 4 in order to prepare 
tripeptide 10 (entry 3). It was rewarding to find that alcalase-mediated ligation led to 
an 53% yield (HPLC) of tripeptide 10, thereby clearly showing that the 
chemoenzymatic coupling is not restricted to the formation of dipeptides. Next, the 
fully acetylated glucosamine-containing triazolylamino acid 5 was utilized as acyl 
donor. Interestingly, contrasting results were encountered with respect to 
condensation of glycine amide (entry 4) and phenylalanine amide (entry 5) as 
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compared to the glucose-containing donor 4. Thus, an HPLC yield of 73% of 12 was 
found employing phenylalanine amide (entry 5), whereas a poor 31% of 11 was 
obtained when glycine amide was applied as the nucleophile (entry 4). Although 
some solubility problems were encountered during the latter enzymatic ligations, 
currently we have no satisfactory explanation for the unexpected reversal in yield 
between substrates 4 and 5.  
Finally, a condensation of the naturally occurring amide-linked glycosidic amino 
acid 6 with glycine and phenylalanine amide was performed under identical 
conditions in the presence of alcalase, as depicted in Scheme 1. In case of this 
particular substrate, both nucleophiles reacted similarly, reaching an optimum yield 
of approximately 50% (HPLC) for both dipeptides 13 and 14. The respective 
dipeptides were eventually isolated in yields somewhat lower than the indicated 
HPLC values. 
13 R = H (HPLC: 48%, isolated :38%)
14 R = Bn (HPLC: 51%, isolated :46%)
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Scheme 1. Application of natural amide-linked glycosidic substrates in enzymatic coupling experiments.  
6.4 CHEMOENZYMATIC GLYCOSYLATION 
Having successfully achieved the chemoenzymatic preparation of glycosylated 
triazole-linked di- and tripeptides, we anticipated that the isosteric triazolylpeptides 
themselves could serve as substrates for further chemoenzymatic functionalization, 
in particular by glycosylation. In this respect, an interesting chemoenzymatic 
procedure was recently described by Xi et al.,16 involving the glycosylation of the 
naturally occurring 34-mer peptide 15. Thus, using arthrobacter as key enzyme, 
undecaglycopeptide 16 was prepared by transglycosylation of glycosylated peptide 
15 as depicted in Scheme 2.  
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In order to evaluate the behavior of triazole-linked glycosidic amino acids several of 
the derivatives prepared earlier (described in Chapter 3) were deprotected to obtain 
the three model substrates 17-19 as well as the C34 glycopeptide 20 depicted in 
Figure 3.  
 
Ac-W-M-E-W-D-R-E-I-N-N-Y-T-S-L-I-H-S-L-I-E-E-S-Q-
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Scheme 2. Chemoenzymatic synthesis of glycopeptides by Xi et al.16 
Currently, compounds 17-20 are under evaluation as transglycosylation acceptors in 
the group of Prof. Lai-Xi Wang (University of Maryland, Maryland, USA). 
Conclusive results cannot be presented at this point, but preliminary experiments 
conducted with the triazole-linked C34-mer have shown that arthrobacter is indeed 
capable of recognizing the substrate so that subsequent glycosylation will provide 
the triazole-linked analogue of 16. 
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Figure 3. Deprotected triazole-linked glycoamino acids and peptides. 
Unfortunately, substrates 17-19 have not been tested yet. Nevertheless, based on the 
successful glycosylation of 20, it is safe to conclude that triazoles appear to function 
as useful amide isosteres in biological active systems. 
6.5 CONCLUSION 
Proof of principle was delivered for the use of triazole-linked glycosyl amino acids as 
acyl donors in the chemoenzymatic ligation with amino acid derivatives and 
peptides as nucleophile. Although coupling reactions proceeded relatively slowly, 
presumably due to low solubility of the substrates and/or steric factors, triazole-
linked glucose or glucosamine were both successfully incorporated into dipeptides, 
similar to the amide-linked glycoamino acids, under the action of the proteolytic 
enzyme mixture alcalase. Conditions may be further optimized to efficiently apply 
alcalase for chemoenzymatic peptide synthesis, including the incorporation of 
triazole-linked glycosidic amino acids. Moreover, a preliminary study towards the 
enzymatic glycosylation of triazole-linked glycopeptides was presented, showing 
that a monoglycosylated 34-mer peptide could be effectively transglycosylated under 
the action of arthrobacter as key enzyme.   
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6.7  EXPERIMENTAL 
Alcalase type DX PLN04842 was purchased from Novozymes (Bagsvaerd, Denmark) as a 
brown liquid with a specific activity of 2.5 U/mL. For the hydrolysis experiments this 
enzyme solution was used as such. For the (anhydrous) peptide coupling reactions the water 
in the alcalase solution was removed using the method of Chen et al.12 As a matter of fact, the 
aqueous alcalase (0.25 mL) and absolute ethanol (0.5 mL) were mixed in an Eppendorf cup 
and the resulting suspension was agitated on a Vortex mixer for 5 min and centrifuged (3000 
rpm) for 10 min to spin down the enzyme. The supernatant was decanted and the enzyme 
resuspended in absolute EtOH (0.5 mL), agitated for 5 min on a Vortex mixer and spun 
down by centrifugation. This procedure was repeated once with absolute EtOH (0.5 mL) and 
finally once with dry tamylOH (0.5 mL). The resulting enzyme was resuspended in tamylOH 
(1.0 mL) for use in the enzymatic peptide coupling reactions. All other commercially 
available reagents were used as received. HPLC analyses were performed with an Inertsil 
RP-18 column (25 × 0.46 cm, RP-18, 5 μm). 
 
General procedure for chemoenzymatic peptide coupling:  
The N-Cbz-protected amino acid methyl ester (0.39 mmol) was dried via coevaporation with 
DMF (2 × 5 mL) and dissolved in tamylOH (4.0 mL). After adding a solution of Phe-NH2 or 
Gly-NH2 (1.5 mmol) in tamylOH (2.0 mL), the reaction mixture was stirred at 37 °C. 
Subsequently, the dried alcalase suspension in tert-amyl alcohol (1 mL) was added and the 
reaction mixture was stirred at 37 °C. Samples were taken at regular time intervals and 
analyzed by HPLC. Workup: After almost complete conversion of 1, the reaction mixture 
was concentrated in vacuo to remove most of the volatiles. The residue was taken up in 
EtOAc (50 mL) and H2O (20 mL), to which a few drops of 1 N aqueous HCl were added. The 
aqueous layer was extracted with EtOAc (3 × 30 mL) and the combined organic phase was 
washed with aqueous KHCO3 (1 M, 40 mL), aqueous HCl (1 N, 40 mL) and brine (40 mL), 
dried (Na2SO4) and concentrated in vacuo. Analytically pure samples were obtained by 
recrystallization. A new load of enzyme (dried precipitate from 500 μL of enzyme solution) 
was added 3 times a week. Quenching solution for HPLC samples: 50% KH2PO4 (0.1 M, pH 
5), 50% MeCN. 
 
Hydrolysis experiments 
To a suspension of methyl (R)–2–[(benzyloxycarbonyl)amino]–3–{1–(2,3,4,6–tetra–O–acetyl–
β–D–gluco pyranosyl)[1,2,3]triazol–4–yl}propionate (95 mg, 0.15 mmol) in 1 M KHCO3 (450 
μL) was added the organic solvent (mixture) (450 μL) and alcalase solution (43 μL). Next, the 
reaction mixture was stirred at room temperature. Samples were taken at regular time 
intervals and analyzed by HPLC. Quenching solution for HPLC samples: 50% KH2PO4 (0.1 
M, pH 5), 50% MeCN. 
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Cbz-(S)-(N-1-Glu(Ac)4-Asn)-OMe (6)  
The amide-linked sugar amino acid was prepared from 
glucopyranosyl amine and Cbz-Asp-OtBu via a procedure reported 
by van Ameijde et al.17 involving peptide coupling catalyzed by 
BOP followed by deprotection using TFA/DCM (4 h, rt) to afford 
the N-glycosylasparagine 6 (550 mg, 0.9 mmol, 73% ) as a white solid . 1H NMR (400 MHz, 
CDCl3): δ = 7.38−7.34 (m, 5H), 6.38 (d, J = 9.2 Hz, 1H), 6.01−5.92 (m, 1H), 5.29 (t, J = 9.5 Hz, 
1H), 5.21 (t, J = 9.3 Hz, 1H), 5.09−5.02 (m, 1H), 4.90 (t, J = 9.6 Hz, 1H), 4.66−4.57 (m, 1H), 4.29 
(dd, J = 12.5 Hz, 1H), 4.07 (dd, J = 12.5 Hz, 1H), 3.78 (ddd, J = 10.4, 2.2 Hz, 1H), 2.93−2.84 (m, 
1H), 2.71 (dd, J = 16.3 Hz, 1H), 2.03 (s, 3H), 2.02 (s, 3H), 2.07 (s, 3H), 2.06 (s, 3H), 3.73 (s, 3H), 
5.12 (s, 2H). Spectral data are in accordance with literature.18 
 
Cbz-(S)-T4M(1-[β-D-Glc(Ac)4])-Gly-NH2 (8) 
Preparation according to the general procedure for the 
peptide coupling afforded 8 (260 mg, 0.38 mmol, 98%) as a 
white solid. Rf (EtOAc) = 0.52. IR (KBr) ν = 3292, 2948, 1753, 
1687, 1535 cm–1. 1H NMR (400 MHz, CDCl3/MeOD): δ = 
7.93 (s, 1 H), 7.42−7.25 (m, 5 H), 5.99−5.90 (m, 1 H), 5.53 (s, 
1 H), 5.50−5.45 (m, 2 H), 5.34−5.23 (m, 1 H), 5.11 (d, J = 12.4 Hz, 1 H), 5.08 (d, J = 12.4 Hz, 1 
H), 4.49 (t, J = 6.2, 6.2 Hz, 1 H), 4.32 (dd, J = 12.6, 4.8 Hz, 1 H), 4.18 (dd, J = 12.6, 2.1 Hz, 1 H), 
4.16−4.10 (m, 1 H), 3.92 (d, J = 17.1 Hz, 1 H), 3.84 (d, J = 17.0 Hz, 1 H), 3.29−3.18 (m, 2 H), 2.09 
(s, 1 H), 2.08 (s, 1 H), 2.04 (s, 1 H), 1.83 (s, 1 H). 13C NMR (75 MHz, CDCl3/MeOD): δ = 172.1, 
171.5, 170.5, 169.7, 169.3, 168.9, 156.3, 135.6, 127.9, 127.6, 127.4, 121.6, 85.0, 74.2, 72.1, 70.2, 
67.3, 66.6, 61.1, 54.1, 41.8, 27.1, 19.7, 19.6, 19.1. HRMS (ESI) m/z calculated for C29H36N6O13Na 
(M+Na)+: 699.2238, found: 699.2213. 
 
Cbz-(S)-T4M(1-[β-D-Glc(Ac)4])-L-Phe-NH2 (9) 
Preparation based on the general procedure for the peptide 
coupling using 1.00 g (1.58 mmol) of 4 afforded 9 (300 mg, 
0.46 mmol, 30%) as a white solid. Rf (EtOAc) = 0.60. IR 
(KBr) ν = 3351, 2942, 1748, 1693, 1666, 1524 cm–1. 1H NMR 
(400 MHz, CDCl3/MeOD): δ = 7.74 (s, 1 H), 7.41−7.16 (m, 
10 H), 5.96−5.87 (m, 1 H), 5.53 (s, 1 H), 5.49−5.41 (m, 2 H), 
5.06 (s, 2 H), 4.63 (dd, J = 8.1, 5.9 Hz, 1 H), 4.42 (t, J = 6.4, 6.4 Hz, 1 H), 4.31 (dd, J = 12.6, 4.9 
Hz, 1 H), 4.16 (dd, J = 12.6, 2.1 Hz, 1 H), 4.11 (ddd, J = 10.2, 4.8, 2.1 Hz, 1 H), 3.20−3.15 (m, 2 
H), 3.05 (dd, J = 15.16, 6.86 Hz, 1 H), 2.96 (dd, J = 13.90, 8.27 Hz, 1 H), 2.09 (s, 3 H), 2.06 (s, 3 
H), 2.04 (s, 3 H), 1.82 (s, 3 H). 13C NMR (75 MHz, CDCl3/MeOD): δ = 173.6, 170.7, 170.5, 
169.8, 169.4, 168.9, 156.1, 143.1, 136.2, 135.6, 128.6, 128.5, 128.0, 127.7, 127.4, 126.3, 121.4, 85.0, 
74.3, 72.2, 70.1, 67.3, 66.6, 61.2, 53.9, 53.6, 36.8, 27.2, 19.8, 19.7, 19.2. HRMS (ESI) m/z calculated 
for C36H42N6O13Na (M+Na)+: 789.2708, found 789.2675. 
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Cbz-(S)-(N-1-Glu(Ac)4-Asn)-Gly-NH2 (13)  
Preparation according to the general procedure for the 
peptide coupling afforded 13 (98 mg, 0.15 mmol, 38%) as a 
white solid. FTIR (ATR): ν = 3317, 1752, 1671 cm-1. 1H NMR 
(400 MHz, CDCl3): δ = 7.37 (bs, 5H), 7.04 (m, 1H), 6.65 (d, J = 
9.0 Hz, 1H), 6.37 (s, 1H), 6.10 (d, J = 7.4 Hz, 1H), 5.46 (s, 1H), 
5.31 (dd, J = 11.4 Hz, 2H), 5.16 (t, J = 12.0 Hz, 1H), 5.05 (t, J = 9.7 Hz, 1H), 4.90 (t, J = 9.6 Hz, 
1H), 4.63−4.52 (m, 1H), 4.27 (dd, J = 12.5 Hz, 1H), 4.18−4.02 (m, 2H), 3.84−3.69 (m, 2H), 3.02 
(dd, J = 16.4 Hz, 1H), 2.91 (d, J = 10.6 Hz, 1H), 2.62 (dd, J = 16.4 Hz, 1H), 2.02 (s, 3H), 2.01 (s, 
3H), 2.08 (s, 3H), 2.07 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 171.5, 171.0, 171.0, 170.8, 170.1, 
169.5, 169.0, 155.7, 135.2, 128.2, 128.0, 127.8, 77.5, 76.7, 73.2, 72.0, 69.9, 67.5, 67.2, 61.1, 51.0, 
42.5, 20.2, 20.2, 20.1. HRMS (ESI) m/z calculated for C28H36N4O13Na (M+Na)+: 675.2126, found 
675.2116.  
 
Cbz-(S)-(N-1-Glu(Ac)4-Asn)- L-Phe-NH2 (14)  
Preparation according to the general procedure for the 
peptide coupling afforded 14 (135 mg, 0.18 mmol, 46%) as a 
white solid. FTIR (ATR): ν = 3399, 1753, 1631 cm-1. 1H NMR 
(400 MHz, D2O): δ = 7.43−7.16 (m, 10H), 6.88 (d, J = 7.9 Hz, 
1H), 6.72 (d, J = 9.3 Hz, 1H), 6.16 (d, J = 7.9 Hz, 1H), 6.00 (s, 
1H), 5.40 (s, 1H), 5.29 (t, J = 9.6 Hz, 1H), 5.16 (t, J = 9.2 Hz, 
1H), 5.09−5.01 (m, 2H), 4.91 (t, J = 9.6 Hz, 1H), 4.60−4.51 (m, 
1H), 4.50−4.40 (m, 1H), 4.26 (dd, J = 12.6 Hz, 1H), 4.16−4.07 (m, 2H), 3.78 (ddd, J = 10.1, 2.0 
Hz, 1H), 3.17−3.01 (m, 2H), 2.76 (dd, J = 16.1 Hz, 1H), 2.59 (dd, J = 16.1 Hz, 1H), 2.07 (s, 3H), 
2.05 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 172.7, 172.0, 171.2, 170.4, 
196.7, 169.6, 169.4, 146.5, 136.0, 127.6, 127.3, 127.2, 76.9, 72.9, 72.9, 70.1, 67.7, 66.2, 61.3, 51.2, 
41.6, 36.5, 29.0, 18.7, 18.7. HRMS (ESI) m/z calculated for C35H42N4O14Na (M+Na)+: 765.2595, 
found: 765.2605. 
 
(S)-T4M(1-[β-D-Glc])-OH (18) 
 Methyl (R)-2-[(benzyloxycarbonyl) amino]-3-{1-(2,3,4,6-tetra-O-
acetyl-β-D-glucopyranosyl) [1,2,3]triazol-4-yl} propionate (43, 
Chapter 3) (100 mg, 0.16 mmol) was dissolved in MeOH (3 mL), 
Pd/C (2 mg, 12 mol%) was added and the reaction was stirred for 
45 min under na atmosphere of H2. Next, the suspension was 
filtrated, a catalytic amount of K2CO3 was added and the mixture was stirred overnight. 
Purification of the product with a basic ion exchange column (IRA-410) afforded the triazole-
linked glycosidic amino acid 18 (40 mg, 80%) as a white solid. FTIR (ATR): ν = 3309, 2362, 
2327, 1623 cm-1. 1H NMR (400 MHz, D2O): δ = 7.98 (s, 1H), 5.61 (d, J = 9.2 Hz, 1H), 3.98 (t, J = 
5.8 Hz, 1H), 3.86 (t, J = 9.2 Hz, 1H), 3.76 (d, J = 11.0 Hz, 1H), 3.66−3.55 (m, 3H), 3.48 (t, J = 9.2 
Hz, 1H), 3.31−3.17 (m, 2H). 13C NMR (75 MHz, D2O): δ = 172.3, 141.7, 123.3, 86.9, 78.4, 75.4, 
71.7, 68.4, 59.9, 53.7, 25.8. HRMS (ESI) m/z calculated for C11H18N4O7Na (M+Na)+: 341.1073, 
found: 341.1081. 
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(S)-T4M(1-[β-D-GlcNAc])-OH (19) 
A solution of  3-{1-[2-(Acetylamino)-3,4,6-tri-O-acetyl-2-deoxy-β-D-
glucopyranosyl]  [1,2,3]     triazol-4-yl}-(R)-2- [(tert-butoxycarbonyl) 
amino]propanoic acid (63, Chapter 3) (100 mg, 0.17 mmol) in 
HCl/EtOAc (2 mL) was stirred for 30 min. Next, the solvent was 
evaporated in vacuo and the crude product was redissolved in 
MeOH (3 mL), a catalytic amount of K2CO3 was added and the mixture was stirred 
overnight. Purification of the product with an acidic ion exchange column (IRA-120) 
afforded the triazole-linked glycosidic amino acid 19 (30 mg, 0.08 mmol, 49%) as a white 
solid. 1H NMR (400 MHz, D2O): δ = 8.02 (s, 1H), 5.69 (d, J = 9.7 Hz, 1H), 4.26 (t, J = 6.1 Hz, 
1H), 4.11 (t, J = 9.9 Hz, 1H), 3.79 (dd, J = 12.3 Hz, 1H), 3.71−3.49 (m, 5H), 3.29 (d, J = 6.1 Hz, 
2H), 2.07 (s, 3H). 13C NMR (75 MHz, D2O): δ = 173.7, 170.2, 140.7, 123.0, 85.9, 78.4, 73.0, 68.8, 
59.9, 54.7, 51.9, 25.1, 21.1. LRMS (ESI) m/z calculated for C13H21N5O7 (M−H)− : 359.14, found: 
358.2.  
 
(S)-Pro-(S)-T4M(1-[β-D-Glc])-OH (20) 
A solution of Methyl (S)-2-{[(2S)-1-(tert-butoxy carbonyl) 
pyrrolidin-2-ylcarbonyl] amino}-3-{1-(2,3,4,6-tetra-O-acetyl-β-
D-glucopyranosyl)[1,2,3]triazol-4-yl}propionate (70, Chapter 3) 
(40 mg, 0.06 mmol) in HCl/EtOAc (2 mL) was stirred for 30 
min. Next, the solvent was evaporated in vacuo and the crude 
product was redissolved in MeOH (3 mL), a catalytic amount 
of K2CO3 was added and the mixture was stirred overnight. Purification of the product with 
an acidic ion exchange column (IRA-120) afforded 20 (16 mg, 0.03 mmol, 53%) as a white 
solid. Data of rotamers: 1H NMR (400 MHz, D2O): δ = 7.97 (s, 1H), 5.58 (d, J = 9.1 Hz, 1H), 
4.28−4.16 (m, 1H), 3.84 (t, J = 9.2 Hz, 1H), 3.77 (d, J = 11.6 Hz, 1H), 3.67−3.51 (m, 4H), 3.47 (t, J 
= 9.2 Hz, 1H), 3.36−3.09 (m, 4H), 2.34−2.20 (m, 1H), 1.96−1.81 (m, 3H). 13C NMR (75 MHz, 
D2O): δ = 172.9, 171.7, 168.9, 142.5, 142.4, 123.2, 86.8, 78.3, 75.4, 71.7, 71.6, 68.4, 59.9, 59.1, 52.7, 
52.3, 52.2, 46.0, 45.9, 29.1, 26.5, 25.9, 23.1. HRMS (ESI) m/z calculated for C16H26N5O8 (M+H)+: 
416.1781, found: 416.1791. 
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A scientist in his laboratory is not a mere technician: he 
 is also a child confronting natural phenomena that 
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Reality is merely an illusion, 
   albeit a very persistent one.  
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Preparation and Evaluation of 
Glycosylated RGD Derivatives 
for Integrin Targeting 
 
 
Abstract*:  
A range of cyclic arginine–glycine–aspartate (RGD) derivatives was prepared by a 
combination of solid phase and solution phase synthesis for selective targeting of αvβ3 
integrin expressed in tumors. In order to evaluate the value of a triazole moiety as an 
amide isostere, the side-chain glycosylated cyclic RGD (cRGD) peptides were synthesized 
with either a natural amide linkage or a triazole. Affinity of the cRGD constructs for αvβ3 
integrin was determined in a solid phase competitive binding assay, showing strong 
similarity in binding affinity for each of the compounds under evaluation. Furthermore, 
the in vivo tumor targeting potential of glycosylated cRGD peptides, linked via amide or 
triazole, was investigated by determining the biodistribution of 125I-labeled derivatives in 
mice with tumors expressing αvβ3. All of the cRGD derivatives showed preferential uptake 
in the subcutaneous tumors, with the highest tumor-to-blood ratio measured for the 
triazole-linked glycosylated derivative. The results of the present study are a clear 
indication of the value of the triazole moiety as a suitable amide isostere in the 
development of glycosylated peptides as pharmaceuticals. 
 
 
 
 
 
*Part of this chapter has been published as: B. H. M. Kuijpers, S. Groothuys, A. C. Soede, P. 
Laverman, O. C. Boerman, F. L. van Delft and F. P. J. T. Rutjes, Preparation and evaluation of 
glycosylated arginine-glycine-aspartate (RGD) derivatives for integrin targeting. Bioconjugate 
Chem. 2007, 18, 1847. 
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7.1 INTRODUCTION 
With the establishment of mild and effective conditions for the stereoselective 
synthesis of 1,4-linked triazoles, the potential of triazole to mimic natural amide 
linkage was put forward. Since then, some precedence for the isosteric value of a 
triazole has been provided for true peptide analogues,1,2 but the synthesis of triazole-
linked glycopeptides with relevant biological activity has hitherto not been reported. 
Moreover, to date little is known about the chemical stability of a glycosyl triazole 
linkage under basic or acidic conditions, with the exception of typical carbohydrate 
chemistry conditions.3 In the light of our recently described technology for the 
preparation of glycopeptides isosteres, it appeared worthwhile to investigate the 
biological relevance of a triazole function as an amide isostere. Consequently, we 
became intrigued by the attachment, via a triazole, of carbohydrates to the so-called 
RGD peptides,4,5 found in proteins of the extracellular matrix such as vitronectin, 
fibrinogen and laminin.  
About 25 years ago the arginine-glycine-aspartic acid (RGD) cell adhesion motif was 
discovered by Pierschbacher and Ruoslahti6 in fibronectin. A few years later the 
vitronectin receptor, or better known as αvβ3 integrin,7 was identified as one of the 
adhesion molecules recognizing this sequence. The αvβ3 integrin, consisting of two 
subunits (α and β) is expressed on the luminal surface of neovasculature, while it is 
absent on the quiescent endothelial cells. Integrins link the intracellular cytoskeleton 
with the extracellular matrix, thereby playing an important role in cell-signaling, cell-
cell adhesion, apoptosis and cell-matrix interactions. More specifically, αvβ3 integrin 
is expressed on endothelial cells and modulates cell migration and survival during 
angiogenesis, while αvβ3 integrin expressed on carcinoma cells potentiates metastasis 
by facilitating extravasation and tissue invasion. In addition, it has been shown that 
αvβ3 integrin is upregulated in tumor blood vessels and is therefore considered as a 
marker of tumor–induced angiogenesis.8 Moreover, αvβ3 integrin is expressed on 
various tumor cell types, including ovarian cancer, neuroblastoma, breast cancer and 
melanoma. As a consequence of the overexpression of αvβ3 integrin on cancer cells, 
the RGD binding site is considered as an attractive pharmaceutical target.9 As a 
result, a large number of synthetic RGD analogues have been prepared over the 
years, which have shown to inhibit the growth of tumor in animal models,10 
presumably by starving the tumors of blood supply. More recently it was reported 
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that cyclic RGD derivatives, especially the ones consisting of five amino acids (e.g. 
cyclic[Arg-Gly-Asp-D-Phe-Val]), showed a 100-fold better affinity for αvβ3 integrin 
compared to the linear counterparts, with IC50 values in the nanomolar range.11, 12 In 
particular, Kessler et al.11 showed that until today cyclo[Arg-Gly-Asp-D-Phe-Val] is 
one of the most active and selective antagonists for targeting αvβ3 integrin. To study 
the angionesis and metastasis in vivo, Haubner et al.13 synthesized the first radionated 
peptide, 125I-c(RGDyV). The 125I-c(RGDyV) demonstrated an affinity of 2 nmol/L and 
high selectivity for αvβ3, but was mainly excreted via the hepatobiliary route. 
Conditions to be fulfilled by the ideal radiolabeled αvβ3 integrin antagonist include, 
apart from high affinity and specificity, rapid clearance from the blood (high 
hydrophilicity) and high metabolic stability. The first two criteria have been 
extensively studied over the years, while more recently, attempts to produce more 
hydrophilic cRGD peptides to promote excretion via the kidneys have led to 
glycosylated cRGD peptides.14 The glycosylated cyclo[Arg-Gly-Asp-D-Tyr-Lys(SAA)] 
showed a longer circulatory half-life in the tumor, greatly reduced liver uptake, and 
yielded higher tumor-to-blood ratios than the non-glycosylated peptide4,14 compared 
with the hydrophobic parent compound. Subsequently, a variety of glycosylated 
cRGD peptides was prepared by Kessler et al. to elucidate the influence of various 
substitutions on the biological properties.15 Based on these studies, we hypothesized 
that triazole isosteres of such glycosylated cRGD peptides would display a 
comparable pharmaceutical profile.  
A strong support for the notion that incorporation of triazoles in natural compounds 
should not compromise the biological activity was recently provided by van 
Maarseveen et al.1 by preparation of three triazole containing analogues of the 
cyclo[Pro–Tyr–Pro–Val] (1), a naturally occurring tyrosinase inhibitor (Figure 1). As 
expected, the natural tetrapeptide 1 could not be synthesized due to the problematic 
ring-closure.16 However, no problems were encountered in the synthesis of the cyclic 
triazole analogues 2-4.  
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Figure 1. Cyclo–[Pro–Tyr–Pro–Val] and triazole-containing analogues thereof. 
Next, the inhibitory effect of the cyclotetrapeptide analogues 2-4 on mushroom 
tyrosinase activity was compared to that of the natural product 1 via an in vitro 
spectrophotometric assay, revealing that the triazolyl cyclotetrapeptides not only 
retained inhibition activity, but in fact, two of the analogues (2 and 3) showed an 
approximately threefold increase in activity as compared to the natural product.  
In analogy to the triazolyl tyrosinase inhibitors, studies were initiated by us on 
triazolyl glycoRGD analogues with two aims. Firstly, to investigate the stability of 
N-triazolyl glycoamino acids and secondly to compare the biological activity with the 
previously described N-glycosylated cRGD peptides. To this end, a representative set 
of ‘regular’ RGD peptides as well as two glycosylated RGD derivatives were 
synthesized by a combination of solid and solution phase techniques. The in vitro and 
in vivo αvβ3-binding characteristics of these compounds were investigated. In 
addition, the chemical stability of the triazole linkage in a simple glycosidic amino 
acid model system was compared with the natural glycosidic amide link found in 
Nature. 
7.2 SYNTHESIS OF GLYCOAMINO ACIDS 
Cyclic RGD peptides represent valuable ligands for selective targeting of αvβ3 
integrins. Consequently, a large number of cyclic RGD analogues has been 
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prepared17 and extensively tested. We have shown that 1-azidosugars and acetylene-
modified amino acids readily undergo [3+2] cycloaddition via a standard protocol for 
the copper-catalyzed Huisgen addition to form triazole isosteres of glycoamino acids 
in high yields. Although synthetically of interest, here we explored the potential 
value of triazolyl glycosylated cRGD peptides as targeting agents. In this respect, the 
first relevant question to answer is to what extent the triazole analogues of 
glycoamino acids have increased stability with respect to the natural compounds. 
Secondly, the medicinal value of the triazole compounds as glycoamino acid mimics 
can only be evaluated by incorporation in biologically active compounds. For this 
reason, the amide-linked c[RGDy(N-1-β-glyco-Asn)] (6) (Figure 2) as well as the 
triazole-linked glycosylated RGD peptide c(RGDy-T4M(1-[β-D-Glc])) (5) were 
prepared to evaluate the binding affinities for αvβ3 integrins. The natural c(RGDfV) 
(7) and c(RGDyV) (8) were prepared for reference purposes. D-Tyr was incorporated 
instead of D-Phe for c[RGDy(N-1-β-glyco-Asn)] (6), c(RGDy-T4M(1-[β-D-Glc])) (5), 
and c(RGDyV) (8) enabling subsequent iodination for tumor imaging as reported by 
Haubner et al.14  
NH
O
H
N
O
N
H
HN
O
HN
O
N
HO
OH
O
X
NH
H2N
6: c(RGDy-[N-1-β-gluco-Asn])5: c(RGDy-T4M(1-[β-D-Glc])) 7: c(RGDfV): X = H
8: c(RGDyV): X = OH
NH
O
H
N
O
N
H
HN
O
HN
O
N
HO
OH
O
HO
NH
H2NNN
N
OHO
HO
OH
HO
NH
O
H
N
OHN
O
HN
O
N
HO
OH
O
HO
N
H
NH
H2NOHO
HO
OH
HO
H
N
O
 
Figure 2. Cyclic RGD peptides for integrin targeting. 
Since solid phase synthesis of peptides typically involves chain elongation by 
coupling with Fmoc-protected amino acids, the requisite building blocks for the 
synthesis of glycoRGD peptides were prepared first. Thus, 1-azido-2,3,4,6-tetra-O-
acetyl-β-D-glucopyranose 918 was condensed with Fmoc-protected (S)-
propargylglycine under the influence of Cu(OAc)2 and sodium ascorbate in a 
mixture of tert-butyl alcohol and water, to give protected Fmoc-T4M(1-[β-D-
Glc(Ac)4])-OH (10), in 91% yield, Scheme 1. Preparation of the amide-linked 
glycoamino acid 15 began with hydrogenation of 9, H2 and Pd/C in the presence of 
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Et3N, to afford β-1-aminoglucose derivative 12. Subsequent coupling to Fmoc-
aspartic acid tert-butyl ester yielded acetylated and Fmoc-protected glycosidic 
asparagine tert-butyl ester 13 in a yield of 87%. Next, the tert-butyl ester was treated 
with TFA in DCM (1/1, v/v) to afford the free acid Fmoc-[N-1-β-glyco(Ac)4-Asn]-OH 
(14) in near quantitative yield. 
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Scheme 1. Synthesis of glycosylated amino acids 11 and 15. 
7.3 EVALUATION OF STABILITY 
In order to investigate the chemical stability of the substrates T4M(1-[β-D-Glc])-OH 
(11), as well as N-1-glycosyl-Asn(OH) (15), the protected glycoamino acids 10 and 14 
were subjected to treatment with 20% piperidine in DMF (v/v) followed by a 
saponification of the acetyl esters by K2CO3 in MeOH. The resulting glycoamino 
acids T4M(1-[β-D-Glc])-OH (11) and N-1-glycosyl-Asn(OH) (15) were subjected to 
various acidic and basic conditions as summarized in Table 1. 
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Table 1. Stability tests for T4M(1-[β-D-Glc])-OH (11) and N-1-β-glyco-Asn (15). 
T4M(1-[β-D-Glc])-OH (11) N-1-β-glyco-Asn (15)
OHO
HO
OH
HO
H2N CO2H H2N CO2H
N
OHO
HO
OH
HO
O
H
NN
N
 
entry condities temperature time stability stability 
1 2M HCl (aq) rt 3 d ++ ++ 
2 2M HCl (aq) reflux 2 h ++ + 
3 4M HCl (aq) reflux 3 h ++ −− 
4 2M NaOH (aq) rt 3 d ++ − 
5 2M NaOH (aq) reflux 3 h ++ −− 
6 2.6M HCl/EtOAc rt 3 d ++ + 
7 Et3N rt 4 d ++ ++ 
8 Et3N reflux 3 h ++ + 
9 Sn(OTf)2, DCMa rt 2 h ++ ++ 
aFmoc- and Ac-protected derivatives were used. 
First of all, it became apparent that the natural and the triazole-linked glycoamino 
acids were both remarkably resistant to 2 M aqueous hydrochloric acid. However, at 
elevated temperature, the hydrolysis of the amide-linked glycoamino acid 15 began 
to take place, while the triazole-linked T4M(1-[β-D-Glc])-OH 11 appeared completely 
robust. Similarly, triazole 11 was also found to be fully compatible with basic 
conditions, in strong contrast with the rapid hydrolysis of the natural amide-linked 
N-1-β-glyco-Asn (15). From these results, it can be concluded that triazole-linked 
substrates are versatile building blocks for the preparation of stable analogues of the 
common asparagine-linked N-glycoproteins. 
7.4 PREPARATION OF GLYCOSYLATED CYCLIC RGD PEPTIDES VIA 
SOLID PHASE SYNTHESIS 
For the cyclic RGD peptides, a solid phase strategy was chosen for synthesis of the 
peptide chain, followed by cleavage from the resin prior to cyclization. In order to 
avoid racemization of the carbonyl α-carbon during cyclization, Fmoc-glycine was 
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elected as C-terminal amino acid and coupled to trityl resin with DiPEA in DCM as 
depicted in Scheme 2. Subsequent elongation of the peptide was executed by 
application of standard Fmoc chemistry, involving HOBt/DIPCDI-mediated 
coupling followed by piperidine-induced Fmoc deprotection. 
Scheme 2. Preparation of the RGD peptides. 
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Besides the amino acids 10 and 14 two different C-triazole-linked amino acids (3019 
and 3119, Figure 3) were incorporated. All four amino acids, Fmoc-T4M(1-[β-D-
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Glc(Ac)4])-OH (10), T1M(4-[β-D-Glc(Bn)4])-OH (30), Fmoc-T1B(4-[β-D-Glc(Bn)4])-OH 
(31) and Fmoc-[N-1-β-glyco(Ac)4]-Asn(OH) (14) were compatible with the coupling 
conditions, although the amide-linked glycoamino acid was incorporated at a much 
slower rate.  
OBnO
BnO
OBn
BnO
FmocHN CO2H
OBnO
BnO
OBn
BnO
CO2H
NHFmoc
30: Fmoc-T1M(4-[β-D-Glc(Bn)4])-OH 31: Fmoc-T1B(4-[β-D-Glc(Bn)4])-OH
NN
N
NN
N
 
Figure 3. T1M(4-[β-D-Glc(Bn)4])-OH (30) and T1B(4-[β-D-Glc(Bn)4])-OH (31). 
After completion of the synthesis, the fully protected pentapeptides were cleaved 
from the resin using a 1% solution of TFA in DCM and purified by extraction and/or 
silica gel column chromatography. Next, cyclization of the linear RGD peptides was 
effected under the influence of BOP to give the protected cyclic peptides 24-29. Since 
the latter glycopeptides still carry protective groups on the carbohydrate moiety, 
attempts were undertaken to deprotect the benzylated RGD peptides 28 and 29. 
Surprisingly, a range of debenzylation conditions failed to produce the desired 
product in acceptable yield (Table 2).  
Table 2. Attempted reaction conditions for the hydrogenation of the benzyl protection groups. 
entry conditions product 
1 Pd/C, MeOH, H2 (1bar) 0% 
2 Pd/C, MeOH, H2 (3bar) 0%a 
3 Pd/C, “Degussa”, MeOH H2 (1bar) 0% 
4 Pd(OH)2, MeOH, H2 (1bar) 0% 
5 Pd(OH)2 “Degussa”, MeOH, H2 (1bar) 0% 
6 Ra-Ni, H2O, H2 (1bar) 0%a 
7 BF3·OEt, EtOH <10% 
aOnly partially deprotected products were formed. 
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Fortunately, the acetyl-protected carbohydrates 26 and 27 were easily deprotected via 
treatment with a K2CO3 solution, affording the desired glycosylated cRGD peptides 5 
and 6 in good overall yield (14-18%). Finally, the glycosylated cRGD peptides 
depicted in Figure 2 (5 and 6) as well as c(RGDyV) (8) and c(RGDfV) (7) were 
purified by semi-preparative RP-HPLC and examined in vitro and in vivo to study the 
αvβ3 receptor affinities. 
7.5 SOLID PHASE αVβ3 BINDING ASSAY  
The affinities of c(RGDfV) (7) , c(RGDyV) (8), c(RGDy-[N-1-β-gluco-Asn]) (6), and 
c(RGDy-T4M(1-[β-D-Glc])) (5) for the αvβ3 integrin as determined in the competitive 
binding assay are summarized in Figure 4.   
 
Figure 4. Competition of specific binding of 111In-DOTA-E-[c(RGDfK)]2 with c(RGDfV) (▲), c(RGDyV) (▼), 
c(RGDy-T4M(1-[β-D-Glc])) (•) and c(RGDy-[N-1-β-gluco-Asn]) (♦). 
From Figure 4, it becomes clear that binding of 111In-DOTA-E-[c(RGDfK)]220 to αvβ3 
was inhibited by each compound in a concentration dependent manner. In fact, only 
relatively small differences between the different peptides could be observed, with 
IC50 values of 65 nM for c(RGDfV), 144 nM for c(RGDyV), 238 nM for c(RGDy-[N-1-β-
gluco-Asn]), and 144 nM for c(RGDy-T4M(1-[β-D-Glc])), indicating that side-chain 
modification had only limited effect on the αvβ3 binding affinity of the compounds, 
which is in agreement with earlier reports.15, 21 In addition, these data showed that 
only a slight difference was noticeable between the carbohydrate containing RGD 
peptides (c(RGDy-T4M(1-[β-D-Glc])) and c(RGDy-[N-1β-gluco-Asn]), which can be a 
HN
H
N
NH
HN
NH
O
O
O O
O
OH
O
NH
NH2
HN
H
N
O
NH
H
N
ONH
H
N
HN
NH
HN
O
O
OO
O
HO
O
HN
H2N
NH
O
N N
NN CO2H
CO2H
HO2C
dimer =
DOTA-E-[c(RGDfK)]2
Preparation and Evaluation of Glycosylated RGD Derivatives for Integrin Targeting   
 
153
first indication that the glycoamino acid binding characteristics are nearly unchanged 
upon substitution of the amide linkage for a triazole linkage. 
7.6 BIODISTRIBUTION STUDIES 
Side-chain glycosylation can improve the pharmacological properties of 
hydrophobic/lipophilic peptides,22 which has also been demonstrated for RGD.14 In 
order to validate the potential of the glycoamino acids 11 and 15 for incorporation in 
glycoRGD peptides, the biodistribution of 125I-c(RGDyV), 125I-c(RGDy-[N-1-β-gluco-
Asn]), and 125I-c(RGDy-T4M(1-[β-D-Glc]))  in athymic mice with subcutaneous (s.c.) 
αvβ3-expressing tumors was determined. The results of the biodistribution studies of 
125I-RGDyV, 125I-c(RGDy-[N-1-β-gluco-Asn]), and 125I-c(RGDy-T4M(1-[β-D-Glc])) in 
athymic mice with SK-RC-52 tumors at 2 h postinjection (p.i.) are summarized in 
Table 3 and Figure 5. In order to determine the non-specific uptake of the peptides, 
the biodistribution was also determined in the presence of excess unlabeled RGD 
compound, i.e. dimeric DOTA-E-[c(RGDfK)]2.  
Table 3. Biodistribution data of 125I-c(RGDyV), 125I- c(RGDy-[N-1-β-gluco-Asn]), and 125I- c(RGDy-T4M(1-
[β-D-Glc])) in the presence and absence of an excess of unlabeled DOTA-E-[c(RGDfK)]2 in athymic mice with 
s.c. SK-RC-52 tumors 2 h after injection. The organ uptake is expressed as %ID/g. 
 125I-c(RGDyV) 125I-c[RGDy-(N-1-β-gluco-Asn)] 125I-c[RGDy-T4M(1-[β-D-Glc]))
  non-specific 
uptake 
 non-specific 
uptake 
 non-specific 
uptake 
Blood 0.13 ± 0.01 0.26 ± 0.12 0.30 ± 0.04 0.28 ± 0.06 0.09 ± 0.04 0.10 ± 0.10
Muscle 0.17 ± 0.08 0.08 ± 0.03 0.45 ± 0.18 0.28 ± 0.24 0.17 ± 0.04 0.06 ± 0.04
Tumor 0.77 ± 0.10 0.34 ± 0.07 2.63 ± 0.45 0.89 ± 0.17 1.31 ± 0.33 0.51 ± 0.01
Lung 0.36 ± 0.08 0.29 ± 0.09 0.74 ± 0.10 0.40 ± 0.07 0.29 ± 0.03 0.13 ± 0.02
Spleen 0.19 ± 0.02 0.20 ± 0.13 1.07 ± 0.07 0.43 ± 0.05 0.46 ± 0.06 0.18 ± 0.04
Kidney 0.84 ± 0.04 0.71 ± 0.24 1.89 ± 0.07 1.43 ± 0.27 1.27 ± 0.32 0.99 ± 0.20
Liver 1.07 ± 0.11 1.49 ± 0.44 0.76 ± 0.05 0.36 ± 0.05 0.37 ± 0.07 0.22 ± 0.05
Intestine 1.93 ± 1.62 1.82 ± 0.36 2.10 ± 0.44 1.15 ± 0.78 0.80 ± 0.20 0.30 ± 0.13
 
All peptides 125I-c(RGDyV), 125I-c(RGDy-[N-1-β-gluco-Asn]), and 125I-c(RGDy-T4M(1-
[β-D-Glc])) rapidly cleared from the blood as blood levels 2 h p.i. did not exceed 0.3% 
ID/g. Two hours after injection, the concentration of 125I-c(RGDy-[N-1-β-gluco-Asn]) 
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and 125I-c(RGDy-T4M(1-[β-D-Glc])) in the tumor was the highest of all tissues 
examined. Co-injection of excess unlabeled DOTA-E-[c(RGDfK)]2 (50 µg) along with 
125I-c(RGDyV), 125I-c(RGDy-[N-1-β-gluco-Asn]), and 125I-c(RGDy-T4M(1-[β-D-Glc])) 
indicated that for each of the three compounds, the major part of the uptake in the 
tumor was αvβ3-mediated.  
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c(RGDy-T4M(1-[β-D-Glc]))   
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Figure 5. Biodistribution of RGD peptides in athymic mice. 
In this mouse model 125I-c(RGDy-T4M(1-[β-D-Glc])) revealed the highest tumor-to-
blood ratio (18 at 2 h p.i.). The carbohydrate bearing cRGD peptides, 125I-c(RGDy-[N-
1-β-gluco-Asn]), and 125I-c(RGDy-T4M(1-[β-D-Glc])) also showed αvβ3-mediated 
uptake in non-target organs like lung, spleen, and intestine. Specific uptake of cRGD 
analogues in normal tissues has been reported in previous studies and is probably 
due to αvβ3 expression in these tissues.23 Furthermore, the conducted studies once 
more show that tumor uptake is not solely dependent on the binding affinity but 
relies on many more factors such as blood residence time, molecular weight, 
structure, charge etc. These aspects may explain the fact that 125I-c(RGDy-[N-1-β-
gluco-Asn]) displayed the highest tumor uptake while the corresponding monomer 
failed to provide the highest binding affinity. Although 125I-c(RGDy-T4M(1-[β-D-
Glc])) showed the highest tumor-to-blood ratio, it showed a lower tumor uptake than 
125I-c(RGDy-[N-1-β-gluco-Asn]). Therefore, it may be concluded that the high tumor 
uptake of 125I-c(RGDy-[N-1-β-gluco-Asn]) can only partially be explained by the 
presence of the carbohydrate moiety. 
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7.7 CONCLUSION 
A high yielding route for the preparation of Fmoc-T4M(1-[β-D-Glc(Ac)4])-OH starting 
from azidoglucose and Fmoc-protected propargylglycine is described by application 
of our technology for the synthesis of triazolyl glycoamino acids. The T4M building 
block displayed significantly improved chemical stability with respect to the ‘natural’ 
amide-linked glycoamino acid, and is fully compatible with basic and acidic 
conditions. The incorporation of the Fmoc-protected T4M derivative in an RGD 
peptide proceeded without incidence, in fact more smoothly than the amide-linked 
glycoamino acids, with the final yield of the substrate being comparable to that of the 
other RGD substrates. The solid phase binding assay revealed no significant 
differences between the different peptides under evaluation confirming that 
modification of the side-chain of the RGD peptide did not affect affinity for αvβ3. The 
125I-labeled cyclic peptides accumulated specifically in SK-RC52 tumors. The uptake 
of the cyclic RGD substrates in the tumor, lung, spleen, and intestine were  
αvβ3-mediated. The biodistribution studies indicated that the side-chain glycosylated 
RGD peptide 125I-c(RGDy-T4M(1-[β-D-Glc])) showed improved pharmacological 
properties as compared to 125I-c(RGDyV) with reduced liver uptake and highest 
uptake in the tumor. Moreover, the in vitro and in vivo tests indicated that  
c(RGDy-T4M(1-[β-D-Glc])) to some extent has the same pharmacological properties 
as c(RGDy-[N-1-β-gluco-Asn]), which may be interpreted as one of the first examples 
of the value of triazoles as amide isosteres. The ease of synthesis of the triazolyl 
glycoamino acids, the improved stability and behavior in solid phase peptide 
synthesis and the similar pharmacological properties comprise a demonstration of 
the potential of T4M building blocks as isosteres of amide-linked glycoamino acids 
for the synthesis of pharmaceutically relevant glycopeptide mimics. 
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7.9 EXPERIMENTAL  
General information 
Analytical reversed-phase high-performance liquid chromatography (RP-HPLC) was 
performed on a Merck Hitachi HPLC using an analytical reversed-phase column (Alltech 
Adsorbosphere C18, 300 Å, 5 μm, 4.6 mm x 250 mm) and a Merck Hitachi (L-4000) UV 
detector operating at 215 nm. Elution was effected using an appropriate gradient from 0.1% 
trifluoroacetic acid (TFA) in H2O/MeCN (95/5, v/v) to 0.1% TFA in MeCN/H2O (95/5, 
v/v). Semi-preparative HPLC was performed using an Alltech Adsorbosphere XL C18 
column (250 x 10 mm, pore size 100 Å, particle size 10 μm) at a flow rate of 5.0 mL/min. For 
other general information see Section 2.6. 
 
(S)-T4M(1-[β-D-Glc])-OH (11).  
Fmoc-(S)-T4M(1-[β-D-Glc(Ac)4])-OH (10) (500 mg, 0.70 mmol) was 
treated with 20% piperidine in DMF (v/v, 5 mL) and stirred for 20 
min before concentration of the solvent in vacuo. The crude product 
was dissolved in MeOH (5 mL), a catalytic amount of K2CO3 was 
added and the mixture was stirred for 1 h. Purification of the product with a basic ion 
exchange column (IRA-410) afforded the triazolyl-linked glycosidic amino acid 3 (125 mg, 
0.39 mmol, 56%) as a white solid. IR (film):  ν 3309, 2362, 2327, 1623 cm−1. 1H NMR (400 MHz, 
D2O): δ = 5.01 (d, J = 8.4 Hz, 1H), 4.04 (s, 1H), 3.89 (d, J = 12.2 Hz, 1H), 3.74 (dd, J = 13.0, 4.8 
Hz, 1H), 3.46−3.39 (m, 2H), 3.44 (m, 2H), 3.14−2.80 (m, 2H). 13C NMR (75 M Hz, CDCl3): δ 
=172.3, 141.7, 123.3, 86.9, 78.4, 75.4, 71.7, 68.4, 59.9, 53.7, 25.7. HRMS (ESI) m/z calculated for 
C34H37N4O13 (M+H)+: 709.2357, found: 709.2344. 
 
2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl amine (12).  
The glucopyranosyl amine was prepared according to a literature 
procedure24 with slight modification. In an oven-dried Schlenk flask filled 
with N2, the azidoglucose 9 (500 mg, 1.34 mmol), Et3N (140 mg, 1.4 mmol) 
and Pd/C (14 mg, 0.1 mmol) were suspended in THF (3 mL). Next the Schlenk flask was 
subjected to a sequence of vacuum and flushing with H2 (3 ×) after which it was vigorously 
stirred while bubbling H2 through the solution. After 30 min, the reaction was completed, the 
slurry was filtrated over Hyflo and THF was evaporated under reduced pressure to yield 4 
as a white solid (455 mg, 1.31 mmol, 98%), which was sufficiently pure for further reactions. 
1H NMR (400 MHz, CDCl3): δ = 5.22 (t, J = 9.3 Hz, 1H), 5.02 (t, J = 9.3 Hz, 1H), 4.83 (d, J = 9.2 
Hz, 1H), 4.21 (d, J = 9.2 Hz, 1H), 4.10 (dd, J = 12.4, 2.1 Hz, 1H), 3.65 (ddd, J = 9.8, 4.6, 2.1 Hz, 
1H), 2.10 (s, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H). Spectral data are in accordance with 
literature.18 
 
Fmoc-(S)-(N-1-Glu(Ac)4-Asn)-OH (14).  
The amide-linked sugar amino acid was prepared from 
glucopyranosyl amine 12 and Fmoc-Asp-OtBu via a procedure 
reported by van Ameijde et al.25 involving peptide coupling 
catalyzed by BOP followed by deprotection using TFA/DCM (4 h, 
rt) to afford the N-glycosylasparagine 14 as a white solid (798 mg, 1.17 mmol, 86%). Rf = 0.12 
(EtOAc/heptane 2:1). IR (film): ν 3313, 2250, 1740, 1506 cm-1. 1H NMR (400 MHz, CDCl3): δ = 
O
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7.76 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.4 Hz, 2H), 
6.70 (d, J = 8.8 Hz, 1H), 6.16 (d, J = 7.6 Hz, 1H), 5.33 (t, J = 9.5 Hz, 1H), 5.26 (t, J = 9.1 Hz, 1H), 
5.08 (t, J = 9.7 Hz, 2H), 4.94 (t, J = 9.5 Hz, 1H), 4.67−4.53 (m, 1H), 4.47−4.34 (m, 2H), 4.30 (dd, J 
= 12.6, 4.4 Hz, 1H), 4.22 (t, J = 7.04 Hz, 1H), 4.08 (dd, J = 12.6, 2.0 Hz, 1H), 3.82 (ddd, J = 10.1, 
4.1, 2.0 Hz, 1H), 2.90 (dd, J = 16.3, 2.8 Hz, 1H), 2.76 (dd, J = 16.3, 5.2 Hz, 1H), 2.06 (s, 5H), 2.04 
(s, 3H), 2.02 (s, 3H). 13C NMR (75 MHz, CDCl3): δ = 176.1, 173.9, 171.4, 170.9, 170.2, 169.8, 
156.6, 143.7, 141.3, 127.9, 127.2, 125.3, 120.1, 78.0, 73.8, 272.9, 70.8, 68.2, 67.6, 61.8, 50.5, 47.1, 
37.7, 20.8, 20.7, 20.7, 20.6. HRMS (ESI) m/z calculated for C33H36N2NaO14 (M+Na)+: 707.2051, 
found: 707.2064. 
 
(S)-N-1-Gluco-Asn (15).  
Fmoc-(N-1-Glu(Ac)4-Asn)-OH (14, 500 mg, 0.73 mmol) was treated 
with 20% piperidine in DMF (v/v, 5 mL) and stirred for 20 min, 
before concentration of the solvent in vacuo. The crude product was 
dissolved in MeOH (5 mL), a catalytic amount of K2CO3 was added 
and the mixture was stirred for 1 h. Purification of the product with a basic ion exchange 
column (IRA-410) afforded the amide-linked glycosidic aspargine 7 (133 mg, 0.45 mmol, 
62%) as a white solid. 1H NMR (400 MHz, D2O): δ = 8.14 (s, 1H), 5.77 (d, J = 9.2 Hz, 1H), 4.10 
(t, J = 5.0 Hz, 1H), 4.02 (t, J = 9.2 Hz, 1H), 3.93 (d, J = 11.4 Hz, 1H), 3.82−3.71 (m, 3H), 3.64 (t, J 
= 9.1 Hz, 1H), 3.43−3.34 (m, 1H). HRMS (ESI) m/z calculated for C33H36N2O14 (M+H)+: 
707.2064, found: 707.2051. 
 
General procedure A for the synthesis of the RGD peptides.  
Loading of the trityl resin, synthesis of the pentapeptides, cleavage, subsequent cyclization 
and deprotection of the cyclic RGD peptides were carried out following standard Fmoc 
peptide chemistry protocols. Side-chain protection was 2,2,5,7,8-pentamethylchromane 
(Pmc) for arginine and tert-butyl (tBu) for aspartic acid and tyrosine.  
 
General procedure B for side chain protecting group removal and resin cleavage. 
The peptides were treated with a solution of 95% trifluoracetic acid (TFA), 2.5% water, and 
2.5% ethanedithiol (EDT) for 4 h at ambient temperature. Next, the glycopeptides were 
precipitated in diethyl ether. The crude product was isolated by centrifugation and washed 
three times with diethyl ether. Purification by extraction and/or silica gel column 
chromatography afforded white solids. 
 
General procedure C for acetyl removal on the carbohydrates. 
The crude product was dissolved in MeOH, a catalytic amount of K2CO3 was added and the 
mixture was stirred for 1 h. Ion exchange resin (Amberlyte IR-120) was added until the 
solution was neutral and the ion exchange resin was filtered off. Evaporation of the solvent 
in vacuo provided the products as white solids. A final purification for the biological studies 
was performed via semi-preparative RP-HPLC as described above. 
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c(RGDfV) (7) 
Preparation according to general procedures A and B afforded 7 (105 mg, 0.18 mmol, 16% 
relative to the resin). Rt (min): 8.1. HRMS (ESI) m/z calculated for C26H39N8O7 (M+H)+: 
575.2914, found: 575.2942. 
 
c(RGDyV) (8) 
Preparation according to general procedures A and B afforded 7 (85 mg, 0.14 mmol, 13% 
relative to the resin). Rt (min): 8.2. HRMS (ESI) m/z calculated for C26H39N8O8 (M+H)+: 
591.2891, found: 591.2891. 
 
c(RGDy-N-[1-β-gluco(OAc)4]-Asn) (26) 
Preparation according to general procedures A and B 
afforded 26 (60 mg, 0.06 mmol, 17% relative to the resin). 1H 
NMR (400 MHz, MeOD): δ = 7.02 (d, J = 8.6 Hz, 2H), 6.70 (d, J 
= 8.6 Hz, 2H), 5.32 (t, J = 9.5 Hz, 1H), 5.23 (t, J = 9.4 Hz, 1H), 
5.04 (t, J = 10.0 Hz, 1H), 4.95 (t, J = 9.5 Hz, 1H), 4.73 (t, J = 6.9 
Hz, 1H), 4.57−4.52 (m, 1H), 4.44−4.39 (m, 1H), 4.28−4.23 (m, 
3H), 4.11 (dd, J = 12.4 Hz, 2.2 Hz, 1H), 3.92 (ddd, J = 10.2 Hz, 
4.6 Hz, 2.4 Hz, 1H), 3.25−3.13 (m, 2H), 3.00−2.95 (m, 1H), 
2.86−2.76 (m, 2H), 2.68 (dd, J = 16.1 Hz, 6.9 Hz, 1H), 2.57 (dd, 
J = 16.5 Hz, 6.8 Hz, 1H), 2.48 (dd, J = 16.1 Hz, 5.3 Hz, 1H), 2.03 (s, 3H), 2.03 (s, 3H), 1.99 (s, 
3H), 1.98 (s, 3H), 1.98−1.55 (m, 4H). LRMS m/z calculated for C39H54N9O18 (M+H)+: 936.4, 
found: 936.4. 
 
c(RGDy-T4M(1-[β-D-Glc(Ac)4])) (27) 
Preparation according to general procedures A and B 
afforded 27 (48 mg, 0.05 mmol, 14% relative to the resin). 1H 
NMR (400 MHz, MeOD): δ = 7.94 (s, 1H), 6.99 (d, J = 8.5 Hz, 
2H), 6.69 (d, J = 8.5 Hz, 2H), 6.09 (d, J = 9.2 Hz, 1H), 5.63 (t, J = 
9.4 Hz, 1H), 5.53 (t, J = 9.4 Hz, 1H), 5.27 (t, J = 9.8 Hz, 1H), 
4.71 (dd, J = 8.3 Hz, 5.7 Hz, 1H), 4.58−4.50 (m, 2H), 4.35−4.24 
(m, 3H), 4.17 (dd, J = 12.3 Hz, 1.7 Hz, 1 H), 4.13−4.09 (m, 1H), 
3.38 (d, J = 15.4 Hz, 1H), 3.26−3.18 (m, 3H), 3.12−3.05 (m, 1H), 
2.99−2.94 (m, 1H), 2.84−2.77 (m, 2H), 2.56 (dd, J = 16.6 Hz, 5.8 
Hz, 1H), 2.06 (s, 3H), 2.00 (s, 3H), 2.00 (s, 3H), 1.83 (s, 3H), 2.00−1.52 (m, 4H). LRMS m/z 
calculated for C40H54N11O17 (M+H)+: 960.4, found: 960.4. 
 
c(RGDy-T1M(4-[β-D-Glc(Bn)4])) (28) 
Preparation according to general procedures A and B afforded 
28. 1H NMR (400 MHz, MeOD): δ = 7.44 (d, J = 2.1 Hz, 1H), 
7.34−6.98 (m, 20H), 6.92 (d, J = 8.6 Hz, 2H), 6.72 (d, J = 8.6 
Hz, 2H), 4.90 (ap s, 1H), 4.71 (t, J = 7.1 Hz, 1H), 4.66−4.42 
(m, 7H), 4.34−4.20 (m, 3H), 4.16 (dd, J = 8.7, 5.4 Hz, 1H), 
3.93−3.65 (m, 7H), 3.25−3.06 (m, 3H), 2.98−2.68 (m, 4H), 
2.56 (dd, J = 16.5, 6.7 Hz, 1H), 1.91−1.43 (m, 5H). HRMS 
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(ESI) m/z calculated for C60H70N11O13 (M+H)+: 1152.5155, found: 1152.5122. HRMS (ESI) 
m/z calculated for C60H69N11O13Na (M+Na)+: 1174.4974, found: 1174.5026.  
 
c(RGDy-T1B(4-[β-D-Glc(Bn)4])) (29) 
Preparation according to general procedures A and B 
afforded 29. 1H NMR (400 MHz, DMSO-D6): δ = 7.44 (ap s, 
1H), 7.31−6.99 (m, 20H), 6.78−6.57 (m, 4H), 6.56 (d, J = 8.4 Hz, 
1H), 4.84−4.61 (m, 5H), 4.53−4.24 (m, 7H), 4.15−3.98 (m, 2H), 
3.77−3.69 (m, 4H), 3.60−3.51 (m, 2H), 2.88−2.66 (m, 4H), 
2.40−2.29 (m, 3H), 1.79−1.35 (m, 6H). HRMS (ESI) m/z 
calculated for C63H76N11O13 (M+H)+: 1194.5624, found: 
1194.5660. HRMS (ESI) m/z calculated for C63H75N11O13Na 
(M+Na)+: 1216.5443, found: 1216.5521.  
 
 
 
c(RGDy-T4M(1-[β-D-Glc])) (5) 
Preparation from c(RGDy-T4M(1-[β-D-Glc(Ac)4])) (27) 
according to general procedure C for the removal of the 
acetyl groups afforded 5 (39 mg, 0.05 mmol, 99%). Rt (min): 
7.9. 1H NMR (400 MHz, D2O): δ = 7.83 (s, 1H), 7.01 (d, J = 8.4 
Hz, 2H), 6.68 (d, J = 8.4 Hz, 2H), 5.72 (d, J = 9.2 Hz, 1H), 4.68 
(t, J = 7.1 Hz, 1H), 4.51 (dd, J = 9.9, 5.9 Hz, 1H), 4.43 (t, J = 6.9 
Hz, 1H), 4.34 (dd, J = 8.9 Hz, 5.6 Hz, 1H), 4.21 (d, J = 14.9 Hz, 
1H), 3.99 (t, J = 9.2 Hz, 1H), 3.94 (d, J = 10.4 Hz, 1H), 3.68−3.55 
(m, 3H), 3.64 (t, J = 9.3 Hz, 1H), 3.50 (d, J = 14.9 Hz, 1H), 
3.09−2.95 (m, 3H), 3.04 (dd, J = 15.3, 6.5 Hz, 1H), 2.94 (dd, J = 13.4, 5.9 Hz, 1H), 2.86 (dd, J = 
13.2, 10.2 Hz, 1H), 2.67 (dd, J = 15.8, 7.0 Hz, 1H), 2.53 (dd, J = 15.7, 7.3 Hz, 1H), 1.75−1.63 (m, 
1H), 1.55−1.42 (m, 1H), 1.35−1.23 (m, 2H). HRMS (ESI) m/z calculated for C32H46N11O13 
(M+H)+: 792.3210, found: 792.3277.  
 
c(RGDy-N-[1-gluco]-Asn) (6) 
Preparation from c(RGDy-N-[1-β-gluco(OAc)4]-Asn) (26) 
according to general procedure C for the removal of the 
acetyl groups according to procedure C afforded 6 (50 mg, 
0.06 mmol, 99%). Rt (min): 6.3. 1H NMR (400 MHz, 
D2O/MeOD): δ = 7.01 (d, J = 8.4 Hz, 2H), 6.68 (d, J = 8.2 Hz, 
2H), 4.88 (ap. d, J = 9.5 Hz, 1H), 4.70 (t, J = 7.2 Hz, 1H), 4.50 
(dd, J = 6.8 Hz, 5.0 Hz, 1H), 4.45−4.38 (m, 2H), 4.24 (d, J = 14.5 
Hz, 1H), 3.89 (ap. d, J = 11.1 Hz, 1H), 3.74 (dd, J = 12.4 Hz, 5.1 
Hz, 1H), 3.58 (t, J = 9.2 Hz, 1H), 3.53−3.40 (m, 3H), 3.38−3.31 (m, 1H), 3.26−3.15 (m, 2H), 2.98 
(dd, J = 13.3 Hz, 5.9 Hz, 1H), 2.89−2.83 (m, 2H), 2.77 (dd, J = 16.4, 7.2 Hz, 1H), 2.65 (dd, J = 
15.6, 6.5 Hz, 1H), 2.55−2.49 (m, 2H), 1.96−1.87 (m, 1H), 1.76−1.67 (m, 1H), 1.65−1.53 (m, 2H). 
HRMS (ESI) m/z calculated for C31H46N9O14 (M+H)+: 768.3101, found: 768.3164.  
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STABILITY STUDIES.  
T4M(1-[β-D-Glc])-OH (11) (50 mg, 0.07 mmol) and N-1-gluco-Asn (15) (50 mg, 0.07 mmol) 
were dissolved in 3 mL of 2 M HCl (aq), 4 M HCl (aq), 2 M NaOH (aq), 2.6 M HCl/EtOAc or 
Et3N, and stirred for the time and temperature indicated in Table 1. The relative stability of 
the substrates was determined by TLC analysis and integration of 1H NMR signals of side-
products and starting material.   
 
SOLID PHASE αvβ3 BINDING ASSAY 
The affinity of c(RGDfV), c(RGDyV), c(RGDy-[N-1-β-gluco-Asn]), and c(RGDy-T4M(1-[β-D-
Glc])) for the αvβ3 integrin was determined in a competitive binding assay using the dimeric 
peptide 111In-DOTA-E-[c(RGDfK)]2 as a tracer. The 111In-labeled peptide (3 MBq/µg) was 
prepared as described earlier.20 Microtiter 96-well vinyl assay plates (Corning B.V., Schiphol-
Rijk, The Netherlands) were coated with 100 µL/well of a solution of purified human 
integrin αvβ3 (150 ng/mL) (Chemicon International, Temecula, CA, USA) in a coating buffer 
(25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2 and 1 mM MnCl2) for 
17 h at 4 °C. The plates were washed twice with binding buffer (0.1% bovine serum albumin 
(BSA) in coating buffer). The wells were blocked for 2 h with 200 µL blocking buffer (1% BSA 
in coating buffer) at room temperature. The plates were washed twice with binding buffer. 
Then 100 µL binding buffer containing 11 kBq of 111In-DOTA-E-[c(RGDfK)]2 and appropriate 
dilutions of nonlabeled c(RGDfV), c(RGDyV), c(RGDy-[N-1-β-gluco-Asn]), and c(RGDy-
T4M(1-[β-D-Glc])) in binding buffer were incubated in wells at 37 °C for 1 h. After 
incubation, the plates were washed three times with binding buffer. The retained 
radioactivity in each well was determined in a γ-counter. IC50 values of the RGD peptides 
were calculated by non-linear regression using GraphPad Prism (GraphPad Prism 4.0 
Software, San Diego, CA, USA). Each data point is the average of three determinations. 
 
RADIOLABELING OF THE RGD PEPTIDES  
The peptides containing tyrosine, c(RGDyV), c(RGDy-[N-1-β-gluco-Asn]), and c(RGDy-
T4M(1-[β-D-Glc])) were labeled with 125I using the Iodogen method. The peptide (10–20 µg) 
was dissolved in 100 µL phosphate-buffered saline (PBS) (pH 7.4) in a 1.5 mL polypropylene 
vial coated with 100 µg Iodogen and [125I]-NaI (37 MBq) was added to the vial. After 10 min, 
the solution was transferred to another vial to terminate the iodination. A sample of the 
mixture was analyzed by HPLC. Radiochemical purity was always higher than 98%. 
 
BIODISTRIBUTION STUDIES  
In the right flank of 6-8 week old female nude BALB/c mice, 0.2 mL of a suspension of 15 x 
106 cells/mL SK-RC-52 cells was injected subcutaneously (s.c.). Two weeks after inoculation 
of the tumor cells, mice were randomly divided into four groups. Mice were injected with 
125I-c(RGDfV) (0.5 MBq, 0.5 µg) , 125I-c(RGDyV) (0.5 MBq, 0.5 µg), 125I-c(RGDy-[N-1-β-gluco-
Asn]) (0.5 MBq, 0.5 µg), or 125I- c(RGDy-T4M(1-[β-D-Glc])) (0.5 MBq, 0.5 µg) via the tail vein. 
Mice were euthanized by CO2 asphyxiation 2 h postinjection (p.i.) (4 mice/group). Blood, 
tumor and all the major organs and tissues were dissected, weighted, and counted in a well-
type γ-counter. The percentage injected dose per gram (%ID/g) was determined for each 
sample. To investigate whether the uptake of each of the 4 RGD peptides (in the dissected 
tissues) was αvβ3 mediated, a separate group of mice was coinjected with an excess (50 µg) of 
non-radiolabeled DOTA-E-[c(RGDfK)]2 to saturate all the αvβ3 integrin receptors, and the 
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biodistribution of the radioiodinated RGD peptide-conjugates was determined as described 
above. All animal experiments were approved by the local animal welfare committee in 
accordance with Dutch legislation and carried out in accordance with their guidelines. 
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SUMMARY 
Triazole-linked Glycosyl Amino Acids and Peptides 
Naturally occurring glycosylated peptides play an important role in various 
biological processes and are therefore interesting lead molecules for the preparation 
of new therapeutic drugs. Synthesis of these natural glycopeptides is frequently 
hampered by the sensitivity of the natural glycosidic linkage towards acidic and 
basic conditions. Another important pathway for glycopeptide degradation involves 
enzymatic cleavage of the carbohydrate moiety.  
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Figure 1. Natural glycosidic linkage and their C-linked analogues. 
A search for new, more stable mimics led to the development of C-linked isosteres, 
providing excellent chemical and enzymatic stability without negatively influencing 
the biological properties (Figure 1). A general introduction of natural glycopeptides 
as well as an overview of recent synthetic approaches for the preparation of new 
glycosidic amino acid isosteres is given in Chapter 1.  
Chapter 2 details our efforts to prepare stable glycosidic C-linked serine isosteres by 
ligation of an open-chain unsaturated sugar to an allylglycine derivative, producing 
acyclic glycoamino acid alkenes. Subsequent mercury(II)-induced cyclization 
followed by a reduction led to the desired product, a mimic of the natural O-linked 
glycoamino acids with the proper number of interconnecting atoms. An example 
hereof is presented in Scheme 1. The resulting C-linked glycosyl serine analogues, 
obtained in a few straightforward steps, are known to surpass the natural O-linked 
analogues in stability. 
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Scheme 1. Cross metathesis / mercury(II)-induced cyclization strategy. 
Chapter 3 discloses a novel, expedient, high-yielding synthesis of triazole-linked 
glycopeptides via Cu(I)–catalyzed [3+2] cycloaddition of azido–functionalized 
glycosides and acetylenic amino acids (Scheme 2). The resulting triazole-linked 
products, mimicking the N-linked glycosides found in Nature, have potentially 
relevant biological properties. By application of this method a small library of 
glycosidic amino acids was prepared. Both α- and β-configured triazolyl 
glycopeptides were accessible by combination of a variety of azido-functionalized 
glycosides with a range of acetylenic amino acids, resulting in a novel class of stable 
glycopeptide mimics.  
 
N
NN
CO2RHN
CO2RHN
+
PG
( )n
PG12 (~ 70-90%)10 11
( )n
ORO
RO
OR
RO N3
ORO
RO
OR
RO
Cu(OAc)2,
Na-ascorbate
H2O / tBuOH
 
Scheme 2. Cu(I)–catalyzed [3+2]-cycloaddition leading to triazolyl glycosidic amino acids. 
In Chapter 4, a range of protective groups were examined for application in an 
orthogonal coupling procedure en route to triazole analogues of natural 
glycopeptides with multiple glycosylated side-chains. Both TMS- and TBDPS-
protected propargylglycines were prepared via an alkylation strategy, subsequent 
enzymatic resolution afforded the enantiopure TMS-derivative. Subsequently, a 
variety of pentapeptides, bearing a free as well as a protected (TMS or TBDPS) 
acetylene side-chain, were prepared via solid-phase chemistry. A stepwise [3+2] 
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cycloaddition, deprotection and again [3+2] cycloaddition, either on resin or in 
solution (Scheme 3) afforded the desired diglycosylated glycopeptides. 
 
CuI 0.1 equiv
DiPEA 1.0 equiv
THF, rt
OAcO
AcO
OAc
AcO N3
2.0 equiv
K2CO3, MeOH
o.n., rt
N
N
N
O
HO
HO
HO
HO
ValAc Gly Gly Gly OH
15 (96%)
Ser(tBu)
16 (98%)
N
N
N
O
AcO
AcO
AcO
AcO
ValAc Gly Gly Gly OHSer(tBu)ValAc Gly Gly Gly OHSer(tBu)
14 (34%)
Cu(OAc)2, Na-ascorbate
H2O/tBuOH
OAcO
AcO
NHAc
AcO N3
2.0 equiv
N
N
N
O
HO
HO
HO
HO
ValAc Gly Gly Gly OHSer(tBu)
N
N
N
O
HO
HO
AcHN
HO
13
TMS TMS
 
Scheme 3. Orthogonal coupling procedure en route to triazole analogues of natural glycopeptides. 
In Chapter 5 a novel copper-catalyzed cycloaddition of bromoalkynes and organic 
azides is described (Scheme 4). Copper-mediated coupling resulted in the formation 
of bromo-containing trisubstituted [1,2,3]-triazole derivatives in high yield and a 
regioselective manner, and was applied in the cycloaddition of a variety of 
bromoacetylenes and azides. The bromide substituent in the resulting triazoles 
provided a versatile synthetic handle for further functionalization to trisubstituted 
[1,2,3]-triazoles. 
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Scheme 4. Novel copper-catalyzed cycloaddition of bromoalkynes and organic azides. 
The chemoenzymatic peptide coupling of glycosylated triazolyl- and amide-linked 
amino acid methyl esters, effected by alcalase, a proteolytic enzyme mixture produced 
by Bacillus licheniformis is described in Chapter 6. Both the common amide-linked as 
well as the unnatural triazole-linked substrates were ligated to amino acid amides in 
moderate to good yields, producing dipeptides. An example is depicted in Scheme 5. 
Moreover, a first study towards the chemoenzymatic glycosylation of triazole-linked 
glycopeptides is presented.   
 
O
AcO
AcO
AcO
N
OAc
NN
CbzHN CO2Me
alcalase
tamylOH, DMF, 35 °C
O
AcO
AcO
AcO
N
OAc
NN
CbzHN
H
N
O
H2N CONH2
NH2
O
21 (98%)20  
Scheme 5. Enzymatic peptide coupling of glycosylated triazolyl-linked amino acid methyl ester. 
Chapter 7 describes the preparation of several cyclic RGD derivatives by a 
combination of solid phase and solution phase synthesis for selective targeting of 
αvβ3 integrin expressed in tumors (Figure 2). In order to evaluate the value of a 
triazole moiety as an amide isostere, the side-chain glycosylated RGD peptides were 
synthesized with either a natural amide linkage or a triazole. Affinity of the RGD 
constructs for αvβ3 integrin was determined in a solid phase competitive binding 
assay, showing strong similarity in binding affinity for each of the compounds under 
evaluation.  
Furthermore, the in vivo tumor targeting potential of glycosylated RGD peptides, 
linked via amide or triazole, was investigated by determining the biodistribution of 
125I-labeled derivatives in mice with tumors expressing αvβ3. All of the RGD 
derivatives showed preferential uptake in the subcutaneous tumors, with the highest 
tumor-to-blood ratio measured for the triazole-linked glycosylated derivative. The 
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results of the present study are a clear indication of the value of the triazole moiety as 
a suitable amide isostere in the development of glycosylated peptides as 
pharmaceuticals. 
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Figure 2. Cyclic RGD peptides for selective integrin targeting. 
 
 
 
  
169
SAMENVATTING 
Triazool gebonden glycosylaminozuren en -peptiden 
Glycopeptiden zijn eiwitten die post-translationeel gefunctionaliseerd zijn met een of 
meerdere (complexe) koolhydraten. Natuurlijk voorkomende glycopeptiden spelen 
een belangrijke rol in diverse biologische processen en vormen bijgevolg een 
mogelijk interessant uitgangspunt voor de ontwikkeling van nieuwe 
geneesmiddelen. De synthese van natuurlijk voorkomende glycopeptiden wordt 
vaak bemoeilijkt door de gevoeligheid van de glycosyl-peptide acetaalbinding voor 
zure en basische omstandigheden. Verder kunnen ook enzymatische processen 
leiden tot hydrolyse van de acetaalbinding en zo aanleiding tot afsplitsing van het 
koolhydraatdeel. 
O
HO
HO
HO
O
N
H
HO
1: O-gebonden
3: N-gebonden
O
NHAc
HO
HO
HO
H
N
O NH
O
O
O
HO
HO
HO
N
H
HO
2: C-isosteer
4: C-isosteer
O
NHAc
HO
HO
HO
NH
O
O
~ ~
 
Figuur 1. Natuurlijk voorkomende acetaalbindingen in glycopeptiden en bijbehorende C-analoga. 
Onderzoek naar nieuwe stabiele mimetica leidde onder meer tot de ontwikkeling 
van C-isosteren met uitstekende chemische en enzymatische stabiliteit, zonder de 
biologische eigenschappen negatief te beïnvloeden (Figuur 1). In hoofdstuk 1 wordt 
een algemene inleiding over natuurlijk voorkomende glycopeptiden gegeven, 
evenals een overzicht van recent gepubliceerde routes voor de synthese van 
glycosylaminozuur isosteren. 
Hoofdstuk 2 beschrijft de inspanningen om stabiele C-gebonden glycosylserine-
isosteren te synthetiseren via cross-metathese van onverzadigde lineaire suikers aan 
allylglycine derivaten. De resulterende lineaire conjugaten kunnen  vervolgens via 
een kwik(II)-geïnduceerde ringsluiting, gevolgd door een reductie tot de gewenste 
producten leiden. De zo verkregen mimetica van de natuurlijke O-gebonden 
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glycoaminozuren bevatten nu het juiste aantal bindingsatomen, waarvan een 
voorbeeld in Schema 1 is weergegeven. Uit de literatuur is reeds bekend dat 
dergelijke C-gebonden glycosylserine analoga stabieler zijn dan de natuurlijke O-
gebonden derivaten. 
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Schema 1. Cross-methathese/kwik-geïnduceerde ringsluitingsstrategie. 
Hoofdstuk 3 behandelt een effectieve  synthese van nieuwe triazool-gebonden 
glycopeptiden via een Cu(I)-gekatalyseerde 1,3-dipolaire cycloadditie van azide-
bevattende glycosiden en aminozuur-houdendeacetylenen (Schema 2). De 
resulterende triazool-gebonden producten, mimetica van de natuurlijke N-gebonden 
glycosiden, hebben mogelijk relevante biologische eigenschappen. Bijgevolg werd 
via deze methode een kleine bibliotheek van glycosylaminozuur analoga 
gesynthetiseerd. Zowel α– als β-triazolylglycopeptiden waren toegankelijk door een 
variëteit van azide-gefunctionaliseerde glycosiden met aminozuuracetylenen te 
combineren, wat tot deze geheel nieuwe klasse van stabiele glycopeptiden leidde. 
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Schema 2. Synthese van triazolyl-glycopeptiden via Cu(I)-gekatalyseerde 1,3-dipolaire cycloadditie.  
In hoofdstuk 4 is een reeks beschermgroepen onderzocht op hun toepasbaarheid in 
orthogonale koppelingsprocedures, met als doel triazool-bevattende analoga van 
natuurlijke glycopeptiden met meervoudig geglycosyleerde zijketens  
eenvoudig toegankelijk te maken. Zowel TMS- als TBDPS-beschermde 
propargylglycinederivaten werden via een alkylering gesynthetiseerd en vervolgens 
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kon via enzymatische resolutie het TMS derivaat omgezet worden in het 
overeenkomnstige enantiozuivere aminozuur. Aansluitend werden verschillende 
pentapeptiden, met een vrije én een beschermde acetyleen zijgroep, bereid via 
synthese op een vast dragermateriaal. Stapsgewijze 1,3-dipolaire cycloadditie, 
ontscherming gevolgd door  nogmaals 1,3-dipolaire cycloadditie, op de vaste fase of 
in de vloeistoffase (Schema 3) gaf de gewenste tweevoudig geglycosyleerde 
glycopeptiden. 
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Schema 3. Orthogonale koppelingsprocedure voor de synthese van triazool analoga van natuurlijke  
glycopeptiden. 
In Hoofdstuk 5 wordt een nieuwe koper-gekatalyseerde cycloadditie van niet 
eindstandige broomalkynen en organische aziden beschreven (Schema 4). Deze 
koper-geinduceerde koppeling, resulterend in de vorming van broom-bevattende 
trigesubstitueerde [1,2,3]-triazoolderivaten (in hoge opbrengst en goede 
regioselectiviteit), werd toegepast voor de cycloadditie van een reeks broom-
acetylenen en aziden. De broom-substituent in de verkregen triazolen kan benut 
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worden als een synthetisch handvat voor verdere functionalisering tot andere 
trigesubstitueerde [1,2,3]-triazolen. 
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Schema 4. Nieuwe koper-gekatalyseerde cycloadditie van broomalkynen en organische aziden. 
De chemoenzymatische peptidekoppeling van geglycosyleerde triazool- en amide-
gebonden aminozure methylesters, geinduceerd door alcalase (een proteolytisch 
enzymmengsel geproduceerd door Bacillus licheniformis), wordt beschreven in 
Hoofdstuk 6. Zowel de amide-gebonden als de niet-natuurlijke triazool-gebonden 
substraten werden aan aminozuuramiden gekoppeld, wat leidde tot dipeptiden in 
een matige tot goede opbrengst. Een voorbeeld is weergegeven in Schema 5. 
Bovendien wordt een eerste studie naar chemoenzymatische glycosylering van 
triazool-gebonden glycopeptiden behandeld. 
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Schema 5. Enzymatische peptidekoppeling van geglycosyleerde triazool-gebonden aminozure methylesters. 
Hoofdstuk 7 beschrijft de synthese van diverse cyclische RGD derivaten, middels een 
combinatie van vaste en vloeistoffase chemie. Deze peptiden zijn zeer geschikt voor 
het selectief targeten van in tumoren tot expressie gebrachte αvβ3 integrine 
receptoren (Figuur 2). Om de biologische waarde van een triazool als amide isosteer 
te evalueren, werden zijketen-geglycosyleerde RGD peptiden met respectievelijk een 
amide en  triazool binding gesynthetiseerd. De affiniteit van de verkregen RGD 
derivaten voor de αvβ3 integrine receptor werd in vitro bepaald in een ELISA assay, 
welke aantoonde dat de bindingsaffiniteit van de geëvalueerde verbindingen 
nagenoeg gelijk was. 
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Het in vivo tumor targeting potentieel van de geglycosyleerde RGD peptiden (met 
een amide of triazool binding) werd onderzocht door de bioverdeling van 125I-
gelabelde RGD derivaten in muizen met αvβ3 bevattende tumoren te bepalen. De 
RGD derivaten werden in muizen met onderhuidse tumoren ingebracht, waarna 
vervogens de muizen werden gedood en de radioactiviteit in de verschillende 
organen en de tumor werd gemeten. Het triazool-bevattende glycoRGD derivaat 
bleek, evenals het overeenkomstige amide derivaat, voor het grootste deel in de 
tumor terecht te komen. Verder werd voor het triazool-gebonden geglycosyleerde 
derivaat de hoogste tumor-tot-bloed verhouding werd gemeten. De resultaten van 
dit onderzoek vormen daarmee een duidelijke aanwijzing voor de potentie van de 
triazool als geschikt amide isosteer in biologische systemen. 
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 Figuur 2. Cyclische RGD peptiden voor het selectief targeten van integrine receptoren.  
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DANKWOORD 
 
Wow, als je hier bent aangekomen heb je al aardig wat uurtjes in mijn proefschrift gelezen, 
respect! Of is dit soms het eerste wat je leest? Het dankwoord, wellicht een van de lastigste 
gedeeltes van het schrijven van een proefschrift, als je niet iemand vergeet, spel je wel iets 
verkeerd. Toch is het een belangrijk deel van mijn proefschrift, want hier krijg ik de kans om 
mijn dank uit te spreken aan een ieder die in fysieke, dan wel morele steun of afleiding heeft 
bijgedragen aan mijn promotie. 
Ik zou willen beginnen met het bedanken van Albert de Boer, mijn leraar Organische Chemie 
van het HLO. Albert, al was u zelf polymeer chemicus, door uw inspirerende manier van 
lesgeven werd ik me ervan bewust dat het “knutselen met moleculen” of te wel organische 
chemie mijn passie was. Bedankt.  
In het bijzonder wil ik Floris Rutjes bedanken voor mogelijkheid om dit promotie onderzoek 
uit te mogen voeren. Floris, jouw vertrouwen en de informele sfeer waardoor we altijd bij jou 
konden binnenlopen heb ik altijd als zeer prettig ervaren. Van je enorme chemische kennis 
en frisse kijk op het onderzoek, heb ik zeer veel opgestoken. Bedankt voor jouw uitstekende 
begeleiding.  
Floris Van Delft, jouw enthousiasme voor de behaalde resultaten en overvloed van creatieve 
ideeën, welke ten grondslag lagen voor menig experiment, zijn onmisbaar voor een 
promovendus. Ik moet wel bekennen dat wij beiden toch een ander idee hebben van ‘even’, 
want jou ‘probeer anders dat eens even’ betekent al gauw een maand werk. Ook wil ik je 
bedanken voor je zorgvuldigheid bij het corrigeren van mijn manuscript, dit is mijn 
proefschrift zeker ten goede gekomen. Ook bedankt voor je hulp op de momenten dat het 
hard nodig was. 
Wat betreft positieve inbreng wil ik ook graag Richard Blauw (Chiralix, Nijmegen) 
bedanken. Richard, het bewonderenswaardig hoe ver en diep jouw kennis reikt en hoe goed 
jij die heldere blik op de materie met anderen, inclusief mezelf, weet te delen. Van DSM 
Pharmaceutical Products (Geleen) wil ik PQ (aka Peter Quaedflieg), Bernard Kaptein en 
Hans Schoemaker bedanken voor hun inbreng tijdens te besprekingen en gastvrijheid 
gedurende de enzymatische resoluties aldaar. Annemieke Soede, Peter Laverman en Otto 
Boerman van de afdeling nuclaire geneeskunde wil ik bedanken voor het ‘testen’ van mijn 
RGD peptiden. Otto Boerman wil ik tevens bedanken voor het plaatsnemen in mijn 
manuscriptcommissie. Dit laast geld ook voor Peter Quaedflieg en Dennis Lowik. 
Het begeleiden van studenten was een van de leukste onderdelen van mijn 
promotieonderzoek. Extra dank gaat dan ook uit naar deze ‘helpende handjes’. Mijn eerste 
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hoofdvakstudent, Bram Keereweer, wil ik in het bijzonder bedanken voor zijn inzet en 
vakkundigheid bij die hij tijdens zijn hoofdvak toonde. Ons gezamenlijk werk heeft dan ook 
mogen lijden tot een schitterende publicatie, welke nog steeds vaak geciteerd word. Bram, 
jou en Suzanne wil ik ook graag bedanken voor de deelname in het front ‘streepjes nee’. Dat 
we er ons uiteindelijk toch maar bij hebben neergelegd, tja, dat is niet verwonderlijk als het 
eigenlijk om borrels, bier en gezelligheid gaat. Ook ben ik blij dat ik mede door jou de 
klimsport heb ontdenkt, wel jammer dat we elkaar nooit in de klimhal hebben mogen 
ontmoeten. Tenslotte wil ik je nog hartelijk danken dat je mijn paranimf wilt zijn, en je heel 
veel succes met de ‘laatste loodjes’ van je eigen promotie onderzoek wensen.  
Ook wil ik graag een woordje van lof spreken over Rik Cleophas. Rik ook jij hebt een flinke 
bijdrage geleverd aan mijn boekje, de vele reacties in hoofdstuk 4 zijn dan ook voornamelijk 
jouw werk. Ik weet zeker dat een ieder op ons lab jouw aanwezigheid zeer goed kon 
waarderen. Wellicht dat je af en toe de getalletjes een extra keertje moet controleren, maar 
met jouw instelling kom je er wel! Als je niet gaat promoveren in Engeland dan vind je vast 
die uitstekend bij jouw passende promotieplek plek hier in Nederland wel. 
Verder was er ook nog een derde hoofdvakstudent, euhhmm…..ohja, Guido (Dijkmans). 
Guido, de rollen aluminium folie zijn op een lab nog nooit zo snel opgegaan als toen jij er 
was. Wat de inhoudsopgave van je verslag betreft, ik dacht dat we die twee weken na je 
presentatie zouden bespreken. Jij hebt waarschijnlijk 2 jaar (of langer) na data in gedachte. Of 
er ooit nog een verslag komt, ik weet het niet, maar wellicht dat je het dan wel beter direct bij 
Floris kunt inleveren.  
Margo, jouw wil wel ik erg bedanken voor je hulp bij de synthese van die ‘vervelende’ RGD 
derivaten, de zuivering van die ‘krengen’ is inderdaad een ellende zo als ik zelf ook heb 
mogen ervaren. Gelukkig was er voor jou een leuke afleiding (Jasper) in de tegenoverstaande 
zuurkast. Wat ik me wel afvraag is of jullie dit jaar wel op tijd geweest om kaartjes voor 
Lowlands te kopen. Ook de studenten die maar voor korte en soms zeer korte tijd hun 
handen uit de mouwen hebben gestoken wil ik graag bedanken voor hun inzet, dit werk is 
dan niet altijd opgenomen in dit manuscript, de resultaten waren wel vaak erg nuttig!  
Ook zou ik Stan Groothuys, partner in crime van het Senter project willen bedanken voor de 
nuttige gesprekken betreffende onze chemie. De theoretische indeling, jij de suikers ik de 
aminozuren verlieten we gelukkig erg snel, wat resulteerde in twee verschillende 
onderzoeklijnen die elkaar nog vaak raakten en kruisten. Deze samenwerking heeft geleid 
tot enkele fantastische publicaties voor ons beide, bedankt voor jouw inbreng in deze.  
Verder wil ik al mijn oude labgenoten bedanken, te beginnen met Roy Storcken en de 
toenmalige ‘SynBio’ (nu Chiralix) leden. Richard, Denis, Christien en Jasper Kl. bedankt voor 
de gezelligheid op het oude ‘suikerlab’! Na alweer een verhuizing, nog steeds in het “oude” 
UL, heb ik de eer gehad op het lab te mogen delen met ‘de nieuwe’ Sjef, en Roel(liboelie). 
Uiteindelijk kwam er dan een schitterende nieuwbouw waar we met Valeria, Jasper Ka., 
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Stan, Koen, Sander, en later Dennis nog vele streepjes hebben mogen zetten om de biertjes 
voor de borrels bij elkaar te sprokkelen. Jullie allen en de vele studenten die in de jaren de 
labs hebben opgevrolijkt bedankt voor de altijd uitstekende sfeer! 
Een organische afdeling kan niet draaien zonder de nodige ondersteuning. Ad Swolfs, Peter 
van Galen en Helène Amatdjais-Groenen wil ik bedanken voor hun bijdrage bij de 
karakterisering van de talloze verbindingen. Pieter van der Meer ben ik dankbaar voor de 
technische zaken. Chris Kroon en de ‘altijd lachende’ Peter van Dijk voor het snel bezorgen 
van al mijn benodigde chemicaliën.  
Werk is één, maar vertier moet er ook zijn, er werd dan ook nogal wat plezier beleefd met de 
collega’s in het bijzonder wil ik iedereen bedanken voor de gezelligheid tijdens de etentjes, 
bowlingcompetities, zeilweekendjes en feesten. In het bijzonder, Hester en Richard, Stan en 
Manon, Jasper Ka. en Margot, Ton en Suzanne, Kasper en Marloes, Joost en Steffi, Denis, 
Henri, Sander, Roel, Johan, Martijn (door jouw ge-MSN heb ik straks weer een nieuwe HD 
nodig), Sjef, Koen, en  Sander. Bowlus (fka Pint), een ding heb ik geleerd, een goed gevulde 
maag en (de eerste) biertjes hebben een positief effect op de score. Ook wil ik natuurlijk al 
mijn andere nog niet genoemde collega’s bedanken voor de schitterende tijd: Bart, Jan, 
Maarten, Bas G., Guuske, Daniel, Dani, Pjotr, Kasia, Claudia, Jurgen, Pieter, Jaap, Irene, 
Hans, Matthijs, Jorge (die wisky was echt goed!) , Rutger, Bas v.d. B., Bas R, Valeria. En 
natuurlijk alle andere leden van de Rutjes, Rowan, en Nolte groep die ik niet expliciet 
genoemd heb.  
Ook bedankt aan al mijn ‘oude’ vriendjes en vriendinnetjes uit het zuiden die ik 
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